Quantifying important risk factors and survival following treatment in people with lung cancer using routinely collected national data by Powell, Helen.
Powell, Helen. (2014) Quantifying important risk factors 
and survival following treatment in people with lung 
cancer using routinely collected national data. PhD 
thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14092/1/HA_Powell_PhD_thesis.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
QUANTIFYING IMPORTANT RISK 
FACTORS AND SURVIVAL FOLLOWING 
TREATMENT IN PEOPLE WITH LUNG 
CANCER USING ROUTINELY COLLECTED 
NATIONAL DATA 
 
 
Dr Helen Powell BMedSci BMBS MRCP 
 
 
 
Thesis submitted to the University of Nottingham for the degree of 
Doctor of Philosophy 
December 2013 
 ii 
TABLE OF CONTENTS 
ABSTRACT ........................................................................................................................................ 1 
ACKNOWLEDGEMENTS .................................................................................................................... 4 
PUBLICATIONS ARISING ................................................................................................................... 5 
LIST OF TABLES ................................................................................................................................. 6 
LIST OF FIGURES ............................................................................................................................... 9 
LIST OF ABBREVIATIONS ................................................................................................................ 12 
CHAPTER 1: INTRODUCTION ....................................................................................................... 15 
1.1 INCIDENCE AND RISK FACTORS ...................................................................................................... 16 
1.1.1 Cigarette smoking ........................................................................................................ 16 
1.1.2 Other risk factors .......................................................................................................... 19 
1.2 CLASSIFICATION OF LUNG CANCER ................................................................................................. 21 
1.2.1 Histology ....................................................................................................................... 21 
1.2.2 Stage ............................................................................................................................. 21 
1.3 TREATMENT OPTIONS AND THEIR EFFECT ON SURVIVAL ...................................................................... 23 
1.3.1 Non-small cell lung cancer ............................................................................................ 23 
1.3.2 Small-cell lung cancer ................................................................................................... 28 
1.3.3 Palliative care ............................................................................................................... 31 
1.4 STRUCTURE OF LUNG CANCER CARE IN THE UK ................................................................................ 33 
1.4.1 Primary care ................................................................................................................. 33 
1.4.2 Secondary care ............................................................................................................. 34 
1.5 SURVIVAL AND INEQUALITIES IN LUNG CANCER ................................................................................ 36 
1.5.1 Lung cancer survival in the UK ...................................................................................... 36 
1.5.2 International differences in survival ............................................................................. 36 
1.5.3 Inequalities in treatment rates ..................................................................................... 37 
1.6 CURRENT STRATEGIES TO REDUCE LUNG CANCER MORTALITY AND IMPROVE SURVIVAL ............................. 39 
 iii 
1.6.1 Screening ...................................................................................................................... 39 
1.6.2 Early diagnosis initiatives ............................................................................................. 40 
1.6.3 Identifying and addressing inequalities ........................................................................ 41 
1.7 CHAPTER SUMMARY................................................................................................................... 44 
1.8 JUSTIFICATION OF THESIS ............................................................................................................ 44 
1.9 THESIS OBJECTIVES..................................................................................................................... 45 
1.10 OUTLINE OF THESIS SECTIONS ....................................................................................................... 46 
1.11 DATA ORGANISATION AND STATISTICAL METHODS ............................................................................ 47 
CHAPTER 2: DESCRIPTION OF DATABASES .................................................................................. 49 
2.1 THE HEALTH IMPROVEMENT NETWORK (THIN) .............................................................................. 50 
2.1.1 Background................................................................................................................... 50 
2.1.2 Ethical approval ............................................................................................................ 50 
2.1.3 Data extract for this thesis ........................................................................................... 51 
2.1.4 THIN variables used for this thesis................................................................................ 52 
2.1.5 Strengths & weaknesses ............................................................................................... 54 
2.2 THE NATIONAL LUNG CANCER AUDIT (NLCA) ................................................................................ 56 
2.2.1 Background................................................................................................................... 56 
2.2.2 Data entry ..................................................................................................................... 56 
2.2.3 Ethical approval ............................................................................................................ 57 
2.2.4 Data extracts for this thesis .......................................................................................... 57 
2.2.5 NLCA Variables used for this thesis .............................................................................. 58 
2.2.6 Strengths and weaknesses ........................................................................................... 63 
2.3 HOSPITAL EPISODES STATISTICS (HES) .......................................................................................... 65 
2.3.1 Background................................................................................................................... 65 
2.3.2 Data extracts for this thesis .......................................................................................... 65 
2.3.3 Linkage with the NLCA database .................................................................................. 66 
2.3.4 Ethical approval ............................................................................................................ 66 
2.3.5 HES variables used for this thesis ................................................................................. 66 
 iv 
2.3.6 Strengths and weaknesses ........................................................................................... 68 
2.4 OFFICE FOR NATIONAL STATISTICS ................................................................................................ 70 
2.4.1 Ethical approval ............................................................................................................ 70 
2.4.2 Data extraction and linkage ......................................................................................... 70 
2.4.3 ONS variables used for this thesis................................................................................. 70 
2.4.4 Strengths and weaknesses ........................................................................................... 70 
2.5 CHAPTER SUMMARY................................................................................................................... 72 
CHAPTER 3: SMOKING QUANTITY AND LUNG CANCER IN MEN AND WOMEN ............................ 73 
3.1 INTRODUCTION ......................................................................................................................... 74 
3.1.1 Background................................................................................................................... 74 
3.1.2 Rationale for this study................................................................................................. 74 
3.1.3 Aim of this chapter ....................................................................................................... 74 
3.2 METHODS ................................................................................................................................ 75 
3.2.1 Dataset & Study Population ......................................................................................... 75 
3.2.2 Definition of Exposures ................................................................................................. 75 
3.2.3 Covariate definitions .................................................................................................... 75 
3.2.4 Statistical methods ....................................................................................................... 76 
3.3 RESULTS .................................................................................................................................. 77 
3.3.1 Sensitivity analysis ........................................................................................................ 78 
3.3.2 Height ........................................................................................................................... 78 
3.4 DISCUSSION ............................................................................................................................. 81 
3.4.1 Main findings ................................................................................................................ 81 
3.4.2 Strengths & weaknesses ............................................................................................... 81 
3.4.3 Previous research ......................................................................................................... 82 
3.4.4 Explaining the difference .............................................................................................. 88 
3.4.5 Conclusion .................................................................................................................... 90 
3.5 CHAPTER SUMMARY................................................................................................................... 92 
 v 
CHAPTER 4: IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE AN INDEPENDENT RISK FACTOR 
FOR LUNG CANCER? ....................................................................................................................... 93 
4.1 INTRODUCTION ......................................................................................................................... 94 
4.1.1 Background................................................................................................................... 94 
4.1.2 Rationale for this study................................................................................................. 94 
4.1.3 Aim of this chapter ....................................................................................................... 95 
4.2 METHODS ................................................................................................................................ 96 
4.2.1 Study population .......................................................................................................... 96 
4.2.2 Definition of Exposures ................................................................................................. 96 
4.2.3 Covariate definitions .................................................................................................... 97 
4.2.4 Statistical methods ....................................................................................................... 98 
4.3 RESULTS .................................................................................................................................. 99 
4.3.1 Risk factors for lung cancer ........................................................................................ 105 
4.3.2 Diagnostic overlap ...................................................................................................... 107 
4.3.3 COPD severity ............................................................................................................. 108 
4.4 DISCUSSION ........................................................................................................................... 109 
4.4.1 Main findings .............................................................................................................. 109 
4.4.2 Strengths .................................................................................................................... 109 
4.4.3 Smoking and ascertainment bias ............................................................................... 109 
4.4.4 Limitations .................................................................................................................. 112 
4.4.5 Summary of previous studies ...................................................................................... 113 
4.4.6 Pneumonia and asthma ............................................................................................. 117 
4.4.7 Clinical relevance ........................................................................................................ 118 
4.5 CHAPTER SUMMARY................................................................................................................. 120 
CHAPTER 5: VALIDATION OF RECORDS OF SURGICAL PROCEDURES ......................................... 121 
5.1 INTRODUCTION ....................................................................................................................... 122 
5.1.1 Background................................................................................................................. 122 
5.1.2 Rationale for this study............................................................................................... 122 
 vi 
5.1.3 Aims of this chapter .................................................................................................... 123 
5.2 RECORDS OF SURGERY IN HES AND THE NLCA .............................................................................. 124 
5.2.1 Methods ..................................................................................................................... 124 
5.2.2 Results ........................................................................................................................ 129 
5.2.3 Interpretation ............................................................................................................. 136 
5.2.4 Conclusion .................................................................................................................. 138 
5.3 DESCRIPTION OF PATIENTS WHO HAD SURGERY AND COMPARISON WITH PUBLISHED DATA ..................... 139 
5.3.1 Methods ..................................................................................................................... 139 
5.3.2 Results ........................................................................................................................ 141 
5.3.3 Comparison with previously published data ............................................................... 148 
5.4 CHAPTER SUMMARY................................................................................................................. 150 
CHAPTER 6: RISK FACTORS FOR EARLY DEATH FOLLOWING SURGERY FOR LUNG CANCER ....... 151 
6.1 INTRODUCTION ....................................................................................................................... 152 
6.1.1 Background................................................................................................................. 152 
6.1.2 Rationale for this study............................................................................................... 153 
6.1.3 Aims of this chapter .................................................................................................... 153 
6.2 HISTORY OF SURGICAL MORTALITY RISK ASSESSMENT ...................................................................... 154 
6.2.1 American Society of Anaesthesiologists ..................................................................... 154 
6.2.2 Goldman cardiac index ............................................................................................... 155 
6.2.3 POSSUM...................................................................................................................... 156 
6.2.4 E-PASS ......................................................................................................................... 160 
6.2.5 The European Society Subjective & Objective Scores ................................................. 161 
6.2.6 Thoracoscore .............................................................................................................. 163 
6.2.7 Thoracic surgery for lung cancer ................................................................................ 165 
6.2.8 Other studies of risk factors for mortality in lung cancer surgery .............................. 166 
6.2.9 Post-operative morbidity ............................................................................................ 167 
6.2.10 Summary .................................................................................................................... 167 
6.3 ANALYSIS OF FACTORS ASSOCIATED WITH EARLY MORTALITY FOLLOWING SURGERY FOR NSCLC .............. 168 
 vii 
6.3.1 Aims ............................................................................................................................ 168 
6.3.2 Methods ..................................................................................................................... 168 
6.3.3 Results ........................................................................................................................ 172 
6.3.4 Discussion ................................................................................................................... 181 
6.4 GENERATION OF A NEW RISK PREDICTION MODEL ........................................................................... 185 
6.4.1 Aims ............................................................................................................................ 185 
6.4.2 Methods ..................................................................................................................... 185 
6.4.3 Results ........................................................................................................................ 186 
6.4.4 Discussion ................................................................................................................... 188 
6.5 CHAPTER SUMMARY................................................................................................................. 192 
CHAPTER 7: VALIDATION OF RECORDS OF CHEMOTHERAPY AND RADIOTHERAPY ................... 193 
7.1 INTRODUCTION ....................................................................................................................... 194 
7.1.1 Background................................................................................................................. 194 
7.1.2 Rationale for this study............................................................................................... 194 
7.1.3 Aim of this chapter ..................................................................................................... 195 
7.1.4 Radiotherapy records ................................................................................................. 195 
7.2 RECORDS OF CHEMOTHERAPY IN HES AND THE NLCA .................................................................... 196 
7.2.1 Methods ..................................................................................................................... 196 
7.2.2 Results ........................................................................................................................ 200 
7.2.3 Interpretation and definitions .................................................................................... 206 
7.3 RADIOTHERAPY IN HES AND THE NLCA ....................................................................................... 208 
7.3.1 Background................................................................................................................. 208 
7.3.2 Methods ..................................................................................................................... 209 
7.3.3 Results ........................................................................................................................ 211 
7.3.4 Interpretation ............................................................................................................. 213 
7.4 CHAPTER SUMMARY................................................................................................................. 214 
CHAPTER 8: TREATMENT DECISIONS AND OUTCOMES IN SMALL CELL LUNG CANCER .............. 215 
8.1 INTRODUCTION ....................................................................................................................... 216 
 viii 
8.1.1 Background................................................................................................................. 216 
8.1.2 Rationale for this study............................................................................................... 216 
8.1.3 Aims of this chapter .................................................................................................... 217 
8.2 CHARACTERISTICS OF PATIENTS AND FACTORS ASSOCIATED WITH CHEMOTHERAPY TREATMENT ............... 218 
8.2.1 Aims ............................................................................................................................ 218 
8.2.2 Methods ..................................................................................................................... 218 
8.2.3 Results ........................................................................................................................ 222 
8.3 CHARACTERISTICS OF PATIENTS AND FACTORS ASSOCIATED WITH COMPLETING A CHEMOTHERAPY COURSE 227 
8.3.1 Aims ............................................................................................................................ 227 
8.3.2 Methods ..................................................................................................................... 227 
8.3.3 Results ........................................................................................................................ 228 
8.4 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH SCLC ........................................................... 234 
8.4.1 Aims ............................................................................................................................ 234 
8.4.2 Methods ..................................................................................................................... 234 
8.4.3 Results ........................................................................................................................ 236 
8.5 DISCUSSION ........................................................................................................................... 243 
8.5.1 Strengths & Limitations .............................................................................................. 243 
8.5.2 Comparison with trial data ......................................................................................... 244 
8.5.3 Clinical relevance ........................................................................................................ 245 
8.5.4 Conclusion .................................................................................................................. 247 
8.6 CHAPTER SUMMARY................................................................................................................. 248 
CHAPTER 9: ONGOING RESEARCH ............................................................................................. 249 
9.1 ATTITUDES TO RISK IN LUNG CANCER SURGERY .............................................................................. 250 
9.1.1 Background & rationale ............................................................................................. 250 
9.1.2 Aims of this study ....................................................................................................... 251 
9.1.3 Ethical approval .......................................................................................................... 251 
9.1.4 Progress ...................................................................................................................... 252 
9.1.5 Methods: Patient interviews ...................................................................................... 254 
 ix 
9.1.6 Current status of recruitment & analysis plan ............................................................ 257 
9.1.7 Methods: Healthcare professional interviews ............................................................ 259 
9.1.8 Timescale for completion of study .............................................................................. 260 
9.2 OTHER ONGOING RESEARCH ...................................................................................................... 261 
9.2.1 Definitions of surgery, chemotherapy and radiotherapy in the NLCA ........................ 261 
9.2.2 Validation of surgical score ........................................................................................ 262 
9.2.3 Stereotactic radiotherapy ........................................................................................... 264 
9.3 CHAPTER SUMMARY................................................................................................................. 266 
CHAPTER 10: SUMMARY OF THESIS AND SUGGESTIONS FOR FURTHER RESEARCH ................. 267 
10.1 SUMMARY OF MAIN FINDINGS .................................................................................................... 268 
10.2 CLINICAL RELEVANCE AND SUGGESTIONS FOR FURTHER RESEARCH ..................................................... 269 
10.2.1 Early diagnosis of lung cancer and screening ............................................................. 269 
10.2.2 Post-operative mortality............................................................................................. 269 
10.2.3 Communication of risk ................................................................................................ 270 
10.2.4 Chemotherapy in NSCLC and the Systemic Anti-Cancer Therapy database ............... 271 
10.2.5 Organisational and NHS trust-level factors ................................................................ 272 
10.3 CONCLUSION .......................................................................................................................... 273 
APPENDICES ................................................................................................................................. 274 
APPENDIX A: ABSTRACTS OF THESIS WORK PRESENTED AT CONFERENCES ........................................................ 275 
APPENDIX B: CLINICAL TRAINING ............................................................................................................ 291 
APPENDIX C: CODE LISTS FOR STUDIES USING THE THIN DATABASE ............................................................... 293 
APPENDIX D: NLCA DATA ENTRY FORM ................................................................................................... 301 
APPENDIX E: CODE LISTS FOR SURGERY STUDIES ........................................................................................ 305 
APPENDIX F: CODE LISTS FOR CHEMOTHERAPY STUDIES .............................................................................. 309 
APPENDIX G: STUDY PROTOCOLS AND DOCUMENTS ................................................................................... 312 
REFERENCES ................................................................................................................................. 344 
 1  
ABSTRACT 
Background 
Survival for people with lung cancer is poor both in comparison with other 
cancers and for the United Kingdom (UK) compared with other developed 
countries. Inequalities in access to care for people with lung cancer have been 
demonstrated using large, routinely collected, datasets. One especially useful 
resource in this context is The National Lung Cancer Audit (NLCA) which was set 
up in 2002 with the aim of improving outcomes for people with lung cancer. It 
has collected data on people with primary lung cancer from hospital trusts in 
England and Wales since 2004. This is now the largest database of people with 
lung cancer in Europe containing over 150,000 cases and with close to 100% 
case ascertainment; approximately 35,000 new cases are added each year. 
Methods 
In addition to the NLCA, routinely collected primary care data from The Health 
Improvement Network, and the database which results from the clinical coding 
of all inpatient hospital admissions in England (the Hospital Episodes Statistics 
(HES) database) were used to investigate several clinical questions in lung 
cancer. Records for people in the NLCA were linked with their HES records by the 
Health and Social Care Information Centre (HSCIC). Death registration is 
mandatory in the UK and these records were obtained from the Office for 
National Statistics (ONS), and linked with HES data. The ONS death data were 
used to provide accurate and complete follow-up for mortality and survival 
analyses. 
The observational studies in this thesis used matched case-control methodology 
and multivariate logistic regression to investigate the association between sex, 
smoking quantity, chronic obstructive lung disease (COPD), and lung cancer. 
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Case control and cohort studies were performed to investigate early mortality 
after lung cancer surgery and treatment decisions in small cell lung cancer 
(SCLC). Multivariate logistic regression was used to generate a score to predict 
the risk of early mortality after lung cancer surgery. Survival analyses including 
Kaplan Meier curves and Cox regression were used to determine the most 
accurate definition of surgery and chemotherapy from the NLCA and HES 
databases and to provide information on outcomes after chemotherapy. 
Results 
Sex significantly modified the effect of smoking on lung cancer (multiplicative 
test for interaction likelihood ratio p<0.0001) with women at higher risk for the 
same quantity smoked. Chronic obstructive pulmonary disease was strongly 
associated with lung cancer in univariate analysis (odds ratio 11.47, 95% 
confidence interval 9.38-14.02 for people with recently diagnosed COPD 
compared with those without COPD) however this was heavily confounded by 
smoking and strongly related to the timing of diagnosis. 
For people with non-small cell lung cancer the 90-day mortality after lung cancer 
surgery was 5.9%. Factors which were significantly associated with this outcome 
(and therefore make up the predictive score) included age, co-morbidity index, 
performance status, procedure type, stage. Seventy per cent of people with 
histologically confirmed SCLC were treated with chemotherapy however this 
varied according to several factors including the referral method and 
socioeconomic status. Survival after chemotherapy for people with SCLC in the 
NLCA was similar to that reported in clinical trials. 
Conclusions 
I have used routinely collected clinical data to address important questions 
surrounding the aetiology and treatment of lung cancer. The work in thesis 
provides evidence to support the growing body of work suggesting that women 
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are at higher risk of lung cancer per quantity of cigarettes smoked, and 
challenges the commonly held belief that COPD is a strong independent risk 
factor for lung cancer.  
I have used the NLCA-HES linked data to add to our knowledge of the validity of 
treatment records in the NLCA, to produce a new predictive score for early 
mortality following lung cancer surgery which is now being validated in more 
than one independent dataset and to provide the oncology community with 
information on real-life treatment decisions and associated outcomes for small 
cell lung cancer.  
Qualitative analyses of patient and clinicians attitudes, new data linkages, and 
information on organisational level variables are highly important in the next 
stages of research into inequalities in lung cancer care, and several studies are 
ongoing as a result of the research in this thesis.  
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CHAPTER 1: INTRODUCTION 
This chapter covers the evolution of our knowledge about risk factors for lung 
cancer, some definitions for the medical and organisational terminology which 
will be used in this thesis, and a brief overview of existing treatments and how 
these affect survival. I will also discuss overall survival from lung cancer, the 
inequalities which are known to exist in lung cancer care, and current strategies 
to reduce the mortality burden and improve survival for people with lung cancer 
in the United Kingdom.  
This is followed by the thesis justification, objectives and an outline of 
subsequent thesis chapters. 
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1.1 Incidence and risk factors 
Lung cancer is the second commonest cancer in the UK, after breast cancer, with 
an estimated 42,000 new cases diagnosed in 2010.(1) Worldwide, lung cancer is 
the most common cancer with approximately 1.61 million new cases diagnosed 
in 2008. Incidence rates are highest in Europe and Northern America and lowest 
in parts of Africa.(2) 
1.1.1 Cigarette smoking 
When deaths from lung cancer started to increase in the UK at the start of the 
20th century, scientists and doctors initially attributed this to increases in air 
pollution due to industrialisation and increasing road traffic. Exposure to gas 
during the war and even a recent influenza pandemic were also suggested as 
potential causes for the rising incidence of this disease. In the late 19th century, 
however, a machine had been developed which rolled cigarettes, making them 
widely available and much more affordable. The prevalence of smoking had risen 
sharply, initially in men, and particularly in the armed forces, and this was 
followed about 20 years later by a dramatic increase in the incidence of lung 
cancer. 
Epidemiological studies first made the link between smoking and lung cancer in 
the 1930s, but it was not widely accepted, even by clinicians (many of whom 
enjoyed smoking cigarettes), until at least the 1950s. A landmark UK study in 
this respect was the British Doctors Study by Doll and Hill who collected 
information on smoking habits and cause of death for a cohort of British doctors 
in the 1930 -40s. They published their findings in 1956, providing evidence of 
the marked increase in incidence of lung cancer since the increase in cigarette 
consumption and of the increased mortality from lung cancer in smokers 
compared with non-smokers, and in heavy smokers compared with lighter 
smokers. In addition they reported that upper respiratory tract and upper 
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gastrointestinal malignancies as well as coronary thrombosis appeared to be 
more common in smokers than non-smokers although numbers with this 
outcome at that time were small; smoking is now a well-established risk factor 
for all of these diseases. (3) 
Overall trend in smoking prevalence 
Figure 1-1 shows the trend in smoking prevalence in the United States from 
1900 to 1998 and some of the measures introduced to encourage smoking 
cessation.(4) Smoking prevalence in other developed countries followed a similar 
pattern and trends in Great Britain since 1950 are shown in Figure 1-2. 
 
Figure 1-1: Annual adult per capita cigarette consumption and major smoking 
and health events United States 1900-1998 (4) 
 
Smoking in women 
By the time Doll and Hill, and other clinicians, began to report the strong 
association between cigarette smoking and lung cancer, tobacco advertising had 
taken off and the prevalence of cigarette smoking in UK males peaked at 
approximately 65% in the early 1940s.(5) When smoking prevalence in men 
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eventually started to decline, tobacco companies targeted women with 
advertising campaigns such as those for Virginia Slims.(6) The prevalence of 
smoking in women in the UK increased to a peak of approximately 45% in the 
1960s (Figure 1-2). In some European countries and particularly in developing 
countries the prevalence of smoking in women is now higher than that of 
men.(7)  
In the United Kingdom (UK) both smoking and lung cancer are still more 
common in men, however the ratio is falling and compared with 39:10 in 1975 
the ratio of lung cancer in men compared with women is now 12:10.(5) 
 
Figure 1-2: Smoking prevalence and lung cancer incidence, by sex, Great Britain, 
1948-2010 (5) 
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Tobacco control and changes in incidence 
The risk of lung cancer reduces significantly in people who stop smoking before 
middle age, (8) and tobacco control has been the single biggest factor to date in 
reducing the number of deaths due to lung cancer. Figure 1-2 demonstrates the 
peaks in incidence of lung cancer in men and women and how this relates to 
changes in smoking prevalence. The incidence of lung cancer in men peaked in 
1980 but in women it continues to rise.  
Financial burden 
Lung cancer remains the second most common cancer in the UK and the 
financial burden is considerable with the estimated cost to the UK economy of 
£2.4 billion each year, £9,071 per patient annually, which is far higher than the 
cost of any other cancer despite survival rates being among the lowest. (9)  
1.1.2 Other risk factors 
There are many reported risk factors for lung cancer.  Radon gas and 
occupational exposure to substances such as asbestos are well established as 
causes of lung cancer, particularly in smokers. It has also been suggested that 
lung cancer is more common in people with other chronic lung diseases such as 
pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), even 
after accounting for smoking. (10, 11) 
A history of lung cancer in a first-degree relative is associated with a two-fold 
increased risk of lung cancer regardless of smoking status and suggests the 
possibility of a hereditary predisposition to lung cancer or shared environmental 
risk factor exposure by members of the same family.  The increased risk in 
individuals less than 60 years of age who have a first degree relative diagnosed 
with lung cancer at less than 60 years has been found to be five-fold. (12, 13) 
There is, however, the possibility of ascertainment bias here in that people may 
be more aware of the symptoms of lung cancer and potentially more likely to 
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present to their doctor if they have seen a relative with the disease, but also 
because people may not know what their relatives died of. 
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1.2 Classification of lung cancer 
1.2.1 Histology 
Lung cancer can broadly be divided into small-cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). Malignant mesothelioma is another tumour which 
affects the thoracic cavity and is strongly associated with asbestos exposure. 
Whilst the pathological features, treatment and prognosis for NSCLC and SCLC 
are discussed in this chapter, mesothelioma is not within the scope of this 
research and will not be covered. Data for patients with a known diagnosis of 
mesothelioma are excluded from the studies in this thesis and where the term 
µOXQJFDQFHU¶LVXVHGWKLVGRHVQRWLQFOXGHPHVRWKHOLRPD 
Non small-cell lung cancer (NSCLC) 
The majority (more than 80%) of lung cancers are NSCLC, and most are of the 
adenocarcinoma, squamous cell carcinoma or large cell subtypes, with 
adenocarcinomas recently having overtaken squamous cell as the most common 
subtype. Adenocarcinoma is much more common than squamous cell carcinoma 
in non-smokers, (14) but both are still more common in smokers than in non-
smokers.  
Small-cell lung cancer (SCLC) 
Small-cell lung cancer accounts for between 10% and 18% of all lung cancer, 
and almost always occurs in smokers. The incidence is declining as a result of 
decreasing prevalence of cigarette smoking.  
Small cell lung cancer is so termed because of the microscopic appearance of the 
tumour cells which, in comparison to NSCLC cells, are small. These tend to be 
rapidly dividing tumours which frequently results in metastases being present at 
the time of diagnosis. (15) 
1.2.2 Stage 
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The extent of disease for any tumour is described as the stage; until recently 
staging systems in lung cancer have differed according to the tumour type. 
The extent of disease in patients with NSCLC is described using the Union 
Internationale Contre Le Cancer (UICC) tumour, node, metastasis (TNM) staging 
system which assigns a stage between I and IV depending on the size of tumour 
DQGDQ\LQYDVLRQLQWRRWKHUVWUXFWXUHVZLWKLQWKHFKHVWWXPRXURUµ7¶VWDJHWKH
ORFDWLRQ RI DQ\ O\PSK QRGHV ZKLFK DUH DIIHFWHG E\ WKH FDQFHU QRGDO RU µ1¶
stage), and the presence or absence of spread to distant structures (metastatic 
RUµ0¶VWDJH(16) 
The staging system used for SCLC was, until recently, that described by the 
9HWHUDQV¶ $GPLQLVWUDWLon Lung Study Group 9$/6* DV µOLPLWHG¶ RU µH[WHQVLYH¶
depending on whether the full extent of the disease is confined to one side of the 
chest and could be captured in a single radiotherapy field (limited stage if this 
would be technically possible, extensive stage if not).(17)  
Research has suggested that further classifying SCLC by the UICC TNM staging 
system used for NSCLC may improve the accuracy with which outcomes and 
treatment response (particularly from radiotherapy) can be predicted, and 
therefore current recommendations are that TNM staging is also used for SCLC. 
(14, 18) If conversion is necessary, limited disease broadly includes T1-4, N0-3, 
M0 and extensive disease includes T1-4, N0-3, M1a/b in the updated TNM 
staging classification. 
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1.3 Treatment options and their effect on survival 
The most effective intervention in reducing the number of deaths due to lung 
cancer has been the promotion of smoking cessation, (8) but for those who have 
already developed the disease treatment options depend on how far the disease 
has spread (the stage) and the general condition of the patient. Common 
treatments for NSCLC are described below; small-cell lung cancer behaves, and 
is therefore treated, differently and the management is described under a 
separate sub-heading. 
1.3.1 Non-small cell lung cancer 
Surgery 
Patients with NSCLC who present at an early stage (stage I-IIIA) may be 
suitable for surgical resection. The most common type of surgical procedure is a 
lobectomy (Figure 1-3), which removes the affected lobe of the lung along with 
the blood vessels and the lymphatics. The aim is to entirely remove the tumour 
so that the patient is cured and surgery therefore offers the biggest 
improvement in survival of all treatments for NSCLC. For patients with early 
stage disease, 5-year survival has been reported as up to 73% following tumour 
resection. (19)  If the tumour is too big or mediastinal lymph nodes are affected 
a bi-lobectomy or pneumonectomy may be performed (Figure 1-3). If the 
tumour has spread outside the lung, or to lymph nodes on the opposite side of 
the chest then it is not possible to completely resect the tumour; these cases are 
VRPHWLPHVGHVFULEHGDVQRWEHLQJµUHVHFWDEOH¶ 
Due to advances in preoperative staging it is quite unusual in current practice to 
find at the time of operation that the tumour has spread to the extent that it is 
not resectable. This still occurs occasionally and these procedures are termed 
µRSHQ DQG FORVH¶ as usually nothing is removed. Even with sophisticated pre-
operative staging techniques some patients will develop a recurrence of the 
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cancer very soon after surgery at the site of the resection or as metastases in 
the lymph nodes or other organs. In these patients it is highly probable that 
micro metastases were present at the time of the operation and unfortunately 
the surgery was not successful at removing the entire tumour. These patients 
will have a considerably poorer prognosis than those for whom surgery is 
successful.  
 
Figure 1-3: Types of surgery for lung cancer 
 
Post-operative complications may occur immediately or later on after surgery. 
Immediate complications include bleeding, leakage of air from the area where 
the lung was removed preventing the lung from re-inflating, infection, pulmonary 
emboli and cardiac complications. In some cases these complications can be fatal 
and some patients are considered too high risk for major thoracic surgery due to 
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co-existing health problems. This is sometimes described as whether or not the 
SDWLHQW LV µRSHUDEOH¶DQG LV WKHVXEMHFWRI&KDSWHURI WKLV WKHVLV ,QVRPH of 
these cases a less complicated procedure such as a wedge resection or 
segmental resection (segmentectomy - Figure 1-3) may be performed in an 
attempt to cure patients who are not considered fit enough for a lobectomy. 
Wedge resections are sometimes performed for both diagnostic and treatment 
purposes in patients who have small lung lesions (termed nodules) confined to a 
small area of lung, however there is concern that a wedge resection is more 
likely to leave residual tumour compared with a segmentectomy or lobectomy. 
Radiotherapy  
If surgery is not an option, RU WKH SDWLHQW¶V SUHIHUHQFH LV IRU D OHVV LQYDVLYH
treatment, µUDGLFDO¶UDGLRWKHUDS\may be given with curative intent. The unit for 
measuring dose of ionising radiation is Gray (Gy) and the total dose is usually 
spread out over time (fractionated) to allow normal cells to recover.  Common 
side effects of radiotherapy are due to damage to normal tissue and when 
radiotherapy is given to the chest they include fatigue, breathlessness, cough 
and inflammation of the oesophagus. There is also a risk of damage to the spinal 
cord if the tumour is close to the vertebrae. 
One form of radical radiotherapy is continuous hyper-fractionated accelerated 
radiotherapy (CHART). A randomised controlled trial which compared CHART (36 
fractions of 1.5 Gy radiotherapy 3 times per day to give 54 Gy in 12 consecutive 
days) with conventional radiotherapy (30 fractions of 2 Gy to a total dose of 60 
Gy in 6 weeks) reported a 2-year survival for people with locally advanced 
NSCLC treated with CHART or radiotherapy of 29% and 20% respectively. (20) 
Stereotactic body radiation therapy (SBRT) has recently been introduced to UK 
practice. This involves a very high dose radiation delivered to a well-defined area 
of lung. It is only suitable for certain small tumours which are an appropriate 
distance from a major airway. At present, SBRT is only used for patients with 
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NSCLC who decline, or who are not felt to be fit enough for, thoracic surgery. 
Local control rates as high as 90% have been reported in some studies however 
it difficult to compare outcomes with surgery when there is such a difference in 
fitness between the patients who undergo each treatment.(21) 
Chemotherapy 
In NSCLC, chemotherapy is not usually given curative intent; it would usually be 
considered a palliative treatment to improve symptoms and quality of life, unless 
given as an adjunct to surgery or induction prior to radiotherapy (see below). It 
is used for people who have advanced disease which is not resectable and 
cannot be radically treated with radiotherapy, including people who have 
previously been treated and the tumour has recurred. Patients must be fit 
enough to withstand the potential side effects and toxicities.  
Common chemotherapy regimens for NSCLC involve a platinum agent (Cisplatin 
or Carboplatin) combined with another drug such as Paclitaxel, Etoposide, 
Vinorelbine, Docetaxel, Gemcitabine or Pemetrexed.  Recent evidence suggests 
that poorer outcomes are seen if Pemetrexed is used for squamous cell lung 
cancer and therefore the National Institute for Health and Clinical Excellence 
(NICE) recommends that Pemetrexed is only used for non-squamous tumours. 
(22) This is also referred to as targeted chemotherapy. The side effects of these 
drugs vary but may include gastro-intestinal disturbance, fatigue, hair loss, 
mouth ulcers and hearing loss. There is also a risk of life-threatening bone 
marrow toxicity which may cause a severe deficiency of white blood cells 
(neutropenia) or platelets which can in turn lead to life-threatening infections or 
bleeding.  
Whilst treatment with chemotherapy alone will not cure patients or even have 
much of an effect on medium to long-term survival, it may prolong survival in 
the short term. Estimates for absolute increase in median survival compared 
with best supportive care suggest that this is in the region of 1.5 months (from 
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4.5 months to six months). (23) Second and third line chemotherapy may be 
given with improvements in survival for some patients. 
Adjuvant and induction chemotherapy 
Adjuvant chemotherapy is given following surgery. Studies have shown an 
absolute improvement in 5-year survival of 4% with adjuvant chemotherapy, 
(24)  and current guidelines recommend that it is considered in patients with 
post-operative pathological stage II or higher and tumours greater than 4cm 
maximum diameter. (14, 25) 
Chemotherapy given with the intention of down-staging the tumour prior to 
conventional radical radiotherapy is sometimes termed induction chemotherapy. 
Meta-analyses suggest that this improves 2-year survival by 4±7%. (26) 
Biological therapy 
Another form of targeted therapy is biological therapy, a relatively recent 
development in systemic therapy for NSCLC, although this has been a part of 
treatment of other solid and haematological tumours for some time. The first 
pathway to be exploited was a mutation on the Epidermal Growth Factor 
Receptor (EGFR) gene; the growth of tumours with this mutation can be slowed 
by tyrosine kinase inhibitors (TKIs). Erlotinib and Gefitinib are the TKIs currently 
recommended for use in the UK. (27, 28) 
Studies of Erlotinib suggest a 2 month overall survival benefit when compared 
with placebo in people with advanced NSCLC previously treated with 
chemotherapy, (29) and in the UK it is now recommended for first line use in 
patients with EGFR mutations.(27) Treatment of advanced pulmonary 
adenocarcinoma in non-smokers or former light smokers with Gefitinib resulted 
in 12-month progression-free survival of 24.9% compared with 6.7% in those 
treated with carboplatin±paclitaxel. (30) Gefitinib  is now approved by NICE as 
an alternative first line treatment for EGFR mutation positive tumours.(28)  
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The side effects of the TKIs are considerably less severe than those of standard 
chemotherapy regimens with the most common being a skin rash and diarrhoea. 
They also have the advantage of being orally administered in contrast to most 
other chemotherapy drugs which usually require the patient to attend a day-case 
unit for intravenous therapy. 
1.3.2 Small-cell lung cancer 
Small cell lung cancer is usually a very aggressive tumour and often presents at 
an advanced stage; the majority of patients die due to systemic disease. Surgery 
is not usually considered to be an option as the tumour has spread too far by the 
time of diagnosis. The rapidly dividing nature of the tumour cells does, however, 
mean that the sensitivity to radiotherapy and chemotherapy is often better than 
in NSCLC.  
Chemotherapy 
Initial studies of chemotherapy in SCLC in the late 1960s using 
cyclophosphamide found a modest improvement in survival compared with 
placebo.(31) It was soon discovered that a combination of a platinum based 
agent and another active agent produced a much greater survival benefit, (32) 
and that administering these drugs at the same time rather than sequentially 
produced the best results.(33) Current practice is therefore to use combination 
chemotherapy, administered simultaneously. The management of small cell lung 
cancer has not really changed over the past decade and there are few clinical 
trials in progress. 
Given there is strong evidence that platinum based chemotherapy improves 
survival compared with non-platinum based regimes,(34) the most commonly 
used chemotherapy regimens for SCLC are Etoposide with either Carboplatin or 
Cisplatin (two dose options for Cisplatin are 60 or 80 mg/m2 depending on 
patient fitness and co-morbidities). Carboplatin and Cisplatin must be 
 29  
administered intravenously and each dose takes approximately 1 hour to 
administer. The side effects and toxicities are similar to those described above 
for chemotherapy in NSCLC. Dose reductions may be necessary for patients with 
liver or renal impairment. The platinum agent is given on day 1 and Etoposide on 
days 1, 2 and 3. Etoposide can be given orally as well as intravenously however 
bio-availability is better if it is given by the intravenous route; often the first 
dose of each cycle is intravenous and the two subsequent doses oral so the 
SDWLHQWGRHVQ¶WKDYHWRDWWHQGKRVSLWDORQVRPDQ\RFFDVLRQV 
,WZRXOG EH XVXDO WR JLYH D µF\FOH¶ D IXOO GRVH RI ERWK GUXJV RQ GD\ DQG RI
Etoposide on days 2 and 3) every 3 weeks. The number of cycles given depends 
on whether the patient experiences intolerable side effects or toxicity, but the 
aim would be to complete 3-4 cycles before assessing whether there has been a 
response to treatment. If there is a good response radiologically and clinically, a 
total of 6 cycles are given. If there is no improvement, or if there is an increase, 
in the burden of disease, the risks of further chemotherapy are felt to outweigh 
the benefits and no further cycles will be given. Once 6 cycles of chemotherapy 
have been given the patient is usually followed up every 2-3 months for 
evidence of progression of disease. In some cases further cycles of 
chemotherapy are given if the disease progresses.  
7KLV VRUW RI FKHPRWKHUDS\ WUHDWPHQW LV VRPHWLPHV UHIHUUHG WR DV µSDOOLDWLYH¶
because it is not given with the aim of curing the patient. The aim is to reduce 
WKH GLVHDVH EXUGHQ DQG WKHUHIRUH WKH SDWLHQW¶V V\PSWRPV DQG LQ DGGLWLRQ
increase life expectancy. Both limited and extensive stage disease can be treated 
with chemotherapy however patients with extensive stage disease are often 
more frail than those with limited disease and frequently may not tolerate 
aggressive chemotherapy due to poor performance status and multiple co-
morbidities.  
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The results of clinical trials show that median survival can improve to 8-12 
months for people with extensive stage disease, (35-37) and up to 2 years for 
those with limited stage disease, particularly when combined with radiotherapy 
(see below).(35, 38, 39) 
Radiotherapy 
For patients with limited stage SCLC (disease confined to one half of the chest 
without any distant metastases), there is good evidence that radiotherapy 
combined with chemotherapy improves survival when compared with 
chemotherapy alone with estimated median survival between 18 and 24 months. 
(38, 40) In a few cases chemo-radiotherapy can lead to long term survival akin 
to cure, however the risks of toxic side effects (pneumonitis, oesophagitis and 
neutropenic sepsis) are increased when both treatment modalities are used.(41, 
42)  
Radiotherapy can either be given at the same time as chemotherapy (usually 
with the first or second cycle) or after 4-6 cycles of chemotherapy have been 
completed; these are termed concurrent and sequential chemo-radiotherapy 
respectively. Radiotherapy would usually be given every weekday for 3 weeks to 
a total of about 45Gy but the optimal dose and dose per treatment (termed 
fractionation) is still unclear.(43, 44)  There is some evidence to suggest that 
concurrent chemo-radiotherapy confers a small survival advantage over 
sequential chemo-radiotherapy, (38, 45) although the former is associated with 
an increased risk of toxic side effects. Some studies, including one in the UK, 
(46) have failed to show a benefit of early over late radiotherapy, however this 
may be due to inadequate or incomplete chemotherapy doses in some patients 
in these studies. In patients who have good performance status and limited 
stage disease current recommendations are for concurrent chemo-radiotherapy. 
(14, 43, 44)  
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Most of the above evidence is based on studies of patients with limited stage 
disease. Some patients with extensive disease respond very well to 
chemotherapy and in these cases thoracic radiotherapy is considered if there is 
complete response at distant sites and a good response in the thorax.(14) 
Prophylactic cranial irradiation 
Small cell lung cancer grows and spreads rapidly and distant metastases are 
often evident at the time of presentation. Micro-metastases may also be present 
outside the lung in patients who appear to have limited stage disease on 
imaging. For this reason patients whose disease burden is reduced, or does not 
progress, after first-line treatment are offered prophylactic cranial irradiation 
with the aim of preventing or delaying the growth of brain metastases.(14) This 
has been shown to confer an overall survival advantage in patients with 
extensive stage disease, (47) and a reduction in the incidence of brain 
metastases in limited stage SCLC. (48) 
Disease recurrence 
In a few cases of, usually limited stage, SCLC the disease becomes undetectable 
both clinically and radiologically after chemo-radiotherapy, however patients are 
followed up as it usually recurs. There are insufficient data from studies of 
second-line chemotherapy to determine the most effective second-line 
chemotherapy agents, but response is dependent on the response to first-line 
therapy, time interval since finishing first-line treatment, residual toxicity and 
performance status.(43) Symptomatic patients who are unlikely to benefit from 
second-line chemotherapy are considered for palliative radiotherapy.  
1.3.3 Palliative care 
Supportive, symptom based, or palliative care is an important part of the 
management of patients with any cancer, and is particularly important in lung 
cancer given the large number of patients with advanced disease at presentation 
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for which there is no possibility of long term survival. Palliative care involves the 
management of symptoms such as cough, breathlessness, pain and haemoptysis 
and covers a range of interventions such as psychological support for patients 
and their families, local radiotherapy for haemoptysis or bone pain, and 
morphine infusions to alleviate the symptoms of pain or breathlessness at the 
end of life. 
A randomised controlled study of early palliative care in patients with advanced 
lung cancer, published in 2010, showed improvements in quality of life, 
reduction in symptoms and even a survival benefit (11.6 months vs. 8.9 months 
median survival) in patients who received standard oncology care plus early 
palliative care compared with those who only received standard oncology care; 
this was despite fewer patients in the early palliative care group receiving 
aggressive end-of-life care. (49) 
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1.4 Structure of lung cancer care in the UK 
Before discussing inequalities in lung cancer care and survival, and current 
strategies to improve these, I will briefly discuss the organisation of care for 
people with lung cancer in the UK and introduce some terminology which will be 
used later in this thesis when assessing the effects of organisational level factors 
on treatment and outcomes. 
1.4.1 Primary care 
General practice 
All UK residents should be registered with a general practitioner and are entitled 
to free consultations and treatment (with the exception of fees for some 
vaccinations and prescriptions) paid for by the National Health Service (NHS). 
General practitioners (GPs) work in primary care practices; each practice is run 
by one or more GPs who are responsible for a proportion of people in their local 
area. 
Presentation and referral 
General practitioners manage chronic disease and should also be the first point 
of call for non-emergency new presentations. People with symptoms suggestive 
of cancer (of any site) should be referred urgently by their GP to the appropriate 
secondary care service; in the case of suspected lung cancer this is the lung 
cancer multi-disciplinary team (MDT, described below). Since the NHS Cancer 
Plan was published in 2000,(50) there has been a 2-week-wait system whereby 
patients referred with suspected cancer must be seen in secondary care within 2 
weeks of referral.  
This system relies on the ability of the GP to recognise the signs of lung cancer, 
organise the appropriate tests, and make the referral to secondary care. The 
National Institute for Health and Care Excellence (NICE) has produced guidelines 
to assist GPs with recognising and managing these patients and advises either a 
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chest radiograph followed by referral or immediate referral to the lung cancer 
team for certain high risk patients.(14) 
1.4.2 Secondary care 
Trusts 
Secondary care in the UK is provided predominantly by NHS hospital trusts 
VRPHWLPHVWHUPHGµ1+6WUXVWV¶RU µKRVSLWDOWUXVWV¶and is also free to patients 
at the point of access (although a few people pay or have medical insurance 
which pays for them to be seen and/or treated in the private sector). Whereas a 
hospital is generally a single secondary care facility on one physical site, an NHS 
trust is made up of one or more (although usually less than four) hospitals which 
are under the same management and usually in fairly close geographical 
proximity.  
Cancer networks 
From 2000 until the NHS reforms of 2012, NHS trusts were further grouped 
geographically in terms of cancer care into cancer networks. Networks consisted 
of between three and twelve NHS trusts, with the exception of the Welsh cancer 
network which comprised all 17 Welsh trusts. Clinicians representing the trusts 
in each network worked together with local primary care representatives and 
other NHS services to improve performance, facilitate communication and 
engagement around cancer issues, and deliver high quality, integrated cancer 
services for their populations.  
Diagnostic pathway 
Patients are usually referred to the lung cancer team by their GP after presenting 
in primary care with relevant symptoms and often having had a chest 
radiograph. Some patients, however, do not present to their GP and are 
identified from acute hospital admissions, emergency department attendances or 
consultations with consultants in other specialities. These cases are referred 
 35  
directly to the lung cancer MDT without the need for the patient to consult their 
GP.  
The first consultation in secondary care is almost always with a respiratory 
physician. In many trusts a computerised tomography (CT) scan is arranged 
prior to this consultation to expedite the diagnostic pathway. The respiratory 
physician usually arranges diagnostic tests and then the patient is discussed at 
WKHWUXVW¶VOXQJFDQFHU0'7PHHWLQJZKHUHDPDQDJHPHQWSODQLVDJUHHG  
The multi-disciplinary team 
The lung cancer MDT should include one or more respiratory physicians with a 
special interest in lung cancer, a radiologist, histo-pathologist, lung cancer 
clinical nurse specialist, an oncologist who can either offer both radiotherapy and 
chemotherapy, a palliative care physician, a thoracic surgeon, and an MDT 
administrator. The team discusses all cases of lung cancer and agrees 
management plans which are then communicated to patients and implemented 
by the appropriate member of the team. Some patients require repeated 
discussions after additional information or investigations are obtained. 
Availability of services 
Most trusts have respiratory physicians and radiologists at one of their hospitals 
(although not all individual hospitals will have them on-site), however services 
such as thoracic surgery are not available at all trusts. Approximately 32 of the 
162 NHS trusts in England have a thoracic surgery service and therefore the 
thoracic surgical representative on the MDT for the majority of trusts will be 
employed and operate at another trust. The same is true for chemotherapy with 
some trusts referring patients elsewhere for treatment; this means that patients 
may have to travel quite long distances for pre-operative assessments and / or 
treatment. 
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1.5 Survival and inequalities in lung cancer 
1.5.1 Lung cancer survival in the UK 
Over 70% of patients with lung cancer in England present at an advanced stage 
when cure is not possible, and thus the prognosis is poor.(51) English data from 
the ONS show that for people who were diagnosed with lung cancer from 2005 
to 2009 who were followed up until 2010, survival at one-year was 29% for men 
and 33% for women, and just 8% and 9% respectively at five years.(52) Five 
year survival from lung cancer in the UK has not changed substantially over the 
last 20 years. 
Five-year survival from lung cancer is extremely poor compared with other 
common cancers. In the UK, 5-year survival from breast and bowel cancer are 
currently estimated at 85% and 54% respectively which means that although 
lung cancer is only the second most common tumour type overall (excluding 
non-melanoma skin cancer), more people die each year from lung cancer than 
from breast, bowel and prostate cancer put together. 
1.5.2 International differences in survival 
People with lung cancer in other countries in Europe, and North America seem to 
have considerably better 5-year survival than the UK. Coleman and colleagues 
reported age standardised 5-year survival based on UK cancer registries to be 
8.8% for people diagnosed in 2005 to 2007, compared with 18.4% and 17.0% 
from Canadian and Australian registries respectively; the figures for Denmark 
and Norway were more similar to the UK but still higher at 10.9% and 14.4%. 
One-year survival for people diagnosed in the same time period followed a 
similar pattern with  29.7% of the UK lung cancer population surviving a year 
after diagnosis compared with 42.8% in Australia, 43.1% in Canada,  34.9% in 
Denmark and 39.2% in Norway.(53) 
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Reasons for these considerable differences are unclear but possible explanations 
include differences in the way that lung cancer cases and survival statistics are 
reported (i.e. who is included in the case definition), or true differences in 
survival due to earlier diagnosis or more aggressive investigation and treatment 
(for example higher histological verification and resection rates) in these 
countries.(54)   
1.5.3 Inequalities in treatment rates 
Histological confirmation 
Radical treatment is not usually completed without histological confirmation, 
although surgery is sometimes offered without prior histological confirmation 
where there is a high probability of cancer. The few patients who have radical 
treatment without histological confirmation are those treated with radical 
radiotherapy where biopsy is considered to be high risk. A study using the large 
EUROCARE database showed that England had the lowest rate of histological 
verification of lung cancer cases of all the European countries included. (54) It 
has also been shown that histological confirmation rates vary between National 
Health Service (NHS) WUXVWV HYHQ DIWHU DFFRXQWLQJ IRU SDWLHQWV¶ DJH DQG
performance status. (55)  
Whilst some of the difference, particularly for international comparisons, may be 
due to differences in data collection and whether or not the population is 
nationally representative, it is also possible that individual clinician and patient 
attitudes in different institutions as well as potential differences in stage at 
presentation affect how aggressively a tissue diagnosis is pursued. 
Surgical resection rates 
It is estimated that 13.7% of all patients with lung cancer in the UK had surgery 
in 2010.(56) Substantially higher resection rates were reported in other 
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countries including the US (27%) and a region of the Netherlands (20%). A 
study using the EUROCARE database confirmed that the proportion of patients 
receiving surgery was higher in Switzerland, France and The Netherlands, than in 
the UK and Spain. (57-59)  
Once more, this variation could partly be explained by the denominator used by 
each country but resection rates also vary between NHS trusts in the UK (Figure 
1-4). Using the National Lung Cancer Audit (NLCA), Rich and colleagues found 
that people were 51% more likely to have surgery if they were first seen at a 
trust where there was a thoracic surgery service on site, (60) and Brown et al 
reported that people with lung cancer identified from the Southend Lung Cancer 
Registry were more likely to have had treatment (surgery or chemotherapy) if 
they were seen by an accredited chest physician at some point in their diagnostic 
pathway. (61) 
 
Figure 1-4: Proportion of cases of lung cancer resected in 2010 by English cancer 
network (Source: NLCA) 
 
Given the dramatic improvements in survival after surgery for those who are 
eligible (section 1.3.1), an understanding of the reasons for the variation in 
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resection rates and whether any of these are modifiable, is important in the drive 
to improve survival. 
1.6 Current strategies to reduce lung cancer mortality and improve 
survival 
The promotion of smoking cessation remains the most important factor in 
reducing the incidence of lung cancer, and thus the annual mortality burden. 
Strategies have included legislation to control the sales and marketing of tobacco 
products, restrictions on smoking in public areas, and mass media campaigns to 
educate the public on the health risks of smoking. (62) 
Several important initiatives have been developed with the aim of improving 
survival for people with lung cancer. These centre on earlier diagnosis so that 
more people can be treated with curative intent. 
1.6.1 Screening 
The potential benefits of screening for lung cancer are that tumours will be 
detected at an earlier stage when curative treatment is more likely to be 
possible, and when patients are potentially more able to withstand these 
treatments. The disease is a huge public health burden, computerised 
tomography (CT) scanning is a highly sensitive test, and there are several well 
established treatments meaning that lung cancer meets the major criteria for 
screening. (63) The target population would consist of smokers and ex-smokers 
between the ages of approximately 40 and 75. Older patients have not been 
included in screening trials because they are often not suitable for curative 
treatment and thus earlier detection would not confer a benefit; the upper age 
limit is, however, debatable. 
The drawbacks of screening programs are that they are expensive to set up and 
run, and that the necessary radiation from a screening CT scan poses a risk of 
future malignancy for the patient. A CT scan is not specific for lung cancer and 
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benign nodules, infections and other inflammatory processes may be detected in 
the process of screening, which require further investigation and treatment; this 
would add to the costs of a screening program. Some tumours may be very slow 
growing and resection or radiotherapy, particularly in patients with other co-
morbidities, may not actually improve survival. There is also concern that the 
patients who would be likely to attend for screening are not those at highest risk 
of lung cancer. This problem is partly related to the higher incidence of lung 
cancer in more deprived areas, and also to beliefs that it is a self-inflicted 
disease not worthy of treatment, or that treatments are futile.(64, 65)  
A large randomised controlled trial in the US recently reported that CT screening 
was associated with a 20% relative reduction in mortality from lung cancer, and 
a 6.7% reduction in all-cause mortality, when compared with chest x-ray 
screening. (66, 67) A European trial and a pilot study in the UK have been 
performed and are currently in the follow-up stages. (68, 69) 
1.6.2 Early diagnosis initiatives 
Further strategies to increase the proportion of patients eligible for radical 
treatment include increasing public and general practitioner awareness of lung 
cancer. The National Awareness and Early Diagnosis Initiative (NAEDI) was set 
up in 2007 by the Department of Health and Cancer Research UK.(70) The 
project covers interventions across several tumour sites but for lung cancer it 
KDVLQFOXGHGDPDVVPHGLDµWKUHH-week-FRXJK¶FDPSDLJQHQFRXUDJLQJSHRSOHWR
see their general practitioner (GP) if they have had a cough for more than 3 
weeks. Following the intervention there was evidence of an increase in 
unprompted awareness of cough and hoarseness (41% to 50%), and persistent 
cough (12% to 15%), as symptoms of lung cancer in the target audience 
(people over 50 years old from deprived areas). (71) There was also an increase 
of approximately 30% in two week wait referrals for suspected lung cancer in the 
campaign months. The campaign has now been implemented nationwide and 
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changes in stage at presentation before and after the campaign are being 
assessed.  
A large proportion of patients with lung cancer are diagnosed as the result of an 
emergency admission rather than outpatient referral to the lung cancer team, 
and these patients have poorer outcomes. (56) There is therefore pressure on 
GPs to identify people with lung cancer earlier, particularly as survival is better in 
countries who do not have the primary care system where patients have direct 
access to secondary care. (72) Epidemiological analyses have been performed to 
describe the features and presenting symptoms in primary care of patients who 
go on to be diagnosed with lung cancer. (73, 74)  
1.6.3 Identifying and addressing inequalities 
Data collection 
The NLCA collects data on people with lung cancer in the UK and produces an 
annual report so that NHS trusts can compare their rates of investigations and 
treatments with national averages. (56) The audit was set up with the aim of 
improving lung cancer survival and one way in which it aims to do this is by 
reducing inequalities in care through publication of these reports. The NLCA is 
described in detail in Chapter 2.  
The European Initiative for Quality Management in Lung Cancer Care was 
established in 2009 by the European Respiratory Society (ERS) with the aim of 
sustainably improving the quality of care for people with lung cancer in Europe. 
The ERS taskforce have piloted the European Lung Cancer Audit which is an 
international program of data collection to evaluate the provision of lung cancer 
care across Europe and survey the resources available so that inequalities can be 
identified without concern over differences in methods of data collection. (75) 
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Resection rates 
There has been a drive to increase resection rates for NSCLC with particular 
focus on older patients and those with poorer performance status or multiple co-
morbidities who anecdotally had not been offered surgery in the past due to 
concerns that they may be at high risk of perioperative mortality. It is important 
that patients are provided with the best possible estimate of their level of 
surgical risk, and the likely benefits, before a treatment plan is decided. There 
are tools available to assist clinicians with estimating perioperative mortality 
risks and these are discussed in detail in chapter 6; they do, however have 
recognised limitations.  
In the drive to increase resection rates it is also important to understand what 
patients and clinicians think is an acceptable level of risk so that people are not 
denied this potentially life-saving treatment because of concerns that their risk is 
too high. Little work has been done on this to date and this will be discussed 
further in chapter 9. 
Resection rates are slowly but steadily increasing, particularly in older patients, 
and it is predicted that this will save lives in the long term. (76) It is too soon, 
however, to see any clinically significant improvement in lung cancer survival in 
the UK. (77)  
Multi-disciplinary Team performance 
The lung cancer MDT was described in section 1.4. Almost all patients with lung 
cancer in the UK are discussed by a lung cancer MDT before their management 
plan is decided.(51) This in itself is expected to have reduced inequalities in lung 
cancer care compared with the previous system where a single clinician was 
responsible for deciding on a management plan, however variation still exists in 
the quality of MDT management of lung cancer,(51); the way that an MDT is run 
and the opinions of individual decision-makers may contribute to ongoing 
inequalities in investigation and treatment rates and consequently survival. 
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Acknowledging these differences, the National Cancer Peer Review programme 
was set up in 2004 to monitor the quality of cancer services in the UK. The 
programme involves self-assessments by individual MDTs and external reviews 
of teams by professional peers against nationally agreed quality measures (78).  
A further initiative, the Improving Lung Cancer Outcomes Project (ILCOP) was 
set up in 2010 and involved members of MDTs from different institutions visiting 
neighbouring MDTs and providing feedback on how improvements could be made 
(79). This resulted in improvements in quality and efficiency of MDT working at 
the local level by providing individual recommendations for each institution (80). 
 
 44  
1.7 Chapter summary 
In this chapter I have described the main risk factors for lung cancer and how 
changes in the prevalence of smoking have affected lung cancer incidence and 
mortality. I have described the classification, staging and main treatment 
options for lung cancer and in so doing have introduced some medical and 
organisational terminology relevant to lung cancer care specifically in the UK. I 
have also described the effect of common treatments on survival and how 
survival in the UK is poor when compared with other developed countries. I have 
introduced the subject of inequalities in lung cancer care and some current 
strategies to reduce these and improve lung cancer survival in the UK.  
This is now followed by the thesis justification, aims and objectives and an 
outline of subsequent thesis chapters. 
 
1.8 Justification of thesis 
The initial studies in this thesis use primary care data to study the start of the 
OXQJ FDQFHUSDWLHQW¶V MRXUQH\E\ LQYHVWLJDWLQJ ULVN IDFWRUV VSHFLILFDOO\ IRFXVLQJ
on smoking. Knowledge and quantification of the effects of these factors on a 
SHUVRQ¶Vrisk of developing lung cancer are important for identifying people with 
the disease in a timely manner. 
The majority of the work in this thesis follows on from work carried out by Dr 
Anna Rich and published in her MD thesis. (81) Dr Rich validated lung cancer 
cases in the National Lung Cancer Audit (NLCA) database, (82) developed a 
method to measure co-morbidity using linked data from the Hospital Episodes 
Statistics (HES) database, and then used records cases first seen up to the end 
of 2008 to provide evidence of inequalities in access to surgery and 
chemotherapy for people with NSCLC and SCLC respectively. (60, 83)  
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I will use the link between the NLCA and HES to examine and validate records of 
surgical and chemotherapy treatment in each database and determine the most 
accurate definition of each to be used in future studies. I will build on the work 
on surgery in NSCLC by investigating the factors associated with early mortality 
after potentially curative resection with the aim of producing a predictive score 
to aid patient selection in clinical practice. I will also build on the work on SCLC 
by using a more recent (and therefore larger) dataset to look for inequalities in 
chemotherapy treatment between trusts, and take the work on survival further 
by including the number of chemotherapy cycles received in the analysis. 
Further rationale for each study is given at the start of each chapter. 
 
1.9 Thesis objectives 
Using data from The Health Improvement Network (THIN), Hospital Episodes 
Statistics (HES), the National Lung Cancer Audit (NLCA) and the Office for 
National Statistics (ONS) which are anonymous patient databases described in 
detail in Chapter 2, I set out to achieve the following objectives: 
1. Investigate whether sex modifies the effect of quantity of cigarettes 
smoked on lung cancer risk. 
2. Establish whether COPD is an independent risk factor for lung cancer. 
3. Identify risk factors for early death after surgery for NSCLC 
4. Identify factors associated with chemotherapy use in people with SCLC 
and how this affects survival 
As a speciality registrar in respiratory medicine I also aimed to maintain and 
further develop the skills required to manage patients with lung cancer and to 
lead a successful lung cancer service. This includes an in depth knowledge and 
understanding of previous and current research and political influences in the 
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field, and how these influence current policies. This objective was met through a 
series of clinical tutorials, observation of clinical practice, and practical 
experience (Appendix B). 
 
1.10 Outline of thesis sections 
A short description of the work described in each chapter is given below: 
Chapter 2: Description of databases - A description of the sources of 
routinely collected data used for this thesis, the populations studied, definitions 
of common variables, and some generic strengths and limitations of the data. 
Chapter 3: Smoking quantity and lung cancer in men and women ± A 
case-control study using primary care data to establish whether the effect of 
smoking is the same in men and women. 
Chapter 4: Is chronic obstructive pulmonary disease an independent risk 
factor for lung cancer? ± A case-control study using primary care data 
investigating in detail the association between chronic obstructive pulmonary 
disease and lung cancer, accounting for smoking and timing of diagnoses. 
Chapter 5: Validation of records of surgical procedures ± A comparison of 
records of thoracic surgical procedures in two different databases with the aim of 
determining the most appropriate definition of surgery for future studies. 
Chapter 6: Risk factors for early death following surgery for lung cancer 
- A description of risk models in thoracic surgery followed by a study 
investigating factors associated with early death after lung cancer surgery 
resulting in a new predictive model. 
Chapter 7: Validation of records of chemotherapy and radiotherapy - A 
comparison of records of chemotherapy and radiotherapy in two databases with 
the aim of determining the most appropriate definitions for future studies. 
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Chapter 8: Treatment decisions and outcomes in small cell lung cancer ± 
A study investigating factors associated with receipt of chemotherapy and 
completion of a course, and how these factors affected survival. 
Chapter 9: Ongoing research ± A description of ongoing studies which have 
resulted from the work in this thesis including validation of the predictive model 
and a qualitative study exploring attitudes to risk in lung cancer surgery. 
Chapter 10: Summary and suggestions for further research ± A summary 
of all of the studies described in this thesis and some proposals for future 
research. 
 
1.11 Data organisation and statistical methods 
All data organisation and statistical analyses were performed using Stata MP 
Version 11 or 12 (StataCorp, Texas).  
In order to acquire skills of data organisation and analysis I completed the 
following modules which are part of the University of Nottingham Masters in 
Public Health degree course: 
x Research methods in epidemiology and basic statistics ± Self-taught from 
lecture notes August- September 2011 
x Data Organisation and Management in Epidemiology (DOME) ± October 
2011- January 2012 
x Advanced statistical methods ± February- May 2012 
Acknowledgements 
The studies described in chapters 3 and 4 used a case-control dataset from a 
large primary care database. As will be described in chapter 2, section 2.1.3, the 
case-control dataset was extracted from the database prior to the start of my 
research. A smoking variable had been defined by Dr Barbara Iyen-Omofoman 
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during the course of her PhD thesis which I adapted for use in this thesis.(74) I 
used Read code lists for chronic obstructive pulmonary disease, asthma and 
pneumonia which had been compiled previously in the Division of Epidemiology 
and Public Health. I performed all other data organisation and all statistical 
analyses, with assistance from Dr Laila Tata (Associate Professor and PhD 
supervisor - University of Nottingham) and Dr Tricia McKeever (Associate 
Professor ± University of Nottingham) for some of the more complex data 
management in the early stages of my research. 
The studies described in chapters 5 to 8 used a linked dataset which I acquired 
from the Health and Social Care Information Centre by completing a data 
sharing agreement. Dr Anna Rich used an earlier extract of this linked dataset 
for her MD thesis and developed a method of calculating a Charlson co-morbidity 
index and a surrogate start date for people with missing date of diagnosis 
(sections 2.2.5 and 2.3.5). The Charlson index and start date variables used for 
this thesis are based on the code lists and methods used by Dr Rich.(81) Dr Laila 
Tata analyses the NLCA data for the annual reports, (56) and had therefore 
defined stage and histological subtype variables in this database; I adapted 
these for the work in this thesis. I performed all other data organisation and 
statistical analysis. 
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CHAPTER 2: DESCRIPTION OF DATABASES 
In this chapter I describe the sources of routinely collected data which were used 
for this thesis:  
x The Health Improvement Network (THIN) 
x The National Lung Cancer Audit (NLCA) 
x Hospital Episodes Statistics (HES) 
x The Office for National Statistics (ONS)  
This is followed by a description of the populations studied and some of the 
common variables used. I will also discuss some of the generic strengths and 
weaknesses of studies using these data. 
 50 
2.1 The Health Improvement Network (THIN) 
2.1.1 Background 
The system of primary care or general practice in the UK was discussed in 
section 1.4. All general practices in the UK keep computerised patient records to 
facilitate consultations, ensure timely and appropriate follow-up, and for 
evidence of activity for audit and financial purposes. In Practice Systems (InPS) 
provide Vision software which is the interface used by about 2000 general 
practices in the UK to record these data. Doctors, nurses and administrative staff 
record data during their day-to-day interactions with patients, and can also 
upload retrospective data into the patients' records. 
The Health Improvement Network is a research database which was set up 
through collaboration between the Epidemiology and Pharmacology Information 
Core (EPIC) and InPS in 2002. The data held in primary care patient records 
using Vision software are downloaded by EPIC on a monthly basis, and added to 
existing files to create a database which is available to researchers. The data are 
contained in four separate files: patient, medical, therapy and additional health 
data (AHD) as described in Table 2-1.(84)  Each patient has a unique identifier 
to allow linkage of patient, medical, additional health, and therapy data. 
Table 2-1: Description of data files in THIN 
Data file Description 
Patient data 
Demographic information (including date of birth, sex, 
practice registration date and date of death) 
Medical 
Read codes for diagnoses, symptoms, investigations, 
procedures and hospital admissions. 
Additional Health 
Data (AHD) 
Information on lifestyle such as smoking, weight and 
height, and preventative healthcare such as screening.  
Therapy Drug prescriptions 
 
2.1.2 Ethical approval 
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The work in this thesis which used the THIN database received ethical approval 
from the Cegedim Strategic Data Medical Research scientific review committee in 
2009. Individual identifiable information was not available to myself or any of 
the researchers involved in the studies.  
2.1.3 Data extract for this thesis 
The THIN database used to identify cases and controls for the studies in chapters 
3 and 4 was extracted in October 2009 and therefore contains data entered 
between 2002 and 2009. In October 2009, 446 UK general practices contributed 
data to THIN and the database contained records for over 8.2 million people.(84) 
More than 3.2 million of these patients were actively registered and could be 
prospectively followed. 
A lung cancer case-control dataset was created from the October 2009 extract of 
THIN by Mr Chris Smith and Dr Barbara Iyen-Omofoman (Department of 
Epidemiology and Public Health, University of Nottingham) in the course of Dr 
Iyen-2PRIRPDQ¶V3K'SURMHFW(74) Cases were patients who had a diagnosis of 
lung cancer first recorded between 1st January 2000 and 28th July 2009 and at 
least 12 months of prospectively computerised data prior to this cancer diagnosis 
date (i.e. they were actively registered with a GP for at least 12 months before 
diagnosis ± this helped to ensure that they were incident cases).  Controls were 
patients with no evidence of current or past lung cancer and were excluded if 
they had less than 12 months of data before their index date, which was defined 
as the date of lung cancer diagnosis in their matched case. 
The methods for creating this dataset are described in detail in Dr Iyen-
2PRIRPDQ¶V 3K' WKHVLV (74) but the stages prior to my use of the data are 
briefly outlined below: 
 52 
1. Barbara Iyen-Omofoman (BIO) compiled a list of Read codes (Appendix 
C) with which people with lung cancer in THIN could be identified, and confirmed 
these with her PhD supervisors. 
2. Chris Smith (CS) extracted all data on all patients with a read code for 
lung cancer from the entire THIN population. 
3. BIO identified the incident cases of lung cancer and performed several 
data cleaning tasks to ensure that these were true incident cases. This included 
the exclusion of any cases where the date of death or final contribution of data 
was >31 days before the lung cancer diagnosis date.  
4. BIO and CS worked together to identify and extract matched controls. Up 
to four controls were matched to each case on sex, year of birth and the general 
practice with which they were registered. They assigned an index date to each 
control which was equal to the date of diagnosis in the matched case. 
This case-control dataset contained 12,121 incident cases with a first record of 
lung cancer between January 2000 and July 2009. A total of 48,216 controls 
were identified: 11,960 cases were matched with 4 controls, 84 with 3 controls, 
47 with 2 controls and 30 with 1 control. The full dataset contained data on 
60,337 people. 
2.1.4 THIN variables used for this thesis 
The following variables were used for the studies in chapters 3 and 4. Further 
details of specific variables for each of these studies are given with the individual 
methods sections. 
Patient data 
Townsend score is a measure of deprivation and disadvantage (commonly 
terPHGµVRFLRHFRQRPLFVWDWXV¶GHULYHGIURPWKHFHQVXVGDWDDQGEDVHGRQ
levels of unemployment, non-car ownership, non-home ownership and home 
overcrowding.(85) Residential areas are divided in to Lower Super Output Areas 
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(LSOAs) by postcode with approximately 1500 homes in each area; each area is 
linked with a Townsend score for deprivation. For the purpose of these analyses 
Townsend scores were divided into quintiles; quintile 5 is the most deprived and 
quintile 1 represents the least deprived (or most advantaged) quintile of society. 
Age at diagnosis was calculated using the first recorded diagnosis of lung cancer 
DQGWKHSDWLHQW¶VGDWHRIELUWKIRUFRQWUROVWKHDJHDWLQGH[GDWHZDVFDOFXODWHG 
Medical data 
Read codes are a standard classification system used by general practitioners in 
the UK to record patientV¶ medical information. Diagnoses made both in general 
practice and in secondary care are recorded and lists of read codes can be used 
to identify people with a particular diagnosis, symptom or procedure in the THIN 
database. Lists of the Read codes used in this thesis can be found in Appendix C. 
Additional health data 
Smoking status: Read code lists for smoking status, including quantity smoked, 
had previously been developed, and validated within the Division of 
Epidemiology and Public Health at the University of Nottingham. These code lists 
(Appendix C) were used to identify all records of smoking status within each 
SDWLHQW¶V UHFRUGCases and controls were categorised as current, ex, or never-
smokers according to the codes recorded prior to their lung cancer diagnosis or 
index date.  
Smoking quantity: The record of number of cigarettes smoked per day was 
identified using the AHD codes in Appendix C.  Quantity was defined as light (1-9 
cigarettes per day), moderate (10-19 cigarettes per day) or heavy (20 or more 
cigarettes per day). Current or ex-smokers who had no record of their daily 
cigarette consumption were recorded as smokers with unknown quantity and 
WKRVHZLWKQRUHFRUGHGVPRNLQJLQIRUPDWLRQZHUHLQFOXGHGDVµPLVVLQJVPRNLQJ
VWDWXV¶ The highest quantity ever recorded was used, but the most recent 
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quantity (excluding records in the six months prior to lung cancer diagnosis or 
index date so as not to capture potential reductions in quantity smoked due to 
suspicion of lung cancer) was used in sensitivity analyses. 
2.1.5 Strengths & weaknesses 
There are some important strengths and weakness which are common to both of 
the studies based on THIN in this thesis. These are briefly introduced here and 
discussed further in the relevant chapters. 
Sample size 
There were 3.2 million actively registered patients in the October 2009 extract of 
THIN. Studies using THIN to investigate diseases such as lung cancer, which 
have a high incidence in the UK, therefore have the advantage of being able to 
include several thousand cases.  
Unselected population 
All sections of the population are represented in THIN due to the number and 
spread of practices which contribute data. A validation study has been performed 
to assess lung cancer cases in THIN, comparing the incidence and survival with 
data from national cancer registries and the National Lung Cancer Audit. 
Incidence and survival both overall and by sex, age at diagnosis and at death, 
geographical area, and level of socioeconomic deprivation in THIN are 
comparable to data from these other sources, although THIN does appear to 
capture a higher proportion of lung cancer incidence in more recent years (after 
2004). (65) 
Prospective data entry 
Exposure data are recorded prospectively which minimises recall bias. 
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Data completeness 
$ SDWLHQW¶V *3 VKRXOG FR-ordinate all of their medical care and should be 
informed of, and record, everything that affects that patient. A primary care 
database should, therefore, contain codes for all diagnoses for every patient. 
There may, however be times when this does not occur if communication from 
secondary care is not clear, or if administrative staff do not consider information 
to be important. In addition, THIN relies on patients consulting their GP which 
does not always happen and therefore some data are incomplete. 
Following the introduction of the new GP contract and Quality and Outcome 
Framework (QOF) there are financial incentives for GPs to ensure that their 
SDWLHQWV¶HOHFWURQLF records are complete and accurate. This has meant that, for 
example, the vast majority of patients now have their smoking status recorded, 
which is clearly important for studies of lung cancer. There are, however, still 
missing data in areas such as smoking quantity. 
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2.2 The National Lung Cancer Audit (NLCA) 
2.2.1 Background 
The NLCA collects data on people with primary lung cancer from trusts in 
England and Wales (the UK system of NHS hospital trusts was described in 
section 1.4). It was set up by the Royal College of Physicians in 2002 with the 
aim of improving outcomes for people with lung cancer and is currently 
commissioned by the Healthcare Quality Improvement Partnership (HQIP). Data 
are collected and held by the Health and Social Care Information Centre (HSCIC) 
in Leeds. 
Data collection began in 2004 and all NHS trusts in England and Wales, plus a 
few private healthcare trusts, now contribute. Input of data is non-mandatory 
and therefore case ascertainment, particularly in the early years, was not 
complete. In 2004 and 2005 case ascertainment was estimated at 19% and 42% 
respectively, in 2006, 60% of the expected cases were entered and from 2009 
onwards at least 97%.(51) Staff members at each trust have secure access to all 
of their own data through the NLCA website and an annual report is published 
providing trusts with overall figures, with which they can compare and evaluate 
their performance.(51) This encourages clinicians to ensure that their data are 
both accurate and complete. 
2.2.2 Data entry 
Data are usually entered as a result of the first discussion at the lung cancer 
multi-disciplinary team (MDT) meeting (as described in section 1.4) and 
consequently patients who are never seen in secondary care are not captured by 
this database. There is no consistent method by which trusts enter or upload 
data to the NLCA database and it may be done by respiratory physicians, lung 
cancer specialist nurses, lung cancer co-ordinators, specialist audit data 
managers, or administrators depending on the facilities available at each trust. 
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Patient data are entered into an online form which is shown in Appendix D.  The 
intention of the audit team was that Trusts uploaded data during the course of 
WKH SDWLHQW¶V MRXUQH\ WKURugh the lung cancer MDT process, and that a final 
check was performed shortly after treatment was completed, thereby ensuring 
all data were accurate and that any changes to treatment plans were updated. 
Due to time constraints in the NHS many trusts actually enter data in chunks, 
often immediately before the closing date which, for patients first seen in each 
calendar year, is the following June.  
Data entry is never closed so information on new patients can be entered, or 
records of existing patients changed, at any point in time. Information about any 
patient can be entered by more than one NHS Trusts, with the latest entry 
overwriting preceding entries. Whilst changes made after June each year would 
not contribute to the NLCA annual report, they replace previous versions of the 
database and therefore are included in the database used for the studies in this 
thesis.   
2.2.3 Ethical approval 
This is discussed in section 2.3.3. 
2.2.4 Data extracts for this thesis 
The HSCIC does not release NLCA data to researchers until the annual report 
which covers the most recent year of data collection has been published.(51) 
Two extracts of the NLCA database were used for this thesis: The first, which 
was used for the study of surgery in NSCLC (chapters 5 and 6), was extracted in 
August 2011. This raw data file contained records for a total of 156,325 people 
with primary lung cancer or mesothelioma first seen in England between 1st 
January 2004 and 31st December 2010.  
The study of chemotherapy in SCLC (chapters 7 and 8) was undertaken 
approximately one year after the work on surgery by which time a more recent 
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extract of data was available. This was extracted in July 2013 and the raw data 
file contained records for a total of 178,428 people with primary lung cancer or 
mesothelioma first seen in England between 1st January 2004 and 31st December 
2011.  
2.2.5 NLCA Variables used for this thesis 
The NLCA database contains demographic data, dates and modalities of referral, 
diagnosis and treatments, and data on stage, performance status and lung 
function. Limited data on co-morbidity are requested but these fields are not 
mandatory and at present are not reliable. Further details of a few key variables 
are given below with further details in Chapters 5 - 8. 
Patient data 
Townsend score: Lower Super Output Area (LSOA) data are included in the 
NLCA (as in THIN ± see section 2.1.4) and can be used to calculate a Townsend 
score. For the purpose of these analyses Townsend scores were divided into 
quintiles where 5 was the most deprived and 1 the least deprived (or most 
advantaged) quintile of society. 
Lung function is recorded in the NLCA as absolute volume and as percentage of 
predicted forced expiratory volume in 1-second (FEV1). During data cleaning any 
measurements of >150% or <10% predicted were deleted as these were felt 
likely to reflect errors in data entry.  
Performance status is a subjective measure of assess how a disease affects 
the daily living abilities of the patient. It is recorded in the NLCA on a scale of 0 
to 4 as defined by the Eastern Cooperative Oncology Group (Table 2-2), at a 
single point in time; this is usually the day of MDT discussion and therefore 
usually reflects the performance status recorded by the respiratory physician at 
the initial consultation. (86) 
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Table 2-2: Description of Eastern Co-operative Group performance status 
Performance 
status Description 
0 
Fully active, able to carry on all pre-disease performance 
without restriction 
1 
Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry out 
any work activities. Up and about more than 50% of waking 
hours 
3 
Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours 
4 
Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair 
5 Dead 
  
Tumour data 
Stage: The standard NLCA definition of tumour stage considers that post-
treatment (usually post-surgical) records of stage are more accurate than pre-
treatment records and therefore prioritises these records, only using pre-
treatment records when post-treatment stage is missing. For the studies 
described in this thesis, however, pre-operative stage was prioritised over post-
operative stage because the focus here was on the pre-operative plan (i.e. 
surgery with curative intent) and pre-operative estimation of operative risks. If 
pre-treatment stage was missing the post-treatment stage was used to reduce 
the amount of missing data. 
NSCLC stage is recorded in the NLCA according to the Union for International 
Cancer Control (UICC) Tumour Node Metastases (TNM) staging system.(16) In 
2009, after work by the International Association for the Study of Lung Cancer 
(IASLC),(19) the UICC staging system changed slightly and Revision 7 was 
introduced.(16)  During 2010 participating trusts were given the option to enter 
stage using revision 6 or revision 7, with a field indicating which system was 
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used. It is not possible to convert stages recorded using version 6 to version 7 
using the data provided in the NLCA, and therefore for this work the recorded 
stage was used without taking into account which version was used. 
SCLC stage is now recorded using the TNM system as recommended by the 
UICC. In the extracts of the NLCA used for this thesis, however, it was almost 
always recorded using the 9HWHUDQV¶ $GPLQLVWUDWLRQ /XQJ 6WXG\ *URXS system 
(limited or extensive). For any cases where the more recent TNM staging system 
was used this was converted to limited (T1-4, N0-3, M0) or extensive (M1a/b) as 
appropriate.(16)  
Histological subtype: The options for entering histological subtypes (using 
Systematised Nomenclature of Medicine (SNOMed) coding), and the NLCA 
classification of NSCLC, SCLC, carcinoid and mesothelioma are shown in Table 2-
3. The NLCA assumes that patients who do not have a record of pre- or post- 
treatment histology have NSCLC unless an ICD-10 code for mesothelioma is 
recorded elsewhere (it would usually be clear clinically and radiologically that the 
diagnosis was mesothelioma, even without histology). This is because the vast 
majority of cases of lung cancer are NSCLC. It would be unusual not to obtain 
tissue in carcinoid given the good prognosis with treatment, but some cases of 
SCLC which did not have a histological diagnosis may be misclassified as NSCLC 
using this definition. 
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Table 2-3: Systematised Nomenclature for Medicine (SNoMed) codes and 
classification of histology in the NLCA 
SNoMed 
code 
Description NLCA histology 
category 
M8010/2 Carcinoma in situ NSCLC 
M8041/3 Small cell carcinoma SCLC 
M8046/3 Non-small cell carcinoma (includes 
adenosquamous carcinoma) 
NSCLC 
M8070/3 Squamous cell carcinoma NOS NSCLC 
M8140/3 Adenocarcinoma NOS (without 
alveolar cell features) 
NSCLC 
M8250/3 Bronchio-alveolar cell carcinoma NSCLC 
M8012/3 Large cell carcinoma NOS NSCLC 
M8020/3 Large cell ± undifferentiated NSCLC 
M8013/3 Large cell neuroendocrine NSCLC 
M8240/3 Carcinoid tumour NOS (includes 
atypical carcinoid) 
Carcinoid 
M8980/3 Carcinosarcoma NOS NSCLC 
M9050/3 Malignant mesothelioma NOS Mesothelioma 
M9052/3 Mesothelioma (epitheliod) Mesothelioma 
M9051/3 Mesothelioma (sarcomatoid) Mesothelioma 
M8940/3 Mixed tumour (malignant) NSCLC 
M9999/3 Other NSCLC 
 
For patients who had surgery there is often a record of post- as well as pre- 
treatment histology. If pre- and post- treatment histological types differ the 
standard NLCA definition considers that post-treatment histological type is the 
most accurate because this is usually based on a larger sample of tissue. In the 
studies described in this thesis, however, the pre-operative stage was prioritised 
over post-operative, for the same reasons described above for stage. If pre-
treatment histological subtype was missing the post-treatment histology was 
used to reduce the amount of missing data. 
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Dates of diagnosis, investigations and treatment 
Date of diagnosis (start date): For survival analyses the date of diagnosis 
was important, however in some cases this information was missing. Dr Anna 
Rich used the NCLA database for her thesis entitled µ9DOLGDWLRQRI WKH1DWLRQDO
/XQJ&DQFHU$XGLWGDWDEDVHDQGDQDO\VLVRIWKHLQIRUPDWLRQLWFRQWDLQV¶,(81) and 
in the course of this research developed a method of determining a surrogate 
date of diagnosis or start-date for each patient as follows: 
The date of diagnosis was used unless this field was missing. Where date of 
diagnosis was missing it was estimated using one the following dates (in order of 
priority as listed) and the median difference between that date and the date of 
diagnosis in the rest of the initial cohort (shown in brackets): Date of first NHS 
Trust appointment (+5 days), date of referral to the lung cancer team (+18 
days) or date of multi-disciplinary team meeting (-9 days).  
Although the data extracts were different to those used by Dr Rich, the median 
differences between each of the dates listed above were the same. It was not 
possible to calculate a start date for a small proportion of patients; in most of 
the analyses these patients were excluded or a sensitivity analysis excluding 
these records was conducted.  
Investigation and treatments are recorded in various sections of the 
database. For most fields this is just the date of the investigation or the date of 
first treatment, but for some treatments more information is given, e.g. 
procedure type for those who had surgery. This is discussed in much greater 
detail in chapters 5-8. 
Hospital trusts (as described in section 1.4) are identified using standard 
coding. The NLCA identifies the trust where the patient was first seen for lung 
cancer, where the diagnosis was made, and also where any treatment was 
given. The cancer network where a patient was first seen or treated is derived 
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from the trust code. Trusts are grouped into networks as listed in the NLCA 
Annual Report 2012. (51) 
2.2.6 Strengths and weaknesses 
There are some important strengths and weakness which are common to all of 
the studies in this thesis which used the NLCA. These are briefly introduced here 
and discussed further in the relevant chapters. 
Sample size 
The NLCA is the largest, unselected, non-Registry lung cancer database in 
Europe.  
Population  
The NLCA collects data from all of the NHS Trusts in England that provide care to 
people with lung cancer, and is therefore much more comprehensive than other 
similar databases such as the registry linked EUROCARE-4 or the North American 
Surveillance, Epidemiology and End Results (SEER) programme. EUROCARE is a 
European collaboration involving 47 cancer registries from 21 countries 
(including 4 regional registries for England), and SEER represents 26% of the 
overall North American population; both are large datasets which contain 
information on incidence, treatment and survival for all major cancers, including 
but not specific to lung cancer.  (87, 88) 
Work from the University of Nottingham published in 2011 found that cases in 
the NLCA database first seen between 2004 and 2008 were representative of 
patients with lung cancer in England when compared with national cancer 
registry data.(82) 
Data fields 
One of the main advantages of the NLCA over cancer registry data is that, 
although registries capture marginally more cases, the NLCA includes far more 
detail in data fields such as performance status, lung function and treatment.  
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The data on co-morbidity collected by the NLCA are, at present, insufficient for 
studies such as those in this thesis. Fortunately the NLCA database has been 
linked with HES from which a measure of co-morbidity has been derived (see 
below).  
Errors in data entry 
All data in the NLCA database are entered manually, usually by administrative 
staff following an MDT discussion, and it is likely that there will be some errors in 
data entry. Provided these errors are random they are unlikely to affect the 
results of studies such as those reported in this thesis, however large 
proportions of missing data may lead to concerns over the validity of results.  
Changes in patient condition 
As described in section 2.2.1, for each patient data are usually entered into the 
NLCA at a single point in time. Whilst it is possible to change the record an 
unlimited number of times, it is only possible to record a single performance 
status, lung function measurement and stage. The NLCA guidelines state that 
WKLVVKRXOGUHIOHFWWKHSDWLHQW¶VFRQGLWLRQDWWKHWLPHWKH\SDWLHQWDUHILUVWVHHQ
but means that changes in patient fitness are not captured. 
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2.3 Hospital Episodes Statistics (HES) 
2.3.1 Background 
The HES database contains data generated through inpatient admissions to NHS 
hospitals in England. Data collection started in 1989, however data completeness 
was not considered to be of a standard suitable for use in research until about 
1997.  Data are grouped by financial year and every admission is divided into 
episodes (one episode is a single period of care under one consultant). There is one 
row of data for each individual episode and therefore one patient may have 
hundreds of rows of data in just one year.  
Data are collected as a part of the process by which NHS Trusts charge for their 
services but are also used for a range of health services research in the NHS, and 
by the UK government and other organisations.(89). The database consists of 
demographic information, dates of admission, discharge, and procedures, diagnosis 
codes (coded using the International Classification of Diseases revision 10, ICD-10) 
and procedure codes (coded using the Office of Population Censuses and Surveys 
Classification of Interventions and Procedures, OPCS-4).  
There are separate databases for outpatient and A&E attendances which record 
diagnoses and procedures made in these settings. These data were not available at 
the time this work took place therefore only inpatient HES data were used.  
2.3.2 Data extracts for this thesis 
Data from HES are collected in financial years. At the close of each financial year 
certain checks and data cleaning procedures are carried out. The data are not, 
therefore, available to researchers until several months after the end of the 
financial year.  
For the studies used in this thesis, the first HES dataset was extracted in August 
2011 and data were available from 1st April 1997 to 31st March 2010 (inclusive). 
The second HES dataset was extracted in July 2013 and contained HES data for 
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financial years 1997/98 to 2011/12. Data were obtained for all patients who had a 
record in the NLCA database at the time of data extraction, linked as described 
below. 
2.3.3 Linkage with the NLCA database 
Whilst the NLCA does collects some co-morbidity data, the fields are not mandatory 
and at present not felt to be reliable. Prior to the start of this thesis, researchers at 
the University of Nottingham arranged for the HSCIC to link the NLCA database 
with HES data so that co-morbidity data from HES were available to supplement 
the NLCA database for lung cancer research.(81, 83)   
Linkage was performed by the HSCIC using NHS numbers, with additional checks 
using date of birth, sex, postal code. The data are pseudonomised meaning that 
researchers have access to a database identifier which links records in the NLCA 
and HES, but not to individual NHS numbers with which they could identify people. 
2.3.4 Ethical approval 
The work in this thesis using the NLCA-HES linked data was approved by the NLCA 
regulatory body, HQIP.  I completed data-sharing agreements with the Health and 
Social Care Information Centre (HSCIC) allowing me to use the NLCA - HES linked 
data for the purpose of this thesis and the publications arising. For the latest 
extract, local ethics committee approval was also required due to changes in 
procedure at the HSCIC. I therefore obtained approval from the University of 
Nottingham Medical School Ethics Committee to use NLCA-HES linked data for the 
work described in chapters 7 and 8. 
2.3.5 HES variables used for this thesis 
A single row of data in this extract of the HES database included a unique patient 
identifier (used to link to the NLCA database), sex, ethnicity, date of admission to 
and discharge from hospital, episode start and end dates, spell start and end dates 
(a spell is made up of several episodes), up to 20 diagnosis codes per episode, and 
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up to 24 procedure codes. The patient identifier and admission date may be the 
same for several rows of data reflecting multiple episodes in a single spell or 
admission. Additional data are available in HES but were not used for these studies.  
Demographics 
Ethnicity as recorded in HES was used for the studies in chapters 5-8, and was 
categorised as White, Black, Asian, other or missing ethnicity. 
Surgical procedures and chemotherapy 
Since procedures, including thoracic surgery and administration of chemotherapy, 
are recorded in both HES and the NLCA, it was possible examine differences 
between treatment records in order to determine which was likely to be the most 
accurate. This work is the subject of chapters 5 and 7. 
Co-morbidity 
When entering data, coding staff are expected to code the primary diagnosis or 
diagnoses for each episode as well as all significant co-morbidities. These ICD-10 
codes (listed in Appendix E) were used to determine whether or not each patient 
had certain diagnoses so that a Charlson co-morbidity index could be calculated.  
The Charlson index, developed in 1987, gives each of 19 medical conditions a 
weighted score, based on their relative mortality risk, and combines them to give 
the Charlson co-morbidity index (CCI). (90) The 19 medical conditions are listed in 
table 2-4. The CCI has been widely used in research as a marker of co-morbidity as 
it provides a means of taking into account several co-morbidities without assigning 
a different estimate of risk to each individual disease. Modern treatments for HIV 
and AIDS are such that this is longer considered a rapidly fatal illness but for the 
purpose of this work the original index was used as the number of patients with 
lung cancer who also have HIV is negligible. The only modification which was 
QHFHVVDU\ZDVWKHH[FOXVLRQRIOXQJFDQFHUIURPµDQ\WXPRXU¶EHFDXVHDOOSDWLHQWV
had lung cancer. 
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Table 2-4: Charlson co-morbidity index, (90) 
Assigned weights for 
diseases Conditions 
1 
Myocardial infarct 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease  
Diabetes 
2 
Hemiplegia 
Moderate or severe renal disease 
Diabetes with end organ damage 
Any tumour 
Leukaemia 
Lymphoma 
3 Moderate or severe liver disease. 
6 Metastatic solid tumour Acquired Immune Deficiency Syndrome 
Assigned weights for each condition that a patient has. The total equals the 
score. Example: Chronic pulmonary (1) and lymphoma (2) =  total score (3) 
 
2.3.6 Strengths and weaknesses 
There are some important strengths and weakness which are common to all of the 
studies in this thesis which used HES data. These are briefly introduced here and 
discussed further in the relevant chapters. 
Data completeness 
The HES data are predominantly used by secondary care trusts to charge for their 
services. There is therefore an incentive for managers to ensure that the data are 
complete, however it is important to remember that the reason for data collection 
was not the same as that for which it is used in research.  
Data entry 
All data in the HES database are entered manually, by administrative staff, usually 
from medical notes at the end of a hospital episode and as such is subject to errors 
in data entry. The data are, however, audited annually for accuracy.(91) 
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Inpatient data only 
If a patient had never had an admission to hospital prior to the diagnosis of lung 
cancer their CCI would be 0 even though they may have had one or more of the 
diagnoses made by their GP. The original Charlson index was also based on 
secondary care records of disease however this is a potential weakness of using 
inpatient HES data to derive a measure of co-morbidity. 
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2.4 Office for National Statistics 
The Office for National Statistics (ONS) LVWKH8.¶VODUJHVWLQGHSHQGHQWSURGXFHURI
official statistics and the recognised national statistical institute of the UK. Part of 
their remit is to collect information on date and cause of death from civil 
registration records.  
2.4.1 Ethical approval 
In order to use ONS death data for the work in this thesis I completed a data 
sharing agreement and became an ONS approved researcher. 
2.4.2 Data extraction and linkage 
The HSCIC obtained ONS death data for all patients in the NLCA database and 
provided it merged with the NLCA dataset for the August 2011 extract, and as a 
separate file with HES identifiers for the July 2013 extract. The linkage was based 
on NHS number as described above for the NLCA-HES linkage. This was done on 8th 
August 2011 for the first NLCA extract and on 31st March 2013 for the second 
extract. Any patient with missing death date could therefore be assumed to be 
alive, and for survival analyses censored, on this date.   
2.4.3 ONS variables used for this thesis 
The only ONS variable used for this thesis was date of death. 
2.4.4 Strengths and weaknesses 
Follow-up time 
The ONS continually collect death data. Cross reference and linkage to the NLCA 
database using NHS number allows almost continuous follow-up and analysis of 
survival without individual trusts having to collect these data for their own patients. 
Accuracy and completeness 
Death registration in the UK is mandatory and therefore these data are highly 
complete and accurate. For a minority of patients there is a delay between death 
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DQGGHDWKFHUWLILFDWLRQXVXDOO\GXHWRWKHQHHGIRUDFRURQHU¶VLQTXLU\7KLVLVQRWD
common occurrence however it may lead to a few patients being classified as alive 
on the censor date because their death has not yet been registered.  
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2.5 Chapter summary 
In this chapter I have described four sources of data which are routinely collected 
for non-research purposes but which can be used for observational studies of the 
aetiology, treatment and outcomes of lung cancer in the UK. The following two 
chapters describe two studies of risk factors for lung cancer using THIN. Chapters 
5-8 describe the use of NLCA-HES-ONS linked data to study treatments and 
outcomes for people with lung cancer. 
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CHAPTER 3: SMOKING QUANTITY AND LUNG CANCER IN 
MEN AND WOMEN 
This chapter describes the use of a matched lung cancer case-control dataset, 
derived from THIN, to establish whether the association between smoking 
quantity and lung cancer is the same in men and women. 
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3.1 Introduction 
3.1.1 Background 
Lung cancer kills more women than any other cancer and deaths have exceeded 
those from breast cancer for the past 20 years. (92) Whilst lung cancer does 
occur in non-smokers, smoking is by far the most important risk factor, with 
over 80% of all lung cancer attributable to smoking cigarettes. (93, 94) As 
described in chapter 1, smoking prevalence in women increased following the 
end of the Second World War to a peak prevalence of about 40% in Northern 
Europe in the 1980s. Worldwide, at least 250 million women smoke and, 
although in high income countries the prevalence is generally decreasing, in 
some European countries it now exceeds that in men. (7) 
3.1.2 Rationale for this study 
Most studies quantifying smoking-related cancer risks are in men and these have 
been extrapolated to female populations, (3, 95) yet evidence from a recent 
systematic review showed that women who smoke have a 25% greater risk of 
coronary heart disease than male smokers. (96) This relationship has also been 
examined in lung cancer but with conflicting results, (97-102) which may in part 
be due to variation in smoking patterns and prevalence between countries. No 
previous study has assessed the effect in a UK population.  
3.1.3 Aim of this chapter 
The aim of this analysis of THIN was to investigate whether the risk of lung 
cancer differs between men and women with the same recorded quantity of 
cigarettes smoked, and to test the hypothesis that if women are at higher risk of 
the effects of cigarette smoke this may be because they have smaller lung 
volumes than men, and hence a higher dose per lung volume for the same 
number of cigarettes smoked.  
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3.2 Methods 
3.2.1 Dataset & Study Population 
The matched lung cancer case-control dataset, extracted from THIN and 
described in section 2.1.3, was used for this study.  
3.2.2 Definition of Exposures 
Sex was obtained from the patient data file. 
Smoking status and smoking quantity were defined using the additional health 
data file as described in section 2.1.4. Smoking was categorised as: Never, light 
(1-9 cigarettes per day), moderate (10-19 cigarettes per day), heavy (20 or 
more cigarettes per day), smoker with missing quantity, or missing smoking 
status.  
Quantity smoked was defined as the highest quantity ever recorded prior to the 
lung cancer diagnosis or index date. The most recent quantity (but excluding 
records in the six months prior to lung cancer diagnosis or index date so as not 
to capture potential reductions in quantity smoked due to suspicion of lung 
cancer) was used in a sensitivity analysis.  
3.2.3 Covariate definitions 
Townsend quintile, as described in section 2.1.4, was used to define socio-
economic status. Quintile 1 represents the most affluent and quintile 5 the most 
deprived people. 
Height: The tallest height ever recorded for each individual was used as a 
surrogate for lung volume (because height is the predominant determinant of 
total lung capacity, (103)). Height was categorised according to quintile, 1 being 
the shortest and 5 the tallest category, for the population overall (i.e. men and 
women combined). Units are often not recorded in THIN and therefore during 
data cleaning values of height in the range 1.2-2.0 were presumed to be in 
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metres and those in the range 120-200 were presumed to be in centimetres. 
Any values outside this range were assumed to be errors and not used.  
3.2.4 Statistical methods 
For the population overall, and for males and females separately, proportions of 
cases and controls across 10-year age bands, Townsend quintiles, smoking 
quantity, and height quintiles were compared. A conditional logistic regression 
model was used to calculate odds ratios for lung cancer by smoking quantity in 
the dataset overall. A multiplicative test for interaction was then used to assess 
whether the effect of smoking quantity on lung cancer differed between men and 
women; a p value <0.01 was considered statistically significant.  
To test the hypothesis that lung volume (represented by height) explains any 
difference in effect of smoking quantity on lung cancer risk the conditional 
logistic regression model was used to estimate odds ratios for lung cancer by 
height quintile and the interaction was re-assessed in the model which adjusted 
for height.  
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3.3 Results 
The dataset contained information on a total of 60,337 people: 12,121 incident 
cases of lung cancer between January 2000 and July 2009, and 48,216 matched 
controls. Fifty-nine patients (of whom 49% were female) had an age at diagnosis 
of less than 40 years and were excluded, as were their 236 matched controls, 
leaving a total of 60,042 patients for analysis.  
Forty-one per cent of cases were female. Overall, patients had a median of 9.6 
years of data available. A larger proportion of women had never smoked (41% 
compared to 26% of men) and the proportion of heavy smokers was higher in 
men (19% compared to 15% of women) (Table 3-1). Fifty-eight per cent of lung 
cancer cases were in moderate or heavy smokers; this was similar for men and 
women, but a higher proportion of females who developed lung cancer were 
recorded as never smokers (13% compared to 8% of males). The height 
distribution was as expected with the majority of females in quintiles 1-3 and the 
majority of males in quintiles 3-5. There were no differences in age at diagnosis 
between men and women and the distribution of socioeconomic deprivation was 
also very similar. 
The odds of lung cancer were much higher in people who smoked compared with 
those who had never smoked, the odds increasing with quantity of cigarettes 
smoked (for the heaviest smokers the odds ratio (OR) overall was 15.13) (Table 
3-2). The multiplicative test for interaction showed strong evidence of a 
difference in the effect of quantity smoked on lung cancer between men and 
women (likelihood ratio test p<0.0001).  
When compared to men within strata of smoking quantity, the  odds ratios for 
lung cancer in women were 1.02 (95%CI 0.91-1.15) for never smokers, 1.06 
(95% CI 0.92-1.23) for light smokers, 1.32 (95%CI 1.20-1.46) for moderate 
smokers, 1.42 (95% CI 1.31-1.54) for heavy smokers, 0.92 (95%CI 0.84-1.02) 
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for smokers with unknown quantity and 1.25 (95%CI 1.04-1.50) for those with 
missing smoking status.  
3.3.1 Sensitivity analysis 
To investigate the relationship further the same analyses were performed using 
the latest smoking status recorded up to 6 months prior to the index date. The 
results were very similar: in current moderate, current heavy, and ex-heavy 
smokers women had significantly higher odds of lung cancer. For ex-moderate 
smokers the odds ratios were higher for women but this was not statistically 
significant (Table 2). 
3.3.2 Height 
The mean height for the study population was 1.68 metres (m) (standard 
deviation 0.1m); this was the same for cases and controls. In the overall 
population, and also when stratified by sex, the odds ratios for lung cancer were 
not significantly different between the first (shortest) and any other height 
quintile (Table 2). There were no differences in smoking quantity according to 
height quintile for men or women.  The interaction for the effect of smoking 
quantity in men and women remained after adjusting for height (p<0.0001).
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Table 3-1: Quantity smoked, height, Townsend score and age at lung cancer diagnosis for cases and controls overall and by sex 
   OVERALL N=60,042 MALES N=35,481 FEMALES N=24,561 
   Cases (n=12,062) Controls 
(n=47,980) 
TOTAL Cases 
(n=7,143) 
Controls 
(n=28,338) 
TOTAL Cases 
(n=4,919) 
Controls 
(n=19,642) 
TOTAL 
Length of data  Median (years) 9.54  9.56  9.56 9.60  9.64  9.63 9.48  9.47  9.47 
   
n Á n Á Á n %* n %* %* n  n   
Smoking   Never 1,213 10.1 17,976 37.5 32.0 577 8.1 8,655 30.5 26.0 636 12.9 9,321 47.5 40.5 
quantity  Trivial/light 1,030 8.5 3,113 6.5 6.9 640 9.0 1,978 7.0 7.4 390 7.9 1,135 5.8 6.2 
  Moderate 2,465 20.4 4,859 10.1 12.2 1,303 18.2 2,904 10.2 11.9 1,162 23.6 1,955 10.0 12.7 
Heavy / very heavy 4,547 37.7 6,051 12.6 17.7 2,712 38.0 4,102 14.5 19.2 1,835 37.3 1,949 9.9 15.4 
Smoker but unknown quantity 2,285 18.9 10,732 22.4 21.7 1,607 22.5 7,364 26.0 25.3 678 13.8 3,368 17.1 16.5 
Missing smoking status 522 4.3 5,249 10.9 9.6 304 4.3 3,335 11.8 10.3 218 4.4 1,914 9.7 8.7 
Height    2,360 19.6 9,387 19.6 19.6 179 2.5 760 2.7 2.6 2,181 44.3 8,627 43.9 44.0 
(quintiles)  ! 1,826 15.1 7,108 14.8 14.9 563 7.9 2,319 8.2 8.1 1,263 25.7 4,789 24.4 24.6 
Metres 
 ! 2,059 17.1 8,150 17.0 17.0 1,454 20.4 5,571 19.7 19.8 605 12.3 2,579 13.1 13.0 
  ! 2,485 20.6 9,623 20.1 20.2 2,288 32.0 8,827 31.1 31.3 197 4.0 796 4.1 4.0 
  >1.78 1,614 13.4 6,584 13.7 13.7 1,590 22.3 6,473 22.8 22.7 24 0.5 111 0.6 0.5 
  Missing 1,718 14.2 7,128 14.9 14.7 1,069 15.0 4,388 15.5 15.4 649 13.2 2,740 13.9 13.8 
Townsend (least deprived) 1  2,064 17.1 10,779 22.5 21.4 1,289 18.0 6,615 23.3 22.3 775 15.8 4,164 21.2 20.1 
score  2 2,233 18.5 10,262 21.4 20.8 1,366 19.1 6,060 21.4 20.9 867 17.6 4,202 21.4 20.6 
  3 2,420 20.1 9,482 19.8 19.8 1,452 20.3 5,579 19.7 19.8 968 19.7 3,903 19.9 19.8 
  4 2,638 21.9 8,755 18.2 19.0 1,530 21.4 5,061 17.9 18.6 1,108 22.5 3,694 18.8 19.6 
 (most deprived) 5 2,232 18.5 6,748 14.1 15.0 1,237 17.3 3,915 13.8 14.5 995 20.2 2,833 14.4 15.6 
  Missing 475 3.9 1,954 4.1 4.0 269 3.8 1,108 3.9 3.9 206 4.2 846 4.3 4.3 
Age at diagnosis 
or 
40-49 315 2.6 1,260 2.6 2.6 168 2.4 672 2.4 2.4 147 3.0 588 3.0 3.0 
index date  50-59 1,367 11.3 5,467 11.4 11.4 793 11.1 3,172 11.2 11.2 574 11.7 2,295 11.7 11.7 
(matched)  60-69 3,236 26.8 12,934 27.0 26.9 1,951 27.3 7,797 27.5 27.5 1,285 26.1 5,137 26.2 26.1 
  70-79 4,520 37.5 18,011 37.5 37.5 2,738 38.3 10,896 38.5 38.4 1,782 36.2 7,115 36.2 36.2 
   2,624 21.8 10,308 21.5 21.5 1,493 20.9 5,801 20.5 20.6 1,131 23.0 4,507 22.9 23.0 
Á3URSRUWLRQRISRSXODWLRQRYHUDOO3URSRUWLRQRIPDOHVRYHUDOO3URSRUWLRQRIZRPHQRYHUDOO 
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Table 3-2: Odds ratios for lung cancer by quantity smoked (highest and latest recorded) for men and women 
  OVERALL (N=60,042) MALE (n=35,481) FEMALE (n=24,561) 
 
 Odds ratio (OR) Adjusted OR* Odds ratio (OR) Adjusted OR* Odds ratio (OR) Adjusted OR* 
    
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 
Smoking  Never 1.00  1.00  1.00  1.00  1.00  1.00  
quantity Trivial / light 5.79 5.26-6.38 5.83 5.30-6.42 5.61 4.94-6.38 5.67 4.99-6.44 5.75 4.95-6.68 5.78 4.97-6.71 
Highest Moderate 9.37 8.63-10.17 9.43 8.69-10.24 8.24 7.36-9.24 8.34 7.44-9.34 10.78 9.57-12.15 10.82 9.61-12.19 
reported Heavy / very 15.13 14.00-16.35 15.30 14.15-16.54 12.81 11.52-14.24 13.04 11.73-14.50 19.10 16.98-21.49 19.19 17.06-21.29 
Smoker unknown quantity 3.61 3.34-3.91 3.65 3.37-3.95 3.60 3.23-3.99 3.64 3.28-4.05 3.32 2.93-3.75 3.34 2.95-3.78 
 Missing smoking status 1.29 1.15-1.45 0.99 0.88-1.12 1.21 1.04-1.41 0.90 0.76-1.05 1.34 1.13-1.60 1.12 0.92-1.35 
Smoking Never 1.00  1.00  1.00  1.00  1.00  1.00  
quantity Ex light 7.01 6.29-7.82 7.19 6.45-8.02 6.58 5.68-7.61 6.79 5.86-7.85 7.43 6.30-8.77 7.57 6.42-8.93 
Latest Ex moderate 8.76 7.92-9.70 9.00 8.12-9.96 7.77 6.78-8.91 8.06 7.02-9.24 10.07 8.62-1.76 10.22 8.75-11.93 
reported  Ex heavy 10.77 9.73-11.92 11.03 9.96-12.21 9.27 8.14-10.56 9.58 8.41-10.92 13.84 11.68-16.41 13.99 11.80-16.58 
 Current light 9.32 8.48-10.25 9.38 8.53-10.31 8.35 7.35-9.48 8.42 7.41-9.56 10.60 9.18-12.24 10.64 9.21-12.30 
 
Current 11.78 10.79-12.87 11.77 10.77-12.86 10.41 9.21-11.77 10.44 9.23-11.81 13.49 11.87-15.34 13.47 11.85-15.32 
 Current heavy 15.02 13.69-16.48 14.97 13.64-16.43 12.73 11.24-14.41 12.72 11.23-14.41 18.74 16.26-21.60 18.67 16.20-21.52 
Ex / current unknown quantity 3.91 3.62-4.23 3.94 3.65-4.26 3.90 3.52-4.33 3.95 3.56-4.38 3.59 3.18-4.01 3.60 3.19-4.06 
 Missing smoking status 1.30 1.16-1.46 1.01 0.90-1.15 1.22 1.05-1.43 0.92 0.78-1.08 1.36 1.14-1.62 1.14 0.94-1.37 
Height  1.00  1.00  1.00  1.00  1.00  1.00  
quintile ! 1.02 0.95-1.09 1.00 0.92-1.08 1.03 0.86-1.24 0.99 0.81-1.21 1.05 0.97-1.13 1.04 0.95-1.14 
Metres >1.66,   1.00 0.93-1.08 0.96 0.88-1.04 1.11 0.94-1.32 1.07 0.89-1.29 0.93 0.84-1.03 0.91 0.81-1.02 
 ! 1.02 0.94-1.10 1.00 0.92-1.09 1.11 0.94-1.32 1.10 0.91-1.32 0.98 0.83-1.16 1.03 0.85-1.24 
 >1.78 0.97 0.89-1.06 0.97 0.88-1.07 1.05 0.89-1.52 1.07 0.88-1.29 0.85 0.56-1.33 0.72 0.44-4.18 
  Missing 0.94 0.87-1.02 1.55 1.42-1.70 1.02 0.86-1.23 1.80 1.48-2.18 0.93 0.84-1.03 1.38 1.22-1.57 
OR Odds ratio; CI Confidence interval. *ORs by smoking quantity adjusted for height, ORs for height adjusted IRUVPRNLQJTXDQWLW\([FOXGHVUHFRUGVZLWKLQ
months of cancer or index date 
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3.4 Discussion 
3.4.1 Main findings 
The results show a highly significant difference between sexes in the effect of 
quantity of cigarettes smoked on the odds of developing lung cancer: as a result 
RIHYHUKDYLQJVPRNHGKHDYLO\ZRPHQ¶VRGGVRIGHYHORSLQJOXQJFDQFHUDUH
higher than that of men.  There was no evidence of an association between 
height and risk of lung cancer to support the original hypothesis that this 
difference is due to women having smaller lungs and hence a higher dose of 
carcinogen per unit lung volume.  
3.4.2 Strengths & weaknesses 
This study has considerable power with over 12,000 incident cases of lung 
cancer; it is therefore the largest study to address this issue in an unselected 
population and also the first UK study on the subject.  The generic strengths of 
studies which use THIN including prospective data collection, data completeness 
and the validity of lung cancer diagnoses were discussed in section 2.1.5. The 
sex distribution of lung cancer cases in THIN has been compared and found to be 
similar to that of the National Lung Cancer Audit. (82)  
Smoking 
Quantity of cigarettes smoked was defined as the highest quantity ever reported 
by the patient before their lung cancer diagnosis or matched index date for 
controls. This method of measuring smoking quantity will not comprehensively 
UHSUHVHQWWKHYDULDWLRQLQSDWLHQWV¶OLIHWLPHVPRNLQJSDWWHUQVKRZHYHULWenabled 
a smoking history to be obtained for over 90% of the population.   
There have been changes in patterns of smoking over time and more recently it 
appears that women are less likely to smoke heavily but also less likely to stop 
smoking. (8) This was accounted for within the limits of the data by estimating 
odds ratios for lung cancer based on last reported smoking quantity and status 
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prior to index date, and significant differences in risk of lung cancer between 
male and female moderate and heavy smokers were still found. 
Histological subtype 
The use of a general practice database allowed the identification of a large 
number of cases and controls and ensured that smoking data were prospectively 
recorded. However, a weakness of THIN is that there is insufficient information 
to assess whether the interaction demonstrated applies to all histological types 
of lung cancer (coding only identifies lung cancer and not the subtype or stage). 
It is well known that adenocarcinomas are more common than any other 
histological type in non-smokers and therefore the relationship between sex and 
smoking for adenocarcinomas may differ from other tumours. This has been 
examined in some of the previous literature (briefly described in table 3-2) but 
without any firm conclusions. 
3.4.3 Previous research 
A summary of previous research on this subject is given in table 3-3 and some of 
the key studies are summarised below. 
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Table 3-3: Summary of previous research examining the association between smoking and lung cancer in men and women  
Author 
(Population) 
Date 
published 
Study design Main findings  
McDuffie (104) 
(Canada) 1987 
Cross-sectional study of 927 lung cancer cases (21% 
women), diagnosed 1979-83. 
 
Retrospectively collected smoking data by postal 
questionnaire. 
Women developed lung cancer at an earlier age while 
smoking fewer cigarettes and for fewer years than men. 
* 
Brownson (101) 
(United States) 1992 
Registry-based case-control study; 14,596 lung cancer 
cases diagnosed 1984 - 1990. Controls had other, non-
smoking related, cancers. 
 
Prospectively recorded smoking data were extracted 
from hospital records. 
Relative risk of lung cancer associated with ever (vs. never) 
smoking and level of smoking was higher in females than in 
males overall. 
 
For the subgroup of adenocarcinomas there was no 
significant difference in smoking related risk between men 
and women. 
* 
Osann (105) 
(United States) 1993 
Registry based case-control study; 1,986 cases (42% 
female) diagnosed 1984-86. Controls had other, non-
smoking related, cancers. 
 
Prospectively recorded smoking data were extracted 
from medical records. 
Overall, no statistically significant differences in odds of 
lung cancer for men and women comparing former or current 
smokers with never smokers.  
 
Odds of small-cell lung cancer relative to never smokers >2-
fold higher in women than men but wide confidence intervals 
and not statistically significant. 
 
Risch (98) 
(Canada) 1993 
Case-control study; 845 cases (52% female) diagnosed 
1981-85 identified through monthly examination of 
medical records in Toronto hospitals. Controls were 
randomly selected from population listings. 
 
Smoking history collected by retrospective 
questionnaire. 
Significantly stronger association between cigarette 
consumption and lung cancer for females than for males 
(p=0.01). In 40-pack year smokers relative to non-smokers 
odds ratio for lung cancer in women was 27.9 (14.9-52) and 
for men 9.6 (5.64-16.3). 
 
Higher odds ratios for females also seen for all histological 
subgroups. 
* 
Harris (106) 
(United States) 1993 
Case-control study, 4,423 lung cancer cases (34% 
women). Controls were patients with non-tobacco related 
diseases from the same hospitals as the cases. 
In both black and white populations women were at higher 
risk of lung cancer than men for each level of smoking 
compared to baseline never smokers or zero tar consumption. 
* 
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Retrospective smoking data collected by interview using 
structured questionnaire. 
Morabia (107) 
(United States) 1991 
Hospital based case-control study; 1,358 lung cancer 
cases (37% women).  All interviewed between 1985 and 
1990.  
 
Retrospective participant reported smoking data 
collected by interview. 
No significant difference in relative risk of lung cancer 
(assessed in subgroups of four histological types), between 
men and women when compared with the lightest smokers of 
the same sex. 
 
Zang (97) 
(United States) 1996 
Hospital based case-control study, 1,887 lung cancer 
cases (41% female). Controls had non-smoking related 
diseases all admitted 1981 -1984. 
 
Retrospective smoking histories by questionnaire and 
interviews. Ex-smokers were excluded. 
Odds ratios for lung cancer were 1.2 ± 1.7-fold higher in 
women than in men for each level of smoking exposure 
(pack years, and most recent quantity) compared with never 
smokers of the same sex. 
 
Adjustments for height and weight did not alter the results. 
 
* 
Engeland (108) 
(Norway) 1996 
Examined trends in the risk of smoking-associated 
cancers based on registry data comparing 1954-58 with 
1989-93; 1,427 lung cancer cases (23% female). 
 
Smoking data were obtained from clinical records.  
Lung-cancer incidence increased more rapidly, relative to the 
other smoking-associated cancers, in females than in males. 
* 
Prescott (109) 
(Denmark) 1998 
Cohort study, 867 cases of lung cancer (23% female) 
diagnosed between 1967 and 1994. 
 
Participant-reported smoking data collected on entry to 
the study and at several points during follow-up. 
Incidence rate ratios for lung cancer compared with never 
smokers of the same sex, did not differ significantly between 
men and women in for any quantity of cigarettes smoked.   - 
Tulinius (110) 
(Iceland) 1997 
Cohort study. Lung cancer was a subgroup analysis as 
the study investigated all cancers; 472 cases identified 
(42% female) between 1968 and 1995. 
 
Prospective smoking data collected on entry. 
Relative risk of developing lung cancer for all smoking 
quantities, compared to never smokers, was increased 
approximately 2-fold in women compared with men but 
differences were not statistically significant.  
- 
Kreuzer  (102) 
(Germany & Italy) 2000 
Case control study, 4623 lung cancer cases (19% female) 
diagnosed 1988 - 94. Controls were randomly recruited 
from the community. 
 
Lung cancer risk in ever compared with never smokers 
higher in men than women. 
 
Further analysis restricted to smokers and adjusted for 
- 
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Smoking history from retrospective interviews and 
questionnaires. 
quantity and duration found no difference in risk between 
sexes. 
Bain (100) 
(United States) 
 
2004 
Cohort study using two established cohorts one male and 
one female; 1,266 lung cancer cases identified between 
1986 and 2000 (25% female). 
  
Prospective smoking data collected on entry to studies. 
No significant difference in hazard ratio for lung cancer 
between men and women within groups of current smokers 
or former smokers. 
 
- 
Henschke (111) 
(United States) 2006 
Analysis of data from a screening trial: 269 screen ±
detected cases of lung cancer, (58% women) between 
1993 and 2005. 
 
Prospective data on smoking collected on entry to trial. 
After adjusting for age and quantity smoked there was a 
significantly higher risk of lung cancer in women compared 
with men (odds ratio for lung cancer in women compared 
with men 1.7 (95% CI 1.3-2.3) 
* 
Freedman (99) 
(United States) 2008 
Cohort study identified 6,324 cases of lung cancer (35% 
women) between 1996 and 2003.  
 
Prospective smoking data collected by postal 
questionnaire on entry to study. 
In current smokers, the hazard ratio for lung cancer in 
women compared with men, adjusted for smoking quantity 
was 0.9 (0.8-0.9). In former smokers the same hazard ratio 
was 0.9 (0.9-1.0). 
- 
Frueh (112) 
(Switzerland) 2009 
Observational cross-sectional study of 683 lung cancer 
cases (30% women), diagnosed 2004-05.  
 
Smoking history from retrospective analysis of medical 
notes. (Abstract) 
Women with lung cancer were more likely to have smoked 
significantly less than men with lung cancer. 
* 
Ryu (113) 
(Korea) 2011 
Comparison of smoking history between 1,490 men and 
104 women diagnosed with lung cancer between 2001 
and 2009. 
 
Prospective smoking data collected as part of clinical 
care. 
Women with lung cancer had a lower number of pack years 
compared to men. 
 
Women had a significantly higher lung cancer susceptibility 
index compared with men. 
* 
Studies marked * found a statistically significant increased risk of lung cancer in females compared with males per quantity smoked; those marked ± did not  
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Studies which support the present findings 
Previous research into the difference in effect of smoking quantity on 
development of lung cancer in men and women includes a study by Zang et al, 
(97) of 1889 cases (781 of whom were female) in which female smokers had a 
1.2 ± 1.7 fold increase in odds of lung cancer compared with males for all 
histological subtypes. In a larger case-control study using cancer registry data, 
14,596 cases of lung cancer were compared with 36,438 controls who were 
people diagnosed with other types of cancer during the same time period. (101) 
The risk of lung cancer was found to be higher in females at each level of 
smoking, however the authors themselves remark that the validity of their 
results are limited by a finding of differential misclassification for smoking status 
among the smoking associated cancers.  
Studies which contradict the present results 
Bain et al. (100) studied the effect of smoking quantity on lung cancer by 
comparing two separate large previously established cohorts. One of these 
VWXGLHV ZDV WKH 1XUVHV¶ +HDOWK 6WXG\ ZKLFK EHJDQ LQ  DQG XVHG SRVWDO
questionnaires to obtain exposure information on 60,296 women.  The second 
was the 1986 Health Professionals Follow-up Study which also used a postal 
questionnaire sent to male health professionals aged 40-75 years; there were 
25,397 men in the study. Both of these studies were updated by follow-up 
questionnaires every two years providing updated smoking data and information 
on newly diagnosed diseases. On comparing these two cohorts Bain et al found 
1266 incident cases of lung cancer in smokers, having excluded never smokers 
from the study. No significant differences in hazard ratios for lung cancer 
between women and men were found when smokers of <25 cigarettes per day 
were compared with those smoking >25 cigarettes per day who started smoking 
before and after 20 years of age. This contradicts our findings to some extent, 
although we compared odds ratios for a different range of smoking habits, 
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included never smokers as the baseline, and studied a population which was not 
restricted to health professionals; it is difficult to compare rates of smoking in 
these cohorts with those of our population due to the exclusion of never 
smokers. 
A more recent prospective cohort study conducted in the United States, (99) also 
failed to demonstrate a difference in quantity of cigarettes smoked and 
subsequent risk of lung cancer between the sexes. This study used smoking data 
collected by questionnaire in the National Institutes of Health ± American 
Association of Retired Persons Diet and Health Study. Smoking status, history 
and quantity were self-reported on entry to the study by postal questionnaire. Of 
the 3.5 million people to whom the questionnaire was originally posted, only 
17.6% responded, however the questionnaire did include a detailed smoking 
history allowing the authors to account for the effects of changes in smoking 
patterns over time. Again, one of the main differences between the population 
we studied and that of this US study is in selection of participants. The 
respondents who were included by Freedman et al (those who provided complete 
smoking histories) had an approximately 5% higher incidence of never smokers 
in both men and women compared to our population which may reflect selection 
bias in their study or a difference in smoking patterns between people in the US 
and those in the UK. 
The importance of a UK population study is supported by the results of an 
analysis of 31 studies (more than 480,000 individuals) which suggested that 
effects of smoking on risk of lung cancer may differ according to sex and country 
of residence. Hazard ratios for fatal lung cancer in smokers compared to never 
smokers were 2.48 for Asian men and 2.35 for Asian women, but in the Australia 
and New Zealand populations 9.87 (95% CI 6.04-16.12) for men and 19.33 
(95% CI 10-37.3) for women.(114) 
 88  
3.4.4 Explaining the difference 
There are several possible explanations for the difference in lung cancer risk 
observed in men and women. 
Misclassification of smoking status 
It is known that women visit the GP more often than men and from this one 
could extrapolate that men would be more likely to have missing data. This was 
true in this study, with 25% of men and 16% of women being known smokers 
with unknown quantity; however all odds ratios for lung cancer in this category 
were very similar, strongly suggesting that a difference in missing data does not 
explain the results.  
The prevalence of smoking in men and women in these data is comparable to UK 
national surveys, (115) however it is still possible that women under-report their 
smoking quantity during consultations in general practice and that they do this 
to a greater extent than men. This would partly explain the results but it seems 
unlikely that the large and significant differences that we have shown can be 
entirely explained by a difference in reporting between sexes. A higher baseline 
risk of lung cancer in men could also explain the differences observed in this 
study, however at least two previous studies have reported similar baseline risk 
for lung cancer in men and women, (98, 109) and this is supported by the 
finding of the same incidence of lung cancer in never smokers of both sexes 
(6%). 
It was not possible to account for passive smoking as this is often not recorded 
in general practice and it is possible that some of the effect demonstrated 
reflects this.(116) Biomarkers, particularly cotinine, have been used to attempt 
to validate self-reported smoking status. This has revealed misclassification but 
mostly confined to trivial smokers and so does not account for the differences 
seen in moderate and heavy smokers.(117)  
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Lung volume 
Height was used as a surrogate for lung volume, as this is the predominant 
determinant of total lung capacity, (103) and no difference in lung cancer risk 
was found across the height quintiles overall or when stratified by sex. The 
Million Women Study, (118)  assessed the effect of height on risk of all cancers 
in a cohort of middle-aged women between 1996 and 2001. Lung cancer was 
analysed as a subgroup (approximately 6000 female cases) and whilst overall 
they found taller stature to be associated with increased relative risk of cancer, 
for lung cancer they did not find a statistically significant effect.  In 2001 a 
systematic review was published (119) which also found taller people to be more 
at risk of cancer overall; only one  of the ten prospective studies of the effect on 
lung cancer found a statistically significant increase in relative risk with taller 
stature (and it is important to note that this study used self-reported height and 
included just 80 cases). (120) This study addressed this question in a much 
larger population than any of these previous studies and found no evidence that 
height has an important effect on the odds of developing lung cancer in males 
nor in females. Both Bain et al and Zang et al (discussed above) reported that 
height, and for Zang et al body mass index and weight, had no effect on risk of 
lung cancer in their populations. 
Breathing patterns 
An alternative explanation for the study findings is related to evidence that men 
and women have different breathing, and thus smoking, patterns. Perhaps 
carcinogens are deposited in female lungs at a higher concentration because of 
the way they smoke. Ragnarsdottir et al. demonstrated a difference in breathing 
pattern in their study of 100 healthy subjects; whilst during quiet breathing the 
pattern appears similar, during deep breathing women tend to use their 
abdominal muscles less than men and their ratio of inspiration to expiration 
differed. (121) Studies specifically investigating differences in the way people 
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smoke cigarettes,(122, 123)  have found that women tend to have a smaller puff 
volumes and take longer between puffs, resulting in a lower nicotine exposure, 
however this ought to make women less, rather than more, susceptible to lung 
cancer and therefore would not explain most of the study findings.   
Metabolic differences 
Hormonal effects, for example the effects of oestrogens on development lung 
tumours, should be considered as a potential explanation for the results. There 
may be differences in the metabolism of carcinogens and the overall 
susceptibility to lung cancer between men and women, or oestrogens may affect 
tumour growth and type. Women with lung cancer have been shown to have 
better overall survival, (124) this could also be due to a difference in the way 
tumours exposed to oestrogens behave biologically. 
3.4.5 Conclusion 
Women are more likely to develop lung cancer than men who smoke similar 
quantities.  This is not explained by the fact that women have smaller lungs than 
men as there was no effect of height on the odds of having lung cancer. That 
women have a greater risk of developing lung cancer due to smoking should be 
taken into account when estimating risk of lung cancer in the context of early 
referral of symptomatic patients and possibly in lung cancer screening. It is not 
clear why women are more susceptible to smoking and this merits further 
research. 
Smoking prevalence in women increased from about 1945 and although it never 
reached the same peak as in men, did not start to decline until the mid-1970s. 
Lung cancer incidence in women continues to climb gradually and, unlike in men, 
we have not yet seen the peak (Chapter 1, figure 1-2). (5) These results raise 
concern that the trajectory of the disease in women may not follow that of men. 
Whilst we are expecting to see a smoking cessation related decline in lung 
cancer incidence and mortality in women, if women are more susceptible to 
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cigarette smoke we may not see this to the same extent that we have witnessed 
in the male population.  
The findings from this study should draw attention to the previously 
unrecognised direction that the lung cancer epidemic is taking and strongly 
support the call for smoking cessation programs specifically aimed at women. 
(125) Reasons for the increased susceptibility of women to cigarette smoke 
remain unclear but we now have robust evidence for an increased effect of 
quantity of smoking in women in heart disease (96) and, from this study, in lung 
cancer. The impact of smoking in women has, until now, been underestimated. 
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3.5 Chapter summary 
In this chapter I have described the use of THIN data to provide further evidence 
that, for each smoking quantity, women are at higher risk of lung cancer than 
men. These findings are important because projected lung cancer incidence 
figures are based entirely on the male population and may therefore be 
underestimates, and also because in some countries smoking prevalence in 
women continues to increase. This work was published in CHEST in January 
2013.(126) 
In undertaking this study I have developed skills in manipulating and 
interrogating a large database, and acquired knowledge of statistical analyses 
including logistic regression and analyses of interaction. In the next chapter I will 
use the same case-control database to investigate the controversial issue of 
chronic obstructive pulmonary disease as an independent risk factor for lung 
cancer. 
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CHAPTER 4: IS CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE AN INDEPENDENT RISK FACTOR FOR LUNG 
CANCER? 
This chapter describes a second study using the lung cancer case-control dataset 
from THIN. In this chapter I investigate in detail the association between chronic 
obstructive pulmonary disease and lung cancer, specifically focusing on adequate 
adjustment for smoking and the timing of diagnoses of COPD in relation to lung 
cancer. 
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4.1 Introduction 
4.1.1 Background 
Chronic obstructive pulmonary disease (COPD) and lung cancer are two of the 
most important smoking related diseases worldwide, with a huge combined 
mortality burden.(127, 128) Many consider COPD to be an independent risk 
factor for lung cancer, (11, 129) but others argue that they are just 
manifestations of the same exposure. 
4.1.2 Rationale for this study 
Brenner et al recently published a meta-analysis of the relationship between lung 
cancer and prior lung diseases.(11) In all of the 39 studies assessing COPD, 
efforts were made to adjust for smoking. The majority of these studies reported 
that COPD was associated with an increase in risk of lung cancer, the highest 
reported increase being 9-fold,(129) although a few, including one study in 
never smokers, (130) showed reduced risks. The combined relative risk of lung 
cancer in people with a diagnosis of COPD, chronic bronchitis or emphysema, 
compared with people without these diagnoses, was 1.83 (95% confidence 
interval (CI) 1.6-2.11) but the authors reported significant heterogeneity across 
studies particularly in the populations studied and in definitions of COPD.(11)  
When patients with lung cancer first present to a clinician their symptoms may 
be consistent with a new diagnosis of COPD, and may be recorded as such 
before the diagnosis of lung cancer is made. Patients referred to secondary care 
for suspected lung cancer may additionally be investigated for COPD. For this 
reason in studies of COPD and lung cancer there is likely to be strong 
ascertainment bias. Brenner et al were not able to account for this in their meta-
analysis as many studies did not have data on when diagnoses were made.  
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The most likely explanation for the alleged link between COPD and lung cancer is 
airway inflammation, (131) and therefore the effect of asthma on lung cancer 
has also been investigated, with conflicting results.(132-134)  
The identification of new factors which contribute to the aetiology of lung cancer 
are important in identifying patients who will benefit the most from screening, 
smoking cessation and perhaps chemoprevention (some studies have suggested 
that the use of statins may reduce the risk of lung cancer, (135)). If there is 
good evidence of an increased risk of lung cancer using a general practice 
diagnosis of COPD this would be of great benefit to those working in primary 
care who decide whether to refer patients for further investigations. 
4.1.3 Aim of this chapter 
This study used the prospectively collected GP data in THIN to quantify the 
association between COPD and lung cancer in the UK population, whilst 
accounting for smoking and the impact of timing of diagnoses. To assess the 
specificity of any association between COPD and lung cancer other common 
pulmonary diseases (asthma and pneumonia) were also considered.  
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4.2 Methods 
4.2.1 Study population 
This study was based on the lung cancer case control dataset described in 
section 2.1.3; however for this study patients had to contribute data to THIN for 
at least the year leading up to their index date to be included. In the previous 
study (Chapter 3) it was not absolutely necessary for all controls to contribute 
data in the few months prior to their index date, provided they contributed at 
least one year of data in total. In this study, which assessed the risk of lung 
cancer according to history of other respiratory conditions, this was necessary 
because people with each diagnosis were divided into categories according to 
when they were first diagnosed.  
4.2.2 Definition of Exposures 
COPD, pneumonia and asthma  
The main exposures of interest were a history of COPD, asthma, or pneumonia. 
Read codes for COPD, asthma and pneumonia (Appendix C) were used to 
identify patients with these diagnoses before the lung cancer diagnosis or index 
date. Dates of first diagnosis were grouped into diagnostic latency categories: 
within 6 months, between 6 months and 1 year, between 1 year and 5 years, 
between 5 years and 10 years and 10 years or more before the lung cancer 
diagnosis or index date. 
 97 
 
4.2.3 Covariate definitions 
Smoking 
Smoking status and smoking quantity were defined using the additional health 
data file as described in section 2.1.4. Smoking was categorised as: Never, light 
(1-9 cigarettes per day), moderate (10-19 cigarettes per day), heavy (20 or 
more cigarettes per day), smoker with missing quantity, or missing smoking 
status. Where there was more than one smoking record the highest smoking 
quantity recorded before the lung cancer or index date was used. 
Socio-economic status 
Townsend quintile, as described in section 2.1.4, was used to define socio-
economic status. Quintile 1 represents the most affluent and quintile 5 the most 
deprived people. 
COPD severity 
Severity of COPD was represented by the percentage of predicted forced 
expiratory volume in 1 second (FEV1) and grouped as recommended in the 2010 
National Institute for Health and Clinical Excellence (NICE) guidelines for the 
management of COPD in adults. (136) FEV1 >80% of predicted with a read code 
for COPD was classed as mild, 50-80% moderate, 30-50% severe and <30% 
very severe. 
Records of FEV1 were extracted from the database, excluding any 
measurements not recorded in litres or millilitres. The most recent measurement 
was used, excluding measurements taken after, or within 6 months of, the lung 
cancer or index date as these values may represent cancer-induced changes in 
lung function. TKH SDWLHQW¶V DJH DW WKH WLPH of the measurement and height 
record closest to that date were used to calculate predicted FEV1 using the 
equations published by Crapo et al. (137)  
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4.2.4 Statistical methods 
Conditional logistic regression was used to estimate odds ratios of lung cancer 
associated with a prior diagnosis of COPD (overall and by severity), asthma and 
pneumonia, according to the timing of diagnoses. Any changes in effect after 
adjusting for smoking and Townsend quintile were explored.  
To account for any diagnostic uncertainty or overlap between asthma and COPD, 
patients who had records of both were identified and analyses repeated in those 
exclusively with COPD or asthma.  
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4.3 Results 
The initial lung cancer case-control dataset contained information on a total of 
60,337 people: 12,121 incident cases of lung cancer between January 2000 and 
July 2009, and 48,216 matched controls.  Following the exclusion of 10,442 
controls for which data recording ended before the cancer diagnosis or index 
date, it also was necessary to exclude 174 cases for which no controls remained. 
A further 228 patients with age at diagnosis <40 years were excluded and this 
left a total of 11,888 cases and 37,605 controls in the analysis (overall 
N=49,493) with 5,256 cases matched with 4 controls, 4,008 cases with 3 
controls, 1,933 cases with 2 controls and 691 cases with one control. 
Patients had a median of 9.6 years (interquartile range 5.7 - 13.5 years) of 
prospectively recorded general practice data before their index date; cases had a 
median of 9.5 years and controls 9.4 years.  
Fifty-nine per cent of cases were male and the majority (59%) were over 70 
years old at diagnosis. Cases had greater socioeconomic deprivation than 
controls, with 19% of cases being in the highest Townsend quintile compared 
with 14% of controls (Table 4-1). 
People with cancer were more likely to smoke (90% of cases compared with 
61% of controls had ever smoked), and were more likely to have smoked heavily 
(38% and 13% respectively). Smoking status was missing for 4% of cases and 
9% of controls. 
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Table 4-1: Description of cases and controls 
  Cases (11,888) Controls (37,605) 
      n % n % 
Sex (matched)  Female 4,863 40.9 15,639 41.6 
    Male 7,025 59.1 21,966 58.4 
Age at diagnosis   40-49 315 2.6 1,056 2.8 
(years, matched) 50-59 1,366 11.5 4,732 12.6 
  60-69 3,229 27.2 10,946 29.1 
  70-79 4,501 37.9 14,499 38.6 
     2,477 20.8 6,372 16.9 
Townsend quintile 1 (least deprived) 2,037 17.1 8,735 23.2 
  2 2,200 18.5 8,187 21.8 
  3 2,380 20.0 7,420 19.7 
  4 2,609 21.9 6,742 17.9 
  5 (most deprived) 2,196 18.5 5,064 13.5 
    missing 466 3.9 1,457 3.9 
Smoking  Never 1,176 9.9 14,527 38.6 
Highest ever  Trivial / light 1,010 8.5 2,409 6.4 
recorded prior  Moderate 233 2.0 3,788 10.1 
to index date  Heavy / very heavy 4,516 38.0 4,829 12.8 
Smoker  but unknown quantity 2,236 18.8 8,710 23.2 
 Missing smoking status 517 4.3 3,342 8.9 
 
COPD, pneumonia and asthma 
Cases were nearly four times as likely to have had a prior diagnosis of COPD 
overall (23% compared with 6% of controls) and across all diagnostic latency 
categories with the most marked difference in the 6 months prior to lung cancer 
diagnosis (3.4% compared with 0.4% of controls) (Table 4-2 and Figure 4-1).  
The prevalence of pneumonia was also higher in cases than in controls, and 
displayed a similar pattern to that of COPD with more marked differences closer 
to the time of lung cancer diagnosis (Table 4-2 and Figure 4-2). 
Asthma was more prevalent in cases than controls however this was less marked 
than for COPD or pneumonia. There was not a clear peak in asthma diagnoses 
just before lung cancer or index date as there was for COPD or pneumonia 
(Table 4-2 and Figure 4-3). 
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Table 4-2: Prior diagnoses of COPD, pneumonia and asthma in cases and 
controls 
  Cases (11,888) Controls (37,605) 
      n % n % 
COPD  No diagnosis prior to index date 9,131 76.8 35,319 93.9 
Interval between within 6 months 404 3.4 140 0.4 
first diagnosis &   6 months up to 1 year  199 1.7 172 0.5 
index date  1 year up to  5 years 1,033 8.7 947 2.5 
  5 years up to 10 years 690 5.8 580 1.5 
    10 years or more 431 3.6 447 1.2 
Asthma No diagnosis prior to index date 9,893 83.2 33,640 89.5 
Interval between within 6 months 111 0.9 108 0.3 
first diagnosis &   6 months up to 1 year  71 0.6 130 0.3 
index date  1 year up to  5 years 616 5.2 1,093 2.9 
  5 years up to 10 years 620 5.2 1,188 3.2 
    10 years or more 577 4.9 1,446 3.8 
Pneumonia No diagnosis prior to index date 10,819 91.0 36,540 97.2 
Interval between within 6 months 378 3.2 88 0.2 
first diagnosis &   6 months up to 1 year  74 0.6 79 0.2 
index date  1 year up to  5 years 318 2.7 422 1.1 
  5 years up to 10 years 164 1.4 220 0.6 
    10 years or more 135 1.1 256 0.7 
COPD Chronic obstructive pulmonary disease     
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Figure 4-1: Timing of first diagnoses of COPD in cases and controls 
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Figure 4-2: Timing of first diagnoses of pneumonia in cases and controls 
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Figure 4-3: Timing of first diagnoses of asthma in cases and controls 
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4.3.1 Risk factors for lung cancer   
Smoking 
Smoking was strongly associated with lung cancer with odds in the heaviest 
smokers over 15 times those in never smokers (odds ratio (OR) 15.58, 95% CI 
14.35-16.91). The association between socio-economic status (Townsend 
quintile) and lung cancer was confounded by smoking but adjusted odds ratios 
remained significantly increased in the most deprived group compared with the 
least deprived (OR 1.58, 95% CI 1.44-1.73) (Table 4-3). 
COPD 
COPD diagnoses made within 6 months of the index date were associated with 
an 11-fold increase in the odds of lung cancer compared with no prior COPD 
diagnosis, however this was heavily confounded by smoking and the odds ratio 
was 6.81 (95% CI 5.49-8.45) after adjusting for smoking and socio-economic 
status. The timing of diagnosis also had a considerable effect, with the adjusted 
odds ratio falling to 2.18 (95% CI 1.87-2.54) when diagnoses made within 10 
years of the lung cancer or index date were excluded.  
Pneumonia 
A previous diagnosis of pneumonia was associated with increased odds of lung 
cancer with the pattern regarding diagnostic timing similar to that seen in COPD 
(Table 2). There was a very strong association with diagnoses of pneumonia 
made within 6 months of index date (OR 14.91, 95% CI 11.75-18.94) and there 
was evidence of confounding by smoking but to a lesser degree than in COPD 
(adjusted OR for diagnoses within 6 months 13.33, 95% CI 10.24-17.35). There 
remained an association when diagnoses of pneumonia made within 10 years of 
lung cancer or index date were excluded (adjusted OR 1.46, 95% CI 1.15-1.86).  
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Table 4-3: Odds ratios for lung cancer according to patient characteristics and 
previous respiratory diseases 
N=49,493 
11,888 cases and 37,605 controls 
  
Odds ratio (OR) Adjusted OR* 
95% CI 95% CI 
Townsend  1 (least deprived) 1.00  1.00  
quintile 2 1.19 1.11-1.28 1.15 1.06-1.24 
 3 1.48 1.38-1.59 1.28 1.18-1.38 
 4 1.88 1.75-2.03 1.43 1.32-1.55 
 5 (most deprived) 2.26 2.08-2.44 1.58 1.44-1.73 
  Missing 1.65 1.41-1.94 1.20 1.00-1.43 
Smoking Never 1.00  1.00  
Highest ever  Light 6.00 5.42-6.65 5.88 5.31-6.52 
recorded prior Moderate 9.67 8.87-10.54 9.33 8.56-10.18 
to index date Heavy  15.58 14.35-16.91 14.88 13.71-16.16 
 Unknown quantity 3.48 3.20-3.78 3.44 3.17-3.74 
  Missing  1.79 1.59-2.02 1.76 1.56-1.99 
COPD None** 1.00  1.00  
Interval between within 6 months 11.47 9.38-14.02 6.81 5.49-8.45 
first diagnosis &   6 months up to 1 year  4.76 3.85-5.89 2.52 2.00-3.19 
index date 1 year up to  5 years 4.34 3.95-4.78 2.48 2.24-2.75 
 5 years up to 10 years 4.83 4.29-5.44 2.68 2.36-3.05 
  10 years or more 3.74 3.25-4.31 2.18 1.87-2.54 
Asthma None** 1.00  1.00  
Interval between within 6 months 3.63 2.77-4.76 2.92 2.15-3.97 
first diagnosis &   6 months up to 1 year  1.94 1.44-2.60 1.51 1.08-2.12 
index date 1 year up to  5 years 1.91 1.72-2.12 1.65 1.20-1.51 
 5 years up to 10 years 1.83 1.65-2.03 1.43 1.27-1.60 
  10 years or more 1.33 1.20-1.47 1.19 1.06-1.33 
Pneumonia None** 1.00  1.00  
Interval between within 6 months 14.91 11.75-18.94 13.33 10.24-17.35 
first diagnosis &   6 months up to 1 year  3.37 2.42-4.70 2.89 1.99-4.18 
index date 1 year up to  5 years 2.59 2.22-3.02 2.16 1.82-2.57 
 5 years up to 10 years 2.52 2.04-3.10 2.11 1.66-2.67 
  10 years or more 1.68 1.35-2.09 1.46 1.15-1.86 
OR, Odds ratio. CI, confidence interval.   COPD, Chronic obstructive pulmonary disease. 
*Adjusted for smoking & Townsend quintile ± odds ratios by smoking quantity are adjusted for 
Townsend quintile and those by Townsend quintile are adjusted for smoking quantity. ** No 
diagnosis prior to index date.  
Asthma 
The strength of association between a diagnosis of asthma and lung cancer was 
less than that of COPD or pneumonia, but there was still evidence of confounding 
by smoking and an effect of timing of diagnosis. After adjusting for smoking and 
socio-economic status, and when excluding diagnoses made within 10 years of 
lung cancer diagnosis odds of lung cancer were 1.19 (95% CI 1.06-1.33) times 
those in people without asthma. 
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4.3.2 Diagnostic overlap 
Of patients with a prior COPD diagnosis, 40% (60% of cases and 33% of 
controls) also had a diagnosis of asthma, showing considerable diagnostic 
overlap.  The effect of COPD on lung cancer remained after excluding the 
patients who also had asthma, with similar odds ratios to those shown in Table 
4-3 across all diagnostic time windows (Table 4-4).  
Table 4-4: Odds ratios for lung cancer in patients with record of COPD without a 
record of asthma 
N for conditional logistic  
regression =  43,404 
Odds ratio (OR) 
 
Adjusted OR*  
95% CI 95% CI  I 
No COPD diagnosis prior to index date 1.00  1.00  
Interval between within 6 months 14.38 11.16-18.53 7.89 6.03-10.34 
first diagnosis &  
 6 months up to 1 year  4.83 3.69-6.32 2.42 1.80-3.25 
index date 1 year up to  5 years 4.93 4.33-5.61 2.81 2.44-3.23 
 5 years up to 10 years 5.47 4.55-6.58 2.89 2.37-3.53 
  10 years or more 3.96 3.14-4.99 2.23 1.74-2.87 
Excludes 2,395 people with diagnoses of both COPD and asthma recorded   
OR, Odds ratio. CI, confidence interval.   COPD, Chronic obstructive pulmonary disease          
*Adjusted for smoking & Townsend score.  
 
However when the effect of asthma on lung cancer risk was assessed excluding 
people who also had a diagnosis of COPD no independent association was found 
except in the most proximal diagnoses (Table 4-5). 
Table 4-5: Odds of lung cancer in patients with record of asthma without a 
record of COPD 
N for conditional logistic  
regression =  43,404 
Odds ratio (OR) 
 
Adjusted OR*  
95% CI 95% CI   
No asthma diagnosis prior to index date 1.00  1.00  
Interval between within 6 months 3.39 2.37-4.85 3.22 2.11-4.93 
first diagnosis &  
 6 months up to 1 year  1.19 0.76-1.86 1.11 0.66-1.86 
index date 1 year up to  5 years 1.10 0.94-1.29 0.99 0.83-1.19 
 5 years up to 10 years 1.03 0.88-1.20 0.96 0.81-1.14 
  10 years or more 0.74 0.64-0.85 0.78 0.66-0.92 
OR, Odds ratio. CI, confidence interval.   *Adjusted for smoking & Townsend score. 
Excludes 2,395 people with diagnoses of both COPD and asthma recorded   
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4.3.3 COPD severity 
There odds of lung cancer increased significantly with increasing severity of 
COPD (p=0.0221), however it was necessary to exclude over 50% of patients 
with COPD from this analysis due to missing data: Fifty-seven per cent of cases 
and 54% of controls had insufficient data to calculate percentage predicted FEV1 
when measurements taken within 6 months of index date were excluded. The 
adjusted odds of lung cancer for patients with missing lung function data was 
increased compared to all categories of severity suggesting that people with 
more severe disease may be less likely to have their lung function recorded.  
Table 4-6: COPD severity based on records of lung function 
5,043 people had COPD 
but for conditional 
logistic regression 
N=1,183 
  
Cases 
(n=2,757) 
Controls 
(n=2,286) 
Unadjusted 
OR 
Adjusted  
OR* 
n      % n            % 95% CI 95% CI 
FEV1 >80% 60 2.2 84 3.7 1.00  1.00  
 50-80% 499 18.1 467 20.4 1.36 0.68-2.74 1.35 0.66-2.77 
 30-50% 472 17.1 373 16.3 2.09 1.01-4.31 1.94 0.92-4.07 
 <30% 158 5.7 131 5.7 2.24 0.95-5.30 2.21 0.92-5.31 
 Missing 
severity 
1,568 56.9 1,231 53.8 2.94 1.42-6.07 2.92 1.38-6.15 
COPD, chronic obstructive pulmonary disease. OR, odds ratio. CI, confidence interval.  
*Adjusted for smoking  
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4.4 Discussion 
4.4.1 Main findings 
There is a strong association between COPD and lung cancer but this is largely 
explained by the effect of smoking and is most apparent in recently diagnosed 
cases of COPD suggesting a strong element of ascertainment bias. The 
association between pneumonia and lung cancer followed a very similar pattern 
with a strong association for proximal diagnoses and less confounding by 
smoking. The effect of timing of diagnosis of asthma was similar to that 
observed with COPD and pneumonia, however after accounting for smoking, 
diagnostic overlap and ascertainment bias there was no evidence of an 
independent association between asthma and lung cancer. 
4.4.2 Strengths 
The strengths of this study are the large, unselected population on which it is 
based and the prospective recording of data, as discussed in section 2.1.5. Lung 
cancer diagnoses in THIN were found to be valid when compared with national 
registry data, (65) and whilst the validity of a GP diagnosis and recording of 
COPD in general practice data has not been tested to date, previous work has 
shown that demographics and smoking habits of patients with COPD in THIN are 
consistent with those in the UK population confirmed as having the disease. 
(138) Over 90% of people in this study had records of smoking status available 
and smoking prevalence in THIN has been shown to be comparable to that 
predicted by the General Household Survey. (139) In addition the strength of the 
association between smoking and lung cancer in this study was as expected. 
4.4.3 Smoking and ascertainment bias 
Further strengths of this study compared with previous work are that it 
incorporates both prospective recording of smoking data and the close 
examination of the timing of diagnoses of COPD in relation to lung cancer in 
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order to demonstrate the effects of ascertainment bias. These issues are 
discussed below in the context of other studies. 
Smoking 
Adequate adjustment for smoking and particularly for any modification of 
smoking behaviour after the onset of symptoms of lung cancer is difficult, with 
patient reported smoking being the only method by which this exposure can be 
measured.  Retrospective collection of smoking data after the diagnosis of lung 
disease, particularly lung cancer, is subject to recall and reporting bias but even 
in studies such as this one that use prospectively recorded data, paWLHQWV¶
current and past smoking habits, and particularly passive smoke exposure, may 
be inadequately reported or recorded.  
Smoking has a massive effect on lung cancer risk and this is potentially why, 
even after adjusting for smoking habit and relative quantity smoked, results 
from this and other studies still suggest an association between lung cancer and 
other smoking related lung diseases (COPD and to a lesser extent pneumonia) 
but not with asthma (sufferers of which are less likely to be smokers). Residual 
confounding by smoking could also explain the graded increase in risk of lung 
cancer with each level of socioeconomic deprivation in this study and in previous 
research.(140, 141) 
In an attempt to address the problem of adequate adjustment for smoking, 
Turner et al used data from 448,600 individuals who reported to be never 
smokers in the baseline survey of the United States Cancer Prevention Study II, 
which then ascertained cancer deaths over the following 20 years.(142) 
Information on prior lung disease was obtained at baseline from participant self-
reports of doctor diagnoses. Lung cancer mortality was not associated with 
chronic bronchitis, but was with emphysema (hazard ratio (HR) 1.66 (95%CI 
1.06-2.59)) or combined emphysema and chronic bronchitis (HR 2.44 (95% CI 
1.22-4.90). However, of the 1,759 who died from lung cancer, those who initially 
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reported diagnoses of chronic bronchitis, emphysema or both were only 48, 20 
and 8 people respectively.   
A more recent study of women in Hong Kong did not detect an association 
between obstructive lung disease and mortality due to lung cancer in a subgroup 
of never smokers (HR 0.97, p = 0.909) but also had a very small number of 
exposed cases. (143) The use of lung cancer mortality as opposed to incident 
cases is potentially problematic when assessing whether COPD modifies 
susceptibility because those without COPD may be fitter and therefore more 
likely to have life-prolonging surgery or chemotherapy.  
Ascertainment bias 
By studying the timing of COPD diagnosis in relation to lung cancer, it was 
possible to clearly demonstrate the importance of clinical ascertainment bias that 
may result from those with symptoms of lung cancer undergoing more 
investigations and clinical assessment than those without, resulting in a 
diagnosis of COPD in the few weeks or months before the diagnosis of lung 
cancer is made.   
In addition, people with any chronic lung disease, particularly COPD, will be 
monitored with more regular contact and investigations by health professionals, 
providing greater opportunity for a subsequent diagnosis of lung cancer.  We 
know that most people with lung cancer present to health services quite late, 
and therefore it is feasible that the remaining association between lung cancer 
COPD diagnoses made 5 and 10 years prior could be explained by such 
ascertainment. 
Some of the previous studies on this subject did assess diagnostic latency 
periods (summarised in Table 4-7), often in subgroup analyses, but they have 
relatively small numbers compared with the present study.(130, 144) In a 
Chinese study, ORs for lung cancer were 2.9 (95% CI 2.0-4.1) and 1.9 (1.2-3.1) 
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in people diagnosed with COPD 1-5 and 6-10 years before, which are similar to 
the results of this study, however there were only 74 and 32 cases in each of 
these groups.(144) In the study by Turner et al of never smokers, authors 
excluded deaths in the first 5 years follow-up, however as reported above, their 
overall number of exposed cases was very small.(142)  
4.4.4 Limitations  
COPD severity 
Missing data makes the analysis according to COPD severity difficult to interpret 
as over half of all patients with COPD had insufficient data to calculate a 
percentage of predicted FEV1. The adjusted odds of lung cancer for patients with 
missing lung function data (Table 4-5) was increased compared to all categories 
of severity suggesting that people with more severe disease may be less likely to 
have their lung function recorded.  
There was a suggestion that people with more severe disease are more likely to 
develop lung cancer, however it is possible that ascertainment bias also affects 
this result if people with more severe disease are more likely than those with 
mild disease to be admitted to hospital and/or undergo investigations which 
result in the diagnosis of lung cancer. 
Definition of COPD 
Diagnoses of COPD, chronic bronchitis and emphysema may be based on 
symptoms, pulmonary function testing or radiological imaging, and a history of 
COPD may be identified by patient or physician-reported diagnoses, or by 
performing imaging or lung function tests on every participant. 
The use of general practice records to identify prior lung disease in this study 
removed recall bias and any errors due to LQDFFXUDF\LQSDWLHQW¶VSHUFHSWLRQVRU
knowledge of their prior lung disease, however it could be argued that a more 
objective measure of COPD such as airflow obstruction on spirometry or 
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radiographic evidence of emphysema is a more accurate method of defining 
COPD. Table 4-7 shows how definitions of COPD vary widely and that results also 
vary, but not consistently, according to the definition used. 
Additional data fields 
Histological type is not recorded in this general practice database however it 
would have been interesting to investigate whether the findings would have been 
modified by histological subtype given the different associations between 
smoking and squamous or adenocarcinoma. Cancer stage is also not recorded 
and therefore it was not possible to determine whether people with prior lung 
disease were diagnosed at an earlier or later stage than those without. 
Occupation is recorded very infrequently in THIN so it was not possible to assess 
its effect; however two previous studies of benign lung diseases and lung cancer 
risk showed that adjusting for occupation or exposure to dusts or asbestos fibres 
made little difference.(145, 146)  
4.4.5 Summary of previous studies 
Table 4-7 summarises previous studies on COPD and risk of lung cancer, some of 
which have already been discussed. The methods of defining COPD, whether or 
not the authors considered the possibility of ascertainment bias and the way in 
which smoking data were collected are briefly described, as well as the overall 
study design and outcomes.  
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Table 4-7: Summary of previous studies investigating the association between COPD and lung cancer 
Author 
(Population) 
Date 
published Study design Definition of COPD 
Smoking 
data 
Main findings after adjusting for 
smoking 
Considered 
ascertainment bias? 
Tockman (147) 
(North America) 1987 
Cohort of people with airflow 
obstruction (AFO) compared 
with people without AFO 
another cohort. Outcome: lung 
cancer deaths.   
AFO defined as FEV1 
<60% predicted on 
entry to cohort. 
Prospective 
on entry to 
cohort. 
27 lung cancer deaths in AFO group, 
14 in non-AFO group. Relative risk of 
lung cancer death: 2.57 in people with 
AFO compared to fev1>85%. 
 
Chest x-ray performed 
on entry to cohorts 
with aim of excluding 
pre-existing lung 
cancer 
Wu 
Williams(148) 
(Chinese women) 
1990 
Case control study: 965 
female lung cancer cases, and 
959 female general population 
controls. 
Participant reported 
history of chronic 
bronchitis and/or 
emphysema 
Retrospective 
participant 
interviews  
Relative risk of lung cancer 1.4 (95% 
CI 1.2-1.8) in those with COPD 
compared with those without. In 
subgroup analysis effect only in 
squamous cell lung cancers, not in 
adenocarcinomas. 
Yes ± excluded lung 
disease within 3y of 
cancer diagnosis 
Islam (149) 
(United States) 1994 
Lung cancer deaths (n=77) in 
a cohort study. Assessed 
incidence of lung cancer in 
quartiles of baseline FEV1 
Per cent of predicted 
FEV1 measured on 
entry to cohort study 
Prospective 
on entry to 
cohort study 
Among smokers, those in lowest 
quartile of FEV1 had 2.7 times 
increased risk of lung cancer compared 
with highest quartile 
Yes ± patients who 
developed cancer 
within 1 year of entry 
were excluded 
Wu (150) 
(US women) 
 
1995 
Case control study: 412 lung 
cancer cases and 1,253 
population controls 
Participant reported 
physician diagnoses of 
chronic bronchitis or 
emphysema 
Retrospective 
participant 
interviews 
Chronic bronchitis (but not emphysema 
± small numbers) was associated with 
increased risk of lung cancer  (OR 
1.60, 95% CI 1.1±2.4) 
Yes ± But small no.s 
when divided by 
latency category and 
associations no longer 
significant 
Brownson (151) 
(US women) 
 
2000 
Case control study: 676 lung 
cancer cases from cancer 
registry and general 
population controls. 
Participant reported 
physician diagnoses of 
chronic bronchitis or 
emphysema 
Retrospective 
patient 
interview or 
questionnaire 
Increased risk of lung cancer with 
chronic bronchitis (OR 1.7, 95% CI 
1.2-2.3) and emphysema (OR 2.7, 95% 
CI 1.8-4.2). 
Yes - but  when 
proximal diagnoses 
were excluded only 
emphysema was 
significantly associated 
Brenner (144) 
(China) 2001 
Case control study, 886 cases 
and  1,968 controls randomly 
sampled from population 
census list 
Patient reported 
physician diagnosis of 
chronic bronchitis or 
emphysema (COPD) 
Retrospective 
patient 
interview 
Increased risk of lung cancer in people 
with COPD: OR 1.4 (95% CI 1.1-1.8) 
 
Yes ± excluding COPD 
diagnoses  1-5 years 
before lung cancer 
made no difference  
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Kishi (129) 
(US Screening 
trial) 
 
2002 
Case control study: 24 cases 
of lung cancer identified by 
screening. Controls matched 
on smoking history.  
Emphysema on CT and 
FEV1 by spirometry on 
entry to trial. 
Prospectively 
collected at 
interview on 
entry to trial 
OR for lung cancer 9.6 (95% CI 1.5-
60.1) if fev1<40% compared to >80% 
(although other degrees of AFO  not 
significant) 
Yes - Excluded year 1 
of follow-up so all 
cancers diagnosed > 1y 
after COPD / 
emphysema 
Mannino (152) 
(United States) 2003 
1st national health & nutrition 
examination cohort: 113 lung 
cancers occurred in the 5,402 
adults in the cohort. 
Spirometry on entry to 
cohort 
Prospective 
reports on 
entry to study 
Moderate or severe AFO was 
associated with increased risk of lung 
cancer (HR 2.8 (1.8-4.4) 
No ±  cancer diagnoses 
in early follow-up 
period do not seem to 
have been excluded  
Littman (133) 
(United States) 2004 
Analysis of 1,028 cases of 
lung cancer from CARET 
cohort study - all heavy 
smokers or asbestos exposed 
Participant-reported 
physician diagnosis of 
chronic bronchitis or 
emphysema (COPD) 
Prospective 
reports on 
entry to study 
Those who developed lung cancer were 
more likely to report a history of 
COPD than controls (HR 1.29, 95% CI 
1.09-1.53). 
Yes ± made no 
difference to results 
Schabath (146) 
(United States) 2004 
Case control study: 1,553 lung 
cancer cases and 1,375 healthy 
controls 
Patient reported 
physician diagnosis of 
bronchitis or 
emphysema 
Retrospective 
interviews 
Emphysema (but not bronchitis) was 
associated with increased lung cancer 
risk (OR 2.87, 95% CI 2.20-3.76). 
Yes - ORs consistent 
after exclusion of 
diagnoses made up to 
10 years before 
Wasswa-Kintu 
(153) 
(Multiple studies) 
2005 
Systematic review and meta-
analysis of 8 studies of 
relationship between FEV1 
and lung cancer,  
Mixed Mixed Risk of lung cancer increased with 
decreasing FEV1 in 4 studies which 
assessed FEV1 in quintiles. 
Some but not all 
studies excluded initial 
follow-up period. 
De Torres (154) 
(European 
screening trial) 
 
2007 
Analysis of 23 lung cancer 
cases from 1166 participants 
in a screening trial. Current or 
ex-smokers only. 
Radiographic evidence 
of emphysema or AFO 
on spirometry on entry 
to trial 
Prospective 
on entry to 
trial ±  
Emphysema on CT (RR, 2.51; 95% CI, 
1.01 to 6.23) but not AFO (RR, 2.10; 
95% CI, 0.79 to 5.58) was associated 
with increased risk of lung cancer  
Yes ±excluded cancer 
at baseline 
 
Turner (142) 
(United States ± 
never smokers) 
2007 
Analysis of lung cancer 
mortality among the never 
smokers in a previously 
established cohort.  
Participant reported 
previous diagnoses of 
emphysema, chronic 
bronchitis or both. 
Prospective 
reports on 
entry to study.  
1,759 lung cancer deaths. Emphysema 
HR 1.66, chronic bronchitis 0.96 and 
both (COPD) 2.44, compared with 
people without each diagnosis. 
Yes - first 1-5 years of 
follow-up excluded in a 
sensitivity analysis ± 
no effect on results. 
Purdue (145) 
(Sweden - male 
construction 
workers) 
 
2007 
Existing cohort with 834 lung 
cancer cases identified from 
cancer registry. 
Spirometry on entry to 
cohort study to 
determine COPD 
diagnoses and severity 
Prospective, 
reported at 
beginning of 
study 
Increased rates of lung cancer for 
COPD (mild: RR 1.5, 95% CI 1.2 - 1.9; 
moderate/severe: RR 2.2, 95% CI 1.8 
to 2.7) relative to normal lung function. 
 
Yes - associations did 
not change with 
follow-up lag times of 
5, 10 or 15 years after 
spirometry 
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Wilson (155) 
(US screening 
trial) 
2008 
99 lung cancer diagnoses 
identified from screening trial 
which only enrolled high risk 
patients - only smokers or ex-
smokers. 
Quantitative CT 
analysis of emphysema 
and lung function on 
entry to the trial. 
Prospective 
prior to 
screening.  
AFO was associated with increased 
risk of lung cancer (OR  2.09, 95% CI 
1.33-3.27).Emphysema also increased 
risk of lung cancer (OR 3.56, 95% CI 
2.21-5.73) 
Yes ± cases identified 
at initial screen were 
excluded 
 
Yang (156) 
(United States) 2008 
1585 lung cancer case-control 
pairs. Aimed to look at effects 
of alpha 1 antitrypsin 
deficiency (A1AT) 
COPD diagnosis in 
medical notes, most 
also had spirometry to 
confirm 
Medical 
records and 
retrospective 
interview 
COPD was associated with a 3.9 fold 
increase in lung cancer risk. A1AT 
deficiency was also independently 
associated with increased risk of lung 
cancer 
No 
Schwartz (130) 
(US women) 2009 
Case-control study of 562 
women with lung cancer and 
population-based controls. 
Investigated risk of lung 
cancer associated with COPD. 
Participant-reported 
history (obtained after 
lung cancer diagnosis) 
of emphysema, chronic 
bronchitis or COPD 
Retrospective 
patient report  
after lung 
cancer 
diagnosis, 
For combined obstructive lung disease 
OR 1.67 (1.15-2.41). 
Yes - excluded 
diagnoses <1y before 
lung cancer and 
analysed according 
timing of diagnosis 
Kiri (157) 
(United Kingdom) 2010 
Used general practice research 
database to determine trends 
in lung cancer in patients with 
COPD compared with general 
population.  
General practice 
records of COPD 
diagnoses 
No smoking 
data. 
Annual incidence rates of lung cancer 
were at least 4-fold higher in people 
with prior COPD compared with the 
general population 
No  
Maldonado(158) 
(US screening 
trial) 
2010 
Case control study of 64 
screen detected cases of lung 
cancer 6 controls matched per 
case on age, sex and smoking. 
All smokers or ex-smokers. 
Quantitative CT 
analysis of emphysema 
and lung function on 
entry to the trial. 
Prospective 
prior to 
screening.  
AFO was associated with an increase 
in risk of lung cancer (OR 1.15, 95% 
CI 1.00-1.32), but radiographic 
emphysema was not. 
No ± incident cases of 
lung cancer detected at 
first CT screen were 
included 
Brenner (11) 
(Multiple studies) 2011 
Systematic review and meta-
analysis: 39 studies assessed 
effects of COPD, chronic 
bronchitis and/or emphysema 
on lung cancer risk. 
Several different 
methods including lung 
function, participant 
report and emphysema 
on CT 
Mixed Relative risk of lung cancer with a 
previous history of COPD, chronic 
bronchitis or emphysema was 1.8 (95% 
CI 1.60-2.11). 
Fewer than half of the 
studies included 
considered diagnostic 
latency 
Leung (143) 
(Hong Kong - 
women) 
2012 
1,297 lung cancer deaths in 
cohort study of elderly people 
in a health maintenance 
programme. 
Participant reports of 
physician diagnosed 
COPD. 
Prospective, 
reported at 
beginning of 
study 
In the overall analysis, obstructive lung 
disease was associated with lung 
cancer mortality (HR 1.86, p< 0.001) 
but not in never smokers 
Yes ± Potentially 
prevalent cases and 
deaths in initial 3 years 
excluded.  
COPD Chronic Obstructive Pulmonary Disease; AFO Airflow obstruction; FEV1 Forced expiratory volume in 1 second; US United States; CT Computerised tomography 
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4.4.6 Pneumonia and asthma 
Prior diagnoses of pneumonia and asthma were assessed in addition to COPD to 
assess the specificity of these findings in relation to COPD and lung cancer. 
Pneumonia 
The association between pneumonia and lung cancer was even stronger than 
that between COPD and lung cancer for diagnoses made within 6 months. Likely 
explanations for this are ascertainment bias, as described above for COPD, 
reverse causation (lung cancer may lead to airway obstruction and distal 
infection and may also weaken immune response) and initial misdiagnosis 
(symptoms, clinical signs and findings on chest radiograph are often similar). 
For diagnoses made over 10 years before lung cancer the association with 
pneumonia is less marked than with COPD. This is probably because the 
strength of association between smoking and pneumonia is not as strong as with 
COPD, and hence there is less residual confounding, and also because 
pneumonia is usually an acute illness and unless there is co-existing chronic 
disease does not result in on-going follow-up. Brenner et al reported very similar 
results: The combined relative risk of lung cancer in people who had had 
SQHXPRQLD ZDV  WLPHV WKDW RI WKRVH ZKR KDGQ¶W  &, -1.68). 
Twenty-two studies contributed to this analysis and whilst all adjusted for 
smoking many did not account for timing of diagnosis. The combined estimate 
from the 8 studies or subgroups of never smokers was similar to the overall 
figure. 
Asthma 
After removing cases that also had records of COPD, adjusting for smoking, and 
accounting for ascertainment bias, there was no evidence of an association 
between diagnoses of asthma and lung cancer in this study. This is consistent 
with some of the previous literature.(133, 159) This suggests that the link may 
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be limited to smoking related diseases (COPD and pneumonia) and further 
supports the hypothesis that the remaining association could be due to residual 
confounding by smoking. Based on these results it seems less likely that airway 
inflammation explains the increase in risk of lung cancer in people with COPD 
since airway inflammation is a prominent feature in asthma.  
The finding of an association between proximal diagnoses of asthma and lung 
cancer suggests that ascertainment bias is not limited to the smoking related 
diseases and should be taken into account when considering whether any 
apparent association is causal. This may be part of the reason that some 
previous studies have reported an independent association between asthma and 
lung cancer.(132)  
4.4.7 Clinical relevance 
Despite the huge element of confounding in many of the initial studies which 
suggested COPD was an independent risk factor for lung cancer, biological 
studies are underway looking for evidence of a molecular link between the two 
diseases which could cause people with COPD to be at even higher risk of lung 
cancer than those who smoke exactly the same amount. (160) These data 
suggest, however, that the association between COPD or pneumonia and lung 
cancer is largely due to confounding by smoking and ascertainment bias.  
There is an extremely strong unadjusted relationship between both COPD and 
pneumonia and lung cancer in the 6 months immediately prior to lung cancer 
diagnosis. This is useful in a clinical context with potential implications for 
patient selection in screening trials: this could facilitate recruitment of heavy 
smokers who are unwilling to admit their smoking status or patients for whom 
smoking data are unavailable or inaccurate, yet are at high risk of developing 
lung cancer. These results also support the current National Institute for Health 
and Clinical Excellence recommendation that all patients should have a chest 
radiograph looking for evidence of lung cancer at the time of COPD diagnosis 
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(136), and to reduce the disease burden, resources should probably remain 
focused on smoking cessation, novel therapies and early detection of lung 
cancer. 
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4.5 Chapter summary 
In this chapter I have presented evidence of the strong association between 
COPD and lung cancer, but argued that this can probably all be explained by 
smoking and ascertainment bias. It is important that the scientific community 
consider this explanation for the apparent independent association between 
COPD and lung cancer so that resources in lung cancer can be appropriately 
allocated to evidence based interventions.  
This work was published in the Journal of Thoracic Oncology in January 
2013.(161) The interpretation of the data presented in this chapter and in the 
published work is that of myself and my co-authors (including my PhD 
supervisors), and not everyone will agree, as demonstrated by the 
correspondence to the journal following publication of our article.(162) 
The studies in this and the previous chapter used primary care data to 
investigate factors which affect lung cancer prior to diagnosis. Diagnosis for 
patients in England occurs in secondary care and therefore the next four 
chapters use the linked HES-NLCA-ONS secondary care data to investigate 
factors which influence treatment and outcomes for people with lung cancer.  
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CHAPTER 5: VALIDATION OF RECORDS OF SURGICAL 
PROCEDURES 
This chapter describes a validation study in which records of potentially curative 
thoracic surgical procedures in the HES and NLCA databases are compared, with 
the aim of determining the most appropriate definition of surgery for future 
studies. The chapter concludes with a description of some of the features of 
patients who had surgery for lung cancer and their survival, and a comparison 
with other published data. 
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5.1 Introduction  
5.1.1 Background 
The National Lung Cancer Audit (NLCA) has collected data on people with lung 
cancer in England since 2004 and contains information on demographics, 
diagnoses and treatments. These data have been used to provide evidence of 
inequalities in access to treatments, (60, 83) however the accuracy of treatment 
records in the NLCA, in particular whether a missing treatment date truly 
represents no treatment, has not been assessed. 
The NLCA data were linked with inpatient admission data from Hospital Episodes 
Statistics (HES) for the initial purpose of assessing co-morbidity (as described in 
Section 2.3.3). Since the HES database also includes a code for every surgical 
procedure which takes place during an inpatient episode these can be compared 
with NLCA treatment records and patient features and outcomes can be analysed 
in order to assess the validity of treatment records in each database.  
5.1.2 Rationale for this study 
The case ascertainment and completeness of individual data fields in NLCA has 
improved substantially in the last few years and the database is now a valuable 
resource for epidemiological studies in lung cancer. It is important to determine 
the most accurate means of identifying exposures so that studies are consistent 
in their methods and are not affected by errors in data entry or recording bias. 
In Chapter 6 I will describe a study in which factors associated with early 
mortality after surgery for lung cancer were explored and a new predictive score 
was developed. It was important to be confident that all cases included in that 
study underwent potentially curative surgery for lung cancer, hence the work 
presented in this chapter. 
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5.1.3 Aims of this chapter 
The aim of the study described in this chapter was to assess the validity of 
records of potentially curative surgical procedures for NSCLC in the HES and 
NLCA datasets in order to agree a definition of surgery for future studies. This 
was done by:  
1. Identifying patients with NSCLC who had a surgical procedure recorded in 
the NLCA, or in the linked HES data, or in both; 
2. Examining and comparing the features of these patients (including 
survival) according to where surgery was recorded; 
3. Describing the features of patients who had potentially curative surgery 
for NSCLC using the new definition and comparing these to the published 
literature. 
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5.2 Records of surgery in HES and the NLCA 
5.2.1 Methods 
Study population 
The August 2011 NLCA-HES data extract was used (see section 2.2.4) but 
patients in the NLCA who were first seen after 31st March 2010 were excluded 
because HES data were not available after this date. Patients first seen prior to 
2004 were also excluded. Cases of NSCLC were identified by excluding records 
where there was a clinical or histological diagnosis of mesothelioma or where 
histology was recorded as SCLC or carcinoid.  
Patients with evidence of advanced disease (stage 3b or 4) were excluded to 
ensure as far as possible that the cases analysed had undergone surgery with 
curative intent.  
Survival was assessed from the date of diagnosis or the start-date where this 
was missing (as described in section 2.2.5). Patients for whom a start-date could 
not be calculated and those with a date of death on or before their start-date 
were therefore also excluded. 
Covariates 
Stage, histology, lung function, performance status and socio-economic status 
(Townsend quintile) were defined as described in section 2.2.5.  
Age refers to the NLCA variable age at time of diagnosis. Age and per cent of 
predicted FEV1 were studied as continuous variables, performance status was 
grouped as 0-1, 2, 3-4 or missing and stage as 1a - 1b, 2a - 2b, 3a or missing. 
HES records of surgery 
Surgical procedures are recorded in HES using OPCS-4 codes. Each of these 
codes is associated with an inpatient episode and the specific date of procedure 
is also recorded.  
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A list of OPCS-4 codes which, in a patient with a recent diagnosis of lung cancer, 
would be likely to represent an attempt at curative surgery was generated: two 
respiratory physicians (HP & Prof David Baldwin) independently rated a list of all 
thoracic surgical procedures before agreeing on the final code list which is given 
in Appendix E. This code list was merged with the HES database to identify every 
record which contained a relevant procedure. Procedures were categorised as 
pneumonectomy (highest priority), bi-lobectomy, lobectomy, segmentectomy / 
sleeve / wedge or other (lowest priority). 
It was possible at this stage for an individual case to have more than one line of 
data, indicating that the patient underwent a procedure which would be 
consistent with lung cancer surgery on more than one occasion (possibly during 
more than one hospital episode). This situation could arise if a patient developed 
complications and required a further surgical procedure, or if they had 
undergone thoracic surgery prior to the diagnosis of lung cancer for a different 
indication. In an attempt to ensure that HES procedures were only included if 
they were for the current NLCA diagnosis of lung cancer, that they were 
performed with curative intent, and to exclude obvious errors in data entry, 
procedures performed more than 3 months before or more than 6 months after 
the NLCA start-date were not included.  
If there were still multiple procedures for one patient the most complicated 
procedure type (highest priority as defined above) was used, followed by the 
procedure with the latest date. 
NLCA records of surgery 
Within the NLCA dataset there are four fields relating to surgery:  
x the date that the decision to operate was made,  
x the type of surgical procedure,  
x the actual date of the procedure, and  
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x the trust where the procedure was carried out.  
Date of decision to operate is not as useful as the other fields in this context as a 
decision to operate does not necessarily mean an operation took place; this 
analysis therefore focused on the remaining three variables. One might expect 
all four data fields to be complete for all patients who had a surgical procedure 
however this is not always the case because, as with any large dataset, data 
may be missing or contain errors. In addition, if the treatment plan changed for 
any reason the fields should be updated but it is possible that busy clinicians or 
administrators do not have time to keep track of changes and / or update the 
database in some cases.  
The 14 different codes used by the NLCA to define type of procedure are given in 
Appendix E. For this study, extra-pleural pneumonectomy, de-bulking 
pneumonectomy, and pleurodesis were excluded as these do not represent 
potentially curative surgery for NSCLC. In records which had a code for one of 
these procedures the three fields of interest (type of surgical procedure, date of 
procedure, and trust where the procedure was carried out) were re-coded to 
missing. 
Dates 
HES records were only available up to March 31st 2010, and any procedures 
recorded in HES which were performed more than 3 months before or 6 months 
after the lung cancer diagnosis date were excluded (see above). Procedures 
recorded in the NLCA which were dated outside these time periods were also 
excluded to allow fair comparison (the procedure date, type and trust were re-
coded to missing). 
The entire record for any patient with a procedure (in either dataset) dated 
before January 1st 2004 or after March 31st 2010 was dropped from the analysis 
for this comparison study (re-coding these as missing as described above would 
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mean they were included in group 5 (see below) when in fact they may have had 
potentially curative surgery before or after the study period.  
Definition of outcome 
The ONS date of death (described in section 2.4) was used for survival analyses, 
patients who were still alive at the last ONS cross-check (8th August 2011) were 
censored on this date.  
Statistical methods 
Following the exclusions and re-coding described above, patients who had non-
missing values in the fields relating to surgery in each dataset were identified 
and grouped as shown in Table 5-1. A Venn diagram was constructed to show 
the overlap between these groups. 
Table 5-1: Criteria for groups which indicate where records of surgery were 
identified 
Group Criteria 
1=Both Date of surgery in HES  
AND  
Date of surgery in NLCA 
1a Date of surgery in HES  
AND  
Procedure type in NLCA 
NO date of surgery in NLCA 
1b Date of surgery in HES  
AND  
Trust of surgery in NLCA 
NO procedure type in NLCA 
NO date of surgery in NLCA 
2=HES only Date of surgery in HES 
NO reference to surgery in NLCA 
3=NLCA only (date) Date of surgery in NLCA 
NO reference to surgery in HES 
4=NLCA only (procedure type or 
trust) 
Procedure type and/ or trust of surgery in NLCA 
NO date of surgery in NLCA 
NO reference to surgery in HES 
5=Neither NO reference to surgery in either database 
  
  
The features (age, stage, lung function, performance status, year of surgery, 
survival after diagnosis and 30- and 90- day post-operative mortality) of patients 
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in each of the groups were examined to identify any patterns. A Kaplan Meier 
survival curve was constructed to compare the overall survival of people in each 
of the groups in table 5-1. 
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5.2.2 Results 
There were 133,689 patients in the NLCA database first seen between 1st 
January 2004 and 31st March 2010. After excluding 6,875 cases of mesothelioma 
and 13,553 histologically confirmed cases of small cell lung cancer or carcinoid, 
the remaining 113,261 cases were classified as NSCLC.  
From the NSCLC population, 46,013 cases with advanced stage and 5,328 for 
whom a start date could not be calculated or was after the recorded date of 
death were excluded, as well as 945 with a procedure date outside the period of 
study. This left 60,975 records for the analysis. 
HES records of surgery 
There were 11,040 records which contained at least one of the OPCS-4 codes 
listed in Appendix E, dated between 1st 2004 and March 31st 2010, and less than 
3 months before / 6 months after the NLCA start date. The distribution of 
procedure types is shown in table 5-2. 
Table 5-2: Distribution of procedure types as recorded in HES 
Procedure category Frequency Percentage 
Pneumonectomy 1105 10.0 
Bi-lobectomy 453 4.0 
Lobectomy 7095 64.3 
Segmentectomy or wedge 1661 15.0 
Other 738 6.7 
 
NLCA records of surgery  
There were 9,373 records with a procedure date in the NLCA within 3 months 
before or 6 months after the start date, and between 1st 2004 and March 31st 
2010. A further 75 records had a procedure type but no date, and 1,862 a trust 
of surgery but no procedure date or type.  
Procedure types for those with a procedure date are shown in Table 5-3. In 16% 
(1,472) of these cases there was a procedure date recorded but the procedure 
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type field was blank. This is likely to be the reason that all other categories 
represent a slightly lower proportion of the total number of procedures when 
compared with the distribution in HES (Table 5-2). 
Table 5-3: Distribution of procedure types recorded in NLCA 
Procedure category Frequency Percentage 
Pneumonectomy 756 8.1 
Bi-lobectomy 215 2.2 
Lobectomy 5,766 61.5 
Wedge resection 854 9.1 
Lung & chest wall resection 63 0.7 
Multiple wedges 46 0.5 
Sleeve resection 64 0.7 
Segmental resection 130 1.4 
Carinal resection 7 0.1 
Missing 1,472 15.7 
 
Comparison of databases 
Procedure dates were recorded in both databases for 8,965 patients. Figure 5-1 
shows the number of patients who had records of surgery in each group as 
defined in Table 5-1. 
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Figure 5-1: Records of procedures in HES and NLCA databases 
 
The overlap between the records of surgical procedures in the databases is 
shown in the Venn diagram (Figure 5-2). 
       
Percentages indicate proportion of overall population, N=60,975 
 
Figure 5-2: Venn diagram depicting the overlap between records of surgical 
procedures in HES and the NLCA 
Group 2: 
HES only 
2,091 (3.4%) 
Group 1: Both 8,949 
(14.7%) 
8,524 procedure dates in 
both 
55 HES date, NLCA 
procedure type (Group 1a) 
370 HES date, NLCA trust 
only (Group 1b) 
Groups 3:     
NLCA only  
849 (1.4%) 
 (Date +/- type & 
trust) 
Group 4:  NLCA only 
1,512 (2.5%) 
Group 5: Neither 
47,574 (78.0%) 
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Patient features 
Features of patients in each of the groups are shown in table 5-4. Due to small 
numbers in groups 1a (n=55) and 1b (n=370) these were included with group 1. 
The mean age of patients in groups 1-3 (who had a procedure date recorded in 
at least one database) was similar; patients in groups 4 and 5 were a few years 
older on average (Table 5-4). Patients with procedure dates recorded in both 
databases had better lung function than those with procedures recorded in one 
database only; lung function was considerably worse in those without a 
procedure date in either database. Performance status was also better in those 
who had a procedure recorded in both databases than any other group. A higher 
proportion of patients in groups 2 and 3 had a performance status of >1 (15% 
and 14% respectively) compared with group 1 (8%). 
Patients with a date of surgery in the NLCA had fewer missing data on 
performance status, stage, and lung function than the other groups. It should be 
noted that these are all NLCA data fields. 
Overall survival 
Overall survival was longest in people who had a record of surgery in both 
databases (median 60 months / 5 years), followed by those with a record in HES 
(42 months) and those with a procedure date in the NLCA (20 months). The 
Kaplan Meier survival curve for all 5 groups is shown in Figure 5-3. 
Overall, the features of patients in group 4 (procedure type or trust recorded in 
NLCA only) were similar to those of the people in group 5 (no record of surgery 
in either database). Survival was poor in both of these groups (median 6.7 and 
9.5 months from diagnosis respectively). 
Perioperative mortality 
Early post-operative mortality was higher in the NLCA only (group 3: 5% 30-day 
mortality) and HES only (group 2: 5% 30-day mortality) compared with the 
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group where procedures were recorded in both databases (group 1: 3% 30-day 
mortality). The proportion of people who appeared to have died within 90-days 
of a procedure date was extremely high for those with a procedure recorded in 
the NLCA only (16% compared with 5% for group 1 and 9% for group 2). 
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Table 5-4: Characteristics of patients according to where surgical procedures were recorded  
N=60,975 Record of surgical procedure 
 Group 1 
Both 
Group 2 
HES only 
Group 3 
NLCA only 
(date) 
Group 4 
NLCA only 
(no date) 
Group 5 
Neither 
 
n=8,949 n=2,091 n=849 n=1,512 n=47,574 
Mean age (years) 67.4 66.8 67.7 70.3 72.6 
Mean % predicted FEV1 77.2 73.8 74.5 63.7 68.3 
Missing FEV1 (% of total) 55.1 79.6 67.7 81.7 83.5 
Stage (% of non-missing) 1a or 1b 66.3 57.0 60.3 44.9 35.7 
2a or 2b 22.3 21.9 20.8 22.6 19.5 
3a 11.4 21.1 18.9 32.4 44.8 
Missing stage (% of total) 15.7 63.7 49.0 77.8 72.5 
Performance status (% of non-missing) 0-1 92.4 84.6 85.7 71.0 47.6 
2 6.3 11.2 9.2 17.4 24.3 
3-4 1.3 4.2 5.1 11.6 28.1 
Missing performance status (% of total) 29.0 61.1 37.3 62.8 49.4 
Median survival (months)* 60.1 41.6 19.6 6.7 9.5 
**Died within 30-days of surgery (%) 2.7 4.6 5.4 - - 
**Died within 90-days of surgery (%) 5.4 9.1 15.6 - - 
*Survival is calculated from start date not date of procedure;FEV1 Forced expiratory Volume in 1 second; **Date of procedure as recorded in 
HES unless NLCA only 
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Figure 5-3: Kaplan Meier curve to show survival according to where surgery was 
recorded 
 
Procedure records by year 
Between 2004 and 2009 the proportion of patients with any record of surgery 
that had this recorded in both databases increased from 59% to 86% (Table 5-
5). Over the same time period the proportion with a record in HES only 
decreased (33% to 9%) but the proportion with a record in the NLCA varied 
between 5% (2009) and 9% (2007) without a clear pattern. 
The proportion with surgery recorded in both databases (group 1) decreased 
between 2009 and 2010 and the proportion in the NLCA only increased to 13%. 
(Table 5-5). This is likely to be because HES data entry stopped on 31st March 
2010 and therefore may not be complete for procedures which took place shortly 
before this date, whereas NLCA data could be entered retrospectively after this 
date. 
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 Table 5-5: Records of procedures in the NLCA and HES by year 
Year (number of 
patients with any 
record of surgery) 
% recorded in 
both datasets 
(Group 1) 
% recorded in 
HES only 
(Group 2) 
% recorded in 
NLCA only 
(Group 3) 
2004 (n=459) 59.0 32.5 8.5 
2005 (n=1301) 61.0 32.7 6.2 
2006 (n=1721) 71.2 21.2 7.6 
2007 (n=2076) 69.5 21.5 9.0 
2008 (n=2410) 78.6 15.2 6.3 
2009 (n=3080) 86.3 8.8 4.9 
2010 (n=842) 78.7 8.2 13.1 
 
5.2.3 Interpretation 
NLCA only 
The methods of data entry in HES and the NLCA differ, as described in Chapter 
2. With this knowledge it was hypothesised that patients who had a record of a 
potentially curative surgical procedure in the NLCA but not in HES may not 
actually have had surgery. This may have been because their performance 
status deteriorated, the patient changed their mind, or new information became 
available showing the tumour to be technically inoperable after the initial 
treatment plan was made. In these situations it is possible that the NLCA record 
was not updated.  
This hypothesis is supported by the observation that patients who only had a 
record of surgery in the NLCA and not in HES had considerably shorter survival 
(median 543 days) compared with those who had surgery recorded in both 
datasets (median 1839 days).  
The analysis of 30-, 60- and 90-day post-operative mortality in these groups 
VKRZV SDWLHQWV LQ WKH µ1/&$ RQO\¶ JURXS WR EH PRUH OLNHO\ WR GLH ZLWKLQ DOO RI
these time periods but the greatest difference is evident within 90 days where 
16.7% of patients with surgery recorded in the NLCA only died compared with 
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5.5% of those with surgery recorded in both datasets. This may indicate that 
some of these patients deteriorated rapidly and were too unwell to have surgery.  
HES only 
In contrast to the NLCA, HES codes were entered at the end of each hospital 
episode and were required for NHS trusts to bill the Primary Care Trust for the 
services they provide. For this reason it was felt that a procedure code in HES 
was likely to indicate that the procedure did actually take place. Figure 5-3 
shows that 2,371 patients had a procedure recorded in HES but not in the NLCA. 
The 30- (and 90-) day mortality is higher in this group of patients, and the 
median survival is lower, than in the group for whom surgery is recorded in both 
datasets, however to a lesser degree than the NLCA only group. This may be 
because these patients were not expected to have surgery initially as they were 
considered borderline in terms of fitness and stage of tumour, and the NLCA 
database was not updated with this new information. This hypothesis is 
supported by the observation that the HES only group of patients were more 
likely to be performance status 2 or worse and stage 3a than those with a 
surgical procedure recorded in both databases (Table 5-4). 
NLCA trust or procedure type only 
The features of patients who only had a procedure type or trust of surgery 
recorded in the NLCA (no date in the NLCA and no reference to surgery in HES) 
were very similar to those of patients with no reference to surgery in either 
database. It is reasonable to conclude therefore that these patients did not have 
surgery. 
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5.2.4 Conclusion 
Given the above observations, the definition of a surgical procedure was 
restricted to those recorded in HES (list of OPCS-4 procedure codes in Appendix 
E). Using this definition we can be most confident that these patients met the 
study criteria, however there may be other patients who also had potentially 
curative thoracic surgery for NSCLC in the study period, not captured by this 
definition; we expect this number to be low given the high level of case 
ascertainment of the NLCA and the incentives for recording procedures in HES.  
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5.3 Description of patients who had surgery and comparison with 
published data 
5.3.1 Methods 
Study population 
The lung cancer population for this study was similar to that described in section 
5.2. Patients with NSCLC first seen between January 1st 2004 and March 31st 
2010 were identified using the NLCA database. In addition to those with 
advanced disease (stage 3b or 4), patients with an ICD-10 code in HES for 
metastatic disease which occurred prior to the procedure date were excluded. 
People with an age at diagnosis <30 were also excluded. 
Definition of exposure 
After the detailed analysis of records of surgical procedures in both databases, 
(described in section 5.2), the decision was made to define surgery for this 
analysis as a surgical procedure code which was:  
1. recorded in HES; 
2. in the list of OPCS-4 procedure codes consistent with potentially curative 
surgery for lung cancer (Appendix E); 
3. dated within 3 months before and less than 6 months after the NLCA start 
date. 
Patients were included in this analysis if they had a record of surgery by the 
above definition which occurred between 1st January 2004 and 31st March 2010. 
Procedure type and date 
The date and type of procedure were obtained from the HES database. If an 
individual patient had more than one appropriate procedure coded in HES (with 
either the same or different dates) the code for the highest priority procedure 
type and then the most recent date was used.  
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Where surgery was also recorded in the NLCA, the difference between the dates 
was calculated: if this was more than 10 days the patient was excluded from the 
analysis. 
Demographics, co-morbidity and tumour features 
All demographic data fields, histological subtypes, lung function, performance 
status and stage were obtained from the NLCA. Further information on these 
variables can be found in section 2.2.5. 
Statistical methods 
Demographic variables, patient fitness (performance status and lung function), 
tumour stage and procedure type were described using averages, histograms, 
proportions and simple tabulations as appropriate. 
Kaplan Meier curves were plotted for the first year after the date of operation by 
age, stage, performance status and procedure type, and for the 5 years after 
surgery for the population overall and by stage. Date of death was obtained from 
ONS records and any record without a date of death was assumed to be alive at 
the last ONS cross-check and censored on this date (8th August 2011). These 
graphs were used to assist in determining the most appropriate time points at 
which to report risk factors for early post-operative death (Chapter 6).  
Demographics, overall survival, and survival by stage were compared with 
previously published international data. 
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5.3.2 Results 
These results describe 10,991 patients who underwent potentially curative 
surgery for NSCLC between 1st January 2004 and 31st March 2010. The process 
of determining the study population is shown in figure 5-4.  
 
 
Figure 5-4: Process diagram for producing study population 
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Demographics 
The majority (56%) of the patients were male and the mean age was 67 years, 
standard deviation 9.3 years.  
Fitness 
The most common performance status was 0 (31%), although performance 
status was not recorded in 38% of cases. Only 108 patients had a performance 
status of 3-4.  The mean percentage of predicted FEV1 was 77%, SD 20.8%, 
(figure 5.6) but FEV1 was not recorded for 61% of patients. 
 
Figure 5-5: Distribution of lung function in patients who underwent surgery 
 
Tumour features 
Stage 1b was the most common stage (28%), although 26% did not have a pre-
or post-operative stage recorded. The most common histological types were 
adenocarcinoma (31%) and squamous cell (28%); 21% did not have a record of 
pre or post-operative histology.  
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Procedure type 
Most patients had a lobectomy (64%) and only 11% had a pneumonectomy.  
Early post-operative mortality 
Three per cent (334) of patients died within 30 days of their procedure.  
The Kaplan Meier survival curves for the first 6 months post-operatively by age, 
stage, performance status and procedure type (figures 5-6 to 5-9) showed the 
rate of death to be slightly higher up to 90 days after surgery, but then more or 
less constant over the following 9 months (note altered scale on y-axes to show 
subtle differences in rate of deaths). This will be discussed further in the 
following chapter, section 6.3.2. 
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Figure 5-6: Kaplan Meier survival curve by age for first year after surgery 
 
Figure 5-7: Kaplan Meier survival curve by stage for first year after surgery 
0.
74
1.
00
0 30 60 90 120 150 180 210 240 270 300 330 360
Time after surgery (days)
<65 years 65-80 years
>80 years
Kaplan-Meier survival estimates
0.
75
1.
00
0 30 60 90 120 150 180 210 240 270 300 330 360
Time after surgery (days)
Stage IA-IB Stage IIA-IIB
Stage IIIA
Kaplan-Meier survival estimates
 145  
 
 
Figure 5-8: Kaplan Meier survival curve by performance status for first year after 
surgery 
 
Figure 5-9: Kaplan Meier survival curve by procedure for first year after surgery 
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Long term survival 
Overall 1-year and 5-year survival were 83% and 48% (figure 5-10).  
 
Figure 5-10: Survival after surgery for population overall 
 
Five-year survival by stage is shown in table 5-6 and figure 5-11 (stage 2A was 
excluded from the figure because the survival curve overlapped almost entirely 
with stage 1B). The stage recorded was pre-operative unless this was missing 
from the NLCA database in which case post-operative stage was used. 
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Table 5-6: 1 and 5 year survival after surgery by stage 
Stage Proportion alive 
1 year after surgery 5 years after surgery 
IA 91% 60% 
IB 85% 51% 
IIA 86% 50% 
IIB 79% 43% 
IIIA 75% 34% 
Missing 79% 43% 
 
 
 
Figure 5-11: Survival after surgery by stage 
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5.3.3 Comparison with previously published data 
The largest contemporary published series of operated lung NSCLC comes from 
the International Association for the Study of Lung Cancer (IASLC) staging 
studies.(19) This work resulted in the re-classification of the lung cancer TNM 
staging system from UICC version 6 (as used in this study) to version 7 based 
on 5 year survival after treatment.(16) Survival for stage Ia was better in the 
IASLC study than in the current study (73% vs. 60%), but worse for stage IIIa, 
with similar figures for other stages (Table 5-7). These differences are likely to 
be due to differences in the definition of staging: Pre-operative (clinical stage) 
was predominantly used in the current study whereas pathological (post-
operative) stage was used the IASLC project. Pre-operative stage is likely to 
under-stage a proportion of patients. There may also be differences in 
populations studied: Australasia, North America and other countries in Europe 
contributed cases to the IASLC project and we know that survival from lung 
cancer in these countries is different to the UK, possibly due to differences in 
selection of patients and surgical techniques.(53, 72) 
A further publication described some of the features of the surgically resected 
patients with NSCLC from the IASLC database revealing a slightly higher 
proportion of men than in the current study. This is consistent with other reports 
(Table 5-7) and is likely to reflect the years in which the studies were conducted 
(lung cancer incidence in males has been falling since the 1980s as described in 
Chapter 1).(163) 
A few other published series of operated lung cancer which included 1- or 5-year 
survival figures are summarised in table 5-7. These studies were based on 
analyses of consecutive patients who underwent lung cancer resection at single 
institutions and are therefore much smaller than the current study. Nonetheless, 
the survival figures are reasonably similar. 
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Table 5-7: Patient features and survival from published series of operated NSCLC 
 Current study Roth             
(164) 
Van der Pijl 
(165) 
Brim             
(166) 
IASLC           
(19, 163) 
Al Kattan     
(167) 
Country England Norway Holland Holland Multi-national England 
Dates 2004-2010 1993-2006 2002-06 1989-2001 1990-2000 1987-88 
Cases 10,991 148 126 766 9,137 200 
Males 56% 68% 69% 78% 74% 71% 
Age (mean) 67 67 63 65 - 64 
Pneumonectomy 10% - 25% 27% - 29% 
1y survival - overall 83% - 86% - - - 
Ia 91% 89% - - - - 
Ib 85% 78% - - - - 
IIa 86% - - - - - 
IIb 79% - - - - - 
IIIa 75% - - - - - 
5y survival - overall 48% 42% - 40% - - 
Ia 60% - - - 73% 60% 
Ib 51% - - - 54% 
IIa 50% - - - 48% 30% 
IIb 43% - - - 38% 
IIIa 34% - - - 25% 16% 
IASLC: International Association for the Study of Lung Cancer. Reference numbers given in brackets after first author names. 
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5.4 Chapter summary 
In this chapter I have described and compared the data available on thoracic 
surgical procedures in HES and the NLCA and used survival analyses to 
determine that a procedure code in HES is likely to be the most accurate means 
(within these datasets) of identifying people who had surgery with curative 
intent for lung cancer. I presented this work as a poster abstract at the British 
Thoracic Society Winter Meeting, London, 2013.(168) 
A brief description of the features of patients who underwent surgery according 
to this definition has been given, and comparison with previously published data 
revealed similar survival. The following chapter uses this population to examine 
30- and 90-day mortality after lung cancer resection, to determine the patient 
and tumour features associated with these outcomes and develop a predictive 
score for use in clinical practice. 
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CHAPTER 6: RISK FACTORS FOR EARLY DEATH 
FOLLOWING SURGERY FOR LUNG CANCER 
This Chapter starts with a description of the history of risk models in thoracic 
surgical practice. This is followed by a study in which I investigate the factors 
associated with early death after lung cancer surgery using the NLCA-HES linked 
dataset, and use multivariate logistic regression to produce a new predictive 
model. 
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6.1 Introduction 
6.1.1 Background 
Following surgical resection 5-year survival can improve to between 25 and 70% 
for patients with non-small cell lung cancer (NSCLC), depending on the stage at 
presentation.(19) However access to this potentially life-saving treatment varies 
not only between countries but also between NHS Trusts in England:  In one 
study patients first seen in a surgical centre (compared with a hospital without 
thoracic surgery on site) were 51% more likely to have surgery for NSCLC, even 
after accounting for variations in factors such as age, performance status and 
co-morbidity.(60) There is also evidence that trusts with higher resection rates 
have improved survival and it has been suggested that if all trusts increased 
their resection rates to this level the proportion of patients surviving lung cancer 
would improve.(169)  
Thoracic surgery is not without risk even in young, relatively fit patients. (170) 
Factors which influence the decision whether or not to operate include the extent 
of disease (i.e. whether surgery is likely to provide a cure), patient fitness and 
the wishes of the individual patient. The extent of disease in which a cure is 
possible is debated and post-operative adjuvant chemotherapy is often 
recommended for patients with more advanced disease.(171) The possibility of 
earlier detection of lung cancer remains an important issue and screening trials 
and patient awareness campaigns are taking place in the hope that more 
patients will present at an earlier stage when potentially curative surgery is more 
likely to be an option. (67, 70) Estimating the level of risk associated with 
surgical resection in patients who have technically resectable NSCLC is therefore 
extremely important, but remains a challenge for clinicians who are faced with 
an aging population who often have multiple co-morbidities.  
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6.1.2 Rationale for this study 
Whilst there are existing tools for the estimation of mortality risk from lung 
cancer surgery (see below), even in the development of Thoracoscore which is 
recommended by the British Thoracic Society,(25) only 57% of the thoracic 
surgical procedures were performed for cancer (not necessarily lung cancer) and 
the study database was limited to those French hospitals that chose to supply 
data.(170)  The NLCA, in contrast, contains data on over 150,000 patients with 
primary lung cancer and has been shown to be representative of patients with 
lung cancer in England through comparison with national cancer registry data. 
(82) No previous study has looked at factors affecting early post-operative 
mortality in a UK population. 
6.1.3 Aims of this chapter 
The first aim of this chapter was to summarise the history and current practice of 
using risk prediction scores in the pre-operative assessment of patients (section 
6.2). Following this, the aim was to use the NLCA, HES and ONS linked data to 
develop a risk prediction model specifically for lung cancer surgery. This was 
achieved as follows: 
1. A survival analysis to establish the important time windows on which to 
base early mortality estimates (sections 5.3 and 6.3). 
2. Calculation of the proportion of patients who died in this early 
postoperative period (section 6.3) 
3. A univariate and multivariate logistic regression analyses to determine 
risk factors for early post-operative mortality (section 6.3).   
4. Construction of a predictive model using the results of multivariate 
analysis of risk factors for early mortality (section 6.4), and 
5. Comparison of the new model with Thoracoscore (section 6.4). (170) 
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6.2 History of surgical mortality risk assessment 
A number of tools have been developed to assist clinicians with the estimation of 
perioperative mortality risk. Initially these were for general surgery and attempts 
were made to apply them to thoracic surgical cases, but more recently some 
have been developed specifically for thoracic surgery and one specifically for 
lung cancer. These predictive models, also known as surgical scoring systems, 
are described in chronological order. 
6.2.1 American Society of Anaesthesiologists 
The American Society of Anaesthesiologists (ASA) physical status classification 
system (figure 6-1) was published in 1941. (172) It is a subjective assessment 
of patient fitness and was originally designed as a tool for statistical studies; 
however several groups claim to be able to assign mortality risk estimates to the 
ASA grades.(173, 174) Surgical mortality risk is related to the type of procedure 
a patient has to undergo as well as patient fitness, but these studies were 
usually undertaken within one area surgery (e.g. gastrointestinal or orthopaedic) 
which to a certain extent removes the variation in risk according to type of 
procedure. 
The classification is subjective and the definitions are ambiguous, which often 
leads to different grades for the same patient if assigned by more than one 
anaesthetist or surgeon. (174, 175) Despite these limitations, the ease of use of 
the ASA grade has meant that it is widely recorded and used (sometimes in 
combination with other factors VXFKDVSDWLHQW¶VDJHDVDWRRO IRUFRPSDUDWLYH
audit between centres and has been suggested as a tool for estimating early 
post-operative mortality risk.(173) 
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I A normal healthy patient. 
     
II A patient with mild systemic disease. 
     
III A patient with severe systemic disease. 
    
IV A patient with severe systemic disease that is a constant threat to life. 
 
V A moribund patient who is not expected to survive without the operation. 
     
VI A declared brain-dead patient whose organs are being removed for donor purposes. 
 
 
 
Figure 6-1: American Society of Anaesthesiologists (ASA) physical status 
classification system (172) 
 
6.2.2 Goldman cardiac index 
In 1977 Goldman published a scoring system to predict risk of cardiovascular 
complications in non-cardiac surgery.(176) Since deaths after major surgery can 
be often be attributed to cardiac complications the index has also been used to 
predict mortality risk: Figure 6-2 shows the factors included in the score, and the 
way in which it has been used to predict mortality.  
Both the ASA grade and to a lesser extent the Goldman index were found to be 
predictive of perioperative mortality when tested in a series of 16,227 patients 
(215 of whom died within 4 weeks of operation) at a European tertiary care 
centre. (173) The majority of these cases had general, orthopaedic, vascular or 
neurosurgery with only 912 cases undergoing thoracic surgery. In thoracic 
surgery, particularly for lung cancer, respiratory disease may be equally or more 
important that cardiac disease and needs to be taken into account when 
estimating operative mortality risk. 
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Clinical finding Score 
Third heart sound (S3)  
 
11 
Elevated jugulo-venous pressure 
 
11 
Myocardial infarction in past 6 months 
 
10 
ECG: premature arterial contractions or any rhythm other than sinus 
 
7 
ECG shows >5 premature ventricular contractions per minute 
 
7 
Age >70 years 
 
5 
Intra-thoracic, intra-abdominal or aortic surgery 
 
3 
Poor general status, metabolic or bedridden 3 
 
Score Incidence of 
death 
Incidence of severe CVS 
complication 
>25 56% 22% 
 
<26 4% 17% 
 
<6 0.2% 0.7% 
 
Figure 6-2: Goldman cardiac index, (176) 
 
6.2.3 POSSUM 
The physiological and operative severity score for the enumeration of mortality 
and morbidity (POSSUM) was published in 1991 as a tool for use in general 
surgical audit. (177) The score was developed by prospective analysis of 1,372 
patients who underwent surgery at a single centre in Liverpool, England, 55 of 
whom died. Procedures carried out for trauma were excluded and the majority of 
operations were gastrointestinal, hepatobiliary or vascular. 
The POSSUM score includes 12 physiological and 6 surgical factors with 4 
possible grades for each (figures 6-3 and 6-4). The total physiological and 
surgical scores are combined and logistic regression analysis is used to give a 
percentage estimate of mortality and morbidity. 
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Brunelli et al applied the POSSUM score to 250 patients undergoing lung 
resection in their Italian centre between 1993 and 1996 to assess its use in 
thoracic as opposed to general surgery. They limited post-operative 
complications and deaths to those occurring within 30 days or prior to hospital 
discharge, replaced peritoneal soiling with thoracic cavity soiling and re-defined 
operative severity to cover the various types of thoracic surgery. There was good 
correlation between observed and predicted morbidity rates but death was 
included as a post-operative complication so there was no specific analysis of 
mortality.(178) 
POSSUM was intended to assist surgeons with audit of their own practice by 
enabling them to account for the type of operations and fitness of their patients 
when comparing their practice with national standards. The total cannot be 
calculated until the procedure is complete (physiological factors are scored at the 
time of surgery and total blood loss cannot be scored until the operation is 
complete), rendering it less useful in providing patients with information 
regarding their operative risk prior to surgery. 
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Score 
 1 2 4 8 
 
    
Operative severity* Minor Moderate Major 
 
Major + 
 
Multiple 
procedures 
1  2 >2 
 
Total blood loss 
(ml) 
PO 101-500 501-999  
 
Peritoneal soiling None Minor 
(serous 
fluid) 
Local pus Free bowel 
content, pus or 
blood 
 
Mode of surgery Elective  Emergency 
resuscitation of >2h 
SRVVLEOHÁ 
Operation <24h after 
admission 
Emergency 
(immediate 
surgery <2h 
needed) 
*Surgery of moderate severity includes appendectomy, cholecystectomy, mastectomy, 
transurethral resection of prostate; major surgery includes any laparotomy, bowel resection, 
cholecystectomy with choledochotomy, peripheral vascular procedure or major amputation; 
major + surgery includes any aortic procedure, abdomino-perineal resection, pancreatic or 
liver resection, oesophagogastrectomy; definitions of surgical procedures with regard to 
severity are guidelines; not all procedures are listed and the closest should bH VHOHFWHGÁ
indicates that resuscitation is possible even if this period is not actually utilised. 
 
Figure 6-3: POSSUM Operative severity score, (177) 
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Score 
 1 2 4 8 
Age (years)  61-70  
 
 
Cardiac signs No failure Diuretic, digoxin, anti-anginal or 
hypertensive therapy 
Peripheral oedema; warfarin 
therapy 
Raised jugulo-venous pressure 
Chest radiograph   Borderline cardiomegaly 
 
Cardiomegaly 
Respiratory history No dyspnoea Dyspnoea on exertion Limiting dyspnoea (1 flight) Dyspnoea at rest 
Chest radiograph  Mild COAD Moderate COAD Fibrosis/consolidation 
 
Systolic blood pressure  110-130mmHg 131-170 or 100-109 RU-99  
 
Pulse (beats/min) 50-80 81-100 or 40-49 101-120 RU 
 
Glasgow coma score 15 12-14 9-11  
 
Haemoglobin (g/100ml) 13-16 11.5-12.9 or 16.1-17.0 10.0-11.4 or 17.1-18.0 RU 
 
White cell count (x 1012/l) 4-10 10.1-20.0 or 3.1-4.0 RU  
 
Urea (mmol/l)  7.6-10.0 10.1-15.0  
 
Sodium (mmol/l)  131-135 126-130  
 
Potassium (mmol/l) 3.5-5.0 3.2-3.4 
5.1-5.3 
2.9-3.1 or 5.4-5.9 RU 
 
Electrocardiogram Normal  Atrial fibrillation (rate 60-90) Any other abnormal rhythm or Q 
waves or ST/T wave changes 
COAD, chronic obstructive airways disease. 
 
Figure 6-4: POSSUM Physiological score - to be scored at the time of surgery (177) 
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6.2.4 E-PASS 
The Estimation of Physiologic Ability and Surgical Stress, known as E-PASS, 
(179) was developed with the aim of reducing postoperative morbidity and 
mortality by giving an estimate of post-operative risk which would assist in 
selection of surgical technique. Data on 292 patients undergoing elective gastro-
intestinal surgery at a single hospital in Japan between 1992 and 1995 were 
used to develop the score and it was evaluated in a series of 989 patients who 
had similar procedures at another Japanese hospital.  
The multiple regression analysis included a total of 11 preoperative factors and 
six surgical factors. The overall score is termed the comprehensive risk score 
and it is calculated from the physiological risk score and the surgical stress score 
(figure 6-5). In order to use the score pre-operatively, individual surgeons are 
expected to estimate the likely blood loss, incision size and operation time based 
on previous experience in their centre. 
The E-PASS score was applied to 282 patients with lung cancer and 458 patients 
who underwent elective thoracic operations by Yamashita and colleagues who 
found reasonable correlation between the comprehensive risk score and 
morbidity; however there were only 5 in-hospital deaths (0.7%) in the study 
period meaning assessment of mortality prediction was not possible and 
furthermore suggesting a very low-risk cohort of patients. (180)  
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Pre-operative risk score = - 0.0686 + 
Age x 0.00345 
Severe heart disease (NYHA III or IV, or 
arrhythmia requiring mechanical support) Presence =1 Absence=0 
x 0.323 
Severe lung disease (VC <60% or 
FEV1<50%) Presence =1 Absence=0 
x 0.205 
Diabetes mellitus Presence =1 Absence=0 x 0.153 
Performance status (Defined by Japanese 
Society for Cancer Therapy) 0-4 
x 0.148 
ASA physiological status 1-5 x 0.0666 
   
Surgical stress score = - 0.342 + 
Blood loss / body weight (g/kg) x 0.0139 
Operation time (hours) x 0.0392 
Extent of skin incision Minor=0, Laparotomy or thoracotomy=1, Both=2 
x 0.352 
   
Comprehensive score = -0.382 + ( 0.936 x physiological score)  + ( 0.976 surgical score) 
The authors suggest that a comprehensive risk score of 1.0 may be taken as a critical 
threshold at which homeostasis is maintained in surgical patients. 
 
Figure 6-5: Equations for E-PASS scores,(179) 
 
6.2.5 The European Society Subjective & Objective Scores  
The European Society Subjective Score (ESSS), published in 2005, was the first 
score to be developed specifically for thoracic surgery, and was intended to 
enable fair comparative audit between thoracic surgeons and surgical centres, 
and to aid prospective clinical decision making. Data were obtained from multiple 
hospitals (27 units in 14 European countries) in the European Thoracic Surgery 
Database Project. (181) The inclusion of data from multiple sites was important 
as surgical skill, equipment and post-operative care (including availability of 
intensive care beds) vary between hospitals and results based on one centre 
cannot necessarily be extrapolated to others.  
The main analysis included data from 3,426 patients who underwent any 
thoracic surgical procedure, 66 (1.9%) of whom died in hospital. The ESSS was 
developed using a randomly selected 60% of this cohort and tested using the 
remaining 40%. It combines Medical Research Council (MRC) dyspnoea score, 
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American Society of Anaesthesiologists (ASA) score, class of procedure and age, 
to give an estimate of the risk of in-hospital mortality.  
The authors reported that the ESSS PRGHO ³SHUIRUPHG ZHOO DW ORZ ULVN
underestimated mortality at medium risk and overestimated mortality at high 
ULVN´ (181). Recognising this, and the subjective nature of most of the 
parameters, the same group went on to develop a further model specifically for 
lung cancer resections based on the objective measures age and predicted post-
operative lung function. This model (the European Society Objective Score 
(ESOS), figure 6-6) performed reasonably well in estimating mortality a though 
it was based on a small number of cases and was not fully tested because it was 
developed after the first part of the study had been completed. 
 
Step 1:  logit2 = -5.8858 + (0.0501 x age) ± (0.0218 x predicted post-operative FEV1%) 
Step 2: Predicted risk of in hospital death = exp (logit2) / (1+ exp (logit2)) 
 
Figure 6-6: European Society Objective Score, (181) 
 
Brunelli and colleagues (who previously applied the POSSUM score to their 
patient group) assessed the performance of the ESOS scoring system for lung 
cancer resection using prospectively collected data on 695 procedures performed 
between 2004 and 2006 at three European centres.(182) They found that the 
score predicted mortality well with no significant differences between observed 
and ESOS-predicted mortality rates. They attempted a sub-group analysis of the 
highest risk patients however there were only 31 patients in this group and no 
deaths were reported. 
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6.2.6 Thoracoscore 
In 2007 Falcoz and colleagues published a 9-factor scoring system  
(Thoracoscore) which estimated post-operative mortality in thoracic 
surgery.(170) Thoracoscore was developed using data entered from 59 French 
hospitals into the thoracic database Epithor. It is based on an analysis of 10,122 
patients who underwent a thoracic surgical procedure between June 2002 and 
July 2005, 218 (2.2%) of whom died before being discharged from hospital. Age, 
sex, dyspnoea score, ASA score, performance status, priority of surgery 
(emergency or planned), diagnosis group, procedure class (pneumonectomy or 
other), and comorbid disease were found to be predictors of early post-operative 
death and thus comprise the score (figure 6-7). Co-morbidities were scored by 
number (none, 0-2 or >2). The score was tested using a further 5,061 patients 
(120 deaths) from the same database and found to perform well in estimating 
the mortality risk in this group of patients (c-index 0.85). 
Thoracoscore was not designed to predict outcomes in lung cancer, although 
does include a field specifying whether the procedure was for benign or 
malignant disease. The study included patients undergoing thoracic surgery for a 
range of indications from the relatively minor spontaneous pneumothorax to 
complicated pneumonectomy for lung cancer. Patients with a malignant 
pathology were more than three times as likely to die in hospital as patients with 
a benign thoracic pathology. For patients with cancer, additional information was 
collected concerning pathologic staging, type of lymphadenectomy, type of 
histologic resection, and any adjuvant chemotherapy or radiotherapy received, 
however none of these fields were included in the final score. Results were only 
reported for pre-operative treatment, which did not have a significant impact on 
early mortality. 
Thoracoscore was independently tested in 1,675 patients who underwent 
thoracic surgery in a New York hospital between 2002 and 2006.(183) It was 
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found to be a strong predictor of mid-term and in-hospital mortality, even when 
dyspnoea score (which was not recorded in this centre) was excluded. A UK 
study, however, found that Thoracoscore was not a significant predictor of in-
hospital mortality.(184) There were only 16 deaths (2%) in the 703 patients 
studied so there may have been insufficient power to detect a significant 
association; further validation studies are needed to assess the performance of 
Thoracoscore in a population undergoing lung cancer resection. 
 
Variable Value Code Coefficient 
Age (years) <55 
55-65 
 
0 
1 
2 
 
0.7679 
1.0073 
Sex Female 
Male 
0 
1 
 
0.4505 
ASA score  
 
0 
1 
 
0.6057 
Performance status  
 
0 
1 
 
0.689 
MRC dyspnoea score  
 
0 
1 
 
0.9075 
Priority of surgery Elective 
Urgent or emergency 
0 
1 
 
0.8443 
Procedure class Other a 
Pneumonectomy 
0 
1 
 
1.2176 
Diagnosis group Benign 
Malignant 
0 
1 
 
1.2423 
Co-morbidity score* 0 
1-2 
>2 
0 
1 
2 
 
0.7447 
0.9065 
Constant - - -7.3737 
 
MRC Medical Research Council, ASA American Society of Anaesthesiologists grade,  
*Number of significant co-morbid conditions including: smoking, history of cancer, chronic 
obstructive pulmonary disease, diabetes mellitus, arterial hypertension, peripheral vascular disease, 
obesity and alcoholism; a Other includes mediastinoscopy or other mediastinal surgery, wedge 
resection, lobectomy or bi-lobectomy.  
Odds =  exp (total of coefficients +  constant); Probability of death =  odds/(1+odds). 
 
Figure 6-7: Thoracoscore: Prediction of risk of in-hospital mortality,(170) 
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6.2.7 Thoracic surgery for lung cancer 
In 2011 Bernard et al published the first model to provide an estimate of 
mortality specifically following lung cancer resection. (185) This was also the first 
model to use lung function in any detail. It was developed using Epithor (the 
same database as Thoracoscore), and was based on data from 18,000 patients 
who had thoracic surgery for NSCLC. Six-hundred and ninety patients died within 
30 days post-operatively or prior to hospital discharge.  
Two models were evaluated with the only difference being that model 2 (figure 
6-8) used number of co-morbidities whereas model 1 used presence or absence 
of individual conditions. They also included interaction terms making the model 
more complex but increasing accuracy by accounting for the difference in effect 
of pre-operative lung function depending on whether the operation was a 
pneumonectomy or not. The authors validated both models using the bootstrap 
sampling method (randomly selecting individuals from the dataset used to 
generate the score to create a test dataset) and found them to be predictive of 
mortality in this dataset with an area under the receiver operating curve of 0.78 
(95% CI, 0.76±0.80) for model 2. They were, however, unable to test their 
models in an independent population. 
This score is more complex than the widely used Thoracoscore, and is based on 
data from those institutions which chose to contribute to the Epithor database. It 
has only been tested in a subgroup of the population used to develop the model 
and perhaps for these reasons it has not been widely adopted in UK practice.
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Variables Categories Coefficient 
Sex Female vs. male -0.745 
Age Increasing years 0.045 
Side Left vs. right -0.42 
ASA score Increasing units 0.39 
Performance status Increasing units 0.3 
Body mass index (kg/m2)  
18-21 
22-26 
>26 
Ref 
-0.89 
1.18 
1.53 
FEV Increasing % -0.01 
Lobectomy Yes vs. no 0.56 
Pneumonectomy Yes vs. no 1.09 
Pneumonectomy - FEV Interaction 0.01 
Side ± pneumonectomy Interaction -0.485 
Extended resection Yes vs. no -0.9 
Extended resection ± FEV  Interaction 0.018 
Stage III vs. (I or II or IV) 0.47 
Stage IV vs. (I or II or III) 0.5 
Number of comorbidities 0 
1 
2 
3 or 4 
Ref 
0.5 
0.81 
0.95 
Intercept (=constant)  -6.64 
 
Figure 6-8: Logistic regression models including the number of co-morbidities 
per patient (model 2) for prediction of in-hospital mortality, (185) 
 
6.2.8 Other studies of risk factors for mortality in lung cancer surgery 
The majority of studies which have investigated risk factors for mortality 
following lung cancer resection incorporate similar patient and surgical factors as 
shown above. A few suggest that other factors should be taken into account 
where possible: In a retrospective study of 310 patients at their institution, Stolz 
et al found that coronary artery disease and respiratory failure (but not COPD, 
induction therapy, smoking habit or obesity) were statistically associated with an 
increased risk of death within 30 days of pneumonectomy for lung cancer. (186) 
One study suggested that adenocarcinoma is associated with reduced mortality 
in comparison with other histological subtypes, (187) however this may be due 
the type of patient who develops adenocarcinoma in comparison with squamous 
cell lung cancer, data on which were not available in this study based on cancer 
registry data. Exercise testing has been suggested as a potential predictor of 
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outcome, (188) but this is time consuming and not routinely performed pre-
operatively and therefore data with which to assess its predictive value are not 
currently available. (189) 
6.2.9 Post-operative morbidity 
Mortality is not the only outcome of interest to patients with lung cancer, or their 
treating physicians. It is important to consider post-operative dyspnoea, of which 
several factors including pre-operative lung function have been suggested as 
predictors,(188, 190-193) and the effects of a sometimes prolonged admission 
to intensive care, both of which adversely affect quality of life. Several studies, 
including some of the mortality studies discussed above, have investigated the 
effects of various factors on morbidity; however compared with mortality it is 
less well defined. Further descriptions of post-operative morbidity are outside the 
scope of this thesis. 
6.2.10 Summary  
I have described a number of predictive models which have been used to 
estimate mortality after thoracic surgery, whether or not they were designed for 
this purpose. Some of the models performed well when tested using clinical data, 
however the numbers of procedures included in these validation studies are 
reasonably small, particularly for high risk patients and those with lung cancer as 
the indication for surgery.  
There is currently no predictive score or tool to facilitate estimation of 
perioperative mortality risk based on thoracic surgery in a UK population, which 
is important given differences in healthcare systems, surgical expertise and 
patient demographics between countries. The most recent British Thoracic 
Society (BTS) guidelines on radical management of patients with lung cancer, 
(25) suggest using a score such as Thoracoscore when evaluating and 
consenting patients for surgery despite the limitations I have described. 
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6.3 Analysis of factors associated with early mortality following 
surgery for NSCLC 
6.3.1 Aims 
The aims of this section were to establish the important time windows on which 
to base early mortality estimates, calculate the proportion of patients who died 
in this early postoperative period and perform univariate and multivariate logistic 
regression analyses to determine risk factors for early post-operative mortality 
(chapter aims 1-3). 
6.3.2 Methods 
Study population 
Patients were included if they had a record in the NLCA-HES linked database and 
were first seen between January 1st 2004 and March 31st 2010. People with 
NSCLC were identified and those with stage 3b or 4, or age less than 30 years, 
were excluded.  
Definition of surgery 
The definition of a potentially curative thoracic surgical procedure, following the 
work described in chapter 5, was an OPCS-4 code in the HES database for a 
thoracic surgical procedure which was likely to have been performed with 
curative intent for NSCLC (Appendix E). Procedures which took place before 1st 
January 2004 or after 31st March 2010 were excluded.  
Procedures were categorised as pneumonectomy, bi-lobectomy, lobectomy, 
segmentectomy / wedge resection or other. Where more than one relevant 
procedure code was identified for an individual, the most extensive procedure 
was used; for the few patients who had codes for more than one procedure of 
the same type, the date of the most recent procedure was used. If recorded 
procedure dates differed between HES and the NLCA the difference between the 
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dates was calculated: if this was more than 10 days the patient was excluded 
from further analysis.  
Patients with a procedure date more than 3 months before or 6 months after 
their lung cancer diagnosis were also excluded so that patient features, which 
are usually recorded at the time of diagnosis, might still be representative of the 
state of the patient at the time of surgery. 
After the procedure date had been defined any record with a code for metastatic 
cancer prior to the date of surgery was excluded. 
Definition of outcome 
Office of National Statistics (ONS) dates of death and HES procedure dates were 
used to determine when a patient died in relation to their operation. 
In order to ensure the analysis was based on the most appropriate postoperative 
period, the Kaplan Meier survival curves for death following surgery were 
inspected to determine the time during which mortality was highest (Chapter 5 
figures 5-6 to 5-9). The rate of death was actually very similar over the six 
months following lung cancer resection, with only a slight increase observed in 
approximately the first 0-90 days. Surgical mortality is traditionally defined as 
within 30 days of the operation and therefore this was one of the outcomes 
used. A review of the literature, however, revealed that recovery usually takes at 
least 3 months.(194) It was therefore decided that deaths should be assessed 
within 30 and 90 days of surgery with an analysis comparing the patients who 
died within 30 days with those who died between 31 and 90 days. 
Covariate definitions 
Stage, histology, lung function, performance status and socio-economic status 
(Townsend quintile) were defined as described in section 2.2.5.  
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Statistical methods 
The proportions of patients who died within 30 and 90 days of surgery were 
calculated. To determine whether there were marked differences in the features 
of patients who died within the first 30 days after surgery and those who died 
between 31 and 90 days, demographic, co-morbid, tumour, and procedure 
related features of patients who died in these two time periods were compared. 
Logistic regression was used to estimate odds ratios (ORs) associated with 
demographic, co-morbid, tumour and procedure-related factors for death within 
30 days and within 90 days. A multivariate model was built including all factors 
that were significantly associated (defined as p<0.1) with death in univariate 
analysis.  The significance of each variable in the multivariate model was then 
assessed using a likelihood ratio test. 
Interactions 
Interactions between the following factors and death within 30 and 90 days of 
surgery were sought: 
- Lung function and procedure type 
- Side of surgery and procedure type 
To improve the power for these analyses, procedure type was re-classified as 
pneumonectomy or non-pneumonectomy. 
Sensitivity analyses 
Previous studies and data reports from the NLCA have found a substantial 
proportion of missing data for performance status, stage, and lung function. (51, 
55, 60) Sensitivity analyses were therefore planned restricted to records with 
complete data for these three variables. Since Charlson Index was a derived field 
no missing values were generated; other fields were considered less important 
and any analysis restricted to records which were entirely complete was not 
considered feasible. Because of the reduced power in this smaller dataset 
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Charlson index was re-coded as a binary variable (0-DQGDJHDV-
65, 66-75 and >75 years. 
Stage may be recorded using either version 6 or version 7 of the UICC system 
from 2009 onwards. In case this affected the results a sensitivity analysis was 
performed restricted to cases where version 6 was used as this would be the 
majority of patients. 
 172   
 
6.3.3 Results 
There were 113,261 patients with NSCLC in the NLCA database first seen 
between January 2004 and March 2010; 46,013 with stage recorded as 3b or 4 
and a further 102 who were aged less than 30 years at diagnosis were excluded. 
Of the remaining patients, 12,269 had an OPCS-4 code for a potentially curative 
procedure in HES between January 1st 2004 and March 31st 2010. Two-hundred 
and ninety-two patients where the difference between the procedure date 
recorded in the NLCA and that recorded in HES was >10 days, 437 who had an 
ICD-10 code for metastatic cancer recorded prior to the procedure date, and a 
further 549 where the procedure date was >3 months before or >6 months after 
the NLCA date of diagnosis were excluded, leaving 10,991 patients for analysis.  
The study population and exclusions are the same as the final part of the 
previous chapter, and were shown in figure 5-4.  
The majority (56%) of patients were male, 20% were aged 70-74 years and 
31% had a performance status of zero (Table 6-1). The most commonly 
performed procedure was lobectomy (64%) with only 10% of patients having 
had a pneumonectomy. Twenty-eight per cent of patients had stage 1b NSCLC, 
although 26% did not have a pre- or post-operative stage recorded. The most 
common pre-operative histological subtype was adenocarcinoma (31%) followed 
by squamous cell (28%). Twenty-one per cent did not have a record of pre- or 
post-operative histology; in most cases this is likely to reflect missing data 
rather than the absence of histological confirmation of lung cancer.  
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Table 6-1: Proportions and characteristics of patients who died within 30-days 
and between 31-and 90 days of surgery 
  Overall N=10,991 Died within 30 days 
(n=334) 
Died between 31-90 days 
              (n=313) 
     n  %  n %a n %b Chi 2 
Sex Female 4,824 43.9 107 2.2 103 2.1  
  
Male 6,167 56.1 227 3.7 210 3.4 p=0.813 
Age group <55 1,008 9.2 12 1.2 23 2.3  
 
55-59 1,090 9.9 21 1.9 24 2.2  
 
60-64 1,847 16.8 31 1.7 32 1.7  
 
65-69 2,128 19.4 56 2.6 49 2.3  
 
70-74 2,226 20.3 84 3.8 78 3.5  
 
75-79 1,828 16.6 88 4.8 62 3.4  
 
80-84 730 6.6 34 4.7 35 4.8  
 
85+ 134 1.2 12 9.0 10 7.5 p=0.331 
Ethnicity White 8,983 81.7 254 2.8 256 2.8  
  
Black 82 0.7 1 1.2 0 0.0  
  
Asian 112 1.0 2 1.8 1 0.9  
  
Other 77 0.7 1 1.3 2 2.6 p=0.643* 
  
Missing 1,737 15.8 76 4.4 54 3.1 p=0.317 
Townsend 1 1,343 12.2 36 2.7 30 2.2  
quintile 2 1,602 14.6 45 2.8 41 2.6  
 
3 1,609 14.6 52 3.2 46 2.9  
 
4 1,723 14.6 64 4.0 55 3.4  
 
(most deprived) 5 2,074 15.7 74 4.3 58 3.4 p=0.985* 
 
Missing 2,640 18.9 63 3.0 83 4.0 p=0.328 
Performance 0 3,422 31.1 72 2.1 60 1.8  
status 1 2,815 25.6 84 3.0 93 3.3  
  
2 465 4.2 23 4.9 28 6.0  
  
3-4 108 1.0 11 10.2 9 8.3 p=0.524* 
  
Missing 4,181 38.0 144 3.4 123 2.9 p=0.523 
Per cent >80% 1,891 17.2 34 1.8 39 2.1  
Predicted 60-79% 1,499 13.6 42 2.8 45 3.0  
FEV1 40-59% 726 6.6 23 3.2 27 3.7  
 
<40% 141 1.3 5 3.5 7 5.0 p=0.975* 
 
Missing 6,734 61.3 230 3.4 195 2.9 p=0.508 
Charlson 0 5,456 49.6 128 2.3 130 2.4  
index 1 2,791 25.4 87 3.1 84 3.0  
  
2-3 2,233 20.3 95 4.3 81 3.6  
  
 511 4.6 24 4.7 18 3.5 p=0.715 
Stage IA 2,249 20.5 37 1.6 41 1.8  
 
IB 3,064 27.9 87 2.8 82 2.7  
 
IIA 334 3.0 6 1.8 3 0.9  
 
IIB 1,494 13.6 55 3.7 47 3.1  
 
IIIA 933 8.5 41 4.4 39 4.2 p=0.812* 
 
missing 2,857 26.0 108 3.8 101 3.5 p=0.903 
Side Right 5,067 46.1 157 3.1 161 3.2  
  
Left 3,930 35.8 105 2.7 114 2.9  
  
Other 85 0.8 5 5.9 4 4.7 p=0.875* 
  
Missing 1,909 17.4 67 3.5 34 1.8 p=0.014 
Histology Adenocarcinoma 3,406 31.0 60 1.8 75 2.2  
 
Squamous cell 3,106 28.3 125 4.0 107 3.4  
 
NSCLC NOS 1,833 16.7 62 3.4 62 3.4  
 
Other 368 3.3 10 2.7 12 3.3 p=0.356* 
 
Missing 2,278 20.7 77 3.4 57 2.5 p=0.235 
Segmentectomy / wedge 1,671 15.2 35 2.1 35 2.1  
Procedure Lobectomy 7,051 64.2 160 2.3 165 2.3  
  
Bi-lobectomy 431 3.9 25 5.8 13 3.0  
  
Pneumonectomy 1,121 10.2 78 7.0 51 4.5  
  
Other 717 6.5 36 5.0 49 6.8 p=0.028 
*Excluding missing; FEV1 forced expiratory volume in 1 second; a % of patients in each subgroup who died within 30 days; 
b
 % of patients in each subgroup who died between 31 and 90 days. 
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Mortality 
Three per cent of patients (334) died within 30 days of their procedure and a 
further 2.9% (313) between 31 and 90 days (therefore a total of 5.9% (647) 
died within 90 days). There were no statistically significant differences in patient, 
co-morbidity or tumour factors between patients who died within 30 days of their 
procedure and those who died between 31 and 90 days (Table 6-1). A higher 
proportion of those who died within 30 days had a pneumonectomy or bi-
lobectomy compared with those who died between 31 and 90 days.  
Given these findings, and the greater degree of accuracy due to a higher number 
of deaths, I have elected to report results for 90-day mortality in this section; 
the results for death within 30 days of surgery are similar and are shown in 
Table 6-3. 
Within 90 days of surgery, males were more likely to die than females (7.1% vs. 
4.4%) and the proportion of patients who died after pneumonectomy was higher 
than for lobectomy (11.5% vs. 4.6%) (Table 6-2). Sixteen per cent of patients 
over 85 years and 18.5% of those with performance status 3-4 died within this 
post-operative period. Age was strongly associated with post-operative 
mortality: Compared with a patient aged 70-74 years, the odds of death within 
90 days of surgery for a patient aged >85 years were markedly increased, even 
after accounting for other demographic, tumour and co-morbidity factors 
(adjusted OR 2.84, 95% confidence interval (CI) 1.71-4.71) (Table 6-2). The 
next most strongly associated factors were procedure type and performance 
status. Significant associations were also observed with percentage predicted 
FEV1, stage, Charlson index, Townsend score, ethnicity, histological subtype and 
sex.  
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Table 6-2: Risk factors for early post-operative death: Death within 90 days 
proportions and odds ratios 
   Overall N=10,991 Died within 90 days of surgery (n = 647) 
        n 
  %     n    %  OR  95% CI AdjustedOR* 95% CI 
Sex Female 4,824 43.9 210 4.4 1.00  1.00  
  
Male 6,167 56.1 437 7.1 1.68 1.42-1.98 1.37 1.15-1.63 
  
       p<0.0001  p=0.0004 
Age  <55 1,008 9.2 35 3.5 0.46 0.32-0.67 0.46 0.32-0.68 
group 55-59 1,090 9.9 45 4.1 0.55 0.39-0.77 0.53 0.37-0.75 
 
60-64 1,847 16.8 63 3.4 0.45 0.33-0.61 0.44 0.32-0.59 
 
65-69 2,128 19.4 105 4.9 0.63 0.49-0.82 0.61 0.47-0.79 
 
70-74 2,226 20.3 162 7.3 1.00  1.00  
 
75-79 1,828 16.6 150 8.2 1.14 0.90-1.44 1.19 0.94-1.51 
 
80-84 730 6.6 69 9.5 1.33 0.99-1.79 1.46 1.07-1.98 
 
85+ 134 1.2 22 16.4 2.50 1.54-4.06 2.84 1.71-4.71 
 
      p<0.0001**  p<0.0001** 
Ethnicity White 8,983 81.7 510 5.7 1.00  1.00  
  
Black 82 0.7 1 1.2 0.21 0.03-1.48 0.21 0.03-1.51 
  
Asian 112 1.0 3 2.7 0.46 0.14-1.44 0.45 0.14-1.46 
  
Other 77 0.7 3 3.9 0.67 0.21-2.14 0.71 0.22-2.31 
  
Missing 1,737 15.8 130 7.5 1.34 1.10-1.64 1.46 1.19-1.80 
  
       p=0.0030  p=0.0005 
Townsend 1 1,343 12.2 66 4.9 1.00  1.00  
quintile 2 1,602 14.6 86 5.4 1.10 0.79-1.53 1.12 0.80-1.57 
 
3 1,609 14.6 98 6.1 1.25 0.91-1.73 1.35 0.97-1.88 
 
4 1,723 14.6 119 6.9 1.44 1.05-1.96 1.59 1.16-2.19 
(most deprived) 5 2,074 15.7 132 6.4 1.32 0.97-1.78 1.45 1.06-1.99 
 
Missing 2,640 18.9 146 5.5 1.13 0.84-1.53 1.13 0.83-1.55 
 
      p=0.0221**  p=0.0028** 
PS 0 3,422 31.1 132 3.9 1.00  1.00  
  
1 2,815 25.6 177 6.3 1.67 1.33-2.11 1.38 1.09-1.75 
  
2 465 4.2 51 11.0 3.07 2.19-4.31 2.40 1.68-3.41 
  
3-4 108 1.0 20 18.5 5.66 3.38-9.49 4.08 2.37-7.02 
  
Missing 4,181 38.0 267 6.4 1.70 1.37-2.11 1.35 1.06-1.73 
  
       p<0.0001**  p<0.0001** 
Per cent >80% 1,891 17.2 73 3.9 1.00  1.00  
predicted 60-79% 1,499 13.6 87 5.8 1.53 1.12-2.11 1.37 0.99-1.90 
FEV1 40-59% 726 6.6 50 6.9 1.84 1.27-2.67 1.64 1.12-2.41 
 
<40% 141 1.3 12 8.5 2.32 1.23-4.38 2.07 1.06-4.04 
 
Missing 6,734 61.3 425 6.3 1.68 1.30-2.16 1.48 1.13-1.95 
 
      p=0.0002**  p=0.0020** 
Charlson 0 5,456 49.6 258 4.7 1.00  1.00  
index 1 2,791 25.4 171 6.1 1.31 1.08-1.60 1.20 0.98-1.48 
  
2-3 2,233 20.3 176 7.9 1.72 1.41-2.10 1.54 1.25-1.90 
  
 511 4.6 42 8.2 1.80 1.28-2.53 1.53 1.07-2.18 
  
       p<0.0001**  p<0.0001** 
Stage IA 2,249 20.5 78 3.5 1.00  1.00  
 
IB 3,064 27.9 169 5.5 1.62 1.24-2.14 1.39 1.05-1.84 
 
IIA 334 3.0 9 2.7 0.77 0.38-1.55 0.67 0.33-1.37 
 
IIB 1,494 13.6 102 6.8 2.04 1.51-2.76 1.59 1.16-2.19 
 
IIIA 933 8.5 80 8.6 2.44 1.77-3.36 1.85 1.32-2.60 
 
missing 2,857 26.0 209 7.3 2.20 1.68-2.87 1.78 1.32-2.41 
 
      p<0.0001**  p=0.0004** 
Side Right 5,067 46.1 318 6.3 1.00    
  
Left 3,930 35.8 219 5.6 0.88 0.74-1.05   
  
Other 85 0.8 9 10.6 1.77 0.88-3.56   
  
Missing 1,909 17.4 101 5.3 0.83 0.66-1.05   
  
       p=0.1063   
Histology Adenocarcinoma 3,406 31.0 135 4.0 1.00  1.00  
 
Squamous cell 3,106 28.3 232 7.5 1.96 1.57-2.43 1.38 1.10-1.73 
 
NSCLC NOS 1,833 16.7 124 6.8 1.76 1.37-2.26 1.36 1.05-1.76 
 
Other 368 3.3 22 6.0 1.54 0.97-2.45 1.14 0.70-1.84 
 
Missing 2,278 20.7 134 5.9 1.51 1.19-1.94 1.08 0.82-1.42 
 
      p<0.0001  p=0.0420 
Segmentectomy/wedge 1,671 15.2 70 4.2 0.90 0.69-1.16 0.80 0.61-1.05 
Procedure Lobectomy 7,051 64.2 325 4.6 1.00  1.00  
  
Bi-lobectomy 431 3.9 38 8.8 2.00 1.41-2.84 1.94 1.35-2.78 
  
Pneumonectomy 1,121 10.2 129 11.5 2.69 2.17-3.33 2.81 2.22-3.56 
  
Other 717 6.5 85 11.9 2.78 2.16-3.57 2.12 1.62-2.77 
  
       p<0.0001  p<0.0001 
OR odds ratio; CI confidence interval; PS performance status; FEV1 forced expiratory volume in 1 second. *ORs are adjusted 
for all other factors for which adjusted ORs are given. All p values calculated using likelihood ratio test; ** LRT p for trend. 
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Table 6-3: Factors associated with death within 30 days of surgery 
  Overall N=10,991 Died within 30 days of surgery  (n= 334 ) 
        n %     n %  OR  95% CI Adjusted 
OR 
95% CI 
Sex Female 4,824 43.9 107 2.2 1.00  1.00  
  
Male 6,167 56.1 227 3.7 1.62 1.33-2.13 1.30 1.02-1.66 
     
 
 
 
 p<0.0001  p=0.0320 
Age group <55 1,008 9.2 12 1.2 0.31 0.17-0.57 0.29 0.16-0.54 
 
55-59 1,090 9.9 21 1.9 0.50 0.31-0.81 0.46 0.28-0.76 
 
60-64 1,847 16.8 31 1.7 0.44 0.29-0.66 0.41 0.27-0.63 
 
65-69 2,128 19.4 56 2.6 0.64 0.45-0.91 0.61 0.42-0.87 
 
70-74 2,226 20.3 84 3.8 1.00  1.00  
 
75-79 1,828 16.6 88 4.8 1.29 0.95-1.75 1.38 1.01-1.88 
 
80-84 730 6.6 34 4.7 1.25 0.83-1.87 1.43 0.94-2.17 
 
85+ 134 1.2 12 9.0 2.51 1.33-4.72 2.84 1.47-5.48 
   
 
   p<0.0001**  p<0.0001** 
Ethnicity White 8,983 81.7 254 2.8 1.00  1.00  
  
Black 82 0.7 1 1.2 0.42 0.06-3.06 0.44 0.06-3.22 
  
Asian 112 1.0 2 1.8 0.62 0.15-2.54 0.66 0.16-2.73 
  
Other 77 0.7 1 1.3 0.45 0.06-3.26 0.45 0.06-3.32 
  
Missing 1,737 15.8 76 4.4 1.57 1.21-2.04 1.73 1.32-2.26 
     
 
   p=0.0088  p=0.0017 
Townsend 1 1,343 12.2 36 2.7 1.10  1.00  
quintile 2 1,602 14.6 45 2.8 1.05 0.67-1.64 1.07 0.68-1.68 
 
3 1,609 14.6 52 3.2 1.21 0.79-1.87 1.33 0.85-2.06 
 
4 1,723 14.6 64 4.0 1.40 0.93-2.12 1.59 1.04-2.43 
(most deprived) 5 2,074 15.7 74 4.3 1.34 0.90-2.01 1.52 1.00-2.31 
 
Missing 2,640 18.9 63 3.0 0.89 0.59-1.34 0.84 0.54-1.29 
   
 
   p=0.0558**  p=0.0098** 
PS 0 3,422 31.1 72 2.1 1.00  1.00  
  
1 2,815 25.6 84 3.0 1.43 1.04-1.97 1.16 0.84-1.61 
  
2 465 4.2 23 4.9 2.42 1.50-3.91 1.84 1.12-3.03 
  
3-4 108 1.0 11 10.2 5.28 2.71-10.27 3.77 1.87-7.58 
  
Missing 4,181 38.0 144 3.4 1.66 1.25-2.21 1.33 0.96-1.85 
     
 
   p<0.0001**  p=0.0001** 
Per cent >80% 1,891 17.2 34 1.8 1.00  1.00  
predicted 60-79% 1,499 13.6 42 2.8 1.57 1.00-2.49 1.41 0.88-2.25 
FEV1 40-59% 726 6.6 23 3.2 1.79 1.05-3.05 1.63 0.94-2.84 
 
<40% 141 1.3 5 3.5 2.01 0.77-5.22 1.96 0.73-5.28 
 
Missing 6,734 61.3 230 3.4 1.93 1.34-2.78 1.72 1.17-2.53 
   
 
   p=0.0176**  p=0.0895** 
Charlson  0 5,456 49.6 128 2.3 1.00  1.00  
 index 1 2,791 25.4 87 3.1 1.34 1.02-1.77 1.23 0.93-1.63 
  
2-3 2,233 20.3 95 4.3 1.85 1.41-2.42 1.66 1.25-2.19 
  
 511 4.6 24 4.7 2.05 1.31-3.20 1.77 1.11-2.81 
     
 
   p<0.0001**  p=0.0002** 
Stage IA 2,249 20.5 37 1.6 1.00  1.00  
 
IB 3,064 27.9 87 2.8 1.75 1.18-2.58 1.42 0.96-2.12 
 
IIA 334 3.0 6 1.8 1.09 0.46-2.61 0.90 0.37-2.19 
 
IIB 1,494 13.6 55 3.7 2.28 1.50-3.48 1.66 1.06-2.59 
 
IIIA 933 8.5 41 4.4 2.57 1.64-4.04 1.85 1.15-2.98 
 
missing 2,857 26.0 108 3.8 2.35 1.61-3.43 1.71 1.12-2.60 
   
 
   p<0.0001**  p=0.0143** 
Side Right 5,067 46.1 157 3.1 1.00    
  
Left 3,930 35.8 105 2.7 0.86 0.67-1.10   
  
Other 85 0.8 5 5.9 1.95 0.78-4.89   
  
Missing 1,909 17.4 67 3.5 1.14 0.85-1.52   
     
 
   p=0.1615   
Histology Adenocarcinoma 3,406 31.0 60 1.8 1.00  1.00  
 
Squamous cell 3,106 28.3 125 4.0 2.34 1.71-3.19 1.57 1.14-2.18 
 
NSCLC NOS 1,833 16.7 62 3.4 1.95 1.36-2.80 1.67 1.01-2.12 
 
Other 368 3.3 10 2.7 1.56 0.79-3.07 1.12 0.56-2.25 
 
Missing 2,278 20.7 77 3.4 1.95 1.39-2.75 1.46 1.00-2.13 
   
 
   p<0.0001  p=0.0643 
 Segmentectomy/wedge 1,671 15.2 35 2.1 0.92 0.64-1.33 0.82 0.56-1.19 
Procedure Lobectomy 7,051 64.2 160 2.3 1.00  1.00  
  
Bi-lobectomy 431 3.9 25 5.8 2.65 1.72-4.09 2.61 1.67-4.07 
  
Pneumonectomy 1,121 10.2 78 7.0 3.22 2.44-4.25 3.54 2.60-4.81 
  
Other 717 6.5 36 5.0 2.28 1.57-3.30 1.69 1.14-2.50 
     
 
   p<0.0001  p<0.0001 
OR odds ratio; CI confidence interval; PS performance status; FEV1 forced expiratory volume in 1 second. *ORs are adjusted 
for all other factors for which adjusted ORs are given. All p values calculated using likelihood ratio test; ** LRT p for trend. 
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Interactions 
No significant interactions were found for death within either 30 or 90 days, 
between procedure (pneumonectomy or not pneumonectomy) and FEV1 or side 
of surgery. 
Missing data and sensitivity analyses 
There were 3,319 patients with complete data on performance status, stage and 
lung function. The proportions of these patients who died within 30 and 90 days 
of surgery were slightly lower (2.5% and 5.1%) than in the overall population of 
10,991, however in multivariate analysis age, procedure type, performance 
status, stage, Charlson index and FEV1 were again found to be significantly 
associated with early post-operative death, with similar odds ratios to the initial 
analysis (Tables 6-4 and 6-5).  
Repeat analysis excluding the 83 records (0.7%) which used staging version 7 to 
record stage and (also excluding the single record in which staging version was 
not recorded) produced results which were almost identical to those displayed in 
tables 1 and 2. 
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Table 6-4: Factors associated with death within 90 days of surgery for patients 
with records of performance status, stage, and lung function. 
  Overall N=3,319 Died within 90 days of surgery (n=169) 
  n % n % OR 95% CI Adjusted  
OR* 
95% CI 
Sex Female 1,482 44.7 57 3.8 1.00  1.00  
  
Male 1,837 55.3 112 6.1 1.62 1.17-2.25 1.24 0.88-1.75 
     
 
 
  p=0.0030  p=0.2196 
Age  <55 268 8.1 5 1.9 0.27 0.11-0.68 0.32 0.12-0.83 
group 55-59 272 8.2 8 2.9 0.43 0.20-0.92 0.40 0.18-0.88 
 
60-64 583 17.6 18 3.1 0.45 0.26-0.78 0.45 0.25-0.80 
 
65-69 665 20.0 29 4.4 0.64 0.40-1.04 0.61 0.37-1.00 
 
70-74 694 20.9 46 6.6 1.00  1.00  
 
75-79 566 17.1 40 7.1 1.07 0.69-1.66 1.15 0.73-1.82 
 
80-84 236 7.1 18 7.6 1.16 0.66-2.05 1.43 0.80-2.58 
 
85+ 35 1.1 5 14.3 2.35 0.87-6.34 3.17 1.12-9.01 
   
 
 
  p<0.0001**  p<0.0001** 
Ethnicity White 2,769 83.4 146 5.3 1.00    
  
Black 21 0.6 - -     
  
Asian 28 0.8 - -     
  
Other 24 0.7 - -     
  
Missing 477 14.4 23 4.8 0.91 0.58-1.43   
Townsend 1 448 13.5 14 3.1 1.00    
quintile 2 512 15.4 23 4.5 1.46 0.74-2.87   
 
3 531 16.0 39 7.3 2.46 1.32-4.59   
 
4 615 18.5 28 4.6 1.48 0.77-2.84   
(most deprived) 5 772 23.3 38 4.9 1.60 0.86-3.00   
 
Missing 441 13.3 27 6.1 2.02 1.05-3.91   
   
 
 
  p=0.3325**   
PS 0 1,674 50.4 51 3.0 1.00  1.00  
  
1 1,390 41.9 97 7.0 2.39 1.69-3.38 1.89 1.31-2.72 
  
2 215 6.5 19 8.8 3.08 1.78-5.33 2.39 1.34-4.28 
  
3-4 40 1.2 2 5.0 1.67 0.39-7.13 1.67 0.27-5.11 
     
 
 
  p<0.0001**  p=0.0055** 
Per cent >80% 1,508 45.4 58 3.8 1.00  1.00  
predicted 60-79% 1,145 34.5 58 5.1 1.33 0.92-1.94 1.25 0.85-1.84 
FEV1 40-59% 557 16.8 43 7.7 2.09 1.39-3.14 2.01 1.30-3.10 
 
<40% 109 3.3 10 9.2 2.53 1.25-5.09 2.78 1.31-5.88 
   
 
 
  p=0.0001**  p=0.0004** 
Charlson  0-1 2,508 75.6 115 4.6 1.00  1.00  
index  811 24.4 54 6.7 1.22 1.03-1.44 1.19 1.00-1.42 
     
    p=0.0233**  p=0.0514 
Stage IA 949 28.6 30 3.2 1.00  1.00  
 
IB 1,237 37.3 63 5.1 1.64 1.06-2.56 1.42 0.90-2.25 
 
IIA 131 3.9 4 3.1 0.96 0.33-2.78 0.77 0.26-2.27 
 
IIB 614 18.5 41 6.7 2.19 1.35-3.55 1.70 1.01-2.87 
 
IIIA 388 11.7 31 8.0 2.66 1.59-4.46 2.18 1.25-3.81 
   
 
 
  p=0.0001**  p=0.0085** 
Side Right 1,841 55.5 96 5.2 1.00    
  
Left 1,365 41.1 64 4.7 0.89 0.65-1.24   
  
Other 18 0.5 1 5.6 1.07 0.14-8.12   
  
Missing 95 2.9 8 8.4 1.67 0.79-3.55   
     
 
 
  P=0.4988   
Histology Adenocarcinoma 1,155 34.8 43 3.7 1.00  1.00  
(Pre-op) Squamous cell 1,151 34.7 74 6.4 1.78 1.21-2.61 1.08 0.72-1.63 
 
NSCLC NOS 662 19.9 35 5.3 1.44 0.91-2.28 1.03 0.64-1.66 
 
Other 82 2.5 3 3.7 0.98 0.30-3.24 0.83 0.25-2.82 
 
Missing 269 8.1 14 5.2 1.42 0.77-2.63 1.37 0.73-2.60 
   
 
 
  P=0.0538  p=0.8873 
 Segmentectomy/wedge 441 13.3 16 3.6 0.88 0.51-1.52 0.76 0.44-1.33 
Procedure Lobectomy 2,275 68.5 93 4.1 1.00  1.00  
  
Bi-lobectomy 131 3.9 12 9.2 2.37 1.26-4.44 2.37 1.23-4.60 
  
Pneumonectomy 335 10.1 40 11.9 3.18 2.15-4.70 3.36 2.17-5.20 
  
Other 137 4.1 8 5.8 1.46 0.69-3.06 1.10 0.51-2.36 
     
 
  
 p<0.0001  p<0.0001 
OR odds ratio; CI confidence interval; PS performance status; FEV1 forced expiratory volume in 1 second. *ORs are 
adjusted for all other factors for which adjusted ORs are given. All p values calculated using likelihood ratio test; ** LRT p 
for trend. 
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Table 6-5: Factors associated with death within 30 days of surgery for patients 
with records of performance status, stage, and lung function. 
   Overall N=3,319 Died within 30 days of surgery (n=82) 
        n  
  %      n    %   OR  95% CI Adjusted 
OR* 
95% CI 
Sex Female 1,482 44.7 24 1.6 1.00  1.00  
  
Male 1,837 55.3 58 3.2 1.98 1.22-3.20 1.47 0.89-2.44 
     
    p=0.0038  p=0.1244 
Age group <55 268 8.1 2 0.7 0.25 0.06-1.09 0.32 0.07-1.38 
 
55-59 272 8.2 3 1.1 0.38 0.11-1.28 0.36 0.10-1.27 
 
60-64 583 17.6 9 1.5 0.53 0.24-1.17 0.54 0.24-1.22 
 
65-69 665 20.0 20 3.0 1.04 0.56-1.96 1.00 0.52-1.91 
 
70-74 694 20.9 20 2.9 1.00  1.00  
 
75-79 566 17.1 19 3.4 1.17 0.62-2.22 1.26 0.66-2.43 
 
80-84 236 7.1 6 2.5 0.88 0.35-2.22 1.11 0.43-2.86 
 
85+ 35 1.1 3 8.6 3.16 0.89-11.19 4.00 1.04-15.38 
   
    p=0.0015**   
Ethnicity White 2,769 83.4 69 2.5 1.00    
  
Black 21 0.6 - -     
  
Asian 28 0.8 - -     
  
Other 24 0.7 - -     
  
Missing 477 14.4 13 2.7 1.10 0.60-2.00   
Townsend 1 448 13.5 7 1.6 1.00    
quintile 2 512 15.4 12 2.3 1.51 0.59-3.87   
 
3 531 16.0 20 3.8 2.47 1.03-5.89   
 
4 615 18.5 13 2.1 1.36 0.54-3.44   
(most deprived) 5 772 23.3 20 2.6 1.68 0.70-3.99   
 
Missing 441 13.3 10 2.3 1.46 0.55-3.88   
   
    p=0.4889**   
PS 0 1,674 50.4 22 1.3 1.00  1.00  
  
1 1,390 41.9 47 3.4 2.63 1.58-4.38 2.26 1.33-3.85 
  
2 215 6.5 12 5.6 4.44 2.16-9.10 3.74 1.74-8.06 
  
3-4 40 1.2 1 2.5 1.93 0.25-14.65 1.93 0.19-11.39 
     
    p=0.0002**  p=0.0046** 
Per cent >80% 1,508 45.4 28 1.9 1.00  1.00  
predicted 60-79% 1,145 34.5 29 2.5 1.37 0.81-2.32 1.26 0.73-2.17 
FEV1 40-59% 557 16.8 20 3.6 1.97 1.10-3.52 1.76 0.95-3.26 
 
<40% 109 3.3 5 4.6 2.54 0.96-6.72 2.25 0.79-6.39 
   
    p=0.0094**  p=0.0408** 
Charlson  0-1 2,508 75.6 56 2.2 1.00    
index  811 24.4 26 3.2 1.20 0.95-1.52   
     
    p=0.1316**   
Stage IA 949 28.6 14 1.5 1.00  1.00  
 
IB 1,237 37.3 29 2.3 1.60 0.84-3.05 1.32 0.68-2.56 
 
IIA 131 3.9 2 1.5 1.04 0.23-4.61 0.72 0.16-3.32 
 
IIB 614 18.5 21 3.4 2.37 1.19-4.69 1.53 0.73-3.21 
 
IIIA 388 11.7 16 4.1 2.87 1.39-5.94 1.93 0.89-4.23 
   
    p=0.0020**  p=0.1093** 
Side Right 1,841 55.5 43 2.3 1.00    
  
Left 1,365 41.1 32 2.3 1.00 0.63-1.59   
  
Other 18 0.5 1 5.6 2.46 0.32-18.90   
  
Missing 95 2.9 6 6.3 2.82 1.17-6.80   
     
    p=0.1820   
Histology Adenocarcinoma 1,155 34.8 16 1.4 1.00  1.00  
(Pre-op) Squamous cell 1,151 34.7 43 3.7 2.76 1.55-4.93 1.54 0.84-2.84 
 
NSCLC NOS 662 19.9 13 2.0 1.43 0.68-2.98 0.95 0.45-2.04 
 
Other 82 2.5 2 2.4 1.78 0.40-7.88 1.61 0.35-7.30 
 
Missing 269 8.1 8 3.0 2.18 0.92-4.15 1.93 0.80-4.66 
   
    p=0.0063  p=0.3348 
 Segmentectomy/wedge 441 13.3 7 1.6 0.88 0.39-1.97 0.76 0.33-1.74 
Procedure Lobectomy 2,275 68.5 41 1.8 1.00  1.00  
  
Bi-lobectomy 131 3.9 6 4.6 2.62 1.09-6.28 2.33 0.93-5.81 
  
Pneumonectomy 335 10.1 25 7.5 4.39 2.64-7.33 4.07 2.28-7.24 
  
Other 137 4.1 3 2.2 1.22 0.37-3.99 0.92 0.28-3.07 
     
    p<0.0001  p=0.0001 
OR odds ratio; CI confidence interval; PS performance status; FEV1 forced expiratory volume in 1 second. *ORs are 
adjusted for all other factors for which adjusted ORs are given. All p values calculated using likelihood ratio test; ** LRT p 
for trend. 
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Post-hoc analysis: Reference tables 
Given the important effects of procedure type, age, and performance status 
(both in terms of significance and size of effect in the univariate model), the 
percentage of patients who died within 90 days of surgery was calculated 
stratified by procedure type, age, and performance status. Figure 6-11 shows 
these results as a simple cross tabulation, which could be used as a reference 
table for clinicians, giving them quick and easy access to data which could help 
them estimate of a VLPLODUSDWLHQW¶VULVNRIG\LQJ within 90 days of surgery. 
 
 Performance status 
 
Age 0 
 
1 2   0 1 2 
 
<70 
1% 
(1-2) 
1504 
4% 
(2-5) 
907 
8% 
(3-12) 
145 
  8% 
(5-12) 
296 
12% 
(7-16) 
197 
7% 
(-3-17) 
29 
 
70-80 
4% 
(3-6) 
777 
7% 
(5-8) 
780 
10% 
(5-15) 
120 
  20% 
(12-28) 
95 
14% 
(6-21) 
87 
24% 
(1-46) 
17 
 
>80 
8% 
(3-12) 
144 
7% 
(3-11) 
200 
23% 
(7-39) 
30 
  25% 
(-14-64) 
8 
19% 
(-3-40) 
16 
0# 
- 
0 
  
LOBECTOMY 
  
 
PNEUMONECTOMY 
 
95% confidence intervals shown in parenthesis; italics show total number of patients in 
each category; #No deaths recorded 
 
Figure 6-9: Proportions of patients who died within 90 days of surgery for NSCLC 
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6.3.4 Discussion 
For people undergoing surgical resection with curative intent for NSCLC, post-
operative mortality was 3.0% within 30 days and 5.9% within 90 days. Patient 
demographic, co-morbidity and tumour-related features were similar in those 
who died within 30 days and those who died 31-90 days after surgery. 
Increasing age, performance status and procedure type were strongly associated 
with an increased risk of early post-operative death.  
Strengths 
The major strengths of this study are the large sample size, the nationally 
representative nature of the lung cancer cases included, and the use of English 
data to inform UK practice. No previous study has examined risk factors for post-
operative mortality in NSCLC based on a UK population or UK surgical practice. 
The definition of surgery was carefully considered prior to conducting the 
analyses and the decision was made to use surgical procedures recorded in HES 
rather than those recorded in the NLCA. All NHS trusts submit data to HES 
through clinical coding and since 2006 this has been used to generate tariffs for 
hospital services. It is unlikely, therefore, that procedures would take place 
without being coded in HES, and the accuracy of clinical coding in the NHS is 
audited annually.(91)   
Limitations 
The main weakness of this study is the amount of missing data. The variable 
with the greatest proportion of missing data was lung function (percentage 
predicted FEV1 was missing in 63% of cases) and it is possible that with more 
data on lung function this may prove to be a better predictor of mortality than 
performance status or co-morbidity score; this would be important as it varies 
more widely and is more objectively measured than performance status. All 
variables were analysed using a separate category for missing data, rather than 
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imputing figures, to ensure that the results were a true representation of the 
available data. The missing data must also be taken in context, and given the 
size of the study it was still possible to analyse data on lung function for over 
4,500 individuals. 
When using HES data to calculate Charlson index a score of zero was assigned to 
any individual who either had no records of hospital admission in the HES 
database, or had no record of an ICD-10 code relating to any of the diagnoses in 
the Charlson index.(90) This method may have missed diagnoses which were 
only recorded in primary care, however 95% of patients in this study had at 
least one complete inpatient episode prior to their procedure date and all 
relevant or major co-morbidities (all Charlson co-morbidities are major co-
morbidities) should be recorded in each episode, particularly since the 
introduction of payment by results for NHS hospitals in 2006.  
It was not possible to tell at which point in the patient pathway information on 
patient fitness was entered into the NLCA database and therefore we cannot be 
sure that performance status in particular reflects that of the patient at the time 
of surgery. The NLCA team suggest that clinicians or administrators enter the 
data at the time the patient is first discussed at an MDT meeting, but it is 
possible to update and replace entries after this point. It would, however, be 
unusual for a treatment with curative intent to take place a long time after a 
diagnosis of lung cancer was made and therefore we expect the majority of 
WKHVHGDWDWRUHIOHFWWKHSDWLHQW¶VFRQGLWLRQDWWKHWLPHRIVXUJHU\ 
Additional data 
Whilst ethnicity is recorded in HES, the majority of patients in the English NLCA 
are white and therefore there were insufficient data to assess whether ethnicity 
affected the outcome. This must be considered when applying these results to 
ethnic minorities in clinical practice. 
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Data on trust factors such as case-load, number of specialist thoracic surgeons 
or number of intensive care beds were not available for this study. It would be 
interesting and important for future service provision to understand the effect of 
these factors on post-operative mortality.  
This study is based on data from 2004 to April 2010. This is more recent than 
any previous study however surgical practice is changing with more video-
assisted thoracic surgery (VATS) and minimally invasive procedures. (195, 196) 
In the future there is likely to be a need for a study investigating whether the 
factors which affect mortality following these procedures differ from the open 
procedures which currently dominate practice.  
Previous studies 
There are few previous reports of 90-day mortality following surgery for lung 
cancer. One Dutch group reported 3.9% 30-day and 6.8% 90-day mortality after 
lobectomy, bi-lobectomy, or pneumonectomy between 2000 and 2008.(197) 
These figures are very comparable to the results of the current study.  
Almost as many people died between 31 and 90 days as in the first 30 days after 
lung cancer resection in our study. Many previous studies included death prior to 
hospital discharge in their definition of 30-day mortality to account for people 
who were alive longer than 30 days due to improvements in perioperative 
management and intensive care. Discharge practices, however, vary between 
hospitals, and there remain a substantial proportion of patients who die after 
discharge but before 90 days.(198) One of the important findings from this study 
is that the features of patients who die within the first 30 days of surgery are no 
different to those of patients who die between 31 and 90 days post-operatively. 
Since post-operative recovery takes several months, perhaps patients should be 
provided with an estimate of their risk of death within 3 months, instead or as 
well as within 1 month.   
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Clinical relevance 
It is important that clinicians are aware of the factors (age, procedure type and 
performance status) which have the greatest effect on risk of early postoperative 
mortality, and that they provide their patients with sufficient information about 
risk for them to make an informed choice about treatment. 
Using the proportion of people who died within 90 days of surgery two simple 
reference tables were developed which display the percentage of patients who 
died within this post-operative period according to age, performance status and 
the necessary procedure type.  These are designed to provide clinicians with 
HDV\DFFHVVWR8.GDWDRQZKLFKDQHVWLPDWLRQRIDSDWLHQW¶VPRUWDOLW\ULVNFDQ
be based. These tables were developed using data on considerably more 
procedures which were performed specifically for lung cancer, and considerably 
more deaths, than previous studies,(181) however estimates for risk in 
subgroups with small numbers of procedures (the high risk categories) must be 
interpreted with caution. The population based data in these tables must also be 
considered in context if they are to be used to assist in the estimation of risk for 
an individual patient; co-morbidities, pre-operative lung function and stage also 
have an effect even after adjusting for performance status, and women have a 
slightly lower risk of early mortality than men.  
With the wide availability of computers and portable technology such as smart 
phones, a more complex risk prediction tool could be used in the clinic setting 
with almost as much ease as these reference tables. In the next section I will 
therefore go on to produce a risk prediction model which includes several 
additional factors and should therefore estimate post-operative risk for an 
individual patient with a greater degree of accuracy ± however this will require 
validation in an independent dataset.  
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6.4 Generation of a new risk prediction model  
6.4.1 Aims 
The aims of this section were to construct a predictive model using the results of 
multivariate analysis of risk factors for early mortality and to compare the new 
model with Thoracoscore (chapter aims 4 and 5). 
6.4.2 Methods 
The predictive score comprised the coefficients and constant from the logistic 
regression model described in section 6.3, restricted to the 3,319 records (169 
deaths) with complete data on performance status, stage and lung function 
(table 6-4). Variables which were significantly associated (p<0.1) with 90-day 
mortality in the multivariate analysis were included in the final score. The 
calculation of percentage risk was based on the methods used by Falcoz et al. 
(170) 
Ninety-day mortality was chosen because a substantial number of deaths 
occurred between 31 and 90 days, and although the traditional postoperative 
period is just 30 days there is evidence that recovery after lung cancer resection 
takes at least 3 months in the majority of cases.(194) There were no significant 
differences in the effects of the major contributing factors for death within 31-90 
compared with 30 days and there were more deaths within 90-days increasing 
the power and therefore the accuracy of the model. 
The predictive score was compared with Thoracoscore because it is 
recommended in national guidelines.(25) The coefficients comprising the final 
model were tabulated with those which make up Thoracoscore and inspected to 
determine whether there were any major differences in contributing factors or 
weighting. To demonstrate the function of the score, and to allow further 
comparison with Thoracoscore, both scores were applied to hypothetical low, 
moderate, and high risk patients. 
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6.4.3 Results 
Age, procedure type, performance status, stage, Charlson index and were 
significantly associated with 90-day mortality in the multivariate model. Sex, 
ethnicity, Townsend quintile, side of surgery and histological subtype were not 
independently associated with 90-day mortality in this analysis but given the 
ease of accurately recording sex this variable was retained in the final model. 
 The coefficients and constant from the multivariate model are presented in 
Table 6-6. The probability of death within 90 days is calculated in two steps as 
follows: 
1) Odds = exp (total of coefficients + constant) 
2) Probability of death = odds / (1+odds) 
,ZLOOUHIHUWRWKLVQHZULVNSUHGLFWLRQPRGHODVWKHµ1/&$VFRUH¶IRUWKHSXUSRVH
of comparison with Thoracoscore and in the discussion. 
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Table 6-6: Coefficients from NLCA score and Thoracoscore 
    Coefficient 
    Thoracoscore (170) NLCA data 
Definition of early mortality 30 days or in-hospital 90 days 
Number of deaths 218 169 
Age (years) <55 - - 
  
55-65 0.77 0.31 
  
>65 1.01  
  
66-75  0.97 
  
>75  1.40 
Sex Female - - 
  
Male 0.45 0.23 
ASA score  0  
  
 0.61  
Performance  0  - 
status   -  
  
1-2  0.68 
  
 0.69 0.2Á 
MRC dyspnoea  -  
score  0.91  
% predicted  >80%  - 
FEV1 61-80%  0.20 
  
40-60%  0.69 
  
<40%  0.95 
Priority Elective -  
  
Urgent/emergency 0.84  
Procedure class Other a -  
(Bi-)lobectomy, wedge, or segmentectomy  - 
  
Other b  0.07 
  
Pneumonectomy 1.22 1.16 
Diagnosis group Benign -  
  
Malignant 1.24  
Comorbidity  0 -  
score* 1-2 0.74  
  
 0.91  
Charlson  0-1  - 
index   0.33 
Stage 1a  - 
  
1b  0.42 
  
2a or 2b  0.51 
  
3a  0.84 
  Constant  -7.37 -5.28 
 
MRC Medical Research Council, ASA American Society of Anaesthesiologists grade, FEV1 forced expiratory 
volume in 1 second; *Number of significant co-morbid conditions including: smoking, history of cancer, chronic 
obstructive pulmonary disease, diabetes mellitus, arterial hypertension, peripheral vascular disease, obesity and 
alcoholism; - indicates baseline group; Á 2QO\  patients and 2 deaths in this group. a Other includes 
mediastinoscopy or other mediastinal surgery, wedge resection, lobectomy or bi-lobectomy. b Other includes 
procedures listed in Appendix E.   
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Table 6-7 shows the predicted outcomes using the NLCA score and Thoracoscore 
for three hypothetical cases. Predicted mortality using the NLCA score was very 
similar to that of Thoracoscore for the low risk patient, slightly higher for 
medium risk and almost double for the high risk patient. 
Table 6-7: Patient features and predicted outcomes 
Description of patient Estimated risk of death 
LOW RISK: 56 y/o female, MRC 1, ASA 2, PS 0, FEV1 
81%, hypertension, ex-smoker, NSCLC stage 1b, elective 
lobectomy 
90-day mortality (NLCA score) 1.0% 
In hospital mortality (Thoracoscore) 1.1% 
MODERATE RISK: 70 y/o male, MRC 2, ASA 3, PS 1, 
FEV1 65%, COPD, hypertension, smoker, NSCLC stage 2b, 
elective lobectomy 
90-day mortality (NLCA score) 6.4%  
In hospital mortality (Thoracoscore) 4.1% 
HIGH RISK: 81 y/o male, MRC 4, ASA 3, PS 2,  FEV1 
50%, COPD, ischaemic heart disease, hypertension, ex-
smoker, diabetes, NSCLC stage 2b, elective pneumonectomy 
90-day mortality (NLCA score) 43.0% 
In hospital mortality (Thoracoscore) 26.2% 
y/o years old, MRC Medical Research Council dyspnoea score, ASA American Society of Anaesthesiologists grade, 
PS performance status, FEV1 forced expiratory volume in 1 second, NSCLC Non-small cell lung cancer COPD 
Chronic obstructive pulmonary disease.  
 
6.4.4 Discussion 
This analysis shows that there are sufficient data in the NLCA to produce a 
model to estimate the risk of death within 90-days after lung cancer surgery. 
This is the first risk score to consider deaths which occur more than 30 days 
after surgery and the first to be developed based on a UK lung cancer population 
and UK surgical practice.  
Strengths 
The main strengths of the study are the large sample size and the 
representative nature of the study population. The data on lung function are 
particularly important as this is an objective measure of patient fitness in 
contrast to performance status, MRC dyspnoea score and ASA grade, all of which 
are subject to different interpretations and assignment by different clinicians. 
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Limitations 
The main limitation of this study was the absence of a suitable independent 
dataset in which to test the performance of the score. Although it has not been 
validated as part of this study this will be possible in the future and is discussed 
further in Chapter 9 (section 9.2.2). 
The components of the model were restricted to the data that were available in 
the NLCA and HES at the time of the study. There were insufficient data to 
calculate predicted postoperative lung function which was found to predict early 
mortality in the ESOS study,(181) and the ASA and MRC dyspnoea scores are 
not recorded in the NLCA. It is possible that these variables would have been 
significantly associated with 90-day mortality in the NLCA population since they 
were associated with in-hospital mortality in previous studies performed 
elsewhere in Europe.(170, 185)  Smoking data are not available in the NLCA or 
HES data and it has been suggested that continued smoking may be associated 
with adverse outcomes after lung cancer surgery.(199)  
Comparison with Thoracoscore 
Most of the discrepancies between mortality risk estimates using the NLCA score 
and Thoracoscore (Table 6-7) are likely to be due to the longer time period in 
this study (deaths within 90 days compared with deaths in-hospital), and the 
differences in populations studied. The overall in-hospital mortality in the data 
on which Thoracoscore was based was 2.2%, compared with 5.1% 90-day 
mortality in this study. Thoracoscore,(170) was based on a larger number of 
procedures than this NLCA score, and a larger number of deaths (218 in-hospital 
deaths), but even though it is currently used by many clinicians in the UK to 
estimate perioperative mortality risks for patients with NSCLC, it was not 
restricted to patients with lung cancer and has not been validated in this 
population. 
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The other main differences between the two scores are the weighting and 
categories used for age, performance status and co-morbidity and the inclusion 
of ASA grade and MRC dyspnoea score, but not stage or lung function in 
Thoracoscore. Whilst data on both stage and lung function were available to the 
authors of Thoracoscore they did not find them to be significantly associated 
with in-hospital mortality, perhaps due to the better overall health of their 
cohort of patients. 
Age was the most important factor in terms of size of effect on postoperative 
mortality in the current study.  In the UK, almost three quarters of patients 
diagnosed with lung cancer between 2004 and 2010 were over 65 years of 
age,(55) and a recent study suggests that the number of older patients 
undergoing surgical resection for lung cancer is increasing.(76) The mean age of 
patients who had potentially curative resection for NSCLC in the NLCA database 
was 67 years and the effect of age appears to be most important over the age of 
65 years.  Thoracoscore uses 3 age categories: less than 55, 55-64 and greater 
than 64 years, and was developed using a dataset in which the mean age at 
operation was 54.7 years thus potentially underestimating the mortality in the 
older age group.  
Neither score has been validated in a large study of lung cancer patients, and 
prospective evaluation needs to be undertaken as a matter of priority. If the 
NLCA score proves to be a useful clinical tool, care must be taken when applying 
it to people of non-white ethnicity given that they contributed such a small 
proportion of our study data (this is also likely to be the case for Thoracoscore 
although ethnicity is not reported in the publication, (170)). 
Clinical relevance 
The estimation of post-operative mortality risk is a crucial part of management 
of patients with NSCLC. In order to ensure that as many patients as possible are 
offered, and consider having, potentially life-saving surgery, estimates of risk 
 191   
 
must be based on the best available evidence. It is also important to be aware of 
WKHSDWLHQW¶VFRQFHUQVDQGH[SHFWDWLRQVUHJDUGLQJSRVW-operative morbidity and 
mortality.  
The use of early deaths after lung cancer surgery as a measure of performance 
of individual thoracic surgeons, which may be introduced for revalidation, has 
raised concerns over risk-averse patient selection by surgeons. It is clearly 
important that if mortality figures are to be used in this way they are adjusted 
for the factors which are strongly associated with early post-operative death and 
ideally fully adjusted. There is potential to use the NLCA risk prediction model to 
adjust mortality figures so that surgeons are not any less inclined to offer 
surgery to a patient of borderline fitness.  
In addition to surgery, new techniques including stereotactic radiotherapy and 
radio-frequency ablation are starting to become available for the treatment of 
early stage lung cancer. These treatments are less invasive and it is thought that 
they provide the possibility of cure in patients for whom surgery may either have 
extremely high risk or for patients who are unwilling to accept the level of risk 
associated with whatever procedure they would require. A tool which estimates 
the risk of 90-day mortality following surgery in patients who are treated with 
stereotactic radiotherapy could prove valuable in comparing the observed 
outcome with the predicted outcome from surgery. 
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6.5 Chapter summary 
In this chapter I have described the use of the linked NLCA-HES-ONS data to 
assess risk factors for early death after lung cancer resection and to develop a 
risk prediction model for use in clinical practice. 
This work was published in Thorax in May 2013, (200) accompanied by an 
editorial on the topic of operative risk in lung cancer. (201) I also presented 
some of the data at the 11th Annual British Thoracic Oncology Group conference 
in January 2013, at the East Midlands Cancer Network meeting in November 
2012, and as a poster abstract at the British Thoracic Society Winter Meeting in 
December 2012.  
The next phase of this research should include a validation study using an 
independent dataset and I will discuss this further in Chapter 9. In the next two 
chapters I will use the same linked dataset and similar statistical techniques to 
investigate treatment decisions and survival for people with small cell lung 
cancer. 
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CHAPTER 7: VALIDATION OF RECORDS OF 
CHEMOTHERAPY AND RADIOTHERAPY  
This chapter describes a validation study in which records of chemotherapy for 
small cell lung cancer in the HES and NLCA databases are compared with the 
aim of determining the most appropriate definition of chemotherapy for future 
studies. This is followed by an exploration of the data on radiotherapy in HES 
and the NLCA. 
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7.1 Introduction 
7.1.1 Background 
Small cell lung cancer (SCLC), as described in Chapter 1, makes up a relatively 
small proportion of the overall lung cancer burden in the UK and is declining in 
incidence as the prevalence of cigarette smoking declines. It remains, however, 
an aggressive disease which is often advanced at presentation and often rapidly 
fatal, despite treatment.  
The NLCA has been used to investigate whether there are inequalities in care for 
people with SCLC, in particular in the receipt of chemotherapy (which is the 
mainstay of treatment for this disease).(83) Both the NLCA and HES contain 
data on treatment with chemotherapy, but to date these have not been 
validated or compared. The NLCA - HES linkage for the purpose of generating a 
measure of co-morbidity means it is now possible to compare records between 
the two databases and to analyse patient features and outcomes in order to 
assess the validity of treatment records in each database. 
7.1.2 Rationale for this study 
It is important to determine the most accurate means of identifying whether or 
not a patient was treated so that future studies are consistent in their methods 
and are not affected by errors in data entry or recording bias. 
In Chapter 8 I will describe a study investigating which factors which were 
associated with increased likelihood of being treated with chemotherapy for 
SCLC and the effect that this had on survival. It was therefore important to use 
a variable which accurately identified people who received chemotherapy and 
those who did not.  
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7.1.3 Aim of this chapter 
The aim of the main study described in this chapter was to assess the validity of 
records of chemotherapy for SCLC in the HES and NLCA databases in order to 
agree a definition for future studies. This was done by:  
1. Identifying patients with SCLC who had a record of chemotherapy in the 
NLCA, or in the linked HES data, or in both (section 7.2); 
2. Examining and comparing the features of these patients (including 
survival) according to the database in which chemotherapy was recorded 
(section 7.2); 
 
7.1.4 Radiotherapy records 
Radiotherapy is also an important part of the treatment for some people with 
SCLC. As part of this study I also attempted to compare records of radiotherapy 
in the NLCA and HES (section 7.3), however, as will be explained, the majority 
of radiotherapy records are not captured in the inpatient HES data and therefore 
it was not possible to assess the completeness of recording in the NLCA. 
 196 
7.2 Records of chemotherapy in HES and the NLCA 
7.2.1 Methods 
Study population 
The July 2013 NLCA-HES extract (see section 2.2.4) was used for this study.  
This included patients first seen between 1st January 2004 and 31st December 
2011. In this extract HES data were available up to 31st March 2012 and 
although new patient records added to the NLCA after the end of 2011 were not 
included, data were entered for the existing patients up to June 2012.  
To ensure each patient had a post-diagnosis follow-up period of at least 3 
months, during which chemotherapy could have been given and recorded in both 
datasets, those diagnosed (or with a start date) after 31st December 2011 were 
excluded. Patients diagnosed before 2004, those for whom it was not possible to 
calculate a start date, and any records with a date of death on or before their 
start date were also excluded.  
To allow fair comparison between HES and the NLCA, any cases with a record of 
chemotherapy in the NLCA after 31st March 2012 were excluded from this 
analysis. 
Cases with histologically confirmed SCLC were identified using pre-treatment 
histology where this was available and post-treatment histology where the pre-
treatment variable was missing. 
Covariates 
Histology, stage and performance status were defined as described in section 
2.2.5. Age refers to the NLCA variable age at time of diagnosis. Route of referral 
was also obtained from the NLCA. 
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NLCA records of chemotherapy 
Chemotherapy is recorded in the NLCA in four fields: 
x the date on which it was decided that the patient should receive 
chemotherapy treatment, 
x the date on which the first dose of chemotherapy was administered,  
x the code for the hospital or trust where the patient received 
chemotherapy, and 
x the reason that chemotherapy was given.  
The reason for chemotherapy can be: chemotherapy alone, chemotherapy 
combined with radiotherapy, adjuvant chemotherapy post-surgery, or induction 
chemotherapy to downstage prior to surgery. There is only a date for the first 
and not subsequent doses, and there is no information regarding the number of 
cycles or which drugs were given. 
HES records of chemotherapy 
In the HES database there are two ICD-10 codes which relate to chemotherapy 
administration: Z51.1 (chemotherapy for neoplasm) and Z51.2 (other 
chemotherapy). There are also several OPCS-4 codes relating to chemotherapy 
procurement and delivery. The ICD-10 code should be recorded as a diagnosis 
and the OPCS-4 code should be recorded as a procedure for each episode where 
chemotherapy was given. 
Following discussion with clinical coding staff at Nottingham University Hospitals 
NHS Trust, both the chemotherapy delivery and procurement OPCS-4 codes, as 
listed in Appendix F, but not the ICD-10 codes, were used to identify cases that 
had chemotherapy. Chemotherapy coding follows national guidelines and 
Nottingham University Hospitals follow a flow chart which is based on these 
guidelines (also shown in Appendix F). 
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Dates 
Chemotherapy regimens for other cancers which were given before or after the 
diagnosis of lung cancer might have been found in HES but would not be 
recorded in the NLCA. Therefore HES episodes were excluded if they were more 
than 3 months before or 6 months after the NLCA start date. For continuity and 
to remove any possible errors in data entry, NLCA chemotherapy dates, trusts 
and reasons were deleted (re-coded to missing) if the date was outside this 
range. 
Given that there may be several records of chemotherapy administration per 
patient in HES, after the above exclusions, the earliest date was considered to 
be the date of first dose (later dates were assumed to reflect subsequent doses 
or cycles). 
Statistical methods 
Records were grouped according to whether chemotherapy was recorded in both 
databases, in neither database or in one database only (as shown in Table 7-1). 
A Venn diagram was constructed to show the overlap between these groups. 
NLCA only records were sub-divided into those with a chemotherapy date with or 
without trust and/or reason, trust with or without reason but no date, or reason 
but no trust or date. People with a record of chemotherapy in HES and any one 
of a date of first dose, trust of administration or reason for chemotherapy were 
considered to have chemotherapy recorded in both datasets (groups 1, 1a and 
1b). 
For each of groups 1-5 the average age and median survival from date of 
diagnosis was calculated. Kaplan Meier survival curves were plotted and 
examined for similarities and differences between the groups that might provide 
an insight into the validity of records in each dataset. The distributions of 
performance status, stage, and source of referral were tabulated for each of the 
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groups, as was the distribution of chemotherapy records according to year of 
diagnosis and region (cancer network) where the patient was first seen. 
Table 7-1: Groups according to where records of chemotherapy were found 
Group 
 
Criteria 
1=Both Date of chemotherapy in HES  
AND  
Date of chemotherapy in NLCA 
1a Date of chemotherapy in HES  
AND  
Trust of chemotherapy in NLCA 
NO date of chemotherapy in NLCA 
1b Date of chemotherapy in HES  
AND  
Reason for chemotherapy in NLCA 
NO date or trust of chemotherapy in NLCA 
2=HES only Date of chemotherapy in HES 
NO reference to chemotherapy in NLCA 
3=NLCA only (date) Date of chemotherapy in NLCA 
NO reference to chemotherapy in HES 
4=NLCA only (trust or reason) Procedure type and/ or trust of chemotherapy in 
NLCA 
NO date of chemotherapy in NLCA 
NO reference to chemotherapy in HES 
5=Neither NO reference to chemotherapy in either database 
 
 
Final definition of chemotherapy 
As with the analysis of records of surgery (Chapter 5), patients with a record of 
having had chemotherapy in both HES and the NLCA were considered very likely 
to have actually had chemotherapy, and those without a record in either were 
considered unlikely to have received chemotherapy. Cases with records of 
chemotherapy in both datasets (group 1) and those in any other group(s) with 
similar features to this group will therefore be used to define receipt of 
chemotherapy for future studies. 
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7.2.2  Results 
There were 178,415 records in the NLCA database with a date first seen 
between 1st January 2004 and 31st December 2011. After excluding 1,803 
patients who were diagnosed outside the study period and 1,462 with start dates 
on or after the recorded date of death, 175,149 remained. One hundred and six 
cases had a record of chemotherapy in the NLCA which started after 31st March 
2012 and of the remaining records 18,398 had histologically confirmed SCLC. 
The exclusions and derivation of the study population are shown in figure 7-1. 
 
 
NLCA National Lung Cancer Audit; SCLC Small cell lung cancer 
Figure 7-1: Exclusions and derivation of study population for chemotherapy 
record validation in SCLC 
 
NLCA records of chemotherapy 
There were 11,867 records with a chemotherapy start date recorded in the NLCA 
which was less than 3 months before and 6 months after the date of diagnosis. 
A further 694 had a trust of administration or reason for chemotherapy but no 
date of first dose.  
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HES records of chemotherapy 
There were 10,221 records which contained at least one of the OPCS-4 codes for 
chemotherapy (Appendix F), dated between 1st 2004 and March 31st 2010, and 
less than 3 months before / 6 months after the NLCA start date. 
Comparison of databases 
Chemotherapy was recorded in both databases in 9,484 (51.5%) of the 18,398 
cases with SCLC; 5,100 (27.7%) had no record of chemotherapy in either 
database. Figure 7-2 shows the distributions of records of chemotherapy for 
SCLC in HES and the NLCA, and where these overlapped. 
           
NLCA National Lung Cancer Audit; HES Hospital Episodes Statistics; percentages 
indicate proportion of overall small cell lung cancer population, N=18,398 
 
Figure 7-2: Venn diagram depicting the overlap between records of 
chemotherapy in HES and the NLCA 
 
Date of first dose  
Of the 9,328 cases where the date of first chemotherapy dose was evident in 
both HES and the NLCA the two dates were exactly the same in 6,925 (74%) 
Group 1: Both 
9,484 (51.5%) 
9,328 (51%) dates in both 
109 (<1%) HES date, NLCA 
trust / type only (Group 1a) 
47 (<1%) HES date, NLCA 
type only (Group 1b) 
Group 2: 
HES only 
737 (4.0%) 
Group 3 &4:      
NLCA only  
3,077 (16.7%) 
 2,539 (13.8%) date  
538 (2.9%) trust / 
type  
Group 5: Neither  
5,100 (27.7%) 
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cases. Of the remaining 2,403, in 1,652 (69%) cases the HES date was the later 
of the two dates. In 8,099 cases (87% of the overall number) the dates were 
within 1 week of each other.  
Patient features 
Overall the features of patients with chemotherapy recorded in HES only or the 
NLCA only (groups 2 and 3) were similar to those of patients with records in 
both databases (group 1). Patients in group 5 (who had no record of 
chemotherapy) and group 4 (who had a trust or reason for chemotherapy 
recorded in the NLCA but no date) were older than those in groups 1-3. The 
mean age was similar across groups 1-3 (Table 7-2). 
There was a much higher proportion of patients with extensive stage and also a 
higher proportion with poor performance status (3-4) in groups 4 and 5 than in 
groups 1-3. A lower proportion of patients in groups 4 and 5 we referred by their 
general practitioner compared with groups 1-3. Performance status and stage 
were missing in a higher proportion (37.3% and 33.5% respectively) of those 
with chemotherapy records in HES only than in any other group (Table 7-2).  
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Table 7-2: Features of patients with small cell lung cancer according to where chemotherapy was recorded  
N=18,398 Record of chemotherapy 
 Both 
Group 1 
HES only 
Group 2 
NLCA only (date) 
Group 3 
NLCA only (no date) 
Group 4 
Neither 
Group 5 
 
n=9,484 n=737 n=2,539 n=538 n=5,100 
Mean age (years) 66.3 66.1 67.1 70.9 72.8 
Stage (% of non-missing)                                                 Limited 37.6 39.4 36.8 24.2 21.5 
Extensive 62.4 60.6 63.2 75.8 78.5 
Missing stage (% of total) 17.5 33.5 22.5 29.4 22.4 
Performance status (% of non-missing)                                 0-1 67.2 63.7 60.9 36.1 24.8 
2 22.9 23.1 28.8 30.4 27.2 
3-4 9.8 15.2 10.3 33.5 48.0 
Missing performance status (% of total) 17.3 35.7 18.7 27.3 23.6 
Source of referral: (% of non-missing)   Emergency admission 13.9 13.7 12.3 17.4 22.8 
General Practitioner referral 56.2 53.5 54.9 37.6 38.7 
Consultant referral 18.6 17.9 19.6 24.7 20.1 
Other 5.4 9.0 6.5 8.1 6.4 
Emergency department 6.0 5.9 6.7 12.3 11.1 
Missing source of referral (% of total) 4.4 8.0 5.4 8.0 4.9 
Median survival after diagnosis (days) (IQR)* 268 (152-434) 242 (106-415) 230 (83-391) 36 (17-111) 32 (14-79) 
NLCA National Lung Cancer Audit; HES Hospital Episodes Statistics; Groups 1-5 defined in text and table 7-1; IQR Interquartile range. *Survival is calculated from start date or 
date of diagnosis ; **Date of first chemotherapy dose as recorded in HES unless NLCA only.  
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Overall survival 
Figure 7-3 shows the overall survival for patients with SCLC according to where 
chemotherapy treatment was recorded. Median survival for patients in groups 4 
and 5 was similar (36 and 32 days respectively) and considerably shorter than 
that of patients in groups 1-3 (Table 7-2). 
 
 
Figure 7-3: Survival after diagnosis by to chemotherapy records 
 
Chemotherapy records by year and network 
The proportion of patients with a record of chemotherapy in both datasets 
increased over time from 28% in 2004 to 57% in 2011. The proportion in HES 
only decreased over the same period from 6% to 3% but the proportion in the 
NLCA only decreased between 2004 and 2008 (31.5% to 11.6%) then stayed at 
this level between 2008 and 2011 (Table 7-3).  
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Table 7-3: Distribution of records of chemotherapy in people with small cell lung 
cancer by year of diagnosis 
Year of Record of chemotherapy (% of year total) 
Diagnosis  
(no. of patients) 
Both 
databases 
Group 1 
HES 
only 
Group 2 
NLCA 
only (date) 
Group 3 
NLCA only 
(no date) 
Group 4 
Neither 
 
Group 5 
2004 (537) 27.6 6.2 31.5 6.5 28.3 
2005 (1,311) 35.7 5.0 24.3 10.8 24.2 
2006 (1,819) 46.4 4.8 17.5 9.0 22.2 
2007 (2,069) 54.0 5.3 12.1 3.3 25.3 
2008 (2,690) 53.4 4.8 11.6 1.3 28.9 
2009 (3,199) 53.7 3.1 11.7 0.8 30.7 
2010 (3,297) 54.1 3.3 11.8 1.1 29.8 
2011 (3,476) 56.7 3.0 11.7 0.9 27.7 
NLCA National Lung Cancer Audit; HES Hospital Episodes Statistics 
Groups 1-5 defined in text and table 7-1 
 
Cancer networks were described in section 1.4. When the distribution of 
chemotherapy records was analysed by network first seen there were two 
outliers; these are highlighted in table 7-4. In network 3, an unusually low 
proportion (8.7%) of cases had chemotherapy records in both databases; 
however 51% had a record in the NLCA only which was higher than any other 
network. The proportion with no record of chemotherapy for this network (31%) 
was similar to the overall figure (28%). For patients first seen in network 21, 
there was also a low proportion with records of chemotherapy in both databases 
(12%) but a high proportion (55%) did not have a record of chemotherapy in 
either database. 
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Table 7-4: Distribution of records of chemotherapy in HES and the NLCA by year 
of diagnosis 
Network first 
Seen* 
(No of patients) 
Record of chemotherapy (% of network total) 
Both 
 
Group 1 
HES 
only 
Group 2 
NLCA 
only (date) 
Group 3 
NLCA only 
(no date) 
Group 4 
Neither 
 
Group 5 
1 (632) 65.7 2.5 6.7 - 25.2 
2 (1,192) 34.1 5.7 23.9 8.4 27.9 
3 (1,077) 8.7 0.4 51.2 8.6 31.1 
4 (1,417) 55.9 2.3 16.5 1.6 23.7 
5 (535) 64.7 3.4 6.5 5.2 20.2 
6 (912) 65.7 7.0 4.2 2.5 20.6 
7 (823) 48.0 3.5 17.1 2.1 29.3 
8 (365) 55.3 8.2 7.1 2.7 26.6 
9 (428) 34.3 3.6 22.6 1.2 38.3 
10 (331) 48.6 6.0 8.2 3.0 34.1 
11 (421) 66.0 2.9 5.2 4.0 21.9 
12 (396) 58.6 4.6 11.1 6.8 18.9 
13 (512) 60.2 9.8 2.7 3.1 24.2 
14 (319) 59.6 6.9 2.2 0.6 30.7 
15 (781) 58.3 3.3 9.7 - 28.7 
16 (230) 64.8 3.5 4.8 - 27.0 
17 (455) 50.1 5.7 19.8 0.2 24.2 
18 (263) 60.1 3.4 1.1 7.2 28.1 
19 (623) 46.2 4.7 11.1 0.2 37.9 
20 (558) 54.5 2.2 18.1 1.4 23.8 
21 (244) 12.3 - 31.6 0.8 55.3 
22 (464) 42.9 1.5 16.6 5.4 33.6 
23 (284) 51.4 7.0 9.5 2.1 29.9 
24 (496) 51.4 5.0 10.5 0.2 32.9 
25 (2,107) 60.1 2.8 6.9 2.4 27.8 
26 (700) 53.3 6.4 7.3 2.0 31.0 
27 (582) 46.7 2.4 15.6 4.1 31.1 
28 (1,427) 59.9 4.5 10.2 1.3 24.1 
Other (4) 50.0 - - - 50.0 
*Network names replaced with numbers to preserve anonymity; NLCA National Lung 
Cancer Audit; HES Hospital Episodes Statistics; Groups 1-5 defined in text and table 7-1 
7.2.3 Interpretation and definitions 
Cases which did not receive chemotherapy 
The features of people with SCLC who had a trust and / or a reason but no date 
for chemotherapy coded in the NLCA (group 4) were very similar to those of 
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people who did not have any reference to chemotherapy in either database. This 
suggests that these people may not, have had chemotherapy and that the trust 
or reason may have been entered in error or not updated when treatment plans 
changed. These people were therefore considered not to have received 
chemotherapy for the rest of the work in this thesis. 
Cases which received chemotherapy 
The features of people who had a start date for chemotherapy in the NLCA only 
or a code (and date) for chemotherapy in HES only, had similar age, lung 
function and performance status to those who had records in both databases. 
Median survival was also similar, although slightly worse for those who only had 
chemotherapy recorded in the NLCA compared with those who had it recorded in 
both datasets. People will therefore be considered to have had chemotherapy 
treatment if a chemotherapy date was recorded in either database. 
Date of first dose 
Where chemotherapy is only recorded in one database that date will be used; 
where it is recorded in both databases the NLCA date will be used because in 
most cases the dates are the same, and in cases where they are different the 
NLCA date is usually the earlier of the two.  
Trusts and networks 
The proportion of patients without a record of chemotherapy in either database 
was unusually high in network 21. Reasons for this are unknown but may include 
a high proportion of patients being treated in the private sector and/or a policy 
of giving more chemotherapy in outpatients. Patients first seen at any of the 
trusts in this cancer network will be excluded from the analysis for the work in 
Chapter 8.   
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7.3 Radiotherapy in HES and the NLCA 
7.3.1 Background 
The use of radiotherapy in the treatment of SCLC is described in detail in section 
1.3.2 but briefly it can be used in two ways: The first is combined with 
chemotherapy either at the same time or one after the other, in a relatively high 
dose over several sessions. This is termed chemo-radiotherapy or radical 
radiotherapy and the aim is to reduce the disease burden and prolong the 
SDWLHQW¶V OLIH LW LVXVHG IRUSDWLHQWVZLWK OLPLWHGVWDJHGLVHDVHZKHUHDOORI WKH
tumour can be captured in one radiotherapy field. 
Secondly radiotherapy can be used to treat or control symptoms which are 
directly related to the tumour. For example, a tumour in the lungs may cause 
the patient to cough up blood, or a tumour which has spread to the bones may 
be painful. This type of radiotherapy tends to be given at a lower dose and often 
only one or two sessions; this is termed palliative radiotherapy and is not 
LQWHQGHGWRSURORQJWKHSDWLHQW¶VOLIH 
Chemo-radiotherapy has been shown to improve survival in clinical trials 
compared with chemotherapy alone, particularly when the two treatments are 
given at the same time.(38, 202, 203) In studies of chemotherapy it is therefore 
important to understand whether or not radiotherapy was also given. The quality 
and extent of radiotherapy data in the NLCA and HES databases is currently not 
known. 
The aim of this study was  
1. to determine the completeness of radiotherapy data in the NLCA  
2. to establish whether the treatment intent could be reliably determined 
from NLCA data, and  
3. to compare NLCA radiotherapy records with those in the HES database.  
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7.3.2 Methods  
Study population 
The same SCLC population was used for this study as in the chemotherapy study 
described in section 7.2. Patients with a record of radiotherapy (rather than 
chemotherapy) given before 2004 or after 31st March 2012 were excluded. 
NLCA records of radiotherapy 
Radiotherapy is recorded in the NLCA in several fields:  
x date of decision to treat with radiotherapy,  
x date radiotherapy was started,  
x trust where radiotherapy was given,  
x anatomical site of radiotherapy (trachea, lung, mediastinum, chest wall, 
brain, bone, skin, or other), and  
x type or intention of radiotherapy (radical, CHART, chemo-radiotherapy, 
adjuvant or palliative). 
There is only a date for the first radiotherapy dose and not subsequent doses (or 
fractions). Patients who respond to first line chemotherapy (with or without 
radiotherapy) may be offered prophylactic cranial radiation (PCI). This is 
intended to reduce the incidence of brain metastases and consequently improve 
survival.(14, 47, 48) In the NLCA there is a separate field for PCI and therefore 
any radiotherapy with anatomical site recorded as µEUDLQ¶LQWKLVfield is likely to 
represent palliative radiotherapy to existing brain metastases. 
HES records of radiotherapy 
In HES there is a code for radiotherapy administration (Z50.0) but this would 
only be recorded in the inpatient HES database for those who had radiotherapy 
as an inpatient or those who attended a day-case unit; radiotherapy is usually 
administered on an outpatient basis. There are also OPCS-4 codes for 
radiotherapy delivery and planning. These are shown in Appendix F but again 
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would only be found in the HES data if radiotherapy was administered as an 
inpatient.  
Following a discussion with clinical coders at Nottingham University Hospitals 
NHS Trust, OPCS-4 codes (and not ICD-10 codes) were used to identify 
radiotherapy in HES. The same methods were used as for the chemotherapy 
study described above to exclude any codes which were dated more than three 
months before or 6 months after the diagnosis of lung cancer and those which 
were prior to 2004. 
Statistical methods 
Records of radiotherapy in the NLCA were identified and the proportion of these 
for which the treatment intent and anatomical site was clear was calculated. 
Records were grouped according to whether radiotherapy was recorded in both 
databases, in neither database or in one database only (as shown in Table 7-2 
above) and the intention was to compare features of patients in each of these 
groups. 
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7.3.3 Results 
The study population was based on the exclusions shown in figure 7-1, excluding 
375 individuals with records of radiotherapy given before 2004 (n=1) or after 
31st March 2012 (n=374), rather than the 106 who received chemotherapy 
outside of this period.  A total of 18,324 cases of histologically proven SCLC 
remained for the analysis. 
NLCA records of radiotherapy 
There were 4,103 cases of SCLC (22.4%) with a start date for radiotherapy in 
the NLCA. A further 934 had a radiotherapy trust or type (treatment intention) 
documented with no date. Of these 5,037 cases, 76% had a record of the type of 
radiotherapy and 48% had a record of the anatomical site. The distributions of 
these variables are shown in table 7-4. Eleven per cent of those where the 
WUHDWPHQW LQWHQWLRQ ZDV µUDGLFDO¶ DQG VHYHQ SHU FHQW RI WKRVH ZLWK WUHDWPHQW
LQWHQWµFKHPR-UDGLRWKHUDS\¶KDGWKHDQDWRPLFDOVLWHUHFRUGHGDVµEUDLQ¶ 
Table 7-5: Treatment intention and anatomical site for patients with 
radiotherapy records in the NLCA 
 
Radiotherapy  %  (N=5,037) 
Type / treatment intention Radical 5.7 
 
CHART 0.1 
Chemo-radiotherapy 18.9 
 Adjuvant 0.3 
 Palliative 50.9 
 Missing 24.1 
Anatomical site Brain 10.1 
 Lung 37.7 
 Missing 41.1 
 Other 11.1 
CHART Continuous Hyper-fractionated Accelerated Radiotherapy 
 
HES records of radiotherapy 
There were only 887 records which contained one of the OPCS-4 codes for 
radiotherapy (Appendix F), dated between 1st 2004 and March 31st 2012, and 
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less than 3 months before / 6 months after the NLCA start date. An extra 259 
records were identified using the ICD-10 codes for radiotherapy however the 
clinical coders had advised that OPCS-4 codes were more likely to be accurate.  
Comparison of databases 
The overlap of records of radiotherapy between the two databases is shown in 
Figure 7-4. 
 
Percentages indicate proportion of overall SCLC population, N=18,324 
 
Figure 7-4 Venn diagram depicting the overlap between records of radiotherapy 
in HES and the NLCA 
 
BOTH: 604 
(3.3%) 
HES only 
283 (1.5%) NLCA only 4,422 
(24.1%) 
 3,499 (19.1%) date  
923 (5.0%) trust / type  
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7.3.4 Interpretation 
Further comparison of patients with radiotherapy recorded in each dataset was 
not felt to be useful because the majority of patients only had a record of 
chemotherapy in the NLCA and the likely explanation that this was that 
radiotherapy was given to most patients on an outpatient basis.  The group with 
radiotherapy recorded in both databases could not, therefore, be used as a 
comparator group to establish the validity of records in each dataset. 
Definition for future studies 
The reason for radiotherapy (whether it was with curative intent or for symptom 
control) is not recorded in HES but is indicated in the NLCA in 76% of cases. Any 
analysis of survival will be strongly affected by the treatment intention (which 
determines the dose and number of sessions) and therefore cases in the NLCA 
with a radiotherapy start date and treatment intent recorded as chemo-
radiotherapy or radical radiotherapy will be used to identify people who received 
chemo-radiotherapy for SCLC in the following chapter. It must be acknowledged 
that this variable has not been validated and that an unknown proportion of the 
records with missing treatment intent also had chemo-radiotherapy but will not 
be captured by this definition.  
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7.4 Chapter summary 
In this chapter I have described and compared the data available on 
chemotherapy and radiotherapy in HES and the NLCA and used survival analyses 
to determine that the most accurate means (within these datasets) of identifying 
people who had chemotherapy for SCLC is the presence of an OPCS-4 code in 
HES and/or a date of chemotherapy first dose in the NLCA. It was not possible to 
perform the complete validation study for radiotherapy however a definition of 
chemo-radiotherapy for SCLC was established. I presented some of this work as 
a poster abstract at the British Thoracic Society Winter Meeting, London, 
2013.(204)  
The following chapter uses this definition to perform a detailed analysis of the 
features of patients with SCLC who received chemotherapy, the number of 
cycles received and the effects that this treatment has on survival. A description 
of the patients who received chemotherapy according to the definition 
established in this is included as part of those results.  
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CHAPTER 8: TREATMENT DECISIONS AND OUTCOMES IN 
SMALL CELL LUNG CANCER 
In this chapter I will describe a study of the characteristics of people with SCLC 
who received chemotherapy. I will then describe the use of HES data to 
determine the number of cycles of chemotherapy that patients were given, and 
the characteristics of patients who completed a 4-cycle course. This is followed 
by a survival analysis taking into account patient and trust-level factors, 
treatment with chemotherapy with or without radiotherapy, and the number of 
chemotherapy cycles.   
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8.1 Introduction 
8.1.1 Background 
The mainstay of treatment for people with small cell lung cancer (SCLC) is 
chemotherapy. The results of clinical trials show that treatment with a platinum 
agent combined with etoposide can result in a median survival of 8-12 months 
for people with extensive stage disease, (35-37) and up to 27 months for those 
with limited stage disease, particularly when combined with radiotherapy.(35, 
38, 39) Since trials tend to include younger patients with relatively good 
performance status the median survival for the full spectrum of patients is likely 
to be less.  
Prompt investigation, diagnosis and review by an oncologist who can initiate 
treatment are thought to be important since the rapid tumour growth means 
that it frequently spreads outside the lung and patients deteriorate quickly in 
terms of their fitness for treatment.  
8.1.2 Rationale for this study 
Current chemotherapy agents for SCLC have significant side effects (as 
GHVFULEHG LQ VHFWLRQ  WKHUHIRUH FOLQLFLDQV PXVW FDUHIXOO\ DVVHVV SDWLHQWV¶
fitness prior to chemotherapy and only treat those who are likely to benefit. It is 
also possible that inequalities in availability of and access to chemotherapy exist 
for SCLC. It is important to determine whether chemotherapy treatment rates 
vary by individual patient factors and/or organisational factors and how these 
are related to survival.  
Data from clinical trials suggest that approximately 75% of patients complete 
the intended number of chemotherapy cycles, (205) but the proportion of 
patients in routine clinical practice for whom this is the case is not known. An 
understanding of the characteristics and outcomes for this group of patients 
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could also help clinicians identify people for whom the risks of starting 
chemotherapy may outweigh the benefits.  
8.1.3 Aims of this chapter 
This aim of the study in this chapter was firstly to update work by Dr Anna Rich 
who used an earlier version of the NLCA-HES database to examine the 
characteristics of people with SCLC who were treated with chemotherapy.(83) 
There are now almost double the number of SCLC cases in the database, and a 
new means of identifying people who had chemotherapy has been defined in this 
thesis (Chapter 7). I also aimed to use HES data to calculate the number of 
chemotherapy cycles received, to determine the factors which were associated 
with completing a course of chemotherapy, and examine survival according to 
number of cycles received. Finally, the aim was to assess organisational factors 
including time from diagnosis to treatment and whether the trust where the 
patient was first seen affected treatment and outcomes.  
The specific aims of this chapter were therefore: 
1. to describe the characteristics of patients with SCLC who received 
chemotherapy (section 8.2);  
2. to describe the characteristics of patients with SCLC who went on to 
complete a full course of chemotherapy (section 8.3); 
3. to use logistic regression to determine the factors which were 
independently associated with a) receiving chemotherapy (section 8.2) 
and b) completing a course (section 8.3); 
4. assess survival according to number of cycles completed (section 8.4); 
and 
5. to quantify overall survival according to patient characteristics and the 
number of cycles completed (section 8.4). 
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8.2 Characteristics of patients and factors associated with 
chemotherapy treatment 
8.2.1 Aims 
The aims of this section were to describe the characteristics of patients with 
SCLC who received chemotherapy and to use logistic regression to determine 
the factors which were independently associated with receiving chemotherapy 
(chapter aims 1 and 3a). 
8.2.2 Methods 
Study population 
The July 2013 extract of the linked NLCA-HES data, which contained NLCA 
records for patients first seen between 1st January 2004 and 31st December 
2011 with linked HES data up to 31st March 2012, was used for this study 
(further details in Chapter 2).  
To give each patient a follow-up period of at least 6 months in both datasets, 
during which chemotherapy could have been given and recorded, those 
diagnosed (or with a start date) after 30th September 2011 were excluded. 
Patients diagnosed before 2006 were also excluded because case ascertainment 
in 2004 and 2005 was known to be lower than in recent years and the more 
recent data allowed a sufficiently large sample size even after excluding these 
records. This study is therefore based on a slightly smaller population than the 
validation study described in Chapter 7 (Figure 7-1).  
Cases of histologically confirmed SCLC were identified and any patients who had 
a record of surgery were excluded. 
Definition of exposure 
First-line chemotherapy treatment was assessed by including any chemotherapy 
JLYHQ LQ WKH ILUVW  PRQWKV DIWHU D SDWLHQW¶V GLDJQRVLV Patients who had 
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chemotherapy were identified by the presence of a chemotherapy start date in 
the NLCA database or an OPCS-4 code for chemotherapy (Appendix F) in HES, 
based on the results of the work in Chapter 7.  
In the Chapter 7 chemotherapy records were included if they were dated within 
3 months before or 6 months after the date of diagnosis or start date. There 
were in fact very few cases with chemotherapy records dated before the start 
date therefore for clarity of methods only chemotherapy records dated on or 
after the start date were included. The time from diagnosis to treatment was 
calculated using the start date and the date of the first record of chemotherapy 
in HES. For patients with records of chemotherapy in the NLCA only the start 
date of chemotherapy was used. 
Covariate definitions 
Data from HES provided the information with which to calculate a Charlson co-
morbidity index, as described in Chapter 2. This was calculated using HES 
episodes which started any time before the chemotherapy start date for patients 
who received chemotherapy and any time up to the date of diagnosis for those 
who did not receive chemotherapy. 
Demographics, histology, stage and performance status were obtained from the 
NLCA and defined as described in section 2.2.5. Age refers to the NLCA variable 
age at time of diagnosis. Route of referral was also obtained from the NLCA. 
Chemotherapy trusts 
The system of hospital trusts in England was described in section 1.4. The NLCA 
records the trust at which the patient is first seen and the trust of chemotherapy 
treatment, which is often but not always the same. The number of patients that 
were both first seen and also treated with chemotherapy at each trust was 
plotted as a proportion of the total number of patients first seen at that trust 
who received chemotherapy at any trust (Figure 8-1, grey bars). For example: 
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Hypothetical Trust A first saw a total of 50 cases of SCLC in the study period and 
35 (70%) of these patients received chemotherapy. Only 5 (14%) of these 35 
patients received the chemotherapy on site at Trust A, with most receiving their 
chemotherapy at Trusts B, C or D; 14% would therefore be plotted for Trust A.  
After inspecting the distribution of this variable, chemotherapy trusts were 
GHILQHGDVWKRVHWUXVWVWKDWDGPLQLVWHUHGFKHPRWKHUDS\WKHPVHOYHVLQRI
their treated cases (Trust A would not be considered a chemotherapy trust). 
Sensitivity analyses were performed usiQJDQGDVFXWRIIV 
This variable was devised to assess whether this lack of services at a trust 
affects patient treatment decisions and outcomes. The assumption was that non-
chemotherapy trusts did not have sufficient expertise and facilities to treat their 
own patients, and that they predominantly relied on the oncology services at 
other trusts for treating SCLC. As evidence that the non-chemotherapy trusts 
treated very few patients overall, Figure 8-1 also includes the total number of 
patients treated at each trust (including those referred for treatment from other 
trusts).  
Statistical methods 
The proportion of people who had chemotherapy according to the patient, 
tumour, and trust characteristics defined above was calculated and multivariate 
logistic regression was used to estimate the odds of receiving chemotherapy 
according to the same characteristics.  
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Figure 8-1: Proportion of patients with SCLC treated with chemotherapy at same trust as first seen, and total number of patients given 
chemotherapy at each trust 2006 - 2011.  
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8.2.3 Results 
Study population 
A total of 15,724 people with histologically confirmed SCLC diagnosed between 
1st January 2006 and 30th September 2011 were identified from the NLCA. 
Exclusions included 289 people who had surgery and 119 with a treatment date 
prior to their diagnosis or after death (Figure 8-2: This differs from the study 
population in the previous chapter (shown in Figure 7-1) predominantly because 
of the exclusion of patients diagnosed before 2006 and after 31st September 
2011). Trusts in one specific geographical area had an extremely high proportion 
of patients (65%) with no record of chemotherapy. This was believed to be due 
to a systematic error in data entry and therefore the 225 patients first seen in 
this group of trusts were excluded, leaving 15,091 people (96% of the original 
SCLC population) for analysis.  
 
Figure 8-2: Study population and exclusions for study of chemotherapy in SCLC 
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Patient and tumour characteristics 
The mean age at diagnosis was 68 years (standard deviation 9.7 years) and 
there were slightly more males than females (53% vs. 47%). More were in the 
most deprived Townsend quintile than any other (25% in quintile 5) (Table 8-1). 
Most people had performance status 0-2, with only 17% recorded as having 
performance status 3 or 4 at presentation (this is likely to be because all 
patients had histologically confirmed SCLC and must therefore have been fit 
enough for an invasive investigation prior to diagnosis). Fifty-five per cent had 
extensive stage disease at presentation (although stage was not recorded in 
20% of cases).  
Referral patterns 
More patients (48%) were referred to the respiratory team by their general 
practitioner than any other route; 23% were referred via an emergency route. 
Chemotherapy trusts 
Seventy-three per cent of patients (n=11,032) were first seen at one of the 94 
chemotherapy trusts; the 52 non-chemotherapy trusts first saw 27% of the 
population. 
Features of patients who received chemotherapy 
Seventy per cent of patients had a record of chemotherapy; 790 (7%) of these 
also had a record that was consistent with concurrent or sequential chemo-
radiotherapy (Table 8-1). In the oldest age group (>84 years) 22% of patients 
received chemotherapy whereas 87% of the <55 year olds were treated. Of the 
2,017 people with performance status 3, 41% had a record of chemotherapy. 
Sixty-six percent of patients first seen at a non-chemotherapy trust had a record 
of having had chemotherapy compared with 72% of those seen at a 
chemotherapy trust. 
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Table 8-1: Features of patients with SCLC who had chemotherapy  
 
Time to treatment 
Within the 10,582 cases treated with chemotherapy, the median time from 
diagnosis to initiation of treatment was 18 days (IQR 12-27) and this did not 
change between 2006 (19 days (13-29)) and 2011 (18 days (11-26)). For 
patients who first presented to a chemotherapy trust, the median time to 
Total  % 
Sex Female 7,126      47.2        5,021             70.5         
Male 7,965      52.8        5,561             69.8         
Age group <55 1,204      8.0          1,043             86.6         
55-59 1,567      10.4        1,314             83.9         
60-64 2,378      15.8        1,923             80.9         
65-69 2,766      18.3        2,133             77.1         
70-74 2,856      18.9        2,002             70.1         
75-79 2,384      15.8        1,435             60.2         
80-84 1,380      9.1          610                 44.2         
>=85 556          3.7          122                 21.9         
Townsend quintile 1 (Least deprived) 2,111      14.0        1,499             71.0         
(socio-economic status) 2 2,704      17.9        1,926             71.2         
3 2,958      19.6        2,083             70.4         
4 3,307      21.9        2,310             69.9         
5 (Most deprived) 3,738      24.8        2,631             70.4         
Missing 273          1.8          133                 48.7         
Performance status 0 2,121      14.1        1,909             90.0         
1 4,494      29.8        3,844             85.5         
2 3,072      20.4        2,094             68.2         
3 2,017      13.4        822                 40.8         
4 567          3.8          68                   12.0         
Missing 2,820      18.7        1,845             65.4         
Charlson co-morbidity 0 4,899      32.5        3,986             81.4         
 index 1 2,644      17.5        1,996             75.5         
2-3 1,987      13.2        1,351             68.0         
>3 5,561      36.8        3,249             58.4         
Stage Extensive 8,293      55.0        5,474             66.0         
Limited 3,845      25.5        3,130             81.4         
Missing 2,953      19.6        1,978             67.0         
Route of referral Emergency admission 2,323      15.4        1,355             58.3         
General practitioner 7,267      48.2        5,624             77.4         
Consultant referral 2,729      18.1        1,869             68.5         
Other (inc private) 887          5.9          589                 66.4         
Emergency department 1,120      7.4          630                 56.3         
Missing 765          5.1          515                 67.3         
Trust first seen Non-chemotherapy trust 4,031      26.7        2,673             66.3         
Chemotherapy trust 11,032    73.1        7,893             71.5         
Missing or trust which saw <20 cases 28            0.2          16                   57.1         
N=15,091
 Had chemotherapy  %
n=10,582  (70%)
 225 
 
chemotherapy was 18 days (12-27); for those who presented to non-
chemotherapy trusts this was 19 days (12-26). 
Factors associated with chemotherapy treatment 
After adjusting for other factors, patients were more likely to have 
chemotherapy if they were younger, had good performance status, limited stage 
disease and a low co-morbidity index (Table 8-2). People living in more 
socioeconomically deprived areas were less likely to be treated (likelihood ratio 
test for trend across Townsend quintiles in adjusted analysis p=0.0002) and 
compared with those referred by a general practitioner (GP) those referred to 
secondary care by any other route were less likely to get chemotherapy, even 
after adjusting for other patient features (Table 8-2). 
For patients first seen at a chemotherapy trust the odds of being treated with 
chemotherapy were increased by 39% compared with patients seen at non-
chemotherapy trusts (adjusted OR 1.39 (1.27-1.52) (Table 8-2). This difference 
SHUVLVWHGZKHQDGMXVWHG25-DQGDGMXVWHG25
1.43 (1.30-1.58)) were used as the cut-off values for defining a chemotherapy 
trust. 
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Table 8-2: Odds ratios for receiving chemotherapy 
 
Sex Female 1.00         1.00         
Male 0.97         0.90        1.04        0.98         0.91        1.07        
Age group <55 2.76         2.30        3.32        2.29         1.87        2.80        
55-59 2.22         1.89        2.59        1.88         1.58        2.23        
60-64 1.80         1.58        2.05        1.73         1.49        1.99        
65-69 1.44         1.28        1.62        1.38         1.20        1.57        
70-74 1.00         1.00         
75-79 0.65         0.58        0.72        0.63         0.56        0.72        
80-84 0.34         0.30        0.39        0.34         0.29        0.40        
>=85 0.12         0.10        0.15        0.12         0.09        0.15        
Townsend quintile 1 (Least deprived) 1.00         1.00         
(socio-economic status) 2 1.01         0.89        1.15        0.96         0.83        1.11        
3 0.97         0.86        1.10        0.94         0.81        1.09        
4 0.95         0.84        1.07        0.82         0.71        0.94        
5 (Most deprived) 0.97         0.86        1.09        0.83         0.72        0.96        
Missing 0.39         0.30        0.50        0.43         0.32        0.58        
Performance status 0 1.00         1.00         
1 0.66         0.56        0.77        0.86         0.72        1.02        
2 0.24         0.20        0.28        0.40         0.33        0.47        
3 0.08         0.06        0.09        0.14         0.12        0.17        
4 0.02         0.01        0.02        0.03         0.02        0.04        
Missing 0.21         0.18        0.25        0.31         0.26        0.37        
Charlson co-morbidity 0 1.00         1.00         
 index 1 0.71         0.63        0.79        0.89         0.78        1.02        
2-3 0.49         0.43        0.55        0.73         0.63        0.83        
>3 0.32         0.29        0.35        0.53         0.48        0.59        
Stage Extensive 1.00         1.00         
Limited 2.25         2.05        2.47        1.63         1.46        1.83        
Missing 1.04         0.96        1.14        1.01         0.91        1.13        
Route of referral Emergency admission 0.41         0.37        0.45        0.68         0.60        0.77        
General practitioner 1.00         1.00         
Consultant referral 0.63         0.58        0.70        0.91         0.81        1.02        
Other (inc private) 0.58         0.50        0.67        0.73         0.61        0.87        
Emeergency department 0.38         0.33        0.43        0.60         0.51        0.70        
Missing 0.60         0.51        0.71        0.79         0.66        0.96        
Trust first seen Non-chemotherapy trust 1.00         1.00         
Chemotherapy trust 1.25         1.16        1.35        1.39         1.27        1.52        
Missing or trust which saw <20 cases 0.88         0.45        1.75        0.69         0.31        1.52        
OR odds ratio; CI confidence interval; *Adjusted for all other variables
Adjusted OR* 
 95% CI 
Odds Ratio (OR) 
 95% CI 
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8.3 Characteristics of patients and factors associated with completing 
a chemotherapy course 
8.3.1 Aims 
The aims of this section were to describe the characteristics of patients with 
SCLC who went on to complete a full course of chemotherapy and to use logistic 
regression to determine the factors which were independently associated with 
completing a course (chapter aims 2 and 3b). 
8.3.2 Methods 
Study population 
This study was based on the population of people with SCLC diagnosed between 
1st January 2006 and 30th September 2011, as described above but was 
restricted to people who had at least one record of chemotherapy in either the 
NLCA or HES database.  
Chemotherapy cycles 
For patients with a record of chemotherapy in HES it was possible to determine 
the number of cycles but for those with chemotherapy only recorded in the NLCA 
this was not possible. The main analysis was therefore restricted to people with 
at least one OPCS-4 code for chemotherapy in the HES database; people with 
chemotherapy recorded in the NLCA only were analysed as a separate group. 
The number of OPCS-4 codes with associated dates at least 18 days apart (to 
avoid inclusion of subsequent doses in the same cycle but to allow for occasions 
where cycles were slightly shorter than the standard 21 days) was determined 
as an estimate of the number of cycles completed.  
$ IXOO FRXUVH RI FKHPRWKHUDS\ZDV GHILQHG DV  F\FOHV EDVHG RQ FXUUHQW 8.
recommendations.(14) 
 228 
 
Covariates 
Most covariates were defined in section 8.2.2. In addition a binary variable for 
time to treatment was generated using above or below the median number of 
days from diagnosis to first chemotherapy dose.  
Patients who had radiotherapy in addition to chemotherapy were identified by 
the presence of a radiotherapy start date, and a record that it was given with as 
chemo-radiotherapy or with radical intent, in the NLCA database (further details 
in Chapter 7, section 7.3). 
Statistical methods 
7KH SURSRUWLRQV RI SDWLHQWV WKDW UHFHLYHG      DQG  F\Fles of 
chemotherapy were calculated. A binary variable for completion of 
chemotherapy was created dividing patients into those with records of 1-3 cycles 
DQGWKRVHZLWK7KHFKDUDFWHULVWLFVRISDWLHQWVLQHDFKJURXSZHUHH[DPLQHG 
The odds of completing a course of chemotherapy (receiving 4 or more cycles) 
were estimated and how this was associated with patient characteristics, time to 
treatment and receipt of chemo-radiotherapy.  
8.3.3 Results 
Study population 
Of the 15,091 cases which met the inclusion criteria, 4,509 (30%) did not have 
a record of chemotherapy in either HES or the NLCA and 1,814 had a record of 
chemotherapy in the NLCA only. The analysis was therefore based on 8,768 
cases of SCLC with at least one record of chemotherapy in HES (Figure 8-3). 
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Figure 8-3: Study population for analysis of chemotherapy cycles 
The study population was very similar to that described in section 8.2.2: most 
cases were male, 52% had extensive stage disease and the majority had a 
performance status of 0-2. Only 790 (9%) had records consistent with having 
received chemo-radiotherapy in the 6 months after diagnosis (Table 8-3).  
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Table 8-3: Characteristics of patients with SCLC and HES records of 
chemotherapy and of patients who completed cycles 
  
Total % Received 1-3 cycles ZĞĐĞŝǀĞĚш ?ĐǇĐůĞƐ %
 N=8,768* N=3,228 (37%) N=5,540 (63%)
Sex Female 4,166      47.5        1,525                              2,641                           63.4        
Male 4,602      52.5        1,703                              2,899                           63.0        
Age group <55 895          10.2        277                                  618                              69.1        
55-59 1,106      12.6        351                                  755                              68.3        
60-64 1,620      18.5        562                                  1,058                           65.3        
65-69 1,777      20.3        608                                  1,169                           65.8        
70-74 1,625      18.5        630                                  995                              61.2        
75-79 1,147      13.1        502                                  645                              56.2        
80-84 496          5.7          252                                  244                              49.2        
>=85 102          1.2          46                                    56                                 54.9        
Townsend quintile 1 (Least deprived) 1,241      14.2        440                                  801                              64.5        
(socio-economic status) 2 1,590      18.1        558                                  1,032                           64.9        
3 1,743      19.9        641                                  1,102                           63.2        
4 1,932      22.0        719                                  1,213                           62.8        
5 (Most deprived) 2,152      24.5        804                                  1,348                           62.6        
Missing 110          1.3          66                                    44                                 40.0        
Performance status 0 1,626      18.5        383                                  1,243                           76.4        
1 3,208      36.6        1,040                              2,168                           67.6        
2 1,664      19.0        761                                  903                              54.3        
3 683          7.8          404                                  279                              40.8        
4 53            0.6          33                                    20                                 37.7        
Missing 1,534      17.5        607                                  927                              60.4        
Charlson 0 3,318      37.8        1,020                              2,298                           69.3        
co-morbidity index 1 1,641      18.7        565                                  1,076                           65.6        
2-3 1,092      12.5        423                                  669                              61.3        
>3 2,717      31.0        1,220                              1,497                           55.1        
Stage Extensive 4,550      51.9        1,838                              2,712                           59.6        
Limited 2,646      30.2        757                                  1,889                           71.4        
Missing 1,572      17.9        633                                  939                              59.7        
Time to treatment <18 days 4,305      49.1        1,532                              2,773                           64.4        
ш18 days 4,463      50.9        1,696                              2,767                           62.0        
Route of referral Emergency admission 1,157      13.2        531                                  626                              54.1        
General Practitioner 4,666      53.2        1,500                              3,166                           67.9        
Consultant referral 1,556      17.7        606                                  950                              61.1        
Other (inc private) 464          5.3          182                                  282                              60.8        
Emergency Department 514          5.9          245                                  269                              52.3        
Missing 411          4.7          164                                  247                              60.1        
Trust first seen Non-chemotherapy trust 2,064      23.5        804                                  1,260                           61.0        
Chemotherapy trust 6,688      76.3        2,417                              4,271                           63.9        
Missing / trust which saw <20 cases 16            0.2          7                                       9                                   56.3        
Radiotherapy No chemo-radiotherapy 7,978      91.0        3,059                              4,919                           61.7        
Chemo-radiotherapy 790          9.0          169                                  621                              78.6        
*Analysis restricted to people with SCLC who had record of chemotherapy in the Hospital Episodes Statistics database.
 231 
 
Number of cycles 
7KH SURSRUWLRQV RI SDWLHQWV WKDW UHFHLYHG      DQG  F\FOHV RI
chemotherapy are shown in Table 8-4. Sixty-three percent of those who started 
FKHPRWKHUDS\UHFHLYHGF\FOHVRQO\KDGDUHFRUGRIF\FOH 
Table 8-4: Number of chemotherapy cycles recorded for patients with SCLC 
Number of cycles Number of patients 
(N=8,768) 
Percentage 
1 1,515 17.3 
2 805 9.2 
3 908 10.4 
4 2,091 23.9 
5 981 11.2 
 2,468 28.2 
 
Characteristics of people who completed a chemotherapy course 
People who completed a chemotherapy course were more likely to be in younger 
age categories and in less deprived Townsend quintiles. A higher proportion of 
those with good performance status (PS) (76% of people with PS 1 compared 
with 41% of those with PS 3) and people with a low Charlson co-morbidity index 
(69% of people with CCI 0 compared with 41% of those with CCI >3) completed 
F\FOHV 
Sixty per cent of people with extensive disease completed their chemotherapy 
course compared with 71% of those with limited stage. People who were 
referred as a result of an emergency admission completed the course less 
frequently (54% of cases) than those referred by their GP (68%). People who 
had chemo-radiotherapy completed the course much more frequently than those 
who only had a record of chemotherapy (79% vs. 62%). 
Factors associated with completing a chemotherapy course 
Increasing age, performance status, stage and co-morbidity score, were 
independently associated with increased odds of completing chemotherapy, as 
was the GP route of referral compared with any other referral method. A 
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diagnosis to treatment interval of <18 days also increased the likelihood of 
completing a course compared with those who waited longer.  
People who had chemo-UDGLRWKHUDS\ZHUHPRUHOLNHO\WRFRPSOHWHF\FOHVRI
chemotherapy than those who only had chemotherapy, even after adjusting for 
other patient characteristics (Table 8-5). There was some evidence that people 
first seen at a chemotherapy trust were more likely to complete a course than 
those seen at non-chemotherapy trusts even after adjusting for age, sex, socio-
economic status, performance status, stage and co-morbidity score (OR 1.14, 
95% CI 1.03-1.27). 
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Table 8-5: FactorVDVVRFLDWHGZLWKFRPSOHWLQJF\FOHVLQSDWLHQWVwith SCLC 
who started chemotherapy 
 
Odds ratio (OR) for Adjusted 
ĐŽŵƉůĞƚŝŶŐш ?ĐǇĐůĞƐ OR** 
Sex Female 1.00                                  1.00                
Male 0.98                                  0.90        1.07        0.99                0.91        1.09        
Age group <55 1.41                                  1.19        1.68        1.29                1.07        1.54        
55-59 1.36                                  1.16        1.60        1.26                1.07        1.49        
60-64 1.19                                  1.03        1.38        1.15                0.99        1.34        
65-69 1.22                                  1.06        1.40        1.21                1.05        1.40        
70-74 1.00                                  1.00                
75-79 0.81                                  0.70        0.95        0.83                0.71        0.98        
80-84 0.61                                  0.50        0.75        0.63                0.52        0.78        
>=85 0.77                                  0.52        1.15        0.80                0.53        1.21        
Townsend quintile 1 (Least deprived) 1.00                                  1.00                
(socio-economic status) 2 1.02                                  0.87        1.19        0.99                0.84        1.16        
3 0.94                                  0.81        1.10        0.93                0.80        1.09        
4 0.93                                  0.80        1.08        0.90                0.77        1.05        
5 (Most deprived) 0.92                                  0.80        1.07        0.89                0.76        1.04        
Missing 0.37                                  0.25        0.55        0.37                0.25        0.56        
Performance status 0 1.00                                  1.00                
1 0.64                                  0.56        0.74        0.71                0.62        0.82        
2 0.37                                  0.31        0.42        0.45                0.38        0.52        
3 0.21                                  0.18        0.26        0.27                0.22        0.33        
4 0.19                                  0.11        0.33        0.23                0.13        0.41        
Missing 0.47                                  0.40        0.55        0.56                0.48        0.66        
Charlson 0 1.00                                  1.00                
co-morbidity index 1 0.85                                  0.75        0.96        0.93                0.81        1.05        
2-3 0.70                                  0.61        0.81        0.81                0.70        0.94        
>3 0.54                                  0.49        0.61        0.69                0.62        0.77        
Stage Extensive 1.00                                  1.00                
Limited 1.69                                  1.53        1.87        1.44                1.29        1.61        
Missing 1.01                                  0.89        1.13        0.95                0.84        1.08        
Time to treatment <18 days 1.00                                  1.00                
ш18 days 0.90                                  0.83        0.98        0.81                0.74        0.89        
Route of referral Emergency admission 0.56                                  0.49        0.64        0.68                0.59        0.78        
General Practitioner 1.00                                  1.00                
Consultant referral 0.74                                  0.66        0.84        0.85                0.75        0.97        
Other (inc private) 0.73                                  0.60        0.89        0.80                0.66        0.98        
Emergency Department 0.52                                  0.43        0.63        0.63                0.52        0.77        
Missing 0.71                                  0.58        0.88        0.82                0.66        1.01        
Trust first seen Non-chemotherapy trust 1.00                                  1.00                
Chemotherapy trust 1.13                                  1.02        1.25        1.14                1.03        1.27        
Missing / trust which saw <20 cases 0.82                                  0.30        2.21        0.63                0.23        1.72        
Radiotherapy No chemo-radiotherapy 1.00                                  1.00                
Chemo-radiotherapy 2.29                                  1.92        2.72        1.74                1.44        2.09        
*Analysis restricted to people with SCLC who had record of chemotherapy in the Hospital Episodes Statistics database; OR odds ratio;
 CI confidence interval; **Adjusted for age, sex, socio-economic status, co-morbidity index, performance status and stage
95% confidence 95% CI
interval (CI)
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8.4 Factors associated with survival in people with SCLC 
8.4.1 Aims 
The aims of this section were to assess survival according to number of cycles 
completed and to quantify overall survival according to patient characteristics 
and the number of cycles completed (chapter aims 4 and 5). 
8.4.2 Methods 
Study population 
The survival analyses included all of the SCLC cases identified in section 8.2 with 
the same exclusions (Figure 8-2).  
Statistical methods 
Kaplan-Meier survival curves were plotted and median survival calculated from 
the date of diagnosis (or start date) for people with limited and extensive stage 
disease, overall and according to the number of cycles of chemotherapy given in 
the 6 months after diagnosis. To minimise the effects of immortal time bias, 
survival for those who had chemotherapy was also plotted from the end of the 
last chemotherapy cycle. 
Cox regression was used to estimate survival from the date of diagnosis 
according to patient and tumour characteristics, whether or not chemotherapy or 
chemo-radiotherapy were given, the route of referral and whether or not the 
patient was first seen in a chemotherapy trust. Hazard ratios were calculated for 
each of these adjusting for age, sex, performance status, co-morbidity and 
stage. Survival was also estimated from the end of the last chemotherapy cycle 
(last chemotherapy cycle start date plus 21 days) according to the number of 
cycles given (1-RUWLPHIURPGLDJQRVLVWRWUHDWPHQWDQGWUXVWILUVWVHHQ
This survival analysis was also performed from the end of the last chemotherapy 
cycle.  
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Patients were followed-up to death or they were censored on 31st March 2013, 
the date of ONS death tracing for this dataset. Interactions were sought between 
stage and all other variables in the effect on survival. The proportional hazards 
assumption was checked by inspecting Nelson-Aalen plots. 
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8.4.3 Results 
Median survival 
Median survival from diagnosis for all patients (N=15,091) was 6.2 months (IQR 
1.5-12.4); this was 11.2 months (5.4-20.3) and 4.2 months (1.1-9.3) for people 
with limited and extensive stage disease respectively.  
For those who did not receive chemotherapy (n=4,509) median survival was 2.6 
months for limited and 0.9 months for extensive stage disease (Table 8-6), 
compared with 12.9 months (7.7-22.5) and 7.3 months (3.5±11.5) for those 
treated with chemotherapy.  
For people with limited stage disease who completed their course of 
chemotherapy (n=1,889), median survival from diagnosis was 15.4 months 
(10.1-26.8); for those with extensive stage disease who completed the course 
(n=2,712) this was 9.6 months (IQR 7.2-14.0).  
Survival by number of cycles 
Survival after diagnosis for people with SCLC according to their stage at 
presentation and number of cycles received is shown in Figures 8-4 and 8-5. 
Figures 8-6 and 8- 7 show the same survival analysis restricted to people with a 
record of chemotherapy in HES from the end of the last chemotherapy cycle. 
People who received 1 or 2 cycles are grouped together, as are those who 
received 4 or 5 cycles because their survival curves were almost identical. 
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Table 8-6: Median survival in days according to stage and number of cycles of 
chemotherapy 
 
Cycles 
No. of patients 
(%) 
N=15,091 
Median survival 
from diagnosis  
(IQR) 
No. of patients 
(%) 
N=7,866* 
Median survival 
from completing 
chemotherapy 
(IQR) 
Overall     
0 4509 (29.9) 30 (14-74)   
1-2 2320 (15.4) 85 (43-185) 1595 (20.2) 70 (24-191) 
3 908 (6.0) 209 (125-377) 818 (10.4) 126 (50-300) 
4-5 3072 (20.4) 316 (213-527) 3000 (38.1) 189 (95-405) 
 2468 (16.4) 377 (270-612) 2453 (31.2) 224 (114-453) 
NLCA only 1814 (12.0) 230 (78-396)   
Extensive stage (N=8,293)  
0 2891 (34.0) 26 (12-56)   
1-2 1399 (16.9) 73 (40-149) 925 (23.8) 53 (20-126) 
3 439 (5.3) 163 (108-276) 386 (9.7) 82 (31-192) 
4-5 1432 (17.3) 260 (187-384) 1391 (35.0) 135 (68-256) 
6 1280 (15.4) 324 (247-485) 1270 (32.0) 168 (88-333) 
NLCA only 924 (11.1) 177 (52-315)   
Limited stage (N=3,845)  
0 715 (18.6) 79 (25-218)   
1-2 465 (12.0) 141 (58-366) 346 (16.7) 134 (50-383) 
3 295 (7.7) 301 (177-552) 276 (13.3) 213 (97-461) 
4-5 1112 (28.9) 420 (280-758) 1098 (53.1) 300 (154-648) 
6 777 (20.2) 505 (342-843) 774 (37.5) 347 (183-690) 
NLCA only 484 (12.6) 356 (199-586)   
NLCA only: record of chemotherapy but insufficient data to calculate number of cycles     
*Excludes 4,509 patients who did not receive chemotherapy, 1,814 NLCA only, and 902 
that died within 21 days of starting a chemotherapy cycle. 
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People ZLWKµ1/&$RQO\¶UHFRUGVKDGFKHPRWKHUDS\EXWWKHUHZHUHLQVXIILFLHQW
data to calculate number of cycles 
  
Figure 8-4: Kaplan Meier curve for people with extensive stage SCLC showing 
survival after diagnosis according to the number of chemotherapy cycles they 
received 
 
Figure 8-5: Kaplan Meier curve for people with limited stage SCLC showing 
survival after diagnosis according to the number of chemotherapy cycles 
received 
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Figure 8-6: Kaplan Meier curve for people with extensive stage SCLC showing 
survival after finishing chemotherapy according to the number of cycles they 
received  
  
Figure 8-7: Kaplan Meier curve for people with limited stage SCLC showing 
survival after finishing chemotherapy according to the number of cycles they 
received 
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Factors associated with survival 
The Cox regression analysis from time of diagnosis showed that for people who 
completed chemotherapy the risk of death was 75% lower than for those who 
received no chemotherapy (adjusted HR 0.25, 95% CI 0.24-0.27) (Table 8-7).  
Survival did not vary significantly by Townsend quintile or according to whether 
the patient was first seen at a chemotherapy trust. There was evidence that 
people diagnosed with SCLC as a result of an emergency admission were more 
likely to die than people referred by their GP (HR 1.69, 95% CI 1.61-1.78); this 
association was attenuated but not fully explained by age, sex, PS, stage and 
co-morbidity index (adjusted HR 1.30, 95% CI 1.23-1.37). Those who waited 
GD\VEHWZHHQGLDJQRVLVDnd treatment had a lower risk of dying compared 
with those who waited <18 days (adjusted HR 0.84, 95% CI 0.81-0.88).  
There was no evidence that stage modified the effect of any of the variables on 
survival and there was no evidence to reject the proportional hazards 
assumption. The results were very similar when survival for those who had 
chemotherapy was assessed from the end of their last recorded cycle (Table 8-
8).  
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Table 8-7: Hazard ratios for death for people with SCLC (analysis from time of diagnosis) 
 
Survival from diagnosis Total patients Hazard Adjusted 
N=15,091 n=10,041 % ratio (HR) HR*
Townsend quintile 1 (Least deprived) 2,111                    1,981      93.8        1.00         1.00         
2 2,704                    2,558      94.6        1.02         0.96  1.08  1.03         0.98  1.10  
3 2,958                    2,788      94.3        1.02         0.96  1.08  1.01         0.95  1.07  
4 3,307                    3,109      94.0        1.01         0.95  1.06  1.03         0.98  1.09  
5 (Most deprived) 3,738                    3,517      94.1        0.99         0.94  1.05  1.02         0.96  1.08  
Missing 273                        262          96.0        1.69         1.49  1.93  1.39         1.22  1.58  
Route ofreferral Emergency admission 2,323                    2,246      96.7        1.69         1.61  1.78  1.30         1.24  1.37  
General Practitioner 7,267                    6,738      92.7        1.00         1.00         
Consultant referral 2,729                    2,566      94.0        1.19         1.14  1.25  1.01         0.96  1.06  
Other (inc private) 887                        836          94.3        1.18         1.10  1.27  1.03         0.96  1.11  
Emergency Department 1,120                    1,086      97.0        1.66         1.56  1.77  1.29         1.21  1.37  
Missing 765                        743          97.1        1.26         1.17  1.36  1.12         1.04  1.21  
Radiotherapy No chemotherapy 4,509                    4,448      98.6        1.00         1.00         
Chemotherapy only 9,590                    8,962      93.5        0.28         0.27  0.29  0.35         0.34  0.37  
Chemo-radiotherapy 992                        805         81.1        0.16         0.15  0.18  0.26         0.24  0.28  
Chemotherapy cycles No chemotherapy 4,509                    4,448      98.6        1.00         1.00         
1-3 cycles 3,228                    3,115      96.5        0.45         0.43  0.47  0.54         0.52  0.57  
ш ?ĐǇĐůĞƐ 5,540                    4,936      89.1        0.20         0.19  0.21  0.25         0.24  0.27  
NLCA record only 1,814                    1,716      94.6        0.31         0.29  0.33  0.39         0.37  0.41  
Time to treatment <18 days 5,137                    4,834      94.1        1.00         1.00         
ш18 days 5,445                    4,933      90.6        0.80         0.77  0.83  0.84         0.81  0.88  
No chemotherapy 4,509                    4,448      98.6        3.30         3.17  3.44  2.64         2.52  2.76  
Trust first seen Non-chemotherapy trust 4,276                    4,011      93.8        1.00         1.00         
Chemotherapy trust 10,779                  10,171    94.4        1.01         0.97  1.04  0.99         0.95  1.02  
Missing / trust which saw <20 cases 36                          33            91.7        0.99         0.70  1.39  0.93         0.66  1.32  
HR hazard ratio; NLCA National Lung Cancer Audit; *Adjusted for sex, age, performance status, co-morbidity index and stage
Deaths
95% CI 95% CI
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Table 8-8: Survival for people with SCLC who had chemotherapy from end of last chemotherapy cycle 
Survival analysis from end of chemotherapy Total patients Hazard Adjusted 
N=7,866 (a) n=7,149 % ratio (HR) HR*
Time to treatment <18 days 3,794                           3,524      92.9        1.00         
ш18 days 4,072                           3,625      89.0        0.84         0.80  0.88  0.88         0.84  0.93  
Chemotherapy cycles 1-3 cycles 2,413                           2,300      95.3        1.00         
ш ?ĐǇĐůĞƐ 5,453                           4,849      88.9        0.58         0.55  0.60  0.61         0.58  0.64  
7,095                           6,538      92.1        1.00         
Chemo-radiotherapy 771                              611          79.2        0.57         0.53  0.62  0.72         0.66  0.78  
1,867                           1,675      89.7        1.00         
Chemotherapy trust 5,984                           5,461      91.3        1.05         1.00  1.11  1.04         0.98  1.09  
Missing / trust which saw <20 cases 15                                 13            86.7        0.85         0.49  1.47  0.76         0.44  1.31  
(a) this excludes the 1,814 cases with chemotherapy only recorded in the NLCA and 902 who died before completing their final cycle 
of chemotherapy; HR hazard ratio; *Adjusted for sex, age, performance status, co-morbidity index and stage
Deaths
95% CI 95% CI
Trust first seen                                  Non-chemotherapy trust
Radiotherapy                                       No chemo-radiotherapy
 243 
 
8.5 Discussion 
The studies described in this chapter used current English data to describe which 
patients with SCLC received chemotherapy treatment and provide real-life 
estimates of survival. 7KHUH LV HYLGHQFH WKDW D SDWLHQW¶V FKDQFHV RI UHFHLYLQJ
and/or completing  chemotherapy treatment were related not only to their 
fitness but also socio-economic status, the trust at which they were first seen, 
the time taken from diagnosis to first treatment, and their route of referral to a 
lung cancer specialist.  
8.5.1 Strengths & Limitations 
The main strengths of these studies are the large sample size and the validity of 
the database. (82)  Mortality data from the ONS ensured that the outcome data 
were both accurate and complete. Chemotherapy records were validated in 
Chapter 7. The main limitations are the lack of detailed trust level data, and the 
limited number of years of therapy data available at present. 
It was necessary to restrict the analysis of chemotherapy cycles to patients with 
chemotherapy records in HES because the NLCA only records a single 
chemotherapy start date. This will have excluded patients who had 
chemotherapy administered as an outpatient rather than inpatient day-case. 
Those with a record in the NLCA only were identified as such and analysed in a 
separate group; the survival curve in figure 8.4 gives no suggestion that these 
patients belong predominantly to any one of the cycle groups, and gives 
reassurance that these are missing from HES in a random manner. 
It is possible that some patients started their chemotherapy during an inpatient 
admission and received further doses as an outpatient; in this case they would 
be misclassified as having only received one cycle. Some reassurance that this is 
an infrequent occurrence comes from the clinical experience of the oncologist 
who co-authored the publication arising from this work: not only would it be 
fairly unusual to treat SCLC before a patient has been discharged from hospital 
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because if they needed to stay in hospital it is unlikely that they would be fit 
enough for chemotherapy, but furthermore the proportion of patients that only 
received one cycle of chemotherapy (17%) correlates with clinical experience 
taking into account that some of these patients will have died before a second 
cycle could be given (personal communication Dr Vanessa Potter, Consultant 
Oncologist, Nottingham University Hospitals NHS Trust - November 2013). 
Inpatient HES data do not capture the majority of radiotherapy episodes and 
therefore this work relied solely on the NLCA for radiotherapy data and may 
have underestimated the number of patients treated.  
8.5.2 Comparison with trial data 
This assessment of chemotherapy within observational population-based data 
cannot be used to directly assess effectiveness, but comparisons with trial data 
are still valuable: 
Number of cycles 
There are few studies examining the number of cycles of chemotherapy actually 
given for SCLC outside of clinical trials. Burgers et al, found no significant 
difference in the proportion of patients who received 4 or more cycles of 
chemotherapy within a trial (49/60) compared with outside of a trial (35/46) in 
their UK hospital.(206) However, they only included patients who were eligible 
for one of these two SCLC chemotherapy trials. 
In this study, completion of 4 cycles was chosen to represent a complete course 
of chemotherapy, but practice does differ in this respect. Median survival was 
longer after completion of 6 or more cycles of chemotherapy compared with 4-5 
cycles, but it cannot be concluded that 6 cycles are preferable to 4 as the fitness 
of the patients at the point of finishing 4 cycles and reasons for discontinuing 
treatment are unknown.  
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Survival 
Median survival for 105 people with limited stage SCLC treated with etoposide 
and carboplatin in a randomised trial by the Norwegian Lung Cancer Study 
Group was 14.5 months from diagnosis, and 8.4 months for 113 people with 
extensive stage.(35) This is similar for patients in the present study (12.9 and 
7.3 months).  
In this study, 71% of patients with limited stage who started chemotherapy and 
60% of those with extensive stage received 4 or more cycles. This is lower than 
in the Norwegian trial where 70% of patients overall received 5 cycles; patients 
treated with chemotherapy in that trial were fitter and younger than those in the 
NLCA (median age 64 vs. 67 years).  
8.5.3 Clinical relevance 
Route of referral 
Those who were diagnosed as a result of an emergency hospital attendance 
were less likely to start chemotherapy, less likely to complete a course, and less 
likely to survive than those referred by a GP, even after adjusting for patient 
fitness and stage. There is likely to be an element of residual confounding by 
patient fitness in these estimates but other studies have also found this group to 
have poor survival.(207, 208) Given that almost a fifth of the patients in this 
study presented by an emergency route (which is similar to or lower than other 
estimates for lung cancer overall in the UK,(207)), this is an extremely 
important group for UK clinicians to target if overall survival from lung cancer is 
to improve.  
Time to initiation of treatment  
The average time from diagnosis to first chemotherapy dose was 18 days with 
25% of patients waiting more than 27 days.  A period of longer than 18 days 
was associated with improved survival and this is likely to reflect the impact of 
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prioritising patients who are unwell with aggressive disease and poor 
performance status. Those potentially fitter patients who waited longer than 18 
days were, however, less likely to complete 4 cycles of chemotherapy than those 
ZKRZHUHWUHDWHGPRUHTXLFNO\&RPSOHWLQJF\FOHVZDVD strong predictor of 
better survival however the direction of causation is very uncertain and it may 
well be that non-completion of chemotherapy is due to death, rather than the 
other way around. Despite this uncertainly earlier treatment for all may improve 
survival. The 2011 UK guidelines on SCLC recommend that all patients are 
assessed by an oncologist within a week of deciding to recommend 
treatment.(14)  
Trust features 
People first seen at chemotherapy trusts did not survive longer than those seen 
at non-chemotherapy trusts despite being more likely to receive chemotherapy. 
Of patients first seen at a non-chemotherapy trust 66.3% had chemotherapy 
compared with 71.5% of those seen a chemotherapy trust. It is possible that 
treating an average of 5% more of their patients was not enough to translate 
into an overall survival benefit for chemotherapy trusts, but also that the 
additional patients treated were less fit and higher risk in ways that are difficult 
to measure. 
The only other work on trust features and rates of treatment in SCLC is a 
previous study using the NLCA which reported increased odds of receiving 
chemotherapy in patients who were first seen in trusts which entered >5% of 
lung cancer patients into clinical trials. (83) Whilst 33 of the 94 chemotherapy 
trusts were classified as high trial participation centres in that study, the 
remaining 61 chemotherapy trusts did not have high trial participation; 7 of the 
52 non-chemotherapy trusts were classified as high trial participation centres 
(personal communication Dr Anna Rich, May 2013).  
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8.5.4 Conclusion  
These national data reflect the decisions that were made about chemotherapy 
treatment in clinical practice in England. This study has provided real-life 
measures of survival in those treated with chemotherapy taking into account 
patient and tumour characteristics and described which patients were less likely 
to complete a full course of treatment based on key socio-demographic and 
clinical features. It was not possible to determine whether 6 cycles of treatment 
are better than 4 cycles due to the influence of immortal time bias and a lack of 
longitudinal data on patient fitness and reasons for stopping treatment. 
There is variation in the time from diagnosis to initiation of treatment, and some 
evidence of inequalities in access to treatment with particularly poor outcomes 
for those who present via the emergency route. This further supports the need 
for initiatives that improve early presentation and diagnosis.   The finding that 
chemotherapy trusts treat a greater proportion of patients but that this does not 
show a survival benefit requires further work to clarify the reasons but it may be 
that better selection of patients for treatment and continuation of treatment is 
key.  
 248 
 
8.6 Chapter summary 
 
In this chapter I have used the NLCA-HES linked data to provide evidence of 
inequalities in access to chemotherapy for SCLC including particularly low 
treatment rates and poor survival for people diagnosed as a result of an 
emergency admission. I was able to demonstrate that the beneficial effects of 
chemotherapy in terms of survival were similar in this unselected population to 
those reported in clinical trials, but also that completing chemotherapy is 
strongly associated with improved survival and that over a third of patients do 
not complete 4 cycles. 
I have described a novel way of defining a chemotherapy trust and found that 
potentially modifiable organisational factors which affect whether or not patients 
receive chemotherapy include the route of admission and whether or not a trust 
has the facilities to administer chemotherapy on site; however the consequent 
effect on survival is unclear and requires further investigation perhaps with 
longer follow-up.  
This work has been accepted for publication in the British Journal of Cancer and 
is currently in press. 
 249  
 
 
 
 
 
 
CHAPTER 9: ONGOING RESEARCH  
In this chapter I will describe ongoing research relevant to this thesis. In 
particular I will describe a qualitative study which I am currently working on 
H[SORULQJSDWLHQWV¶DQGFOLQLFLDQV¶DWWLWXGHV WR WKH ULVNVVXUURXQGLQJ WUHDWPHQWV
for lung cancer, and two studies which I have helped to design that will test the 
NLCA early surgical mortality score in independent datasets.  
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9.1 Attitudes to risk in lung cancer surgery 
When deciding whether or not a patient should have surgery it is important to 
recognise that the estimation of risk is not the only aspect which should be 
considered. The decision will also be influenced by the SDWLHQW¶VDQGKHDOWKFDUH
SURIHVVLRQDOV¶SHUFHSWLRQVRIWKHVHULVNV9HU\ OLWWOHZRUNKDVEHHQGRQHRQWKH
attitudes of patients and clinicians in this area and therefore a qualitative study 
was set up to explore these issues:  
 
A qualitative study to map attitudes to risks surrounding treatment for 
lung cancer 
9.1.1 Background & rationale 
As has been described elsewhere in this thesis, if NSCLC is detected at an early 
stage then 5-year survival is much better than the overall figure of 8-9%, 
predominantly because of surgical resection. The overall proportion of lung 
cancer patients in England and Wales having an operation to try to cure their 
cancer varies between hospitals from less than 5% to more than 25%, (51) and 
the UK average is lower than other parts of Europe and North America 
There are many points to consider when assessing a patient who has technically 
resectable lung cancer for surgery. One aspect is the likelihood that they will 
survive the operation and the immediate postoperative period; this was the 
subject of Chapter 6. However there is also a need for research which explores 
what level of risk is acceptable to people with lung cancer, and whether this 
differs from the level of risk which clinicians are willing to accept for their 
patients.   
It is possible that given the poor survival for NSCLC, many patients might 
choose to have an operation even if their immediate mortality risk is high. The 
current National Institute for health and Clinical Excellence (NICE),(14) and 
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British Thoracic Society (BTS),(25) guidelines do not specifically state an 
acceptable mortality rate but they do publish the average 30-day mortality for 
lobectomy (2.3%) and pneumonectomy (5.8%). The previous BTS guidelines 
from 2001 recommended that surgical mortality should not be greater than 4% 
for lobectomy and 8% for pneumonectomy.(209) Anecdotal evidence says that 
most surgeons still use these figures as a guideline and would not want their 
own surgical mortality figures to be much higher than the national average; 
most would want to be lower.  
Few VWXGLHVKDYHDGGUHVVHGSDWLHQWV¶RUFOLQLFLDQV¶DWWLWXGHVWRZDUGVWKHULVNVRI
treatment, particularly surgical mortality, in patients with lung cancer. The 
available evidence would suggest that when faced with a guarantee of 
progressive lung cancer and no alternatives for cure, patients are willing to take 
relatively high risks of postoperative complications and surgery-related 
death.(210)  
9.1.2 Aims of this study 
The aim of this study was to amass qualitative data concerning patient and 
KHDOWKFDUH SURIHVVLRQDOV¶ DWWLWXGHV WR WKH ULVNV DVVRFLDWHG ZLWK WUHDWments, 
particularly surgery, for lung cancer. Specifically the aims were: 
1. To recruit patients with a recent diagnosis of technically resectable lung 
cancer for semi-structured in-depth interviews (section 9.1.6) 
2. To recruit and interview healthcare professionals who are involved with 
the management of patients with potentially resectable lung cancer 
(section 9.1.8) 
3. To analyse interview data using the Framework method (section 9.1.7). 
9.1.3 Ethical approval 
The full study protocol was approved by the University of Nottingham, who 
provided sponsorship and indemnity, and the Nottingham Research Ethics 
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Committee in August 2012; a summary of the protocol submitted for ethical 
approval is given in table 9-1. The study was also approved by Nottingham 
University Hospitals NHS Trust (NUH) Research and Innovation department so 
that NHS patients could be identified and recruited from the lung cancer multi-
disciplinary team (MDT) meetings and clinics. Individual approval from each 
trust is not required for studies involving healthcare professionals.  
Copies of the ethics approval letters and study documents (patient and 
healthcare professional information sheets and consent forms, case report 
forms, interview guides and generic letters to participants and health 
professionals) can be found in Appendix G. 
 
9.1.4 Progress 
This study involves recruiting and interviewing patients with resectable lung 
cancer (who only make up approximately 10% of the lung cancer population) 
after they receive their diagnosis but (if they are going to have surgery) before 
their pre-operative assessment date. For logistical regions this is a single centre 
study and for continuity there is only one interviewer (HP). This has resulted in 
very slow recruitment of patients and therefore the study is still in progress.  
At the time of writing (December 2013) 15 patients have been recruited and 
interviewed. Saturation of themes may have been reached but detailed analysis 
of transcripts is needed to confirm this; if new themes are identified in the later 
interviews it will be necessary to recruit and interview more patients until no 
new themes emerge. Detailed analysis by framework method is in progress, and 
is currently at the stage of double coding. 
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Table 9-1: Attitudes to risk in lung cancer surgery: Summary of study protocol 
Objectives 
7RPDSSDWLHQWV¶DQGKHDOWKFDUHSURIHVVLRQDOV¶EHOLHIVDQGEHKDYLRXUV
concerning treatment with curative intent, particularly mortality 
following surgery, for lung cancer. 
Configuration 
This will be a qualitative study consisting of semi-structured in-depth 
interviews with patients and healthcare professionals (HCP). It will 
be a multi-centre study with participants recruited for interviews from 
multiple trusts. 
Setting Secondary care lung cancer service. 
Number of 
participants 
The maximum number of participants is expected to be 20 patients 
and 20 of each of the 3 categories of HCP. Numbers will remain 
flexible and change depending on emergence, and saturation of, 
themes in the interviews. The first few participants in each group will 
be pilots to test the interview guides. 
Eligibility 
criteria 
Participants must be over 18 years of age, able to give informed 
consent and communicate in English. Patients must have clinically 
diagnosed lung cancer stage I-IIIa and be aware of their diagnosis. 
HCPs must be employed by the NHS caring for lung cancer patients. 
Description of 
interventions 
Qualitative semi-structured in-depth interviews for all participants, 
following documentation of informed consent. Patient demographics 
and relevant medical information will be recorded from medical 
notes.  
Duration of 
study 
Interviews are expected to last approximately one hour each. 
Recruitment and interviews will continue until there are no new 
themes emerging or until the end of the recruitment period 
(approximately 2 years). The interview will take place within four 
weeks of the initial contact for patients and three months for HCPs. 
No further contact will be required after completion of the interview.  
Outcome 
measures 
The primary objective is to amass qualitative data which maps 
SDWLHQWV¶ DQG +&3V¶ YLHZV RQ WKH VXEMHFW of risk associated with 
treatment with curative intent, predominantly surgery, for lung 
cancer. 
Methods of 
Analysis 
The anonymised transcripts from each interview will be 
systematically analysed using the Framework method. NVivo 
software will be used to facilitate analysis of the emergent themes 
and exploration of data trends and patterns. 
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9.1.5 Methods: Patient interviews 
A schematic diagram for this part of the study is given in Appendix G 
Inclusion criteria 
Eligible patients met the following criteria: 
1. Over 18 years of age (no upper age limit). 
2. Able to give informed consent. 
3. Patients with a diagnosis of lung cancer stages 1a to 3a (these stages are 
potentially resectable), who were aware of their diagnosis. 
Exclusion criteria 
Patients were not eligible for the study if they had any of the following: 
1. Cognitive impairment. 
2. Unable to communicate in English 
3. Metastatic or high stage cancer (>IIIa) which was clearly not amenable 
to surgery. 
4. Patients who had had, or would have had their pre-operative 
appointment and consented for surgery for lung cancer before an 
interview could take place. 
Recruitment 
Recruitment started in March 2013. Eligible patients were identified by HP as 
they were discussed at lung cancer MDT meetings at NUH. The initial approach 
ZDV IURP D PHPEHU RI WKH SDWLHQW¶V FOLQLFDO FDUH WHDP 6XLWDEOH SDWLHQWVZKR
expressed an interest in participating were given an invitation letter and 
participant information sheet (Appendix G) and informed that they would be 
contacted by the research team via telephone to answer any further questions. 
If they gave verbal consent to participate during that telephone call, an 
appointment for a single semi-structured in-depth interview was arranged.  
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It was explained to potential participants that entry into the study would be 
entirely voluntary and that their treatment would not be affected by their 
decision. It was also explained that they could withdraw at any time but that 
attempts would be made to avoid this occurrence. In the event of their 
withdrawal it was explained that their data collected so far could not be erased 
and consent would be sought to use the data in the final analyses where 
appropriate. 
Duration of participation 
Patients participated in the study for up to 4 weeks from first contact to 
completion.  
Informed consent  
After ensuring that the patient had at least 24 hours to consider whether or not 
they wished to participate, a researcher (HP) answered any questions 
concerning study participation over the telephone prior to arranging an 
interview. 
All participants provided written informed consent on the day of the interview, 
before the interview commenced. To ensure that I was appropriately trained in 
obtaining informed consent for clinical research I completed the Good Clinical 
Practice training at the University of Nottingham in February 2013. 
Interviews 
,QWHUYLHZVWRRNSODFHDWWKHSDWLHQW¶VKRPHRUDWWKH8QLYHUVLW\RI1RWWLQJKDP
GHSHQGLQJRQWKHSDWLHQW¶VSUHIHUHQFH3DWLHQWVZHUHLQIRUPHGWKDWWKHLQWHUYLHZ
would last approximately 60 minutes. If during the interview it became apparent 
that it was going to take longer than 60 minutes verbal permission to continue 
was sought from the patient. Interviews were digitally audio-recorded and 
transcribed verbatim by an external transcription company who signed a 
confidentiality agreement. Each transcript was checked for transcription errors to 
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ensure data quality. All identifiers were removed and a unique identifier assigned 
to each participant to ensure anonymity. The interviewer kept an interview log of 
impressions and interpretations which was completed after each interview.   
The interviews initially followed the guide shown in Appendix G however this 
evolved as the interviews progressed. The first few participants were pilots to 
test the interview guide and this was followed by a pause in recruitment while 
the research team met to re-discuss the study in light of preliminary data. 
Interviewer bias 
All interviews were conducted by HP to ensure that any interviewer effects were 
consistent throughout the study. Patients were not specifically informed that the 
interviewer was medically trained unless they asked; they were told that I was 
conducting the interviews in my role as a researcher at the University of 
Nottingham.  
Case report forms 
6KRUWO\DIWHUWKHLQWHUYLHZWKHSDWLHQW¶VKRVSLWDOQRWHVZHUHXVHGWRFRPSOHWHD
case report form (Appendix G) recording demographic information, stage of 
cancer, histology where known, co-morbidities, performance status and 
treatment plan. The healthcare professionals with whom the patient had 
consulted with prior to their interview was also recorded. This was done after the 
interview to ensure that written consent to access medical records had been 
obtained and so that the interview was noW DIIHFWHG E\ WKH LQWHUYLHZHU¶V SULRU
NQRZOHGJHRIWKHSDWLHQW¶VPHGLFDOKLVWRU\ 
Analysis skills 
In order to develop some initial skills in qualitative analysis I attended the 
University of Nottingham Analysing Interview Transcripts short course in May 
2012. 
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9.1.6 Current status of recruitment & analysis plan 
Patient recruitment 
Recruitment up to September 2013 is shown in Figure 9-1. At this point the 
interviewer felt that no new themes were emerging and therefore recruitment 
may be complete. Recruitment was therefore stopped and detailed analysis 
started (see below). If this confirms that saturation of themes no further 
recruitment will be necessary, if not then recruitment and interviews will 
continue from January 2014. 
 
Figure 9-1: Recruitment of patients to qualitative study during March and May-
September 2013 
 
The demographics, stage, clinicians seen and treatment plan for the patients 
interviewed up to September 2013 are shown in Table 9-2. The majority of 
patients interviewed to date were male; there was a wide age range with 
median age 76 years. Most patients had stage I lung cancer and for all but two 
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the treatment plan was surgery. All patients had seen a respiratory physician 
prior to their interview and all but one had seen a thoracic surgeon (the 
treatment plan for this patient was surgery). Only 13% of patients (n=2) had 
seen a clinical oncologist (radiotherapist) prior to the interview and both of these 
patients went on to have radiotherapy rather than surgery; one of these patients 
had also seen a surgeon, the other did not have a surgical appointment planned. 
Table 9-2: Features of patients interviewed up to September 2013 
  N=15 % 
Age Median 76 (Range 58-87) 
Sex Male 10 33 
 
Female 5 67 
Stage 1a or 1b 8 53 
 
2a or 2b 4 27 
 
3a 3 20 
Clinicians seen Respiratory physician 15 100 
 
Thoracic surgeon 14 93 
 
Clinical oncologist 2 13 
 
Lung cancer nurse specialist 14 93 
Treatment plan Surgery 13 87 
 
Radiotherapy 2 13 
 
Analysis plan  
The anonymised transcripts from each patient interview are currently being 
systematically analysed using the Framework method.(211) The first stage of 
this process is open coding of transcripts to facilitate the generation of a code 
book. The coding system will be valLGDWHG WKURXJK µGRXEOH FRGLQJ¶ E\ WZR
independent researchers (HP and Dr Manpreet Bains, Lecturer in Qualitative 
Research Methods, University of Nottingham). 
Once the validated code book has been finalised, NVivo software will be used to 
facilitate systematic analysis of the emergent themes and exploration of data 
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trends and patterns. The resulting analysis matrix will be used to show the 
results for discussion with other members of the research team including a 
thoracic surgeon, lung cancer nurse and lung cancer physician. 
9.1.7 Methods: Healthcare professional interviews 
I have written the protocol and obtained ethical approval for recruitment and 
interviews of healthcare professionals, however this aspect of the study will be 
performed by a lecturer in qualitative research methods and a research assistant 
at the University of Nottingham and recruitment has not yet started. 
A schematic diagram for this part of the study is shown in Appendix G. The 
methods will be similar to those described for patients, differences are detailed 
below. 
Recruitment 
Healthcare professionals will include thoracic surgeons, respiratory physicians 
and lung cancer specialist nurses, and will be recruited through their 
professional bodies (the Society of Cardiothoracic Surgeons, British Thoracic 
Society and the Association of Respiratory Nurse Specialists), via email which 
will include an invitation letter and participant information sheet (Appendix G). 
Those who are interested in participating will contact the research team (by 
telephone or e-mail) who will arrange an appointment for a single semi-
structured in-depth interview to be conducted at a place of their choosing. The 
first 20 responders from each target group will be recruited, if we have more 
responses than this or if we reach saturation of themes before all 20 have been 
interviewed we will thank the respondent for their interest but they will not 
participate in the study.  
Healthcare professionals will not be required to complete a questionnaire; the 
introductory questions within the interview will cover the nature of their 
employment and how long they have held that post. 
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Inclusion criteria 
Healthcare professionals will be eligible if they are employed by the NHS in a job 
which involves contributing to treatment decisions for lung cancer patients. 
Duration of participation 
Healthcare professionals will participate for up to 3 months from first contact.  
The interviews are expected to last no longer than an hour. 
Consent 
If telephone interviews are used the healthcare professional will be asked to 
return a signed copy of the consent form by post prior to the interview taking 
place. 
Interviews 
Interviews with healthcare professionals will take place at their place of work or 
at an agreed conference facility depending on the participaQW¶V SUHIHUHQFH ,I
necessary these interviews may take place using teleconferencing; however, 
face-to-face interviews will be conducted wherever possible. The participant will 
be asked to discuss with their manager in order to decide whether the interview 
takes place in their own or work time.  
Healthcare Professionals will be asked their own general opinions on the subject, 
developed over the course of their career, rather than those from or of the Trust 
by whom they are currently employed.  
 
9.1.8 Timescale for completion of study 
The results of the patient interviews will be compiled into manuscript format and 
submitted for publication in a peer reviewed journal before August 2014. 
Recruitment and interviews of healthcare professionals is expected to begin in 
August 2014. 
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9.2 Other ongoing research 
9.2.1 Definitions of surgery, chemotherapy and radiotherapy in the NLCA 
Research using the NLCA and HES data 
The work described in chapters 5 and 7 has informed, and will continue to 
inform, other studies using the NLCA-HES linked data. I have co-authored two 
studies which used the definitions of surgery, chemotherapy, and radiotherapy 
resulting from this thesis. These studies assessed changes in treatment and 
survival for NSCLC and SCLC over the course of the NLCA. (77) A further study 
is in progress assessing organisational factors and how these affect rates of lung 
cancer resection. 
NLCA annual reports 
Only NLCA surgical data are used to calculate the proportion of patients who 
receive surgery and chemotherapy for the NLCA annual report. Given that NHS 
trusts are compared using these results the potential under-reporting of 
treatment rates has important implications. I presented work in chapters 5 and 
7 to the NLCA co-clinical lead (Dr Paul Beckett) and members of the NLCA 
steering committee and this has triggered further analysis of cases which have 
surgery recorded in one but not both datasets. Two clinicians are analysing data 
from their own trusts and will review case notes to try and establish why some 
patients only have a record of surgery in one database and whether there is a 
systematic reason for this. 
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9.2.2 Validation of surgical score 
The work described in chapters 5 and 6 produced a model (the NLCA score) 
which could be used in clinical practice to estimate the risk of early post-
operative mortality for patients with NSCLC. It is important that the performance 
of the score is tested in an independent population before we advocate its use 
and criticisms of previous scoring systems have included a lack of robust 
validation in large independent cohorts. A prospective study would be the ideal 
methodology but in the absence of the resources necessary to conduct such a 
study a retrospective analysis of prospectively collected data in an unselected 
population would also provide useful results. 
Local audit data 
I obtained a local thoracic surgical audit database from Mr John Duffy, 
consultant thoracic surgeon at NUH, with a view to testing the performance of 
the NLCA score in these patients. The database contained records for 2,916 
patients who underwent thoracic surgery between 14th May 1974 and 5th 
November 2012. After excluding patients who had undergone thoracic surgery 
for reasons other than potentially curative lung cancer resection, and those with 
insufficient data to calculate the score only 315 cases remained (Figure 9-3), of 
which 21 died within 90 days of surgery.  
Further analysis was not performed as it was unlikely to produce useful results 
with this small number of deaths. In addition, the data were not truly 
independent as a proportion of the cases (those who had surgery between 
January 1st 2004  and 31st March 2010) were likely to have been included the 
NLCA data from which the score was derived. 
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Figure 9-2: Nottingham University Hospitals thoracic surgical audit data: Cases 
which would have been suitable to use in testing a predictive score 
 
NLCA-HES linked data 
I obtained a more recent extract of the linked NLCA-HES dataset in July 2013 
(which I used for the work described in chapters 7 and 8) and I am currently 
assisting another clinical research fellow with a study evaluating the 
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performance of the score in approximately 6,000 cases of NSCLC who underwent 
surgery between 1st April 2010 and 31st March 2012; we estimate that 
approximately 6% (n=360) would have died within 90 days and given 
improvements in data completeness in the NLCA we expect to be able to test the 
score in at least 70% of this population. 
Danish Lung Cancer Registry 
In addition to the above study I have been working with a lecturer in 
HSLGHPLRORJ\ DW .LQJ¶V &ROOHJH /RQGRQ ZKR KDV H[SHULHQFH RI ZRUNLQJ ZLWK D
large Danish database of thoracic surgery (part of the Danish Lung Cancer 
Registry (DLCR)). We have established that this database would be also suitable 
to test the performance of the NLCA score and we devised a protocol for a 
validation study (Appendix G) so that approval could be obtained from the DLCR. 
This work will involve collaboration between epidemiologists and thoracic 
VXUJHRQV DW WKH 8QLYHUVLW\ RI 1RWWLQJKDP DQG .LQJ¶V &ROOHJH /RQGRQ DQG
representatives from the DLCR. The analysis will be performed by Dr Margreet 
Luchtenbörg (LectuUHU LQ (SLGHPLRORJ\ .LQJ¶V &ROOHJH /RQGRQ DQG VKRXOG EH
underway early in 2014. 
9.2.3 Stereotactic radiotherapy 
Stereotactic body radiotherapy (SBRT) was described in Chapter 1. It has 
potential to change the way patients with NSCLC are managed in the future. 
Trials comparing these methods of radiation treatment with surgical resection, 
particularly in patients for whom surgery carries a significant risk of mortality 
and morbidity have begun, and the treatment is becoming more widely available 
in the UK. 
Comparison of outcomes after SBRT with predicted surgical outcomes 
I was invited to assist with a study using the NLCA risk prediction model to 
compare actual short-term outcomes from SBRT with predicted outcomes from 
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surgery in patients who were considered too high risk for an operation. The 
estimation of death within 90 days (as opposed to the traditional 30 days used 
in all other predictive models) is particularly important for this study and others 
comparing SBRT with surgery because the time taken to complete the course of 
SBRT is often longer than 30 days. This study is based in Leeds and is being led 
E\ 'U 0DW &DOOLVWHU GDWD FROOHFWLRQ WKURXJK UHWURVSHFWLYH DQDO\VLV RI SDWLHQWV¶
medical notes is underway and I will assist with data analysis and interpretation. 
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9.3 Chapter summary 
In this chapter I have described several ongoing research projects which are 
closely related to the work in this thesis; in particular a qualitative study 
H[SORULQJWKHSDWLHQWV¶DWWLWXGHVWRWKHULVNVDVVRFLDWHGZLWh lung cancer surgery 
and three studies which I am continuing to contribute to because they are based 
the NLCA score derived in Chapter 6. It is expected that when completed all of 
these studies will be submitted for publication in peer review journals.  
In the following chapter I will summarise all of the work in this thesis, draw 
some conclusions and make suggestions for future research. 
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CHAPTER 10: SUMMARY OF THESIS AND SUGGESTIONS 
FOR FURTHER RESEARCH  
In this chapter I will summarise the work described in this thesis, discuss some 
ideas for future research, and draw some conclusions.  
 268  
10.1 Summary of main findings 
The initial stages of this thesis add to existing evidence that women are more 
susceptible to cigarette smoke that men in terms of risk of lung cancer, and 
challenge the widely held belief that COPD is an independent risk factor for lung 
cancer. In carrying out these studies I developed the necessary skills to go on 
and use the linked NLCA-HES database to examine records of chemotherapy and 
surgery. 
This is the first time that records of surgery and chemotherapy in HES and the 
NLCA have been explored. By examining patient characteristics and patterns of 
survival I was able to deduce that patients with a record of chemotherapy in 
either HES or the NLCA were likely to have received chemotherapy whereas it 
appeared that a record of surgery in HES was the most accurate means of 
identifying people who had surgery.  
I was able to use the data in the NLCA-HES linked dataset to develop a 
predictive score which provides an estimate of the risk of death within 90 days 
of lung cancer surgery. This is currently undergoing evaluation in a more recent 
extract of the NLCA and, if it proves successful in this assessment, will be 
extremely useful to clinicians both nationally and internationally in the pre-
treatment assessment of patients. I also used the NLCA-HES data to provide 
information on treatment decisions and real-life survival for people with small 
cell lung cancer, including an assessment of who completed chemotherapy and 
how this affected survival. 
$TXDOLWDWLYHDVVHVVPHQWRISDWLHQWV¶ DQGKHDOWKFDUHSURIHVVLRQDOV¶ DWWLWXGHV WR
risk is in progress. This is the first time researchers have attempted to interview 
patients and / or clinicians about their attitudes to risk in lung cancer treatment. 
This study will provide a wealth of new lines of research into acceptable levels of 
risk and methods of communication with patients. 
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10.2 Clinical relevance and suggestions for further research 
10.2.1 Early diagnosis of lung cancer and screening 
The strong association between COPD and lung cancer is important in identifying 
people at high risk of lung cancer in general practice and greater awareness of 
the risk in this population could lead to earlier diagnosis for some patients. 
Further research in this area is needed and a study implementing a 
computerised alert system based on the presence of risk factors, including 
COPD, and coding of symptoms has been proposed.  
Screening for lung cancer has now been introduced in the United States and is 
likely to be introduced in the United Kingdom at some stage. There is, however, 
controversy over which group to screen to ensure the most effective service. The 
fact that people with COPD, particularly those recently diagnosed, are at high 
risk of lung cancer could assist in identifying people who should be screened.  
10.2.2 Post-operative mortality 
The work in this thesis examined risk factors for early death after lung cancer 
surgery using the information available in the NLCA and HES. I hope that the 
validation studies will find this tool to perform well when tested in the 
independent data, so that it can be used in clinical practice; however there are 
potential areas for improvement. Performance status was one of the strongest 
predictors of early death in this study however this is a subjective measure 
which may be recorded differently by different clinicians. Collection of data such 
as pre-operative serum albumin, creatinine, and haemoglobin levels, and 
medication and smoking histories from patient records may enable us to develop 
a more objective means of assessing mortality risk.  
The field of thoracic surgery is constantly evolving and new developments 
include the use of video assisted thoracic surgery (VATS) which is less invasive 
and therefore potentially safer in terms of operative mortality. At present VATS 
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lobectomy is becoming more established in clinical practice but is not offered at 
all thoracic centres across the UK. The factors which affect early mortality after 
this type of surgery may differ from those which are important after more 
traditional thoracic surgical procedures, and therefore repeating this analysis in 
5-\HDUV¶WLPHPD\\LHOGQHZLQIRUPDWLRQ 
Postoperative morbidity and quality of life 
It can be argued that mortality is the most important post-operative 
complication; however lung resection also risks leaving patients with long term 
health problems (morbidity), particularly breathlessness, which can affect their 
quality of life. Morbidity is more difficult to quantify, and more difficult to predict, 
than mortality but for some patients it is equally or even more important. A 
balance must be struck between extending life with surgery and the quality of 
life, as perceived by the individual patient, during those extra years. 
In terms of predicting post-operative breathlessness, this is unlikely to be 
recorded in a comprehensive manner in routinely collected data. A study of 
factors associated with post-operative breathlessness specifically would 
therefore need to be a prospective cohort study; however there may be 
surrogate markers for morbidity which can be extracted from routinely collected 
data: A proportion of the patients in the NLCA-HES dataset will have their data 
linked with data from THIN (their primary care records) in the near future. This 
dataset could then be used to determine the number of consultations a patient 
has in a specified time period (such as a year) after their operation, the reasons 
for these consultations, and the number and nature of prescriptions they 
receive. The number of days spent in hospital in the year after surgery (which 
could be extracted from the HES database) could also be used as a surrogate 
marker of morbidity in these patients.  
10.2.3 Communication of risk 
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Preparation of the interview guides for the qualitative study exploring 
perceptions of risk highlighted a lack of research into the way the risk and 
benefits of treatments are communicated to patients by clinicians. Once this 
study has been completed it will inform further research, which is also likely to 
require qualitative methodology, into the most effective ways of discussing 
operative risks with patients.   
10.2.4 Chemotherapy in NSCLC and the Systemic Anti-Cancer Therapy database 
The factors which influence who gets chemotherapy for NSCLC, and their 
subsequent survival, are currently unknown, however investigating this would be 
far more complicated than the analysis of chemotherapy in SCLC presented in 
this thesis. In contrast to SCLC, there are many different chemotherapy 
treatment regimens and intents for people with NSCLC, and also several other 
treatment options which affect survival making it difficult to determine the 
precise effect that chemotherapy has on long term survival.   
The UK Systemic Anti-Cancer Therapy (SACT) database has collected data 
directly from computerised prescriptions of chemotherapy since April 2012. 
(212) When these data mature, and when they are linked with resources such as 
HES and the NLCA, this will be a valuable resource not only to look at 
chemotherapy in NSCLC but also to repeat the work in this thesis with 
information on precise chemotherapy regimens, tumour response and reasons 
for stopping treatment. It may be possible at that stage to provide the oncology 
community with some evidence on which to base their decision regarding the 
optimum number of cycles to aim for.  
Non-small cell lung cancer is treated with TKIs as well as standard 
chemotherapy (as described in Chapter 1). These only became part of routine 
use in the UK in 2010 and therefore the number of patients in the NLCA 
database who received these drugs is still relatively small. The NLCA does not 
collect specific drug data for chemotherapy and therefore the link with the SACT 
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will be necessary before we can start to plan observational studies of the effects 
of these drugs in the unselected NLCA population (rather than current data 
which are from the highly selected patients in clinical trials).  
10.2.5 Organisational and NHS trust-level factors 
In this thesis I described a novel means of defining a chemotherapy trust using 
the proportion of patients who were referred elsewhere for their chemotherapy 
DVDVXUURJDWHPDUNHURIDWUXVW¶Vcapacity to give chemotherapy on site. Data 
on the actual number of oncologists with expertise in lung cancer at each trust 
would further inform the results and these data are needed before 
recommendations for workforce planning can be made based on patient 
outcomes. 
Work is underway at the University of Nottingham collecting organisational level 
data on thoracic surgery, including the number of surgeons at each trust, in a 
study investigating inequalities in access to lung cancer surgery. The NLCA 
steering committee also appreciate the importance of collecting organisational as 
well as patient level data and intend to perform a national survey of resources 
during the next data collection period. This will not only include the number of 
clinicians with a specialist interest in lung cancer but also information on 
resources such as whether the trust has a positron emission tomography (PET) 
scanner on site (personal communication Dr Ian Woolhouse, August 2013). 
Research using this information combined with the NLCA-HES data will provide 
further insights into the effects of organisational level features on patient 
outcomes.  
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10.3 Conclusion 
The studies described in this thesis demonstrate that data collected 
prospectively as part of routine clinical practice are valuable in answering 
important clinical questions in lung cancer.  It is important to ensure that data 
such as these are representative of the study population, that outcome 
measures are accurate, and that any potential bias or systematic anomalies in 
data entry are identified. Validation studies are therefore essential and the lung 
cancer cases in both THIN and the NLCA have previously been found to be 
representative of lung cancer in England. In this thesis I have made progress in 
the validation of treatment records in HES and the NLCA. 
Clearly there are questions that cannot be answered using retrospective analysis 
of routinely collected data; however numerous research questions remain which 
can and should be addressed. The linkage of primary care, chemotherapy 
treatment, and secondary care organisational level data with the NLCA and HES 
will be key to identifying areas where lung cancer care can be improved with the 
ultimate aim of improving lung cancer survival.  
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Appendix A: Abstracts of thesis work presented at conferences 
 
10th Annual British Thoracic Oncology Group Conference, January 2012 
 
Poster presentation of original research: 
Smoking and lung cancer in women 
Powell HA,1 Iyen-Omofoman B,2 Hubbard RB,1,2 Baldwin DR,3 Tata LJ.1 
1 Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, 
UK  
2 Division of Epidemiology and Public Health, University of Nottingham, 
Nottingham, UK  
3 Nottingham University Hospitals NHS Trust, Nottingham, UK. 
 
Introduction: Women have smaller lungs than men and yet often smoke similar 
quantities of cigarettes of the same size. Recent studies have shown that for the 
same quantity of cigarettes smoked women are more likely to develop heart 
disease. We investigated whether this increased effect of smoking in women is 
also true for lung cancer. 
 
Methods: Using prospectively collected general practice (GP) data from The 
Health Improvement Network (a medical research database containing 
anonymised patient records) we generated a dataset consisting of 12,121 
incident cases of lung cancer and 48,216 controls. We classified patients by 
smoking quantity using the highest smoking quantity ever recorded.  The 
dataset was matched on age, sex, and GP practice so we stratified our 
population by sex and used conditional logistic regression to calculate odds ratios 
(OR) for lung cancer. We used a multiplicative test for interaction to see whether 
the effect of smoking quantity on lung cancer differed between men and women. 
 
Results: The odds of lung cancer were much higher in people who smoked 
compared to those who had never smoked, the odds increasing with quantity of 
cigarettes smoked (for the heaviest smokers OR 12.01, 95% confidence interval 
(CI) 11.16-12.92).  The odds of lung cancer in women who had ever smoked 
heavily compared to those who had never smoked were increased nearly 14-fold 
(OR 13.85, 95% CI 12.45-15.41) which was more than for men smoking the 
same quantity (OR 10.66, 95% CI 9.64-11.79). The test for interaction showed 
strong evidence of a difference in effect of quantity smoked on lung cancer 
between men and women (p<0.0001).   
 
Conclusion: Our findings reinforce the importance of smoking cessation 
programmes targeted at women.  Further research into the effects of cigarette 
dose per litre lung volume may help to establish reasons for the differences we 
have observed. 
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10th Annual British Thoracic Oncology Group Conference, January 2012 
Poster presentation of original research: 
Is Chronic Obstructive Pulmonary Disease an Independent Risk Factor 
for Lung Cancer? 
 
Powell HA,1 Iyen-Omofoman B,2 Hubbard RB,1,2 Baldwin DR,3 Tata LJ.1 
1 Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, 
UK  
2 Division of Epidemiology and Public Health, University of Nottingham, 
Nottingham, UK  
3 Nottingham University Hospitals NHS Trust, Nottingham, UK. 
 
 
Introduction: Chronic obstructive pulmonary disease (COPD) and lung cancer 
are two of the most important smoking related diseases, with a huge combined 
mortality burden.  There is some evidence that COPD may be an independent 
risk factor for lung cancer, with airway inflammation being the 
pathophysiological link. This association is heavily confounded by smoking but if 
confirmed would be important in identifying patients who will benefit from 
screening, smoking cessation and perhaps chemoprevention. Current evidence 
comes from predominantly small studies, with few using prospectively collected 
data and many studying only high risk populations.  
 
Methods: We used prospectively collected general practice (GP) data from The 
Health Improvement Network (a medical research database containing 
anonymised patient records) to generate a matched case-control dataset. We 
assessed the effect of a diagnosis of COPD on lung cancer and when this 
diagnosis was made in relation to lung cancer diagnosis (within 1 year, 1 to 5 
years, 5 to 10 years or more than 10 years before). Using a conditional logistic 
regression model we adjusted the effect for smoking, socioeconomic status, 
asthma and previous pneumonia. 
 
Results: We analysed 12,121 cases of lung cancer and 48,216 controls matched 
on age, sex and GP practice. The odds ratio (OR) for lung cancer was increased 
over fourteen-fold for patients who had a diagnosis of COPD within 6 months of 
lung cancer diagnosis (OR 14.39, 95% confidence interval 11.83-17.51). The 
effect remained when using diagnoses made more than 10 years before (OR 2.7, 
95% confidence interval 2.39-3.05), and after adjusting this for smoking (OR 
1.66, 95% confidence interval 1.45-1.91).  
 
Conclusion: In this GP population a diagnosis of COPD confers an increased risk 
of lung cancer. The prospective nature of this study and the use of latency 
variables are valuable in predicting who is at higher risk of lung cancer. 
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British Thoracic Society Winter Meeting, December 2012 
Oral presentation of original research: 
Chronic obstructive pulmonary disease and risk of lung cancer: The 
importance of smoking and timing of diagnosis of COPD 
 
1HA Powell, 2B Iyen-Omofoman, 3DR Baldwin, 2RB Hubbard, 2LJ Tata.  
 
1NottinghamRespiratory Research Unit, University of Nottingham, Nottingham, 
UK; 2Division of Epidemiology and Public Health, University of Nottingham, 
Nottingham, UK; 3Nottingham University Hospitals NHS Trust, Nottingham, UK  
 
Background: The majority of cases of both lung cancer and COPD are 
attributable to cigarette smoking. Some consider COPD to be an independent 
risk factor for lung cancer, even after accounting for smoking, with estimates of 
increased risk up to 9-fold in previous studies. We undertook a large case-
control study using prospectively collected data which allowed us to quantify this 
association in the UK population, whilst carefully controlling for smoking and the 
impact of timing of diagnoses. 
  
Methods: We used The Health Improvement Network, a UK general practice 
database, to identify incident cases of lung cancer and controls matched on age, 
sex and the practice with which they were registered. Using conditional logistic 
regression, we assessed the effects of timing of first diagnoses of COPD, 
pneumonia and asthma on the odds of lung cancer, adjusting for smoking habit 
and socioeconomic status. 
 
Results: Of 11,888 incident cases of lung cancer, 23% had a prior diagnosis of 
COPD compared with only 6% of the 37,605 controls. The odds of lung cancer in 
patients who had COPD diagnosed within 6 months of their cancer diagnosis 
were eleven-fold those of patients without COPD (Table 1). However, when 
restricted to earlier COPD diagnoses, with adjustment for smoking, the effect 
markedly diminished (for COPD diagnoses >10 years before lung cancer 
diagnosis OR 2.18, 95% CI 1.87-2.54). The pattern was similar for pneumonia 
(see table). There was some diagnostic overlap between asthma and COPD but 
analyses which accounted for this produced similar results.  
 
Conclusion: The association between COPD and lung cancer is largely explained 
by smoking habit, strongly dependent on the timing of COPD diagnosis and not 
specific to COPD. There is, however, an extremely strong unadjusted relationship 
of both COPD and pneumonia with lung cancer in the 6 months immediately 
prior to lung cancer diagnosis. This is useful in a clinical context highlighting the 
need to consider a diagnosis of lung cancer when making new diagnoses of 
COPD or pneumonia, and supporting the current NICE recommendation that all 
patients should have a chest radiograph looking for evidence of lung cancer at 
the time of COPD diagnosis. 
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Table 1: Odds ratios for lung cancer (N=49493, 11,888 cases and 37,605 controls) 
 
  Odds ratio (OR) Adjusted OR* 
    95% CI 95% CI 
Smoking Never 1.00  1.00  
Highest ever recorded Trivial / light 6.00 5.42-6.65 5.88 5.31-6.52 
prior to index date Moderate 9.67 8.87-10.54 9.33 8.56-10.18 
 Heavy / very heavy 15.58 14.35-16.91 14.88 13.71-16.16 
 Smoker but unknown quantity 3.48 3.20-3.78 3.44 3.17-3.74 
  Missing smoking status 1.79 1.59-2.02 1.76 1.56-1.99 
COPD No diagnosis prior to index date 1.00  1.00  
Interval between within 6 months 11.47 9.38-14.02 6.81 5.49-8.45 
first diagnosis &   6 months up to 1 year  4.76 3.85-5.89 2.52 2.00-3.19 
index date 1 year up to  5 years 4.34 3.95-4.78 2.48 2.24-2.75 
 5 years up to 10 years 4.83 4.29-5.44 2.68 2.36-3.05 
  10 years or more 3.74 3.25-4.31 2.18 1.87-2.54 
Pneumonia No diagnosis prior to index date 1.00  1.00  
Interval between within 6 months 14.91 11.75-18.94 13.33 10.24-17.35 
first diagnosis &   6 months up to 1 year  3.37 2.42-4.70 2.89 1.99-4.18 
index date 1 year up to  5 years 2.59 2.22-3.02 2.16 1.82-2.57 
 5 years up to 10 years 2.52 2.04-3.10 2.11 1.66-2.67 
  10 years or more 1.68 1.35-2.09 1.46 1.15-1.86 
OR, Odds ratio. CI, confidence interval.   COPD, Chronic obstructive pulmonary disease             
*Adjusted for smoking & Townsend quintile (a measure of socioeconomic status) 
 
 279 
 
British Thoracic Society Winter Meeting, December 2012 
Poster and short oral presentation of original research: 
Early mortality after lung cancer surgery: An Analysis of the UK National 
Lung cancer Audit 
 
1HA Powell, 2LJ Tata, 3DR Baldwin, 2A Khakwani, 4R Stanley, 2RB Hubbard.  
 
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, 
UK; 2Division of Epidemiology and Public Health, University of Nottingham, 
Nottingham, UK; 3Nottingham University Hospitals NHS Trust, Nottingham, UK; 
4The NHS Information Centre, Leeds, UK 
 
Introduction: Surgical resection is the best chance of cure for most patients 
with non-small cell lung cancer (NSCLC), for whom 5-year survival is otherwise 
poor. Selection of patients for surgery should include an estimation of the likely 
post-operative mortality risk but the tool often used in UK practice is a predictive 
score that was developed using a French database of thoracic surgical 
procedures, not specific to lung cancer. 
 
Methods: We used data from the National Lung Cancer Audit linked with 
Hospital Episode Statistics to estimate the influence of pre-operative patient and 
tumour factors, and the type of procedure on the odds of death at 30 and 90 
days after potentially curative surgery for NSCLC. We used logistic regression to 
determine which factors were associated with early post-operative mortality and 
then calculated the percentage of patients who died within 90 days of surgery, 
stratified by the strongest predictors of early post-operative mortality. 
 
Results: We identified 12,096 patients who had potentially curative surgery for 
NSCLC in England between January 2004 and March 2010. Three per cent 
(n=387) and 6% (n=792) of patients died within 30 and 90 days respectively. Of 
the 12 clinical and socio-demographic factors assessed, age and type of 
procedure were consistently the most important predictors of early post-
operative mortality: Odds ratio (OR) for death at 30 days for pneumonectomy 
compared with lobectomy 3.03, 95% confidence interval (CI) 2.32-3.94; and for 
each year increase in age OR 1.06, 95% CI 1.04-1.07. Performance status, co-
morbidity score and sex and were also significantly associated with the 
outcomes. Table 1 shows the percentage of patients who died within 90 days of 
either lobectomy or pneumonectomy, stratified by age and performance status. 
 
Conclusion: The estimation of post-operative mortality risk is a crucial part of 
management of patients with NSCLC. Overall mortality following surgery for 
NSCLC in England is currently 3% at 30-days and 6% at 90-days. We present UK 
data, stratified by age and performance status, which could be used in clinical 
practice to assist with the estimation of early post-operative mortality risk. 
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Table 1: Proportion of patients who died within 90 days of lobectomy or 
pneumonectomy for NSCLC (italics show total number of patients who 
underwent the procedure in each category; # no deaths occurred in these 
groups) 
 
 
 Performance status 
 
 
Age 0 
 
1 2 3-4  0 1 2 
 
<70 
 
1% 
1,611 
 
4% 
974 
 
7% 
160 
 
10% 
30 
  
8% 
307 
 
12% 
205 
 
6% 
31 
 
70-80 
 
4% 
831 
 
7% 
833 
 
9% 
128 
 
13% 
30 
  
19% 
106 
 
14% 
94 
 
22% 
18 
 
>80 
 
7% 
151 
 
6% 
209 
 
24% 
29 
 
# 
4 
  
22% 
9 
 
19% 
16 
 
# 
0 
  
 
LOBECTOMY 
   
 
PNEUMONECTOMY 
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11th Annual British Thoracic Oncology Group Conference, January 2013 
Oral and poster presentation of original research. 
Awarded 1st prize for abstract. 
90-day mortality after surgery for lung cancer ± An analysis of the 
National Lung Cancer Audit 
 
Powell HA, Tata LJ, Baldwin DR, Stanley RA, Khakwani A & Hubbard RB. 
 
Introduction: Almost all previous estimates of early mortality after lung cancer 
surgery are based on deaths within 30-days of operation: in the UK this has 
been estimated at 2.3% and 5.8% for lobectomy and pneumonectomy 
respectively. An estimate of the chances of surviving longer than 30-days may 
be more important to patients, especially if there is a substantial difference from 
30-day mortality. 
 
Methods: We used data from the National Lung Cancer Audit, linked with 
Hospital Episodes Statistics, to determine the proportion of patients who died 
within 30- and 90-days of potentially curative surgery for NSCLC. We then 
compared demographic, co-morbid, tumour and procedure related factors of 
patients who died between 0 and 30 days of surgery with those who died 
between 31 and 90 days. 
 
Results: Of 10,991 patients who underwent surgery with curative intent for 
NSCLC between 2004 and 2010, 3% (334) died within 30 days of surgery and a 
further 2.9% (313) between 31 and 90 days. There were no significant 
differences in age, performance status, lung function or co-morbidity (measured 
by the Charlson index) between these two groups. Stage, laterality and histology 
also showed similar distributions within the groups. A higher proportion of those 
who died within 30-days had a pneumonectomy or bi-lobectomy compared with 
those who died between 31 and 90 days (31% vs. 20%) (see table). 
 
Conclusion: It is important to recognise that a similar number of patients die 
between 31 and 90 days after lung cancer surgery as die within the first 30 
days, and the features of patients who die within both of these early post-
operative time periods are similar. Given that full post-operative recovery usually 
takes at least 2 months, we would suggest that 90-day mortality risk is a more 
appropriate outcome to discuss with patients prior to surgery. 
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Table: Comparison of features of patients who died within 30 days of surgery 
and between 31 and 90 days 
 
  Overall N=10,991 Died within 30 
days n=334 
Died 31 ± 90 
days n=313 
 
         n % of total n n 
Sex Female 4,824 43.9 107 103 
  
Male 6,167 56.1 227 210 
Age group <55 1,008 9.2 12 23 
 
55-59 1,090 9.9 21 24 
 
60-64 1,847 16.8 31 32 
 
65-69 2,128 19.4 56 49 
 
70-74 2,226 20.3 84 78 
 
75-79 1,828 16.6 88 62 
 
80-84 730 6.6 34 35 
 
85+ 134 1.2 12 10 
Performance 0 3,422 31.1 72 60 
status  1 2,815 25.6 84 93 
  
2 465 4.2 23 28 
  
3-4 108 1.0 11 9 
  
Missing 4,181 38.0 144 123 
Per cent >80% 1,891 17.2 34 39 
predicted 60-79% 1,499 13.6 42 45 
FEV1 40-59% 726 6.6 23 27 
 
<40% 141 1.3 5 7 
 
Missing 6,734 61.3 230 195 
Stage IA 2,249 20.5 37 41 
(pre-op) IB 3,064 27.9 87 82 
 
IIA 334 3.0 6 3 
 
IIB 1,494 13.6 55 47 
 
IIIA 933 8.5 41 39 
 
missing 2,857 26.0 108 101 
 Segmentectomy/sleeve/wedge 1,686 15.3 35 35 
Procedure Lobectomy 7,036 64.0 160 165 
  
Bi-lobectomy 431 3.9 25 13 
Pneumonectomy 1,121 10.2 78 51 
  
Other 717 6.5 36 49 
FEV1 Forced expiratory volume in 1 second 
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British Thoracic Society Winter Meeting, December 2013 
Poster and short oral presentation of original research: 
Identifying patients who receive Chemotherapy for small cell lung 
cancer from large Datasets  
Powell HA, Tata LJ, Stanley RA, Baldwin DR, Hubbard RB 
Introduction: The National Lung Cancer Audit (NLCA) has collected data on 
primary lung cancer in England since 2004, and has now been linked with 
Hospital Episodes Statistics (HES) for research into inequalities in access to 
treatment. How well these two large datasets capture chemotherapy for small 
cell lung cancer (SCLC) is not known. 
 
Methods: We identified all cases of SCLC in the NLCA diagnosed between 
January 2004 and March 2012. We calculated the proportion of patients with a 
HES code for chemotherapy, and the proportion with a start date for 
chemotherapy in the NLCA, within 6 months of diagnosis. We inspected survival 
curves for people with a chemotherapy record in HES only or the NLCA only, 
people who had records of chemotherapy in both databases (who we could be 
reasonably sure had chemotherapy), and those with no record of chemotherapy. 
We assessed whether the results changed over time as case ascertainment in 
the NLCA increased from 19% to 98% between 2004 and 2009. 
 
Results: We identified 18,398 cases of histologically confirmed SCLC; 9,484 
(52%) had chemotherapy records in both databases and 5,100 (28%) had no 
record of chemotherapy in either. 737 patients (4%) had chemotherapy recorded 
only in HES and 2,539 (14%) only in the NLCA. For people with a record of 
chemotherapy in a single database (NLCA only or HES only) survival was similar 
to that of people with records of chemotherapy in both datasets (figure 1); the 
average age, stage and performance status was also very similar for people in 
these three groups. Survival patterns were the same when we analysed the data 
by year of diagnosis however the proportions with chemotherapy records in HES 
only or the NLCA only decreased to 3% and 12% respectively in 2011. 
 
Conclusion: Our results suggest that it is best to identify people who received 
chemotherapy using data in the NLCA and HES combined. A record of 
chemotherapy in either database appears to be a valid means of determining 
who received chemotherapy but if a single database is used the proportion 
treated is likely to be an under-estimate.  
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Figure 1: Survival after diagnosis for people with SCLC according to records of 
chemotherapy 
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British Thoracic Society Winter Meeting, December 2013 
Poster and short oral presentation of original research: 
Identifying patients who had surgical resection for Non-small cell lung 
cancer in large datasets 
Powell HA, Tata LJ, Stanley RA, Baldwin DR & Hubbard RB 
Introduction: Surgical resection rates have become an important indicator of 
NHS Trust performance and efforts to increase them are on-going with the aim 
of improving overall survival. The National Lung Cancer Audit (NLCA) has 
collected data on primary lung cancer since 2004 and has now been linked with 
Hospital Episode Statistics (HES) for research into inequalities in access to 
treatment. How well these two large datasets capture surgical data is not known.  
 
Methods: We used the NLCA to identify all cases of NSCLC, excluding stage IIIB 
or IV, diagnosed between January 2004 and March 2010. We calculated the 
proportion of cases with a procedure date in the NLCA, and the proportion with a 
code in HES, for potentially curative surgery less than 6 months after or 3 
months before diagnosis. We looked at the age, lung function, performance 
status, stage and survival according to where surgery was recorded. Given the 
increase in NLCA case ascertainment from approximately 19% in 2004 to 98% in 
2009 we also looked for changes in our results over time.  
 
Results: There were 60,196 people in the NLCA who met the inclusion criteria; 
8,535 (14%) had a record of surgery in both databases. An additional 2,568 
(4%) had a record of surgery in HES and 795 (1%) in the NLCA. The features of 
people who had surgery in HES only or the NLCA only were similar, however 
median survival was shorter, and the proportion that died soon after surgery was 
higher, in the NLCA only group compared with those with surgery records in both 
databases (table 1). The proportion with HES only records of surgery decreased 
from 6% (n=215) in 2004 to 3% (n=367) in 2009; the patterns of survival each 
year were similar to the overall results.  
 
Conclusion: The proportion of people who had potentially curative surgery 
differed according to the database used to identify surgical procedures. There 
are many possible explanations for our results; however use of either database 
alone is likely to under-estimate the proportion of people who had surgery and 
this should be taken into account in studies investigating access to surgery.
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Table:  Features and survival of people according to the database in which records of surgery were present 
 Record of surgical procedure 
N=60,196 Both HES only NLCA only Neither 
 
n=8,535 (14%) n=2,568 (4%) n=795 (1%) n=48,298 (80%) 
Mean age (years) 67.4 66.8 67.8 72.6 
Mean % predicted FEV1 77.1 74.7 74.2 63.8 
Missing FEV1 (% of total) 54.6 77.8 68.7 81.8 
Stage (% of non-missing) 1a or 1b 67.2 56.4 58.4 36.2 
2a or 2b 21.9 23.0 21.7 19.6 
3a 10.9 20.6 19.9 44.2 
Missing stage (% of total) 14.5 60.6 52.0 72.9 
Performance status (% of non-missing) 0-1 92.3 86.2 85.5 47.9 
2 6.4 10.2 9.0 24.1 
3-4 1.2 3.6 5.5 27.9 
Missing performance status (% of total) 28.2 58.9 38.2 50.4 
Median survival (months)* 62 41 18 7 
**Died within 30-days of surgery (%) 2.6 4.4 5.8  
Died within 90-days of surgery (%) 5.3 8.6 16.7  
*Survival is calculated from date of diagnosis not date of procedure;FEV1 Forced expiratory Volume in 1 second; **HES date 
of procedure  unless NLCA only 
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12th Annual British Thoracic Oncology Group Conference, January 2014 
 
Poster presentation of original research: 
Small-cell lung cancer: Chemotherapy cycles and survival 
Powell HA, Tata LJ, Baldwin DR, Potter VA, Stanley RA, Khakwani A, Hubbard RB. 
Introduction 
Chemotherapy is the mainstay of treatment for small cell lung cancer but is 
associated with side effects and toxicity that can limit the number of cycles 
given. We used the English National Lung Cancer Audit (NLCA) and Hospital 
Episodes Statistics (HES) to investigate how many cycles of chemotherapy were 
given to patients with SCLC, and the associated differences in survival. 
 
Methods 
We identified people in the NLCA with histologically confirmed SCLC diagnosed 
between January 2006 and September 2011. We used HES data to identify those 
who received at least one cycle of chemotherapy, and to determine the number 
of chemotherapy cycles each patient received, in the first 6 months after 
diagnosis. We calculated survival from the end of the last cycle of chemotherapy 
(to minimise immortal time bias), according to disease stage and the number of 
cycles received.  
 
Results 
Of 7,866 patients who had evidence in HES of having started chemotherapy, 
63% received four or more cycles and 26% only received 1 or 2 cycles. Survival 
according to number of cycles received, for limited and extensive stage disease, 
is shown in Figure 1. People who received 1 or 2 cycles are grouped together, as 
are those who received 4 or 5 cycles because their survival curves were almost 
identical. Median survival for people who received four or more cycles was 4.9 
months for extensive stage and 10.9 months for limited stage disease. 
 
Conclusion 
Patients who received more cycles of chemotherapy survived longer, even after 
taking into account the time during which they were undergoing treatment. We 
are not, however, able to recommend that patients should receive more cycles of 
chemotherapy from these data as we do not know the degree of tumour 
response to chemotherapy or the reasons for stopping treatment. 
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Figure 1: Kaplan Meier curves showing survival after last chemotherapy cycle 
according to number of cycles received 
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12th Annual British Thoracic Oncology Group Conference, January 2014 
 
Poster presentation of original research: 
Less chemotherapy and Poor outcomes for people with small-cell lung 
cancer diagnosed through emergency admission 
 
Powell HA, Tata LJ, Baldwin DR, Potter VA, Stanley RA, Khakwani A, Hubbard RB. 
 
Introduction 
People with lung cancer in England are often diagnosed as the result of an 
emergency admission rather than through referral from their General Practitioner 
(GP), despite the existence of referral guidelines. We used the English National 
Lung Cancer Audit (NLCA) to examine the routes to diagnosis for people with 
small cell lung cancer (SCLC) and to determine how this was associated with 
treatment rates and survival. 
 
Methods 
Cases of SCLC diagnosed between 2006 and 2011 were identified. Linked data 
from Hospital Episodes Statistics (HES) were used combined with NLCA 
treatment records to identify patients who were treated with chemotherapy. 
Office for National Statistics death records were used to measure survival.  
Emergency presentations were defined as referral to the lung cancer team from 
an emergency department or as the result of an emergency hospital admission. 
We used logistic regression to estimate odds of receiving chemotherapy, and Cox 
regression to assess survival after diagnosis. 
 
Results 
Of 15,091 cases of histologically confirmed SCLC, 48% were referred by their GP 
and 23% presented as an emergency. After adjustment for age, sex, 
performance status, co-morbidity and stage, those who presented as an 
emergency were less likely to have been treated with chemotherapy compared 
with those who were referred by their GP (table). They were also less likely to 
survive (HR for death 1.30 (95% confidence interval 1.23-1.37) compared with 
GP referrals). Median survival for emergency admissions and GP referrals was 
2.6 and 7.8 moths respectively.  
 
Conclusion 
A substantial number of patients with SCLC were diagnosed via the emergency 
route. These patients were significantly less likely to receive chemotherapy and, 
perhaps consequently, less likely to survive. Further research is needed to 
determine how much of this effect is due to residual confounding or whether 
there are organisational factors which could be modified to improve outcomes. 
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Table: Routes of referral and receipt of chemotherapy for people with small-cell lung cancer 
Route of referral 
 
 Total    %    Had          % Adjusted* odds ratio for receiving 
chemotherapy 
(N=15,091) chemotherapy 95% confidence interval 
Emergency admission 2,323 15.4 1,355 58.3 0.68 0.60 0.77 
General Practitioner 7,267 48.2 5,624 77.4 1.00   
Consultant referral 2,729 18.1 1,869 68.5 0.91 0.81 1.02 
Other (includes private) 887 5.9 589 66.4 0.73 0.61 0.87 
Emergency department 1,120 7.4 630 56.3 0.60 0.51 0.70 
Missing 765 5.1 515 67.3 0.79 0.66 0.96 
*Adjusted for stage, co-morbidity, performance status, socio-economic status, age and sex. 
 
 
 291 
 
Appendix B: Clinical training 
Clinics 
Combined lung oncology clinic 
Lung cancer nurses 
Oncology - chemotherapy 
Oncology - radiotherapy 
Surgical (pre and post-op) 
Meetings 
Multi-disciplinary team meetings 
Network / local lung cancer policy planning meetings 
National Cancer Intelligence Network lung cancer leads workshops 
Procedures 
Electrocautery, brachytherapy catheter placement, TBNA & EBUS  
Papworth EBUS course 14-15th October 2012 
Thoracoscopy 
Observed thoracic surgery (open and VATS) 
Observed radiotherapy sessions (palliative and SBRT) 
Tutorials 
The National Agenda for lung Cancer and Mesothelioma 
Essential Documents in Lung Cancer and Mesothelioma 
The Cancer Reform Strategy 
Running an MDT meeting 
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Professional relationships and the MDT 
An effective lung cancer service 
Clinical aspects 1 ± selection for radical treatment 
Clinical aspects 2 ± palliative chemotherapy 
Clinical aspects 3 ± palliative radiotherapy 
Clinical aspects 4 ± endo-bronchial therapy 
Clinical aspects 5 ± Specialist palliative Care 
Clinical aspects 6 ± keeping patients informed 
Clinical aspects 7 ± The lung cancer nurse specialist 
Change management 
Managing Conflict 
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Appendix C: Code lists for studies using the THIN database 
 
Lung cancer Read codes 
Read code Description 
B22..00 Malignant neoplasm of trachea, bronchus and lung 
B220.00 Malignant neoplasm of trachea 
B220z00 Malignant neoplasm of trachea NOS 
B221.00 Malignant neoplasm of main bronchus 
B221000 Malignant neoplasm of carina of bronchus 
B221100 Malignant neoplasm of hilus of lung 
B221z00 Malignant neoplasm of main bronchus NOS 
B222.00 Malignant neoplasm of upper lobe, bronchus or lung 
B222.11 Pancoast's syndrome 
B222000 Malignant neoplasm of upper lobe bronchus 
B222100 Malignant neoplasm of upper lobe of lung 
B222z00 Malignant neoplasm of upper lobe, bronchus or lung NOS 
B223.00 Malignant neoplasm of middle lobe, bronchus or lung 
B223000 Malignant neoplasm of middle lobe bronchus 
B223100 Malignant neoplasm of middle lobe of lung 
B223z00 Malignant neoplasm of middle lobe, bronchus or lung NOS 
B224.00 Malignant neoplasm of lower lobe, bronchus or lung 
B224000 Malignant neoplasm of lower lobe bronchus 
B224100 Malignant neoplasm of lower lobe of lung 
B224z00 Malignant neoplasm of lower lobe, bronchus or lung NOS 
B225.00 Malignant neoplasm of overlapping lesion of bronchus & lung 
B22y.00 Malignant neoplasm of other sites of bronchus or lung 
B22z.00 Malignant neoplasm of bronchus or lung NOS 
B22z.11 Lung cancer 
B26..00 Malignant neoplasm, overlap lesion of resp & intrathor orgs 
B2zz.00 Malignant neoplasm of respiratory tract NOS 
B551100 Malignant neoplasm of chest wall NOS 
B551z00 Malignant neoplasm of thorax NOS 
Byu2.00 Malignant neoplasm of respiratory and intrathoracic orga 
Byu2000 Malignant neoplasm of bronchus or lung, unspecified 
Byu2400 Malignant neoplasm/ill-defined sites within resp system 
 
Smoking status Read codes 
Read code Description Status 
137..00 Tobacco consumption see AHD 
137..11 Smoker - amount smoked Current 
1371.00 Never smoked tobacco Never 
1371.11 Non-smoker see AHD 
1372.00 Trivial smoker - < 1 cig/day Current 
1372.11 Occasional smoker Current 
1373.00 Light smoker - 1-9 cigs/day Current 
1374.00 Moderate smoker - 10-19 cigs/d Current 
1375.00 Heavy smoker - 20-39 cigs/day Current 
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1376.00 Very heavy smoker - 40+cigs/d Current 
1377.00 Ex-trivial smoker (<1/day) Ex 
1378.00 Ex-light smoker (1-9/day) Ex 
1379.00 Ex-moderate smoker (10-19/day) Ex 
137A.00 Ex-heavy smoker (20-39/day) Ex 
137B.00 Ex-very heavy smoker (40+/day) Ex 
137C.00 Keeps trying to stop smoking Current 
137D.00 Admitted tobacco cons untrue ? Unknown 
137E.00 Tobacco consumption unknown Unknown 
137F.00 Ex-smoker - amount unknown Ex 
137G.00 Trying to give up smoking Current 
137H.00 Pipe smoker Current 
137J.00 Cigar smoker Current 
137K.00 Stopped smoking Ex 
137L.00 Current non-smoker see AHD 
137M.00 Rolls own cigarettes Current 
137N.00 Ex pipe smoker Ex 
137O.00 Ex cigar smoker Ex 
137P.00 Cigarette smoker Current 
137P.11 Smoker Current 
137Q.00 Smoking started Current 
137Q.11 Smoking restarted Current 
137R.00 Current smoker Current 
137S.00 Ex smoker Ex 
137T.00 Date ceased smoking Ex 
137V.00 Smoking reduced Current 
137X.00 Cigarette consumption see AHD 
137Y.00 Cigar consumption see AHD 
137Z.00 Tobacco consumption NOS see AHD 
137a.00 Pipe tobacco consumption see AHD 
137b.00 Ready to stop smoking Current 
137c.00 Thinking about stopping smoking Current 
137d.00 Not interested in stopping smoking Current 
137e.00 Smoking restarted Current 
137f.00 Reason for restarting smoking Current 
137g.00 Cigarette pack-years Unknown 
137h.00 Minutes from waking to first tobacco consumption Current 
13p..00 Smoking cessation milestones Unknown 
13p0.00 Negotiated date for cessation of smoking Current 
13p1.00 Smoking status at 4 weeks Unknown 
13p2.00 Smoking status between 4 and 52 weeks Unknown 
13p3.00 Smoking status at 52 weeks Unknown 
13p4.00 Smoking free weeks Unknown 
13p5.00 Smoking cessation programme start date Current 
13p6.00 Carbon monoxide reading at 4 weeks Unknown 
4I90.00 Expired carbon monoxide concentration Unknown 
6791.00 Health ed. - smoking Current 
67A3.00 Pregnancy smoking advice Current 
67H1.00 Lifestyle advice regarding smoking Current 
6893.00 Tobacco usage screen see AHD 
68T..00 Tobacco usage screen see AHD 
745H.00 Smoking cessation therapy Unknown 
745H000 Nicotine replacement therapy using nicotine patches Current 
745H100 Nicotine replacement therapy using nicotine gum Current 
745H200 Nicotine replacement therapy using nicotine inhalator Current 
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745H300 Nicotine replacement therapy using nicotine lozenges Current 
745H400 Smoking cessation drug therapy Current 
745Hy00 Other specified smoking cessation therapy Current 
745Hz00 Smoking cessation therapy NOS Unknown 
8B2B.00 Nicotine replacement therapy Current 
8B3Y.00 Over the counter nicotine replacement therapy Current 
8B3f.00 Nicotine replacement therapy provided free Current 
8BP3.00 Nicotine replacement therapy provided by community 
pharmacist 
Current 
8CAL.00 Smoking cessation advice Current 
8CAg.00 Smoking cessation advice provided by community 
pharmacist 
Current 
8H7i.00 Referral to smoking cessation advisor Current 
8HTK.00 Referral to stop-smoking clinic Current 
8I2I.00 Nicotine replacement therapy contraindicated Current 
8I39.00 Nicotine replacement therapy refused Current 
9N2k.00 Seen by smoking cessation advisor Unknown 
9N4M.00 DNA - Did not attend smoking cessation clinic Unknown 
9OO..00 Anti-smoking monitoring admin. Unknown 
9OO..11 Stop smoking clinic admin. Unknown 
9OO..12 Stop smoking monitoring admin. Unknown 
9OO1.00 Attends stop smoking monitor. Unknown 
9OO2.00 Refuses stop smoking monitor Unknown 
9OO3.00 Stop smoking monitor default Unknown 
9OO4.00 Stop smoking monitor 1st letter Unknown 
9OO5.00 Stop smoking monitor 2nd letter Unknown 
9OO6.00 Stop smoking monitor 3rd letter Unknown 
9OO7.00 Stop smoking monitor verb.inv. Current 
9OO8.00 Stop smoking monitor phone inv Current 
9OO9.00 Stop smoking monitoring delete Unknown 
9OOA.00 Stop smoking monitor. check done Unknown 
9OOZ.00 Stop smoking monitor admin.NOS Unknown 
9hG..00 Exception reporting: smoking quality indicators Exception 
9hG0.00 Excepted from smoking quality indicators: Patient 
unsuitable 
Exception 
9hG1.00 Excepted from smoking quality indicators: Informed 
dissent 
Exception 
E023.00 Nicotine withdrawal Unknown 
E251.00 Tobacco dependence Current 
E251100 Tobacco dependence, continuous Current 
E251300 Tobacco dependence in remission Ex 
E251z00 Tobacco dependence NOS Current 
ZG23300 Advice on smoking Current 
ZRBm200 Fagerstrom test for nicotine dependence Current 
ZRBm211 FTND - Fagerstrom test for nicotine dependence Current 
ZRaM.00 Motives for smoking scale Current 
ZRaM.11 MFS - Motives for smoking scale Current 
ZRao.00 Occasions for smoking scale Current 
ZRh4.00 Reasons for smoking scale Current 
ZRh4.11 RFS - Reasons for smoking scale Current 
ZV11600 Personal history of tobacco abuse Unknown 
ZV4K000 Tobacco use see AHD 
ZV6D800 Tobacco abuse counselling Current 
137j.00 Ex-cigarette smoker Ex 
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Quantity smoked Read codes 
Read code Description Quantity 
1374.00 Moderate smoker - 10-19 cigs/d current/moderate 
1373.00 Light smoker - 1-9 cigs/day current/light 
1375.00 Heavy smoker - 20-39 cigs/day current/heavy 
1372.00 Trivial smoker - < 1 cig/day current/trivial 
1376.00 Very heavy smoker - 40+cigs/d current/very heavy 
1379.00 Ex-moderate smoker (10-19/day) Ex/moderate 
1378.00 Ex-light smoker (1-9/day) Ex/light 
137A.00 Ex-heavy smoker (20-39/day) Ex/heavy 
1377.00 Ex-trivial smoker (<1/day) Ex/trivial 
137B.00 Ex-very heavy smoker (40+/day) Ex/very heavy 
137..00 Tobacco consumption see AHD 
137Z.00 Tobacco consumption NOS see AHD 
137a.00 Pipe tobacco consumption see AHD 
137Y.00 Cigar consumption see AHD 
137X.00 Cigarette consumption see AHD 
ZV4K000 Tobacco use see AHD 
 
Quantity smoked Additional Health Data (AHD) codes 
AHD code Description Value 1 Value 2 
1003040000 Smoking No. of cigarettes smoked/ day Smoking status  
1003040001 Smoking type No. of cigars smoked/ day Ounces of tobacco/ day 
1003040002 Smoking dates Date started smoking Date stopped smoking 
 
Smoking status: Y=Current; N=Never; D=Ex. 
 
COPD Read codes 
Read code Description 
66YI.00 COPD self-management plan given 
66YL.00 Chronic obstructive pulmonary disease follow-up 
66YL.11 COPD follow-up 
66YL.12 COAD follow-up 
66YM.00 Chronic obstructive pulmonary disease annual review 
8H2R.00 Admit COPD emergency 
14B3.00 History of COPD 
H3...00 Chronic obstructive pulmonary disease 
H3...11 Chronic obstructive airways disease 
H31..00 Chronic bronchitis 
H310.00 Simple chronic bronchitis 
H310000 Chronic catarrhal bronchitis 
H310z00 Simple chronic bronchitis NOS 
H311.00 Mucopurulent chronic bronchitis 
H311000 Purulent chronic bronchitis 
H311100 Fetid chronic bronchitis 
H311z00 Mucopurulent chronic bronchitis NOS 
H312.00 Obstructive chronic bronchitis 
H312100 Emphysematous bronchitis 
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H312200 Acute exacerbation of chronic obstructive airways disease 
H312z00 Obstructive chronic bronchitis NOS 
H313.00 Mixed simple and mucopurulent chronic bronchitis 
H31y.00 Other chronic bronchitis 
H31y100 Chronic tracheobronchitis 
H31yz00 Other chronic bronchitis NOS 
H31z.00 Chronic bronchitis NOS 
H32..00 Emphysema 
H320.00 Chronic bullous emphysema 
H320000 Segmental bullous emphysema 
H320100 Zonal bullous emphysema 
H320200 Giant bullous emphysema 
H320300 Bullous emphysema with collapse 
H320z00 Chronic bullous emphysema NOS 
H321.00 Panlobular emphysema 
H322.00 Centrilobular emphysema 
H32y.00 Other emphysema 
H32y000 Acute vesicular emphysema 
H32y100 Atrophic (senile) emphysema 
H32y111 Acute interstitial emphysema 
H32y200 MacLeod's unilateral emphysema 
H32yz00 Other emphysema NOS 
H32z.00 Emphysema NOS 
H36..00 Mild chronic obstructive pulmonary disease 
H37..00 Moderate chronic obstructive pulmonary disease 
H38..00 Severe chronic obstructive pulmonary disease 
H3y..00 Other specified chronic obstructive airways disease 
H3y..11 Other specified chronic obstructive pulmonary disease 
H3z..00 Chronic obstructive airways disease NOS 
H3z..11 Chronic obstructive pulmonary disease NOS 
Hyu3000 Other emphysema 
Hyu3100 Other specified chronic obstructive pulmonary disease 
H312000 Chronic asthmatic bronchitis 
H312011 Chronic wheezy bronchitis 
H312300 Bronchiolitis obliterans 
H320311 Tension pneumatocoele 
H32yz11 Sawyer - Jones syndrome 
H3y0.00 Chronic obstruct pulmonary disease with acute lower resp infection 
H3y1.00 Chronic obstruct pulmonary dis wth acute exacerbation, unspecified 
 
Asthma Read codes  
Read code Description 
173A.00 Exercise induced asthma 
173c.00 Occupational asthma 
173d.00 Work aggravated asthma 
178..00  Asthma trigger 
1780.00 Aspirin induced asthma 
1J70.00  Suspected asthma 
1O2..00 Asthma confirmed 
2126200 Asthma resolved 
212G.00 Asthma resolved 
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663..11  Asthma monitoring 
663d.00 Emergency asthma admission since last appointment 
663e.00 Asthma restricts exercise 
663e000 Asthma sometimes restricts exercise 
663e100 Asthma severely restricts exercise 
663f.00  Asthma never restricts exercise 
663h.00 Asthma - currently dormant 
663j.00  Asthma - currently active 
663m.00 Asthma accident and emergency attendance since last visit 
663N.00 Asthma disturbing sleep 
663n.00 Asthma treatment compliance satisfactory 
663N000 Asthma causing night waking 
663N100 Asthma disturbs sleep weekly 
663N200 Asthma disturbs sleep frequently 
663O.00 Asthma not disturbing sleep 
663O000 Asthma never disturbs sleep 
663P.00 Asthma limiting activities 
663p.00 Asthma treatment compliance unsatisfactory 
663q.00 Asthma daytime symptoms 
663Q.00 Asthma not limiting activities 
663r.00  Asthma causes night symptoms 1 to 2 times per month 
663s.00  Asthma never causes daytime symptoms 
663t.00  Asthma causes daytime symptoms 1 to 2 times per month 
663u.00 Asthma causes daytime symptoms 1 to 2 times per week 
663U.00 Asthma management plan given 
663v.00 Asthma causes daytime symptoms most days 
663V.00 Asthma severity 
663V000 Occasional asthma 
663V100 Mild asthma 
663V200 Moderate asthma 
663V300 Severe asthma 
663w.00 Asthma limits walking up hills or stairs 
663W.00 Asthma prophylactic medication used 
663x.00 Asthma limits walking on the flat 
663y.00 Number of asthma exacerbations in past year 
66Y5.00 Change in asthma management plan 
66Y9.00 Step up change in asthma management plan 
66YA.00 Step down change in asthma management plan 
66YC.00 Absent from work or school due to asthma 
66YE.00 Asthma monitoring due 
66YJ.00 Asthma annual review 
66YK.00 Asthma follow-up 
66YP.00 Asthma night-time symptoms 
66YQ.00 Asthma monitoring by nurse 
66YR.00 Asthma monitoring by doctor 
66YZ.00 Does not have asthma management plan 
679J.00  Health education - asthma 
8791.00 Further asthma - drug prevent. 
8793.00 Asthma control step 0 
8794.00 Asthma control step 1 
8795.00 Asthma control step 2 
8796.00 Asthma control step 3 
8797.00 Asthma control step 4 
8798.00 Asthma control step 5 
8B3j.00 Asthma medication review 
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8CR0.00 Asthma clinical management plan 
8H2P.00 Emergency admission, asthma 
8HTT.00 Referral to asthma clinic 
9hA..00 Exception reporting: asthma quality indicators 
9hA1.00 Excepted from asthma quality indicators: Patient unsuitable 
9hA2.00 Excepted from asthma quality indicators: Informed dissent 
9Q21.00 Patient in asthma study 
G581.11 Asthma - cardiac 
H312000 Chronic asthmatic bronchitis 
H33..00 Asthma 
H33..11 Bronchial asthma 
H330.00 Extrinsic (atopic) asthma 
H330.11 Allergic asthma 
H330.12 Childhood asthma 
H330.13 Hay fever with asthma 
H330.14 Pollen asthma 
H330000 Extrinsic asthma without status asthmaticus 
H330011 Hay fever with asthma 
H330100 Extrinsic asthma with status asthmaticus 
H330111 Extrinsic asthma with asthma attack 
H330z00 Extrinsic asthma NOS 
H331.00 Intrinsic asthma 
H331.11 Late onset asthma 
H331000 Intrinsic asthma without status asthmaticus 
H331100 Intrinsic asthma with status asthmaticus 
H331111 Intrinsic asthma with asthma attack 
H331z00 Intrinsic asthma NOS 
H332.00 Mixed asthma 
H333.00 Acute exacerbation of asthma 
H334.00 Brittle asthma 
H33z.00 Asthma unspecified 
H33z000 Status asthmaticus NOS 
H33z011 Severe asthma attack 
H33z100 Asthma attack 
H33z111 Asthma attack NOS 
H33z200 Late-onset asthma 
H33zz00 Asthma NOS 
H33zz11 Exercise induced asthma 
H33zz12 Allergic asthma NEC 
H35y600 Sequoiosis (red-cedar asthma) 
H35y700 Wood asthma 
H47y000 Detergent asthma 
SLF7.00 Antiasthmatic poisoning 
SLF7z00 Antiasthmatic poisoning NOS 
TJF7.00 Adverse reaction to antiasthmatics 
TJF7300 Adverse reaction to theophylline (asthma) 
TJF7z00 Adverse reaction to antiasthmatic NOS 
U60F600 Antiasthmats caus adverse effects in therapeut use, NEC 
U60F611 Adverse reaction to antiasthmatics 
U60F615 Adverse reaction to theophylline - asthma 
U60F61A Adverse reaction to antiasthmatic NOS 
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Pneumonia Read codes 
Read code Description 
H26..00 Pneumonia due to unspecified organism 
H25..00 Bronchopneumonia due to unspecified organism 
H062.00 Acute lower respiratory tract infection 
H21..00 Lobar (pneumococcal pneumonia) 
H2z..00  Pneumonia or Influenza NOS 
H2...00  Pneumonia and influenza 
H261.00 Basal pneumonia due to unspecified organism 
H28..00 Atypical pneumonia 
H260.00 Lobar pneumonia due to unspecified organism 
H231.00 Pneumonia due to mycoplasma pneumoniae 
H20..00 Viral pneumonia 
H20z.00 Viral pneumonia NOS 
H22z.00 Bacterial pneumonia NOS 
H540000 Hypostatic pneumonia 
SP13100 Other aspiration pneumonia as a complication of care 
H56y100 Interstitial pneumonia 
H540100 Hypostatic bronchopneumonia 
H22..00 Other bacterial pneumonia 
H23..00 Pneumonia due to other specified organisms 
H470312 Aspiration pneumonia due to vomit 
H223.00 Pneumonia due to streptococcus 
H201.00 Pneumonia due to respiratory syncitial virus 
H2y..00 Other specified pneumonia or influenza 
H22..11 Chest infection- other bacterial pneumonia 
H22y200 Pneumonia-legionella 
H25..11 Chest infection- unspecified bronchopneumonia 
H270000 Influenza with bronchopneumonia 
A3BXA00 Mycoplasma pneumoniae (PPLO) cause/dis classifd/oth 
H224.00 Pneumonia due to staphylococcus 
H270.00 Influenza with pneumonia 
H20..11 Chest infection- viral pneumonia 
H220.00 Pneumonia due to klebsiella pneumoniae 
H23z.00 Pneumonia due to specified organism NOS 
A3BXB00 Klebsiella pneumoniae/cause/disease classifd/oth chapt 
A789300 HIV disease resulting in Pneumocystis carinii pneumonia 
H060A00 Acute bronchitis due to mycoplasma pneumoniae 
H221.00 Pneumonia due to pseudomonas 
H233.00 Chlamydial pneumonia 
H24y200 Pneumonia with pneumocystis carinii 
H262.00 Postoperative pneumonia 
H270.11 Chest infection- influenza with pneumonia 
A116.00 Tuberculous pneumonia 
A380300 Septicaemia due to streptococcus pneumoniae 
AB24.11 Pneumonia- candidal 
H06z112 Acute lower respiratory tract infection 
H20y.00 Viral pneumonia NEC 
H222.00 Pneumonia due to haemophilus influenzae 
H22y000 Pneumonia due to Escherichia coli 
H22yz00 Pneumonia due to bacteria NOS 
H24..00 Pneumonia with infectious disease EC 
H24y700 Pneumonia with varicella 
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Appendix D: NLCA data entry form 
Demographics 
NHS Number  Organisation Code  
Forenames  Surname  
Sex  Date of Birth  
Postcode    
 
Referral Information 
Source of 
referral 
 Following an emergency admission  Following a domiciliary visit 
 Referral from consultant other than in A&E  Referral from GP 
 Following A&E attendance  General Dental Practitioner 
 Community Dental Service  Other source of referral 
 Not known  
Date of decision to refer (2-week patients only)  
Lung cancer specialist referral date (non-2-week patients)  
Date first seen  
Place first seen  
 
Investigations 
Had a CT scan?  No           Yes........Date: 
Had a PET scan?  No           Yes........Date: 
Had a bronchoscopy?  No           Yes........Date: 
Had a CT-guided biopsy?  No           Yes........Date: 
Had other diagnostic biopsy?  No           Yes........Date: 
 
 
 
Staging 
Staging procedure performed?  
Mediastinoscopy/Mediastinotomy  
FNA staging procedure 
performed? 
 
Other staging procedure 
performed? 
 
Unknown staging procedure 
performed? 
 
Pre-treatment Stage T N M 
NSCLC Stage Will be calculated based on TNM above 
SCLC Stage  Limited  Extensive  Unknown 
Diagnosis 
Date of diagnosis  
Place of diagnosis  
Pre-treatment histology  
Pri
mar
y 
site 
dia
gno
sis 
 Bronchus or lung, unspecified  Malignant neoplasm of bronchus or lung 
 Main bronchus, Carina, Hilus of lung  Upper lobe, bronchus or lung (incl. pancoast) 
 Middle lobe/lingular, bronchus or lung  Lower lobe, bronchus or lung 
 Trachea  Overlapping lesion of bronchus and lung  
 Mediastinum, part unspecified  Pleura 
 Malignant neoplasm of heart, 
mediastinum and pleura 
 Overlapping lesion of heart, mediastinum and 
pleura 
 Mesothelioma   Mesothelioma of pleura 
Laterality  Left  Midline  Right  Bilateral  Unknown  Not applicable 
Basis of 
diagnosis 
 Death certificate  Clinical 
 Clinical investigation  Specific tumour markers 
 Cytology  Histology of a metastasis 
 Histology of a primary tumour  Unknown 
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Co-Morbidities 
Was there any reason 
why the patient did not 
receive the first choice 
of treatment? 
 Died  COPD  Refused 
 Co-morbidity precluding treatment 
Co-morbidities 
 Dementia/Cerebrovascular 
disease 
 Cardiovascular disease 
 Renal failure  Other malignancy 
 Severe weight loss  Other 
FEV1 Absolute  
FEV1 percentage  
Performance Status  0  1  2  3  4  Not recorded 
 
 
Treatment - Surgery 
Hospital code  
Date of decision to operate  
Date of surgery  
Main 
surgical 
procedu
re 
 Wedge resection of lesion of lung  Multiple wedges resected 
 Segmental resection  Sleeve resection 
 Lung resection with resection of chest wall (not identifying which 
lobe resection) 
 Carinal resection  
 Lobectomy  Pneumonectomy 
 Open operation on lung (open and close)  Bilobectomy 
 Other open operation on lung  Extrapleural pneumonectomy 
 Debulking pleurectomy  Pleurodesis 
Complet
eness of 
resectio
n 
 Presence of 
residual tumour 
cannot be assessed 
 No residual 
tumour 
 Microscopic 
residual tumour 
 Macroscopic 
residual tumour 
Surgical histology  
Date of surgical histology  
Pathological stage pT pN pM 
Pathological NSCLC Stage  
Pathological SCLC Stage  
 
Treatment - Chemotherapy 
Hospital code  
Care Plan/MDT 
Discussed at 
MDT? 
 <HV««'DWH  No  Unknown 
Treatment 
intent 
 Curative  Palliative 
 Palliative (supportive care only)  Unknown 
 No specific anti-cancer treatment 
Treatment 
modalities 
 Single modality  Multiple modality  Unknown 
Suggested plan 
 Surgery  Radiotherapy 
 Chemotherapy  Brachytherapy 
 Palliative care  Active monitoring 
 Sequential chemotherapy and radiotherapy 
 Concurrent chemotherapy and radiotherapy 
 Induction chemo to downstage before surgery 
 Neo-adjuvant chemotherapy and surgery 
 Surgery followed by chemotherapy 
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Treatment - Chemotherapy 
Date of decision to 
treat 
 
Date of start of 
treatment 
 
Chemotherapy intent 
 
 
 Chemotherapy alone 
 Neo-adjuvant chemotherapy before surgery 
 Part of a chemotherapy / radiotherapy treatment plan 
 Adjuvant chemotherapy post surgery 
 Induction chemotherapy to down stage before surgery 
 
 
 
 
 
Treatment - Radiotherapy 
Hospital code  
Date of decision to 
treat 
 
Date of start of 
treatment 
 
Radiotherapy site 
 Trachea  Lung 
 Mediastinum  Skin 
 Chest wall  Bone 
 Mesothelioma drain site  Other Region of Body 
 Brain  
Radiotherapy intent 
 Curative (radical) radiotherapy 
 Curative (CHART / CHARTWEL) 
 Part of a chemotherapy / radiotherapy treatment plan 
 Adjuvent following surgical treatment 
 Palliative Radiotherapy 
Treatment - Brachytherapy 
Hospital code  
Date of decision to 
treat 
 
Date of start of 
treatment 
 
Treatment ± Palliative Care 
Hospital code  
Date of decision to treat  
Date of start of treatment  
Palliative Care Provider 
Type 
 Hospital  Community 
Palliative Care Community 
Provider 
 Hospice  Nursing Home 
 Home care  Other 
 Unknown  
Palliative Care Intervention 
Given 
 No           Yes........Date: 
Treatment ± Active Monitoring 
Hospital code  
Date of decision to 
treat 
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Outcomes 
Trial status 
 Patient eligible, consented to and entered trial 
 Patient not entered into clinical trial 
 Clinical trial status unknown 
Date of death  
Was death treatment-
related? 
 Yes  No  Unknown 
Morbidity type  Surgery  Chemotherapy  Radiotherapy  Combination 
Was PCI given  Yes  No  Unknown 
Was the original plan 
carried out? 
 Yes  No  Unknown 
Reason for failure of 
original plan 
 Cancer progressed through treatment such that a 
new treatment plan required 
 Patient choice 
 Patient died 
 Treatment toxicity 
 Disease progression 
Lung Cancer Nurse Specialist 
Was patient assessed by LCNS?  Yes  No  Unknown 
Date of first assessment by LCNS  
How was patient first assessed by 
LCNS? 
 In clinic  Home visit 
 Ward Visit  Telephone 
 Other  Unknown 
 Not recorded  
At what stage was the patient 
assessed by LCNS? 
 Before diagnosis  After diagnosis 
 Before and after diagnosis  At diagnosis only 
 Unknown  Not recorded 
Was LCNS present when patient 
received their diagnosis? 
 Yes  No  Unknown 
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Appendix E: Code lists for surgery studies 
Surgical procedure codes: OPCS-4 codes for potentially curative surgery 
for NSCLC 
Categories in order of priority (most complicated first): Pneumonectomy (P), bi-
lobectomy (B), lobectomy (L), segmentectomy / wedge resection (S), Other (O). 
E391 Open excision of lesion of trachea (O) 
E398 Other specified partial excision of trachea (O) 
E399 Unspecified partial excision of trachea (O) 
E438 Other specified other open operations on trachea (O) 
E439 Unspecified other open operations on trachea (O) 
E461 Sleeve resection of bronchus and anastomosis HFQ (L) 
E463 Excision of lesion of bronchus NEC (O) 
E468 Other specified partial extirpation of bronchus (O) 
E478 Other specified other open operations on bronchus (O) 
E528 Other specified other operations on bronchus (O) 
E529 Unspecified other operations on bronchus (O) 
E541 Total pneumonectomy (P) 
E542 Bi-lobectomy of lung (B) 
E543 Lobectomy of lung (L) 
E544 Excision of segment of lung (S) 
E545 Partial lobectomy of lung NEC (S) 
E548 Other specified excision of lung (O) 
E549 Unspecified excision of lung (O) 
E552 Open excision of lesion of lung (O) 
E558 Other specified open extirpation of lesion of lung (O) 
E559 Unspecified open extirpation of lesion of lung (O) 
E578 Other specified other open operations on lung (O) 
E598 Other specified other operations on lung (O) 
E599 Unspecified other operations on lung (O) 
T013 Excision of lesion of chest wall (O) 
T038 Other specified opening of chest (O) 
T039 Unspecified opening of chest (O) 
T058 Other specified other operations on chest wall (O) 
T059 Unspecified other operations on chest wall (O) 
 
NLCA surgical procedure codes 
Categories in order of priority (most complicated first): Pneumonectomy (P), bi-
lobectomy (B), lobectomy (L), segmentectomy / wedge resection (S), Other (O). 
E54.4A  Wedge resection of lesion of lung (segment)   (S) 
E54.8A  Multiple wedges resected     (S) 
E54.4B  Segmental resection      (S) 
E54.8B  Sleeve resection      (S) 
E54.8 + T01  Lung resection with resection of chest wall   (O) 
E44.1   Carinal resection      (S) 
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E54.3   Lobectomy       (L) 
E54.1   Pneumonectomy      (P) 
E54.2   Bi-lobectomy       (B) 
E57.4  Open operation on lung (Incision of lung NEC)   (O) 
E57.8   Other open operation on lung     (O)  
01   Extrapleural pneumonectomy    (Excluded) 
02  Debulking pleurectomy    (Excluded) 
03  Pleurodesis     (Excluded) 
            
Charlson index ICD 10 codes 
Myocardial Infarction 
I210 I211 I212 I213 I214 I219 I220 I221 I228 I229 I252 
Congestive Heart Failure 
I110 I130 I132 I500 I501 I509 I420 I425 I426 I427 I428 I429 I430 I431 I432 
I438 I099  
Peripheral Vascular disease 
I700 I701 I702 I708 I709 I710 I711 I712 I713 I714 I715 I716 I718 I719 I731 
I738 I739 I771 I790 I792 K558 K559 K551 Z958 Z959 
Cerebrovascular disease 
I600 I601 I602 I603 I604 I605 I606 I607 I608 I609 I610 I611 I612 I613 I614 
I615 I616 I618 I619 I620 I621 I629 I630 I631 I632 I633 I634 I635 I636 I638 
I639 I640 I650 I651 I652 I653 I658 I659 I660 I661 I662 I663 I664 I668 I669 
I670 I671 I672 I673 I674 I675 I676 I677 I678 I679 I680 I681 I682 I688 I690 
I691 I692 I693 I694 I698 G450 G451 G452 G453 G454 G458 G459 G460 G461 
G462 G463 G464 G465 G466 G467 G468 H340 
Dementia 
F000 F001 F002 F009 F010 F011 F012 F013 F018 F019 F020 F021 F022 F023 
F024 F028 F030 F051 G300 G301 G308 G309 G311 
Chronic Pulmonary disease 
I278 I279 J400 J410 J411 J418 J420 J430 J431 J432 J438 J439 J440 J441 J448 
J449 J450 J451 J458 J459 J460 J470 J600 J610 J620 J628 J630 J631 J632 J633 
J634 J635 J638 J640 J650 J660 J661 J662 J668 J670 J671 J672 J673 J674 J675 
J676 J677 J678 J679 J684J701 J703 
Connective Tissue disease 
M050 M051 M052 M053 M058 M059 M060 M061 M062 M063 M064 M068 M069 
M315 M320 M321 M328 M329 M330 M331 M332 M339 M340 M341 M342 M348 
M349 M351  M353 M360 
Ulcer disease 
K250 K251 K252 K253 K254 K255 K256 K257 K258 K259K260 K261 K262 K263 
K264 K265 K266 K267 K268 K269K270 K271 K272 K273 K274 K275 K276 K277 
K278 K279K280 K281 K282 K283 K284 K285 K286 K287 K288 K289 
Diabetes Mellitus 
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E100 E101 E109 E110 E111 E119 E120 E121 E129 E130 E131 E139 E140 E141 
E149 
Diabetes Mellitus with Chronic Complication 
E102 E103 E104 E105 E106 E107 E108 E112 E113 E114 E115 E116 E117 E118 
E122 E123 E124 E125 E126 E127 E128 E132 E133 E134 E135 E136 E137 E138 
E142 E143 E144 E145 E146 E147 E148 
Hemiplegia 
G041 G114 G801 G802 G830 G831 G832 G833 G839 G834 G810 G811 
G819G820 G821 G822 G823 G824 G825 
Moderate/Severe Renal Failure 
I120 N032 N033 N034 N035 N036 N037 N052 N053 N054 N055 N056 N057 
N181 N182 N183 N184 N185 N189 N190 N250 Z490 Z491 Z492 Z940 Z992 
Mild Liver disease  
B180 B181 B182 B188 B189 K702 K703 K709 K713 K714 K715 K717 K730 K731 
K732 K738 K739 K743 K744 K745 K746 Z944 K760 K700 K701 K740 K741 K742 
Moderate/Severe Liver disease 
K766 I850 I859 I864 I982 K711 K704 K721 K729 K765 K767  
AIDS 
B200 B201 B202 B203 B204 B205 B206 B207 B208 B209 B210 B211 B212 B213 
B217 B218 B219 B220 B221 B222 B227 B240 
Any Tumour 
Excluded: C340 C341 C342 C343 C348 C349 (lung cancer) 
C000 C001 C002 C003 C004 C005 C006 C008 C009 C010 C020 C021 C022 C023 
C024 C028 C029 C030 C031 C039 C040 C041 C048 C049 C050 C051 C052 C058 
C059 C060 C061 C062 C068 C069 C070 C080 C081 C088 C089 C090 C091 C098 
C099 C100 C101 C102 C103 C104 C108 C109 C110 C111 C112 C113 C118 C119 
C120 C131 C132 C138 C139 C140 C142 C148 C150 C151 C152 C153 C154 C155 
C158 C159 C160 C161 C162 C163 C164 C165 C166 C168 C169 C170 C171 C172 
C173 C178 C179 C180 C181 C182 C183 C184 C185 C186 C187 C188 C189 C190 
C200 C210 C211 C212 C218 C220 C221 C222 C223 C224 C227 C229 C230 C240 
C241 C248 C249 C250 C251 C252 C253 C254 C257 C258 C259 C260 C261 C268 
C269 C300 C301 C310 C311 C312 C313 C318 C319 C320 C321 C322 C323 C328 
C329 C330 C370 C380 C381 C382 C383 C384 C388 C390 C398 C399 C400 C401 
C402 C403 C408 C409 C410 C411 C412 C413 C414 C418 C419 C431 C432 C433 
C434 C435 C436 C437 C438 C439 C450 C451 C452 C457 C459 C460 C461 C462 
C463 C467 C468 C469 C470 C471 C472 C473 C474 C475 C476 C478 C479 C480 
C481 C482 C488 C490 C491 C492 C493 C494 C495 C496 C498 C499 C500 C501 
C502 C503 C504 C505 C506 C508 C509 C510 C511 C512 C518 C519 C520 C530 
C531 C538 C539 C540 C541 C542 C543 C548 C549 C550 C560 C570 C571 C572 
C573 C574 C577 C578 C579 C580 C600 C601 C602 C608 C609 C610 C620 C621 
C629 C630 C631 C632 C637 C638 C639 C640 C650 C660 C670 C671 C672 C673 
C674 C675 C676 C677 C678 C679 C680 C681 C688 C689 C690 C691 C692 C693 
C694 C695 C696 C698 C699 C700 C701 C709 C710 C711 C712 C713 C714 C715 
C716 C717 C718 C719 C720 C721 C722 C723 C724 C725 C728 C729 C730 C740 
C741 C749 C750 C751 C752 C753 C754 C755 C758 C759 C760 C761 C762 C763 
C764 C765 C767 C768  
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Metastatic Solid Tumor 
C770 C771 C772 C773 C774 C775 C778 C779 C780 C781 C782 C783 C784 C785 
C786 C787 C788 C790 C791 C792 C793 C794 C795 C796 C797 C798 C799 C800 
C809 
Leukemia 
C910 C911 C913 C914 C915 C916 C917 C918 C919 C920 C921 C922 C923 C924 
C925 C926 C927 C928 C929 C930 C931 C933 C937 C939 C940 C942 C943 C944 
C946 C947 C950 C951 C957 C959 D450 
Lymphoma 
C810 C811 C812 C813 C814 C817 C819 C820 C821 C822 C823 C824 C825 C826 
C827 C829 C830 C831 C833 C835 C837 C838 C839 C840 C841 C844 C845 C846 
C847 C848 C849 C851 C852 C857 C859 C880 C900 C901 C902 C903 C960 C962 
C964 C965 C966 C967 C968 C969 
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Appendix F: Code lists for Chemotherapy studies 
OPCS-4 chemotherapy codes 
Code Definition 
X35.2 Intravenous chemotherapy ±only chemotherapy code available until 1/4/2006 
X72.1 Delivery of complex chemotherapy for neoplasm including prolonged infusional 
treatment at first attendance 
X72.2 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
X72.3 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
X72.4 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
X72.8 Other specified delivery of chemotherapy for neoplasm 
X72.9 Unspecified delivery of chemotherapy for neoplasm 
X70.1 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 1 
X70.2 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 2 
X70.3 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 3 
X70.4 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 4 
X70.5 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 5 
X70.8 Other specified procurement of drugs for chemotherapy for neoplasm Bands 1-5 
X70.9 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X71.1 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 6 
X71.2 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 7 
X71.3 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 8 
X71.4 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 9 
X71.5 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 10 
X71.8 Other specified procurement of drugs for chemotherapy for neoplasm Bands 6-10 
X71.9 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
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OPCS-4 radiotherapy codes 
Code Description 
X651 Delivery of a fraction of total body irradiation 
X652 Delivery of a fraction of intracavitary radiotherapy 
X653 Delivery of a fraction of interstitial radiotherapy 
X654 Delivery of a fraction of external beam radiotherapy NEC 
X656 Delivery of a fraction of intraluminal brachytherapy 
X658 Other specified radiotherapy delivery 
X659 Unspecified radiotherapy delivery 
Y918 Other specified Delivery of Radiotherapy 
Y919 Unspecified Delivery of Radiotherapy 
X671 Preparation for intensity modulated radiation therapy 
X672 Preparation for total body irradiation 
X673 Preparation for hemi body irradiation 
X674 Preparation for simple radiotherapy with imaging and dosimetry 
X675 Preparation for simple radiotherapy with imaging and simple calculation 
X676 Preparation for superficial radiotherapy with simple calculation 
X677 Preparation for complex conformal radiotherapy 
X678 Other specified preparation for external beam radiotherapy 
X679 Unspecified preparation for external beam radiotherapy 
X681 Preparation for intraluminal brachytherapy 
X682 Preparation for intracavitary brachytherapy 
X683 Preparation for interstitial brachytherapy 
X688 Other specified preparation for brachytherapy 
Y921 Technical support for preparation for radiotherapy 
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Flow chart for clinical coding at Nottingham University Hospitals 
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Appendix G: Study protocols and documents 
Proposal for analysis of Danish Lung Cancer Registry (DCLR) surgical 
data 
Introduction 
In pre-operative assessment of mortality risk the commonly used Thoracoscore 
was not developed using data solely on people with lung cancer, nor has it been 
validated in such a population.(170) There is concern in the lung cancer 
community that Thoracoscore may under (or over-) estimate risks when used for 
people with lung cancer, and there is enthusiasm for a more sophisticated score 
Using English National Lung Cancer Audit (NLCA) data, supplemented with data 
from inpatient hospital episodes the Nottingham group has produced a score 
(Table 1) which is designed to estimate the risk of death within 90 days of 
surgery for lung cancer. (200) This has not been tested in an independent 
dataset. 
Study population 
The score was based on all patients in the NLCA with confirmed or presumed 
NSCLC (in the NLCA if histology data are not entered the patient is presumed to 
have NSCLC) who had a surgical procedure which, in a patient with lung cancer, 
could reasonably represent an attempt at cure.  
Procedures which took place between 1st January 2004 and 31st March 2010 
were included.  A list of procedure codes is attached as an appendix. People with 
stage 3b or 4 disease were excluded as surgery for these people would not be 
curative. People with missing FEV1, stage or performance status were also 
excluded.  
Variables 
The score comprises the following patient, tumour and procedure related 
variables: 
Age At diagnosis as surrogate for age at surgery 
Sex M/F 
Performance status As defined by ECOG 
FEV1 Percentage of predicted  
Procedure type Pneumonectomy; (bi-)lobectomy, wedge or 
segmentectomy; other (see attached code list). 
Charlson co-morbidity index See below 
Stage UICC TNM version 6 lung cancer stage, see text 
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The method of calculating co-morbidity score may require some discussion. The 
NLCA score was developed using the original Charlson co-morbidities and 
weighting, identified through coding from inpatient hospital episodes which took 
place any time before the procedure date.(90) The only exception was that lung 
FDQFHUZDVQRWLQFOXGHGLQµWXPRXU¶ 
It is not possible to convert between UICC TNM staging versions 6 and 7 with 
the information available in the NLCA database (during 2010 clinicians in the UK 
started to use version 7 rather than version 6). If the same is true for the DCLR 
it would probably be necessary to accept this as a limitation to the validation 
study and use stage regardless of TNM system accepting the minor differences. 
Outcome variables 
Death within 90 days of surgery requires the date of procedure and date of 
death, or a censor date at least 90 days after the latest procedure date. 
Table 1: NLCA predictive score for 90 day mortality after lung cancer surgery 
    Coefficient 
Age (years) <55 0 
  
55-65 0.31 
  
66-75 0.97 
  
>75 1.40 
Sex Female 0 
  
Male 0.23 
Performance status 0 0 
  
1-2 0.68 
  
 0.2Á 
% predicted  >80% 0 
FEV1 61-80% 0.20 
  
40-60% 0.69 
  
<40% 0.95 
 Procedure type Pneumonectomy 1.16 
(Bi-)lobectomy, wedge, or segmentectomy 0 
  
Other b 0.07 
Charlson  0-1 0 
index  0.33 
Stage 1a 0 
  
1b 0.42 
  
2a or 2b 0.51 
  
3a 0.84 
  Constant  -5.28 
)(9IRUFHGH[SLUDWRU\YROXPHLQVHFRQGÁ2QO\SDWLHQWVDQGGHDWKVLQWKLVJURXSE2WKHU
includes procedures listed in Appendix. See text for method of calculating percentage risk of death 
within 90 days. 
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Plan for statistical analysis 
The NLCA score was developed using a multivariate logistic regression model. 
The risk of death within 90 days of surgery, as a percentage, for an individual 
patient is estimated as:  
odds / (1+ odds) where odds = exp (total of coefficients + constant) 
This is the same methodology as used in Thoracoscore.(170) 
We would use ROC modelling to test the performance of the score in the DCLR 
(which from 2005 onwards contains >90% of people diagnosed with lung cancer 
in Denmark) complemented with data from the Central Population Register, 
National Pathology Registry and National Hospital Register. We would restrict the 
study population to those with complete data for all components of the score 
and would use all available data from 2005 onwards. 
We would also use multivariate logistic regression to produce a score using the 
DCLR data. This would include all variables with significant univariate 
associations with 90 day mortality, which remain significant in a multivariate 
model. We would include additional variables such as height and weight (which 
would be used to calculate BMI) if they had significant associations in the 
multivariate model. We could then test the performance of this score in the 
English data using ROC modelling. 
Power 
In order to achieve 90% power at the 0.05 significance level, based on the age 
variable (< or >70 years in which groups the 90-day post-operative mortality 
was 4% and 7% respectively) we would require data on 2,556 people who had 
undergone surgery for lung cancer.  
The DLCR data from 2005 to 2010 (inclusive) contains at least 3,152 people with 
NSCLC who underwent surgical resection. (213) Assuming the 90-day mortality 
is approximately the same as that in England, even if some of these people are 
excluded due to incomplete data, we will have sufficient power to assess 
whether the actual outcomes were significantly different to those predicted by 
the score.   
H Powell, M Luchtenbörg & R Hubbard ± August 2013 
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Qualitative study to map attitudes to risks surrounding treatment for 
lung cancer ± study documents 
Schematic diagram of study design ± patient interviews 
1. Members of MDTs (lung cancer nurse specialists, surgeons, respiratory 
physicians and oncologists) asked to assist with recruitment. 
 
 
2. Study, including inclusion and exclusion criteria, explained to  
members of lung cancer MDTs. 
 
 
3. Suitable patients invited to participate by a member of the MDT (who is also 
part of their clinical care team), given an invitation letter and participant 
information sheet and asked if they would be happy to be contacted by a 
researcher.  
 
 
4. Patients who agree to be contacted receive a telephone call from a 
researcher who answers questions about the study and, if the patient gives 
verbal consent to participate, arranges a time and place for interview.  
 
 
5. Participant allocated unique study identifier 
 
 
6. Patient signs consent form in presence of investigator  
(at least 24 hours after step 3) 
 
 
7. INTERVIEW takes place, audio recorded. No further  
patient participation required from this point. 
 
 
8. 5HVHDUFKHUXVHVSDWLHQW¶VPHGLFDOQRWHVWR complete case report form. 
 
 
9. Data entered into database and stored with audio recordings on  
password protected UoN computer. All identifiers apart from unique study 
identifier removed. 
 
 
10. Audio-recordings transcribed by external transcription company 
 
 
11. Transcripts analysed as per study protocol for analysis. Analysis of 
transcripts looking for saturation of themes will determine when recruitment 
stops.  
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Letter to MDT members asking for assistance with recruitment 
 
              
(Final version 1.1 08/05/12) 
 
Study title: A qualitative study to map attitudes to risks surrounding treatment 
for lung cancer. 
Research team: The University of Nottingham, Department of Public Health 
and Epidemiology 
Names of Researchers:  Professor Richard Hubbard, Dr Helen Powell, Dr Laura 
Jones, Dr Manpreet Bains, Dr Laila Tata and Dr David Baldwin. 
 
 
Dear MDT member, 
 
We are writing to ask for your assistance in recruiting patients for our study. We 
would like to talk to patients who have recently been diagnosed with lung 
cancer, to explore their opinions about the risks associated with treatment for 
lung cancer, and in particular with surgery. 
 
The enclosed information sheet and letter of invitation explain the study in full. 
We would be grateful if you would inform your patients about the study if they 
meet the inclusion criteria and you feel may agree to participate. If they express 
an interest please give them the enclosed information pack, confirm that they 
agree to be contacted by a researcher and give us their details so that we can 
contact them to discuss the study further. 
 
Inclusion criteria for the study are: any patient recently diagnosed with lung 
cancer stage 1a to 3a (inclusive), who is aware of their diagnosis, and has not 
yet had or is not going to have surgery. They must be over 18 years of age, able 
to give informed consent and able to communicate (hear, speak and 
understand) in English without an interpreter. Patients will be interviewed in 
their own home by one of the researchers after we have obtained informed 
consent. After the interview we will collect some information on tumour stage, 
co-PRUELGLW\DQGWUHDWPHQWSODQIURPWKHSDWLHQW¶VKRVSLWDOQRWHVWRDVVLVWZLWK
interpreting our data. 
 
If you would like any further information, please contact Helen Powell, who is a 
member of the research team on 0115 8231378 or at 
helen.powell@nottingham.ac.uk. 
 
Many thanks for your assistance. 
Yours faithfully,  
 
 
Helen Powell  
Clinical Research Fellow, University of Nottingham 
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Invitation letter to patients 
 
              
 
 
(Final version 1.1 08/05/12) 
 
Study title: A qualitative study to map attitudes to risks surrounding treatment 
for lung cancer. 
Research team: The University of Nottingham, Department of Public Health 
and Epidemiology 
Names of Researchers:  Professor Richard Hubbard, Dr Helen Powell, Dr Laura 
Jones, Dr Manpreet Bains, Dr Laila Tata and Dr David Baldwin. 
 
Dear Patient, 
 
Thank you for thinking about taking part in our study. We would like to talk to 
people, like you, who have recently been diagnosed with lung cancer, to find out 
how patients feel about the treatments for lung cancer and in particular the risks 
associated with surgery. 
 
The enclosed information explains the study in full and you should read it 
carefully before deciding if you would like to take part. 
 
If you decide that you would like to be involved in the study, you will be invited 
to take part in an individual interview with a researcher at a time convenient to 
you. The interview will take about an hour and you can choose whether the 
researcher comes to your house or whether you are interviewed at Nottingham 
City hospital. This informal one to one discussion will focus on lung cancer and 
your feelings about treatment. 
 
The interview will be audio recorded to allow the researcher to pay full attention 
to what you are saying. Recording the interview will also allow the research 
team to do further analysis at a later date. In addition, we will ask for your 
permission to collect a few pieces of information from your medical notes. This 
information and the audio-recordings will be kept strictly confidential, stored 
securely within our department and only used for the purposes of the study. 
 
Thank you for taking the time to read this letter. If you would like any further 
information, you can talk to your lung cancer nurse specialist or Helen Powell, 
who is a member of the research team on 0115 8231378 or at 
helen.powell@nottingham.ac.uk. 
 
Yours faithfully,  
 
 
Helen Powell  
Clinical Research Fellow, University of Nottingham 
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Participant information sheet ± patients 
 
 319 
 320 
 321 
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Consent form for patients 
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Letter to lung cancer clinical nurse specialists 
 
              
 
 
(Final version 1.0 13/02/12) 
 
Study title: A qualitative study to map attitudes to risks surrounding treatment 
for lung cancer. 
Research team: The University of Nottingham, Department of Public Health 
and Epidemiology 
Names of Researchers:  Professor Richard Hubbard, Dr Helen Powell, Dr Laura 
Jones, Dr Manpreet Bains, Dr Laila Tata and Dr David Baldwin. 
 
Dear colleague, 
 
Re:  Patient name: 
 
Date of Birth: 
 
Hospital number: 
 
We are writing to inform you that your patient has agreed to take part in the 
above study.  
 
The enclosed participant information sheet explains the study in full. We do not 
need you to do anything in response to this letter, however it is possible that as 
a result of taking part in an interview your patient may wish to discuss aspects 
of their diagnosis or treatment with you or a member of your team and we are 
very grateful to you for facilitating this. 
 
If you would like any further information, please contact Helen Powell, who is a 
member of the research team on 0115 8231378 or at 
helen.powell@nottingham.ac.uk. 
 
Many thanks for your assistance. 
 
Yours faithfully,  
 
 
Helen Powell  
Clinical Research Fellow, University of Nottingham 
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Initial interview guide for patients 
 
Introduction 
x Thank them for coming and taking part. 
x Check consent form has been signed. Keep a copy and give participant a 
copy. 
x Statement on confidentiality, right to withdraw consent, recording of the 
interview. 
x Explain the purpose of the study in general:  
x To explore attitudes towards treatment in lung cancer 
x Their opinions on risks of treatment 
x Ask if they have any further questions before starting interview 
x The interview will last between 30 and 60 minutes. 
 
Background 
x Tell me a bit about yourself 
o Do you have family nearby? 
o Do you work? 
x You are taking part in this study because you have recently been 
diagnosed with lung cancer, can you tell me about what happened when 
you were diagnosed? 
o When? 
o What tests did you have? 
o Who broke the news? 
o Were you expecting it? 
o How did you feel? 
o How did your family feel? 
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x What is going to happen now? 
o What is the plan for treatment or more investigations? 
o What do you want to happen? 
o When is your next consultation? 
o Are you happy with the plan? 
 
Knowledge 
x What do you know about lung cancer and the possible treatments? 
o What did you know at the time you were diagnosed? 
o How have you found out what you know? 
o What have the hospital / your GP told you? 
o What treatments are you aware of? 
o Were you offered a choice of treatments? 
o Did you understand what they told you? 
o Did you ask many questions? 
o Did they talk about prognosis? Did you want them to? 
o Who was most helpful? 
o Do you have enough information now? 
 
Risks & communication of risks 
x What sort of problems do you know about that can arise from lung cancer 
treatments? 
x What sort of risks did your doctors and nurses tell you about? 
x How do you feel about the possibility that something might go wrong? 
x Discuss risk in the context of the treatment they are going to have, or 
were offered. 
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o If the risk had been quoted as X instead of Y what would your 
thoughts be? 
o Present and ask them to discuss different scenarios including 
different degrees of mortality risk, survival and post-op disability. 
 
Closing questions 
x +DVWKLVLQWHUYLHZUDLVHGLVVXHVZKLFK\RXKDYHQ¶WFRQVLGHUHGEHIRUH" 
o What are they? 
o Will you want more information? 
x Advise them that if they think of any further questions about their 
diagnosis or treatment they can contact their lung cancer specialist 
nurse. 
 
Conclusion 
 
x Tell the patient that they have reached the end of the interview 
x Do they have any questions in return?  
x Remind them about confidentiality.  
x Thank them for their time.  
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Case report form 
 
 328 
Schematic diagram of study design ± healthcare professionals 
1. Representatives of professional bodies (SCTS, ARNS and BTS) asked 
                                   to assist with recruitment 
 
 
2. Study inclusion and exclusion criteria explained to representatives. 
 
 
3. HCPs invited to participate by a member of their professional body and given 
a participant information sheet. 
 
 
4. HCPs who wish to participate contact the named investigator who answers 
any additional questions and arranges a time and place for interview. 
 
 
5. Participant allocated unique study identifier 
 
 
6. Participant signs consent form in presence of investigator to confirm 
informed consent to participate (at least 24 hours after step 3)*  
 
 
7. Participant completes questionnaire (on day of interview)* 
 
 
8. INTERVIEW takes place, audio recorded. No further participation from  
individual HCP required after this point. 
 
 
9. Data entered into database and stored with audio recordings on password 
protected UoN computer. All but unique study identifier removed. 
 
 
10. Audio-recordings transcribed by external transcription company 
 
 
11. Transcripts analysed as per study protocol for analysis. Analysis of 
transcripts looking for saturation of themes will determine when recruitment 
stops. 
 
 
* If the interview is not face-to-face the participant will be sent a consent form 
and questionnaire which they will sign and return by post prior to the interview. 
 
Abbreviations: ARNS Association of Respiratory Nurse Specialists; BTS British 
Thoracic Society; HCP Healthcare Professional; MDT Multi-Diciplinary Team;  
SCTS Society of Cardiothoracic Surgeons; UoN University of Nottingham;  
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Letter to representatives of professional bodies asking for assistance with 
recruitment 
 
 
(Final version 1.0 13/02/12) 
 
 
Study title: A qualitative study to map attitudes to risks surrounding treatment 
for lung cancer. 
Research team: The University of Nottingham, Department of Public Health 
and Epidemiology 
Names of Researchers:  Professor Richard Hubbard, Dr Helen Powell, Dr Laura 
Jones, Dr Manpreet Bains, Dr Laila Tata and Dr David Baldwin. 
 
 
Dear Colleague, 
 
We are writing to ask for your assistance in recruiting participants to our study. 
We would like to interview healthcare professionals who are involved in 
treatment decisions, particularly those involving surgery, for patients with lung 
cancer, in order to investigate how and why opinions and practice vary. 
 
Inclusion criteria for the study are that the participant is aged over 18 years old, 
able to give informed consent and can communicate in English. Healthcare 
professionals must be employed by the NHS and involved in caring for patients 
with lung cancer, in particular in contributing to the decision whether or not the 
patient will be offered surgery. 
 
The enclosed information sheet and letter of invitation explain the study in full 
and we would be grateful if you would distribute this to members of your 
professional society who you feel meet our inclusion criteria and may agree to 
participate.  
 
If you would like any further information please contact Helen Powell, who is a 
member of the research team, on 0115 8231378 or at 
helen.powell@nottingham.ac.uk. 
 
Yours faithfully,  
 
 
Helen Powell 
Clinical Research Fellow, University of Nottingham. 
 
Invitation letter to healthcare professionals 
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(Final version 1.0 13/02/12) 
 
Study title: A qualitative study to map attitudes to risks surrounding treatment 
for lung cancer. 
Research team: The University of Nottingham, Department of Public Health 
and Epidemiology 
Names of Researchers:  Professor Richard Hubbard, Dr Helen Powell, Dr Laura 
Jones, Dr Manpreet Bains, Dr Laila Tata and Dr David Baldwin. 
 
 
Dear Colleague, 
 
Thank you for considering taking part in our study. We would like to interview 
healthcare professionals who are involved in treatment decisions, particularly 
those involving surgery, for patients with lung cancer, in order to investigate 
KRZDQGZK\SHRSOHV¶RSLQLRQVDQGSUDFWLFHYDU\ 
 
The enclosed information sheet explains the study in full and you should read it 
carefully before deciding if you would like to take part. 
 
If you decide that you would like to be involved in the study, you will be invited 
to take part in an individual interview with a researcher at a time convenient to 
you. The interview will take about an hour. We will endeavour to find a location 
which is convenient for you, but if this is not possible and you would be willing to 
take part in a telephone or video interview this would also be an option.  The 
interview will be an informal one-to-one discussion focusing on treatment for 
lung cancer and your opinions about the risks. 
 
The interview will be audio recorded then transcribed for analysis. The audio-
recordings and transcripts will be kept strictly confidential, stored securely within 
our department and only used for the purposes of the study. 
 
Thank you for taking the time to read this letter. If you would like any further 
information please contact Helen Powell, who is a member of the research team, 
on 0115 8231378 or at helen.powell@nottingham.ac.uk. 
 
Yours faithfully,  
 
 
Helen Powell 
Clinical Research Fellow, University of Nottingham. 
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Participant information sheet ± Healthcare professionals
 332 
 333 
 334 
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Consent form for healthcare professionals 
 
 336 
Initial interview guide for healthcare professionals 
 
Introduction 
x Thank them for coming and taking part. 
x Check consent form has been signed. Keep a copy and give participant a 
copy. 
x Statement on confidentiality, right to withdraw consent, recording of the 
interview. 
x Explain the purpose of the study in general:  
o To explore attitudes towards treatment in lung cancer 
o Their opinions on risks of surgery 
x Ask if they have any further questions before starting interview 
x Interviews will last between 30 and 60 minutes 
 
Background 
x Tell me briefly about your job. 
o How long have you held that role? 
o Has it changed over time? 
x How do you see your role in relation to lung cancer patients? 
x What role do you take in deciding what sort of treatment they should 
have? 
Risks 
x What are the risks involved with treatment for lung cancer? 
x Do you have a particular figure in your mind of an acceptable mortality: 
o For your patients? 
o If you were a patient? 
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x Do you feel there is enough evidence available to help you predict risk? 
 
Treatment decisions 
x Who do you think should contribute to the decision of which treatment a 
patient is offered? 
x In your practice who makes this decision? 
o Do MDT members always agree? 
 
Communication of risks 
x Who should tell the patients about the risks involved with treatments? 
x Talk me through a typical consultation with a patient with lung cancer 
regarding treatment. 
o Are there certain things you tell everyone? 
o What risks do you discuss? 
o How do you express the risks? 
o What would you say specifically about cure? 
o Do you talk about treatments which you are not offering them? 
x How important do you think it is that the patient fully understands the 
risks? 
o Do you think this is usually the case? 
 
Conclusion 
x Tell the participants that they have reached the end of the interview 
x Do they have any questions in return?  
x Remind them about confidentiality. 
x Thank them for their time.  
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Ethical approval letters 
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